IDO inhibitors

BACKGROUND OF THE INVENTION

Field of the Invention

The present disclosure relates to compounds and methods for inhibition of indoleamine 2,3-dioxygenase; further the disclosure relates to method of treatment of diseases and disorders mediated by indoleamine 2,3-dioxygenase.

Summary of the Related Art

Tryptophan (Trp) is an essential amino acid required for the biosynthesis of proteins, niacin and the neurotransmitter 5-hydroxytryptamine (serotonin). The enzyme indoleamine 2,3-dioxygenase (also known as INDO or IDO) catalyzes the first and rate limiting step in the degradation of L-tryptophan to N-formyl-kynurenine. In human cells, IFN-γ stimulation induces activation of IDO, which leads to a depletion of Trp, thereby arresting the growth of Trp-dependent intracellular pathogens such as Toxoplasma gondii and Chlamydia trachomatis. IDO activity also has an antiproliferative effect on many tumor cells, and IDO induction has been observed in vivo during rejection of allogeneic tumors, indicating a possible role for this enzyme in the tumor rejection process.

It has been observed that HeLa cells co-cultured with peripheral blood lymphocytes (PBLs) acquire an immunoinhibitory phenotype through up-regulation of IDO activity. A reduction in PBL proliferation upon treatment with interleukin-2 (IL-2) was believed to result from IDO released by the tumor cells in response to IFN-γ secretion by the PBLs. This effect was reversed by treatment with 1-methyl-tryptophan (1MT), a specific IDO inhibitor. It was proposed that IDO activity in tumor cells may serve to impair antitumor responses (Logan, et al., 2002, Immunology, 105: 478-87).

Several lines of evidence suggest that IDO is involved in induction of immune tolerance. Studies of mammalian pregnancy, tumor resistance, chronic infections and autoimmune diseases have shown that cells expressing IDO can suppress T-cell responses and promote tolerance. Accelerated Trp catabolism has been observed in diseases and disorders associated with cellular immune activation, such as infection, malignancy, autoimmune diseases and AIDS, as well as during pregnancy. It was proposed that IDO is induced chronically by HIV infection, and is further increased by opportunistic infections, and that the chronic loss of Trp initiates mechanisms responsible for cachexia, dementia and diarrhea and possibly immunosuppression of AIDS patients (Brown, et al., 1991, Adv. Exp. Med. Biol., 294: 425-35). To this end, it has recently been shown that IDO inhibition can enhance the levels of virus-specific T cells and, concomitantly, reduce the number of virally infected macrophages in a mouse model of HIV (Portula et al., 2005, Blood, 106:2382-90).

IDO is believed to play a role in the immunosuppressive processes that prevent fetal rejection in utero. More than 40 years ago, it was observed that, during pregnancy, the genetically disparate mammalian conceptus survives in spite of what would be predicted by tissue transplantation immunology (Medawar, 1953, Symp. Soc. Exp. Biol. 7: 320-38). Anatomic separation of mother and fetus and antigenic immaturity of the fetus cannot fully explain fetal allograft survival. Recent attention has focused on immunologic tolerance of the mother. Because IDO is expressed by human syncytiotrophoblast cells and systemic tryptophan concentration falls during normal pregnancy, it was hypothesized that IDO expression at the maternal-fetal interface is necessary to prevent immunologic rejection of the fetal allografts. To test this hypothesis, pregnant mice (carrying syngeneic or allogeneic fetuses) were exposed to 1MT, and a rapid, T cell-induced rejection of all allogeneic concepti was observed. Thus, by catabolizing tryptophan, the mammalian conceptus appears to suppress T-cell activity and defends itself against rejection, and blocking tryptophan catabolism during murine pregnancy allows maternal T cells to provoke fetal allograft rejection (Munn, et al., 1998, Science 281: 1191-3).

Further evidence for a tumoral immune resistance mechanism based on tryptophan degradation by IDO comes from the observation that most human tumors constitutively express IDO, and that expression of IDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice. This effect is accompanied by a lack of accumulation of specific T cells at the tumor site and can be partly reverted by systemic treatment of mice with an inhibitor of IDO, in the absence of noticeable toxicity. Thus, it was suggested that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor (Uyttenhove et al., 2003, Nature Med., 9: 1269-74). It has also been shown that the IDO inhibitor, 1-MT, can synergize with chemotherapeutic agents to reduce tumor growth in mice, suggesting that IDO inhibition may also enhance the anti-tumor activity of conventional cytotoxic therapies (Muller et al., 2005, Nature Med., 11:312-9).

One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs. A subset of human IDO-expressing antigen-presenting cells (APCs) that coexpressed CD123 (IL3RA) and CCR6 and inhibited T-cell proliferation have also been described. Both mature and immature CD123-positive dendritic cells suppressed T-cell activity, and this IDO suppressive activity was blocked by 1MT (Munn, et al., 2002, Science 297: 1867-70). It has also been demonstrated that mouse tumor-draining lymph nodes (TDLNs) contain a subset of plasmacytoid dendritic cells (pDCs) that constitutively express immunosuppressive levels of IDO. Despite comprising only 0.5% of lymph node cells, in vitro, these pDCs potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs. Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19. Thus, it was hypothesized that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses (Munn, et al., 2004, J. Clin. Invest., 114(2): 280-90).

IDO degrades the indole moiety of tryptophan, serotonin and melatonin, and initiates the production of neuroactive and immunoregulatory metabolites, collectively known as kynurenines. By locally depleting tryptophan and increasing proapoptotic kynurenines, IDO expressed by dendritic cells (DCs) can greatly affect T-cell proliferation and survival. IDO induction in DCs could be a common mechanism of deletional tolerance driven by regulatory T cells. Because such tolerogenic responses can be expected to operate in a variety of physiopathological conditions, tryptophan metabolism and kynurenine production might represent a crucial interface between the immune and nervous systems (Grohmann, et al., 2003, Trends Immunol., 24: 242-8).

Small molecule inhibitors of IDO are being developed to treat or prevent IDO-related diseases such as those described above. For example, PCT Publication WO 99/29310 reports methods for altering T cell-mediated immunity comprising altering local extracellular concentrations of tryptophan and tryptophan metabolites, using an inhibitor of IDO such as 1-methyl-DL-tryptophan, p-(3-benzofuranyl)-DL-alanine, p-[3-benzo[b]thienyl]-DL-alanine, and 6-nitro-L-tryptophan) (Munn, 1999). Reported in WO 03/087347, also published as European Patent 1501918, are methods of making antigen-presenting cells for enhancing or reducing T cell tolerance (Munn, 2003). Compounds having indoleamine-2,3-dioxygenase (IDO) inhibitory activity are further reported in WO 2004/094409; and U.S. Patent Application Publication No. 2004/0234623 is directed to methods of treating a subject with a cancer or an infection by the administration of an inhibitor of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities.

In light of the experimental data indicating a role for IDO in immunosuppression, tumor resistance and/or rejection, chronic infections, HIV-infection, AIDS (including its manifestations such as cachexia, dementia and diarrhea), autoimmune diseases or disorders (such as rheumatoid arthritis), and immunologic tolerance and prevention of fetal rejection in utero, therapeutic agents aimed at suppression of tryptophan degradation by inhibiting IDO activity are desirable. Inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibition of IDO may also be an important treatment strategy for patients with neurological or neuropsychiatric diseases or disorders such as depression. The compounds, compositions and methods herein help meet the current need for IDO modulators.

SUMMARY OF THE INVENTION

According to the various aspects of the present disclosure are provided methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein.

In a particular aspect, the present disclosure provides methods for (a) modulating activity of indoleamine 2,3-dioxygenase comprising contacting indoleamine 2,3-dioxygenase with an effective modulating amount of a compound of formula (XXI); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (XXI); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (XXI); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (XXI); (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (XXI); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (XXI),

embedded image

DETAILED DESCRIPTION OF THE INVENTION

In one aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of Formula (I); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (I); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (I); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (I); (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (I); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (I),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

n is 0, 1, 2, 3 or 4;

Z is —N═, —N⁺(R¹)═, —N(R¹⁰)—, —O—, or —S—, provided that when Z is —N⁺(R¹)═, then a pharmaceutically acceptable anion is present;

bonds a and b are independently a single or double bond provided that (i) when bond a is a double bond, then Z is —N═ and R^2ais absent; and (ii) when bond b is a double bond, then Z is —N(R¹)—, —O—, or —S— and R^2aand R^3aare absent;

R¹is —R^N, C₃-C₈cycloalkyl, aryl, heteroaryl, arylC₁-C₆alkyl, heteroarylC₁-C₆alkyl, or -G¹;

R¹⁰is —R¹or —OR;

R²and R³are each independently —R¹, halogen, cyano, nitro, —OR, —OOH, —N(R^N)₂, —N(H)(OH), —ONH₂, —ON(R^N)C(O)OR;

or R²and R³taken together with the atoms to which they are attached form a fused 5 or 6 membered aryl or a 5 or 6 membered heteroaryl group, wherein the aryl and heteroaryl groups are optionally substituted with one or more R⁴groups;

R^2aand R^3aare independently hydrogen, C₁-C₆alkyl, hydroxyC₁-C₆alkyl, cyano, —OOH, —OH, or G¹;

or R²and R^2ataken together form ═R^D; or R³and R^3ataken together form ═R^D;

each R⁴is independently hydrogen, halogen, cyano, nitro, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —CH₂COOR, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl;

each G¹is independently —C(O)NH(R⁷⁰), —CH₂—R⁵⁰⁰, -L¹-R⁵, or -L¹⁰-R⁵⁰, wherein

R⁷⁰is (i) phenyl substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH; or (ii) a 5 or 6 membered heteroaryl, optionally substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH;

L¹is —C₂-C₆alkyl-, —C₂-C₆alkenyl-, —C₂-C₆alkynyl-, wherein the alkyl, alkenyl, or alkynyl group is optionally substituted with one or two groups which are independently phenyl, halogen, —OR, or —N(R^N)₂; and

R⁵is cyano, nitro, —NH₂, —NH(C₁-C₆alkyl), —NH(OH), —OH, —C(O)OR, —C(O)NH₂, —C(O)R, —C(NH)NH₂, —C(NOH)NH₂, —C(O)N(H)OH, —OC(O)NH₂, —N(H)C(O)OR, —N(H)C(O)NH₂, —N(OH)C(O)R, —C(O)CF₃, —C(O)CH₃, —S(O)R, —S(O)₂R, —S(O)OR, —S(O)₂OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —N(H)S(O)R, —N(H)S(O)₂R, —C(O)S(OR), —C(O)S(N(R)₂), —N(H)SC(O)CH₃, —O—SC(O)R, —P(O)(OR)₂, —C(O)CH₂P(O)(OR)₂, —C(O)N(H)R⁷⁰, —C(S)N(H)R⁷⁰, —NHC(O)R⁷⁰, —NHC(S)R⁷⁰, —NHC(O)NHR⁷⁰, —NHC(S)NHR⁷⁰, or —N(H)C(S)SR⁸, wherein

R⁸is —C₁-C₆alkyl-G⁴, wherein

G⁴is (i) aryl or heteroaryl, each optionally substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl;

or (ii) saturated or unsaturated heterocyclyl, each optionally substituted with one or more groups which are each independently ═R^D, halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl;

or (iii) hydrogen, cyano, —N(R^N)₂, —NR^N(OH), —OR, —ONH₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —C(O)N(H)OH, —N(H)C(O)NH₂, or —P(O)(OR)₂;

L¹⁰is a bond or —C₁-C₆alkyl-,

R⁵⁰is a group of the formula,

embedded image

wherein q is 0 or 1; r is 0, 1, or 2;

bonds d and e are independently a single or double bond;

each R⁶is independently hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, or phenyl;

each X is independently ═O or ═S;

X¹and X²are both hydrogen or X¹and X²taken together form ═R^D; and

each Y is independently —O—, —S—, or —N(R^N)—;

R⁵⁰⁰is —C(O)OR, —C(O)NH₂, —C(O)N(H)R⁷⁰, —C(S)N(H)R⁷⁰, —NHC(O)NHR⁷⁰, —NHC(S)NHR⁷⁰, —NHC(O)R⁷⁰, —NHC(S)R⁷⁰, —N(H)C(O)NH₂, —C(O)CF₃, —C(O)CH₃, —C(O)N(H)OH, —N(OH)C(O)R, —N(H)C(S)SR⁸, or —R⁵⁰;

each R is independently hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, phenyl or benzyl, wherein each of group is optionally substituted with one or more groups which are independently halogen, hydroxyl, C₁-C₆alkoxy, amino, carboxy, and carbamoyl;

each R^Dis independently ═O, ═S, ═N(R^N), ═N(OR), ═N(NH₂), or ═N(CN); and

each R^Nis independently (i) hydrogen; (ii) C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, phenyl, or benzyl, wherein each group is optionally substituted with one or more groups which are independently halogen, hydroxyl, C₁-C₆alkoxy, amino, carboxy, and carbamoyl; or (iii) formyl, —C(O)C₁-C₆alkyl, —C(O)OC₁-C₆alkyl, —C(O)N(H)C₁-C₆alkyl, or —S(O)₂C₁-C₆alkyl;

provided that

(a) one and only one G¹is present;

(b) when bond b is a double bond, Z is —N(H)—, O, or S, R³is —(CH₂)_1-3—N(H)C(S)S—R⁸, then R⁸is not —CH₂-G⁴;

(c) the compound is not β-(3-benzofuranyl)alanine, β-(3-benzo[b]thienyl)alanine, 1-methyltryptophan, 1-ethyltryptophan, hexyl (1H-indol-3-yl)methylcarbamodithioate and 2-amino-(3-indolin-3-yl)propanoic acid; and

(d) when bond b is a double bond, Z is —N(H)—, —N(CH₃)—, or —N(CH₂CH₃)—, R³is -G¹, and G¹is —CH₂CH(NH(R^N))COOR, —CH₂C(CH₃)(NH₂)COOR, —CH(CH₃)CH(NH₂)COOH, —CH₂CH₂NH₂, —CH₂CH₂COOH, —CH₂CH(OH)COOH, or —CH═CH—COOR, then either n is not 0 or R²is not hydrogen and R²or R⁴are not C₁-C₂alkyl, aryl, halogen, —OH, —OCH₃, OCH₂Ph, —COOH, or nitro.

In an embodiment of the first aspect, the compound is of one of formulae (Ia)-(In),

embedded image

and the remaining variables are as defined for formula (I).

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C(O)NH(R⁷⁰), wherein R⁷⁰is a phenyl substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C(O)NH(R⁷⁰), wherein R⁷⁰is a 5-membered heteroaryl optionally substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C(O)NH(R⁷⁰), wherein R⁷⁰is a thiazolyloptionally substituted with one to three groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is -L¹-R⁵, wherein L¹is —C₂-C₆alkyl- wherein the alkyl group is optionally substituted with one or two groups which are independently phenyl, halogen, —OR, or —N(R^N)₂; and R⁵is cyano, nitro, —NH₂, —NH(C₁-C₆alkyl), —NH(OH), —OH, —C(O)OR, —C(O)NH₂, —C(NH)NH₂, —C(O)N(H)OH, —OC(O)NH₂, —N(H)C(O)OR, —N(H)C(O)NH₂, —N(OH)C(O)R, —C(O)CF₃, —N(H)S(O)R, —N(H)S(O)₂R, —N(H)SC(O)CH₃, —P(O)(OR)₂, —C(O)N(H)R⁷⁰, —NHC(S)R⁷⁰, —NHC(S)NHR⁷⁰, or —N(H)C(S)SR⁸.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C₂-C₆alkyl-C(O)NH(R⁷⁰).

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C₂-C₆alkyl-C(O)NH(R⁷⁰), wherein R⁷⁰is a phenyl substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C₂-C₆alkyl-C(O)NH(R⁷⁰), wherein R⁷⁰is thiazolyl optionally substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C₂-C₆alkyl-C(O)NH(R⁷⁰), wherein R⁷⁰is thiazolyl.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C₂-C₆alkyl-NHC(S)R⁷⁰.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C₂-C₆alkyl-NHC(S)R⁷⁰, wherein R⁷⁰is a phenyl substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C₂-C₆alkyl-NHC(S)R⁷⁰, wherein R⁷⁰is thiazolyl optionally substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C₂-C₆alkyl-NHC(S)R⁷⁰, wherein R⁷⁰is thiazolyl.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C₂-C₆alkyl-N(H)C(S)SR⁸.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂CH₂N(H)C(S)SR⁸.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —C₂-C₆alkyl-N(H)C(S)SR⁸, wherein R⁸is —C₁-C₆alkyl-G⁴, wherein G⁴is aryl or heteroaryl, each optionally substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂CH₂N(H)C(S)SR⁸, wherein R⁸is —C₁-C₆alkyl-G⁴, wherein G⁴is aryl or heteroaryl, each optionally substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂CH₂N(H)C(S)SR⁸, wherein R⁸is —C₁-C₆alkyl-G⁴, wherein G⁴is phenyl optionally substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂CH₂N(H)C(S)SR⁸, wherein R⁸is —C₁-C₆alkyl-G⁴, wherein G⁴is phenyl substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂CH₂N(H)C(S)SR⁸, wherein R⁸is —CH₂CH₂G⁴, wherein G⁴is aryl or heteroaryl, each optionally substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂CH₂N(H)C(S)SR⁸, wherein R⁸is —CH₂CH₂G⁴, wherein G⁴is phenyl optionally substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂CH₂N(H)C(S)SR⁸, wherein R⁸is —CH₂CH₂G⁴, wherein G⁴is phenyl substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is -L¹⁰-R⁵⁰.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is -L¹⁰-R⁵⁰, herein L¹⁰is a bond, and R⁵⁰is a group of the formula,

embedded image

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is -L¹⁰-R⁵⁰, wherein L¹⁰is —C₁-C₆alkyl-, and R⁵⁰is a group of the formula,

embedded image

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is -L¹⁰-R⁵⁰, wherein L¹⁰is —C₁-C₆alkyl-, and R⁵⁰is a group of the formula,

embedded image

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂—R⁵⁰⁰, wherein R⁵⁰⁰is —C(O)OR, —C(O)NH₂, —C(O)N(H)R⁷⁰, —C(S)N(H)R⁷⁰, —NHC(O)NHR⁷⁰, —NHC(S)NHR⁷⁰, —NHC(O)R⁷⁰, —NHC(S)R⁷⁰, —N(H)C(O)NH₂, —C(O)CF₃, —C(O)CH₃, —C(O)N(H)OH, —N(OH)C(O)R, or —R⁵⁰.

In a an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂—R⁵⁰⁰, wherein R⁵⁰⁰is —C(O)OR.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂—R⁵⁰⁰, wherein R⁵⁰⁰is —C(O)NH₂.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂—R⁵⁰.

In an embodiment of the first aspect, the compound is of one of formulae (I) and (Ia)-(In), and G¹is —CH₂C(O)CF₃.

In a second aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of Formula (II); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (II); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (II); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (II); (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (II); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (II),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

bonds a and b are each a single or double bond provided that

(i) when bond a is a single bond, then Z is —O—, —S— or —N(R^N)—;

(ii) when bond a is a double bond, then R²is absent and Z is —N═;

(iii) when bond b is a double bond, then R²and R³are absent and Z is —O—, —S— or —N(R^N)—; and

(iv) only one of bonds a and b is a double bond;

R²and R³are independently hydrogen, hydroxy, C₁-C₆alkyl, or -G¹;

R⁴is hydrogen, halogen, cyano, nitro, —OR, —SR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(NR^N)CH₃, C₁-C₆alkyl, C₁-C₆haloalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted with one or more groups which are independently halogen, cyano, nitro, —OR, SR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(N—NH₂)CH₃, C₁-C₆alkyl, or C₁-C₆haloalkyl, and the aryl and heteroaryl groups are optionally fused to a 3-8 membered unsaturated heterocyclyl group; and

ring A is a 3-8 membered saturated or unsaturated cycloalkyl or 3-8 membered saturated or unsaturated heterocyclyl group wherein ring A is optionally substituted by one or more groups which are each independently ═O, ═S, ═N(R^N), ═N(OR), ═N(NH₂), ═N(CN), R⁴, or G¹;

G¹is independently -L¹-R⁵wherein

L¹is —C₁-C₆alkyl-, —C₂-C₆alkenyl-, —C₂-C₆alkynyl-, wherein the alkyl, alkenyl, or alkynyl group is optionally substituted with one or two groups which are independently phenyl, halogen, —OR, or —N(R^N)₂; and

R⁵is cyano, nitro, —NH₂, —NH(OH), —OH, —C(O)OR, —C(O)NH₂, —C(O)R, —C(NH)NH₂, —C(NOH)NH₂, —C(O)N(H)OH, —N(H)C(O)R, —N(H)C(S)R, —N(H)C(O)OR, —N(OH)C(O)R, —C(O)CF₃, —C(O)CH₃, —S(O)R, —S(O)₂R, —S(O)OR, —S(O)₂OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —N(H)S(O)R, —N(H)S(O)₂R, or —P(O)(OR)₂; and

each R is independently hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, phenyl, benzyl, heteroaryl, or heteroarylC₁-C₆alkyl, wherein each group is optionally substituted with one or more groups which are independently halogen, hydroxyl, C₁-C₆alkoxy, amino, carboxy, and carbamoyl; and

provided that the compound is not 7-methoxy-1-methyl-4,9-dihydro-3H-pyrido[3,4-b]indole, 1-methyl-4,9-dihydro-3H-pyrido[3,4-b]indol-7-ol, 2,3,4,9-tetrahydro-1H-pyrido[3,4-b)]indole, and 7-methoxy-4,9-dihydro-3H-pyrido[3,4-b)]indol-1-ol.

In an embodiment of the second aspect, G¹is -L¹-R⁵wherein L¹is —C₁-C₆alkyl- or —C₂-C₆alkenyl-, wherein the alkyl or alkenyl group is optionally substituted with one or two groups which are independently —OR or —N(R^N)₂; and R⁵is cyano, —NH₂, —NH(OH), —OH, —C(O)OR, —C(O)NH₂, —C(O)R, —C(NH)NH₂, —C(NOH)NH₂, —C(O)N(H)OH, —N(H)C(O)R, N(H)C(S)R, —N(H)C(O)OR, or —N(OH)C(O)R.

In an embodiment of the second aspect, G¹is -L¹-R⁵wherein L¹is —C₁-C₆alkyl-optionally substituted with one group which is —OR or —N(R^N)₂; and R⁵is —NH₂, —NH(OH), —OH, —C(O)OR, —C(O)NH₂, —C(O)N(H)OH, —N(H)C(O)R, or —N(H)C(O)OR.

In an embodiment of the second aspect, G¹is -L¹-R⁵wherein L¹is —C₁-C₃alkyl-substituted —N(R^N)₂, and R⁵is —C(O)OR, —C(O)NH₂, or —C(O)N(H)OH.

In another embodiment of the second aspect, the compound is of one of formulae (II)-(IIe),

embedded image

wherein Q is —O—, —N(H)—, —S—; q is 0, 1, or 2, and the remaining variables are as defined for formula (II).

In one embodiment of the second aspect, the compound is of one of formulae (II) and (II)-(II) and G¹is as defined in any one of the preceding embodiments of the second aspect.

In another embodiment of the second aspect, the compound is of the formula,

embedded image

and the remaining variables are as defined for formula (II).

In an embodiment of the second aspect, the compound is according to one of the formulae (II), and (IIi)-(IIl) and one R⁴is —OR, —SR, —N(R^N)₂, —C(O)OR, or —C(O)N(R^N)₂.

In another embodiment of the second aspect, the compound is according to one of the formulae (II), and (IIi)-(IIl) and one R⁴is —C(O)OR or —C(O)N(R^N)₂.

In a third aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of Formula (III); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (III); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (III); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (III), (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (III); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (III),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

Z is —N═, —N(R^N), —O—, or —S—;

bond a is a single or double bond provided that when bond a is a double bond, then Z is —N═ and R^2ais absent;

R²and R^2aare each hydrogen, or R²and R^2ataken together form ═R^D;

ring A is a spiro ring which is either (i) a saturated or unsaturated C₄-C₈cycloalkyl optionally substituted with one or more groups which are each independently R²⁰or R²¹; or (ii) a saturated or unsaturated 3-8 membered heterocyclyl optionally substituted with one or more groups which are each independently R²⁰or R²¹;

R⁴is independently hydrogen, halogen, cyano, nitro, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl;

each R²⁰is independently ═R^D, ═C₃-C₈cycloalkyl, or =heterocyclyl;

each R²¹is independently halogen or -L¹-R⁵, wherein

L¹is a bond, —C₁-C₆alkyl-, —C₂-C₆alkenyl-, —C₂-C₆alkynyl-, wherein the alkyl, alkenyl, or alkynyl group is optionally substituted with one or two groups which are independently phenyl, halogen, —OR, or —N(R^N)₂; and

R⁵is cyano, nitro, —NH₂, —NH(OH), —OH, —C(O)OR, —C(O)N(R)₂, —C(O)R, —C(NH)NH₂, —C(NOH)NH₂, —C(O)N(H)OH, —N(H)C(O)R, —N(H)C(S)R, —N(H)C(O)OR, —N(OH)C(O)R, —C(O)CF₃, —C(O)CH₃, —S(O)R, —S(O)₂R, —S(O)OR, —S(O)₂OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —N(H)S(O)R, —N(H)S(O)₂R, or —P(O)(OR)₂;

each R is independently hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, phenyl or benzyl, wherein each group is optionally substituted with one or more groups which are independently halogen, hydroxyl, C₁-C₆alkoxy, amino, carboxy, and carbamoyl;

each R^Dis independently ═O, ═S, ═N(R^N), ═N(OR), ═N(NH₂), or ═N(CN); and

In an embodiment of the third aspect, the compound is of one of formulae (IIa)-(IIId),

embedded image

wherein X is —O—, —S—, or —NH—, and the remaining variables are as defined for formula (III).

In an embodiment of the third aspect, the compound is of one of formulae (IIIe)-(IIIh),

embedded image

wherein X is —O—, —S—, or —NH—, and the remaining variables are as defined for formula (III).

In an embodiment of the third aspect, the compound is of one of formulae (III) and (IIIe)-(IIIh) and R²¹is -L¹-R⁵.

In another embodiment of the third aspect, the compound is of one of formulae (III) and (IIIe)-(IIIh) and R²¹is -L¹-R⁵, wherein L¹is a bond or —C₁-C₆alkyl- optionally substituted with —OR or —N(R^N)₂.

In an embodiment of the third aspect, the compound is of one of formulae (III) and (IIIe)-(IIIh) and R²¹is -L¹-R⁵, wherein L¹is a bond or —C₁-C₆alkyl- optionally substituted with —OR or —N(R^N)₂; and R⁵is cyano, —NH₂, —NH(OH), —OH, —C(O)OR, —C(O)N(R)₂, —C(O)N(H)OH, —N(H)C(O)R, —N(H)C(O)OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —N(H)S(O)R, —N(H)S(O)₂R, or —P(O)(OR)₂.

In a fourth aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of Formula (IV); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (IV); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (IV); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (IV); (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (IV); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (IV),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

bond a is a single or double bond;

Y is ═R^D;

both X are —S— or —N(R^N)—;

R¹and R²are independently C₁-C₆alkyl, —OR, —N(R^N)₂, or —SR;

or R¹and R²taken together with the carbon atoms to which they are attached form

(i) a fused phenyl ring optionally substituted with one or more groups which are independently halogen, cyano, nitro, C₁-C₆alkyl, —OR, —N(R^N)₂, or —SR; or

(ii) a fused 5-8 membered heterocyclyl ring optionally substituted with one or more groups which are independently ═R^D, C₁-C₆alkyl, —OR, —N(R^N)₂, or —SR;

each R^Dis independently ═O, ═S, ═N(R^N), ═N(OR), ═N(NH₂), or ═N(CN); and

each R^Nis independently (i) hydrogen, hydroxyl, cyano, or amino; (ii) C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, phenyl, or benzyl, wherein each group is optionally substituted with one or more groups which are independently halogen, hydroxyl, C₁-C₆alkoxy, amino, carboxy, and carbamoyl; or (iii) formyl, —C(O)C₁-C₆alkyl, —C(O)OC₁-C₆alkyl, —C(O)N(H)C₁-C₆alkyl, or —S(O)₂C₁-C₆alkyl;

provided that when X and Z are both N(R^N), then one is not NH.

In an embodiment of the fourth aspect, the compound is of formulae (IVa),

embedded image

wherein R¹, R², and R^Nare as defined for formula (IV).

In an embodiment of the fourth aspect, the compound is of formulae (IV) or (IVa), and R¹and R²are independently —OR, or R¹and R²taken together with the carbon atoms to which they are attached form a fused 5-8 membered heterocyclyl ring.

In an embodiment of the fourth aspect, the compound is of formulae (IV) or (IVa), and each R^Nis independently hydrogen, hydroxyl, or C₁-C₆alkyl optionally substituted with one halogen, hydroxyl, C₁-C₆alkoxy, amino, carboxy or carbamoyl group.

In another embodiment of the fourth aspect, the compound is of formulae (IVb),

embedded image

wherein R^Nis as defined for formula (IV).

In an embodiment of the fourth aspect, the compound is of formulae (IV) or (IVb), and each R^Nis independently hydrogen, hydroxyl, or C₁-C₆alkyl optionally substituted with one halogen, hydroxyl, C₁-C₆alkoxy, amino, carboxy or carbamoyl group.

In another embodiment of the fourth aspect, the compound is of formulae (IVc),

embedded image

wherein R¹, R², and Y are as defined for formula (IV).

In an embodiment of the fourth aspect, the compound is of formulae (IV) or (IVc), and R¹and R²each —SR, or R¹and R²taken together with the carbon atoms to which they are attached form a fused 5-8 membered heterocyclyl ring optionally substituted with ═R^D, C₁-C₆alkyl, —OR, —N(R^N)₂, or —SR, wherein each R is independently hydrogen or C₁-C₆alkyl, substituted with one halogen, hydroxyl, cyano, C₁-C₆alkoxy, amino, carboxy, or carbamoyl group.

In a fifth aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of Formula (V); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (V); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (V); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (V); (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (V); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (V),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

X, Y, and Z are independently —N═, —N⁺(R³)═, —N(R³)—, —C(R⁴)═, —O—, or —S—; provided (i) one and only one of X, Y, and Z is —N(R³)—, —O—, or —S—, (ii) no more than one of X, Y, and Z is —N⁺(R³)═; (iii) when one of X, Y, and Z is —N(R³)—, —O—, or —S— and the other two are both —C(R⁴)═, then R¹and R²taken together are not a phenyl ring; (iv) when X and Z are —N(R³)— and —N═ or —N═ and —N(R³)—, then R³is not hydrogen; (v) provided that when one of X, Y, and Z is —N⁺(R³)═, then a pharmaceutically acceptable anion is present; and (vi) R¹, R², and R³or R⁴are not simultaneously H.

R¹, R², and R⁴are independently hydrogen, halogen, cyano, nitro, —OR, —SR, —N(R^N)₂, —N(H)NH₂, —C(O)R, —C(O)N(R^N)₂, C₁-C₆alkyl, C₁-C₆halo alkyl, —C₁-C₆alkyl-OR, —C₁-C₆alkyl-SR, —C₁-C₆alkyl-N(R^N)₂, —C₁-C₆alkyl-C(O)OR, —C₁-C₆alkyl-C(O)N(R^N)₂, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or G¹, wherein the aryl and heteroaryl groups are optionally substituted with one or more groups which are independently halogen, cyano, nitro, —OR, —SR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, C₁-C₆alkyl, C₁-C₆halo alkyl, —C₁-C₆alkyl-OR, —C₁-C₆alkyl-SR, —C₁-C₆alkyl-N(R^N)₂, —C₁-C₆alkyl-C(O)OR, or —C₁-C₆alkyl-C(O)N(R^N)₂;

R³is hydroxyl, amino, cyano, R^Nor G¹;

or R¹and R²taken together with the atoms to which they are attached form a fused ring which is G²;

or R³and R⁴, when present on adjacent atoms, taken together with the atoms to which they are attached form a fused ring which is G²;

or two R⁴, when present on adjacent carbon atoms, taken together with the atoms to which they are attached form a fused ring which is G²;

G²is (i) a saturated or unsaturated 4-8 membered cycloalkyl optionally substituted with one or more groups which are each independently R²⁰or R²¹;

(ii) a saturated or unsaturated 4-8 membered heterocyclyl optionally substituted with one or more groups which are each independently R²⁰or R²¹;

(iii) phenyl optionally substituted with one or more R²¹groups, or

(iv) a 5 or 6 membered heteroaryl group optionally substituted with one or more R²¹groups; wherein

each R²⁰is independently ═R^D, ═C₃-C₈cycloalkyl, or =heterocyclyl; and

each R²¹is independently halogen, hydroxyl, amino, cyano, C₁-C₆alkyl, C₁-C₆halo alkyl, or G¹;

each G¹is independently —C(CH₃)═NOCH₂C(O)OH, —C(CH₃)═NOCH₂C(O)NH₂, —C(CH₃)═NOC(O)C(O)NH₂, —C(O)NH(R⁷⁰), —W-L¹-R⁵or -L¹⁰-R⁵⁰, wherein

R⁷⁰is (i) phenyl substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, —OCH₃or —OH; or (ii) a 5 or 6 membered heteroaryl, optionally substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH;

W is a bond, —S(O)—, —S(O)₂—, —C(O)N(R^N)—, —C(O)O—, —C(O)S—, —OC(O)—, —N(R^N)C(O)—, —O—, —S—, or —N(R^N)—;

R⁵is cyano, nitro, amino, —OR, mercapto, —NH(OH), —NHN(H)R, —C(O)OR, —C(O)NH₂, —C(O)R, —C(NH)NH₂, —C(NOH)NH₂, —C(O)N(H)OH, —N(H)C(O)OR, —N(OH)C(O)R, —C(O)CF₃, —S(O)R, —S(O)₂R, —S(O)OR, —S(O)₂OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —SC(NH)NH₂, —N(H)S(O)R, —N(H)S(O)₂R, —C(O)S(OR), —C(O)S(N(R)₂), —N(H)SC(O)CH₃, —P(O)(OR)₂, —C(O)N(H)R⁷⁰, —C(S)N(H)R⁷⁰, —C(O)N(H)N═C(H)R, —C(O)N(H)N(H)R, —SC(NH)NH₂, —C(O)NH(R⁷⁰), —C(S)NH(R⁷⁰), —NHC(O)R⁷⁰, —NHC(S)R⁷⁰, —NHC(O)NHR⁷⁰, —NHC(S)NHR⁷⁰, or —N(H)C(S)SR⁸, wherein

R⁸is -L²-G⁴, wherein

L²is —C₁-C₆alkyl- optionally substituted with one or more groups which are each independently —OR, —N(R^N)₂, —N(R^N)C(O)R, —N(R^N)C(O)OR, —C(O)OR, —C(O)N(R)₂, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl; and

G⁴is (i) hydrogen; (ii) aryl or heteroaryl, each optionally substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl;

(iii) saturated or unsaturated heterocyclyl, each optionally substituted with one or more groups which are each independently ═R^D, halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl;

or (iv) cyano, —N(R^N)₂, —NR^N(OH), —OR, —ONH₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —C(O)N(H)OH, —N(H)C(O)OR, —N(H)C(O)NH₂, —N(OH)C(O)R, or —P(O)(OR)₂;

L¹⁰is a bond or —C₁-C₆alkyl-,

R⁵⁰is a group of the formula,

embedded image

wherein q is 0 or 1; r is 0, 1, or 2;

bonds d and e are independently a single or double bond;

each R⁶is independently hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, or phenyl;

each Q is independently ═O or ═S;

each T is independently is —O—, —S—, or —N(R^N)—; and

X¹and X²are both hydrogen or X¹and X²taken together form ═R^D;

each R^Dis independently ═O, ═S, ═N(R^N), ═N(OR), ═N(NH₂), or ═N(CN); and

provided that (i) one and only one G¹is present; (ii) no more than one G²is present; (iii) the compound is not 2-amino-3-(1H-azaindol-3-yl)propanoic acid; and 2-amino-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propanoic acid; and (iv) when G¹is —CH₂)_1-3—N(H)C(S)S-L²-G⁴, then L²is not methylene.

In an embodiment of the fifth aspect, the compound is according to one of formulae (Va)-(Vj),

embedded image

and the remaining variables are as defined for formula (V).

In another embodiment of the fifth aspect, the compound is according to one of formulae (Vk)-(Vo),

embedded image

and the remaining variables are as defined for formula (V).

In an embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is -L¹-R⁵.

In an embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl- or —C₂-C₆alkenyl-, wherein the alkyl or alkenyl is optionally substituted with one groups which is —OR or —N(R^N)₂.

In a an embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl- or —C₂-C₆alkenyl-, wherein the alkyl or alkenyl is optionally substituted with one groups which is —OR or —N(R^N)₂; and R⁵is cyano, nitro, amino, hydroxyl, mercapto, —NH(OH), —NHN(H)R, —C(O)OR, —C(O)NH₂, —C(O)N(H)OH, —N(H)C(O)R, —N(H)C(O)OR, —S(O)R, —S(O)₂R, —S(O)OR, —S(O)₂OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —N(H)S(O)R, —N(H)S(O)₂R, or —P(O)(OR)₂.

In another embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl- and R⁵is —N(H)C(S)SR⁸.

In another embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is —W-L¹-R⁵wherein W is —S(O)—, —S(O)₂—, —C(O)N(R^N)—, —C(O)O—, —C(O)S—, —OC(O)—, —N(R^N)C(O)—, —O—, —S—, or —N(H)—.

In another embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is —W-L¹-R⁵, wherein W is —S(O)—, —S(O)₂—, —C(O)N(R^N)—, —O—, —S—, or —N(H)—.

In another embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is —W-L¹-R⁵, wherein W is —S(O)— or —S(O)₂—.

In another embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is —W-L¹-R⁵, wherein W is —C(O)N(R^N)—.

In another embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is —W-L¹-R⁵, wherein W is —O—, —S—, or —N(H)—.

In another embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is -L¹⁰-R⁵⁰.

In an embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is -L¹⁰-R⁵⁰, wherein L¹⁰is a bond

In an embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is -L¹⁰-R⁵⁰, wherein L¹⁰is a bond; and R⁵⁰is a group of the formula,

embedded image

In another embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is -L¹⁰-R⁵⁰, wherein L¹⁰is —C₁-C₆alkyl-.

In another embodiment of the fifth aspect, the compound is of any one of formulae (V) and (Va)-(Vo), and G¹is -L¹⁰-R⁵⁰, wherein L¹⁰is —C₁-C₆alkyl-; and R⁵⁰is a group of the formula,

embedded image

In a sixth aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of Formula (VI); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (VI); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (VI); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (VI); (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (VI); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (VI),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

Z is —C(R⁴)═, —N═, or —N⁺(R³)═, and Z¹is —C(R⁴)═, or —N═, provided that at least one of Z and Z¹is —N═, and when Z is —N⁺(R³)═, then a pharmaceutically acceptable anion is present;

R¹, R², and R⁴are independently hydrogen, halogen, cyano, nitro, —OR, —SR, —N(R^N)₂, —C(O)R, —C(O)O(R), —C(O)N(R^N)₂, —S(O)R, —S(O)₂R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or G¹;

or R¹and R²taken together with the atoms to which they are attached form a fused

(i) phenyl ring optionally substituted with one or more R⁴;

(ii) pyridyl or pyridiniumyl ring, each optionally substituted with one or more R⁴; or

(iii) 4-8 membered saturated or unsaturated cycloalkyl or 4-8 membered saturated or unsaturated heterocyclyl ring, each optionally substituted with one or more ═R^Dor —R⁴;

R³is R^Nor G¹;

each G¹is independently -L¹-R⁵, -Q-L¹-R⁵, -L¹⁰-R⁵⁰, -Q-L¹⁰-R⁵⁰, —C(O)N(H)R^N—N(H)C(O)R^N, —C(O)N(H)R⁷⁰, —N(H)C(S)SR⁷⁰, or -Q-L¹-R⁷⁰, wherein

Q is —O—, —S—, or —N(R^N)—;

R⁵is cyano, nitro, amino, hydroxyl, mercapto, —NH(OH), —N(R)N(H)C(O)NH₂, —C(O)R, —C(O)CF₃, —C(O)CH₃, —C(O)OR, —C(O)NH₂, —C(O)N(H)R⁷⁰, —C(S)N(H)R⁷⁰, —C(O)N(H)OH, —C(NH)NH₂, —C(NO H)NH₂, —C(NNH₂)R, —C(H)═NN(H)C(O)R; —N(H)C(O)OR, —N(OH)C(O)R, —S(O)R, —S(O)₂R, —S(O)OR, —S(O)₂OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —N(H)S(O)R, —N(H)S(O)₂R, —C(O)S(OR), —C(O)S(N(R)₂), —N(H)SC(O)CH₃, —P(O)(OR)₂, —C(O)N(H)N═CH(C₁-C₆alkyl), —NHC(O)R⁷⁰, —NHC(S)R⁷⁰, —NHC(O)NHR⁷⁰, —NHC(S)NHR⁷⁰, —NHC(S)N(H)NH₂, —N(H)C(S)SR⁸, or —C(S)N(H)N(H)C(O)NH₂, wherein

R⁸is -L²-G⁴, wherein

L²is —C₂-C₆alkyl- optionally substituted with one or more groups which are each independently —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl; and

G⁴is (i) aryl or heteroaryl, each optionally substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₁-C₆haloalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl;

(ii) saturated or unsaturated heterocyclyl, each optionally substituted with one or more groups which are each independently ═R^D, halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl;

or (iii) cyano, —N(R^N)₂, —NR^N(OH), —OR, —ONH₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —C(O)N(H)OH, —N(H)C(O)OR, —N(H)C(O)NH₂, —N(OH)C(O)R, or —P(O)(OR)₂; and

L¹⁰is a bond or L¹;

R⁵⁰is a group of the formula,

embedded image

wherein q is 0 or 1; r is 0, 1, or 2;

bonds d and e are independently a single or double bond;

each X is independently ═O or ═S;

X¹and X²are both hydrogen or X¹and X²taken together form ═R^D; and

each Y is independently —O—, —S—, or —N(R^N)—,

each R⁶is independently hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, or phenyl;

each R is independently (i) hydrogen or (ii) C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl, wherein each is optionally substituted with one or more groups which are independently halogen, hydroxyl, cyano, nitro, C₁-C₆alkoxy, amino, carboxy, and carbamoyl; and

each R^Dis ═O, ═S, ═N(R^N), ═N(OR), ═N(NH₂), or ═N(CN);

each R^Nis independently (i) hydrogen; (ii) C₁-C₆alkyl, C₂-C₆alkenyl, or C₂-C₆alkynyl, wherein each group is optionally substituted with one or more groups which are independently halogen, hydroxyl, C₁-C₆alkoxy, amino, carboxy, and carbamoyl; or (iii) —C(O)C₁-C₆alkyl, —C(O)OC₁-C₆alkyl, —C(O)N(H)C₁-C₆alkyl, or —S(O)₂C₁-C₆alkyl;

provided that (i) one and only one G¹is present; (ii) the compound is not 2-amino-3-(quinolin-3-yl)propanoic acid; and (iii) when G¹is —(CH₂)_1-3—N(H)C(S)S-L²-G⁴, then L²is not methylene.

In an embodiment of the sixth aspect, the compound is of any one of formulae (VIa)-(VIe),

embedded image

and the remaining variables are as defined for formula (VI).

In an embodiment of the sixth aspect, the compound is of any one of formulae (VI) and (VIa)-(VIe), and G¹is -L¹-R⁵.

In an embodiment of the sixth aspect, the compound is of any one of formulae (VI) and (VIa)-(VIe), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl-.

In an embodiment of the sixth aspect, the compound is of any one of formulae (VI) and (VIa)-(VIe), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl-; and R⁵is cyano, nitro, amino, hydroxyl, mercapto, —NH(OH), —C(O)R, —C(O)CF₃, —C(O)OR, —C(O)NH₂, —C(O)N(H)R⁷⁰, —C(S)N(H)R⁷⁰, —C(O)N(H)OH, —N(H)C(O)R⁷⁰, —N(H)C(S)R⁷⁰, —N(H)C(O)OR, —S(O)R, —S(O)₂R, —S(O)OR, —S(O)₂OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —N(H)S(O)R, —N(H)S(O)₂R, —P(O)(OR)₂, or —N(H)C(S)SR⁸.

In another embodiment of the sixth aspect, the compound is of any one of formulae (VI) and (VIa)-(VIe), and G¹is -L¹⁰-R⁵⁰.

In an embodiment of the sixth aspect, the compound is of any one of formulae (VI) and (VIa)-(VIe), and G¹is -L¹⁰-R⁵⁰, wherein R⁵⁰is a group of the formula,

embedded image

In another embodiment of the sixth aspect, the compound is of any one of formulae (VI) and (VIa)-(VIe), and G¹is —C(O)N(H)R⁷⁰.

In another embodiment of the sixth aspect, the compound is of any one of formulae (VI) and (VIa)-(VIe), and G¹is —N(H)C(S)SR⁷⁰.

In another embodiment of the sixth aspect, the compound is of any one of formulae (VI) and (VIa)-(VIe), and G¹is -Q-L¹-R⁷⁰.

In a seventh aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of Formula (VII); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (VII); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (VII); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (VII); (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (VII); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (VII),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

n is 0, 1, 2, or 3;

R¹, R², and R⁴are independently hydrogen, halogen, cyano, nitro, —OR, —SR, —N(R^N)₂, —N(R^N)(OR), —C(O)R, —C(H)(R^N)ONH₂, —C(H)(R⁸)ONH₂, —C(O)O(R), —C(O)N(R^N)₂, —S(O)R, —S(O)₂R, C₁-C₆alkyl, hydroxyC₁-C₆alkyl, aminoC₁-C₆alkyl, C₁-C₆halo alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, or G¹;

or R¹and R²taken together with the atoms to which they are attached form

(i) a fused phenyl ring optionally substituted with one or more R⁴groups;

(ii) a 6-membered fused unsaturated heterocyclyl ring optionally substituted with one to three groups which are independently ═R^Dor —R⁴;

(iii) a 6-membered fused unsaturated cycloalkyl ring optionally substituted with one to three —R⁴groups;

(iv) a 4- or 5-membered fused unsaturated heterocyclyl ring optionally substituted with one to three groups which are independently ═R^D, halogen, cyano, nitro, —OR, —SR, —N(R^N)₂, —N(R^N)(OR), —C(O)R, —C(O)O(R), —C(O)N(R^N)₂, —S(O)R, —S(O)₂R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl,

each G¹is independently —C(O)NH(R⁷⁰), —C(H)═NN(H)C(═R^D)NH₂, -Q-L¹-R⁵, or -L¹⁰-R⁵⁰, or -L¹⁰-R⁵⁰⁰, wherein

R⁷⁰is (i) phenyl optionally substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH; or (ii) a 5 or 6 membered heteroaryl, optionally substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH;

Q is a bond, —C(O)—, —S(O)—, —S(O)₂—, —C(O)N(R^N)—, —C(O)O—, —C(O)S—, —OC(O)—, —N(R^N)C(O)—, —O—, —S—, —N(R^N)—, —CH(R)O—, —CH(R)S—, or —CH(R)N(R^N)—;

R⁵is cyano, nitro, —NH₂, —NH(OH), —N(R)N(H)C(O)NH₂, —OH, —ONH₂, —C(O)OR, —C(O)NH₂, —C(O)R, —C(NH)NH₂, —C(NOH)NH₂, —C(O)N(H)OH, —C(H)═NN(H)C(O)R; —N(H)C(O)OR, —N(H)C(O)NH₂, —N(OH)C(O)R, —OC(O)NH₂, —ON(H)C(NH)NH₂, —C(O)CF₃, —C(O)CH₃, —S(O)R, —S(O)₂R, —S(O)OR, —S(O)₂OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —N(H)S(O)R, —N(H)S(O)₂R, —C(O)S(OR), —C(O)S(N(R)₂), —N(H)SC(O)CH₃, —P(O)(OR)₂, —C(O)N(H)R⁷⁰, —C(S)N(H)R⁷⁰, —NHC(O)R⁷⁰, —NHC(S)R⁷⁰, —NHC(O)NHR⁷⁰, —NHC(S)NHR⁷⁰, —NHC(S)N(H)NH₂, —N(H)C(S)SR⁸, or —C(S)N(H)N(H)C(O)NH₂, wherein

R⁸is -L²-G⁴, wherein

L²is —C₁-C₆alkyl- optionally substituted with one or more groups which are each independently —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl; and

or (iii) cyano, —N(R^N)₂, —NR^N(OH), —OR, —ONH₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —C(O)N(H)OH, —N(H)C(O)OR, —N(H)C(O)NH₂, —N(OH)C(O)R, or —P(O)(OR)₂; and

L¹⁰is a bond or L¹,

R⁵⁰is a group of the formula,

embedded image

wherein q is 0 or 1; r is 0, 1 or 2;

bonds d and e are independently a single or double bond;

each R⁶is independently hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, or phenyl;

each X is independently ═O, ═N(R^N), or ═S;

X¹and X²are both hydrogen or X¹and X²taken together form ═R^D; and each Y is independently —O—, —S—, or —N(R^N)—, and

R⁵⁰⁰is —N(R^N)C(NH)N(H)R⁵⁰¹, wherein R⁵⁰¹is hydrogen, —NH₂, or —C(NH)NH₂;

each R^Dis independently ═O, ═S, ═N(R^N), ═N(OR), ═N(NH₂), or ═N(CN); and

provided that

(i) one and only one G¹is present; and

(ii) the compound is not 2-amino-4-(2-aminophenyl)butanoic acid; and 2-amino-4-(2-amino-3-hydroxyphenyl)butanoic acid;

(iii) when G¹is —(CH₂)_1-3—N(H)C(S)S-L²-G⁴, then L²is not methylene; and

(iv) the compound is not of the formula,

embedded image

In an embodiment of the seventh aspect, the compound is according to formulae (VIIa) or (VIIb),

embedded image

and the remaining variables are as defined for formula (VII).

In another embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is —C(O)NH(R⁷⁰).

In another embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is —C(H)═NN(H)C(═R^D1)NH₂, wherein R^D1is ═O, ═N(OH), or ═N(H).

In another embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl- or —C₂-C₆alkenyl-, wherein the alkyl or alkenyl, or alkynyl group is optionally substituted with one —OR or —N(R^N)₂; and R⁵is cyano, —NH₂, —NH(OH), —OH, —ONH₂, —C(O)OR, —C(O)NH₂, —C(O)R, —C(NH)NH₂, —C(NOH)NH₂, —C(O)N(H)OH, —N(H)C(O)R⁷⁰, —N(H)C(O)OR, —N(H)C(O)NH₂, —OC(O)NH₂, —C(O)CF₃, —C(O)CH₃, —S(O)R, —S(O)₂R, —S(O)OR, —S(O)₂OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —N(H)S(O)R, —N(H)S(O)₂R, —N(H)SC(O)CH₃, —P(O)(OR)₂, —C(O)N(H)R⁷⁰, —C(S)N(H)R⁷⁰, —NHC(O)NHR⁷⁰, —NHC(S)NHR⁷⁰, or —N(H)C(S)SR⁸.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl- optionally substituted with one —OR or —N(R^N)₂; and R⁵is cyano, —NH₂, —NH(OH), —OH, —ONH₂, —C(O)OR, —C(O)NH₂, —C(O)R, —C(O)N(H)OH, —N(H)C(O)R⁷⁰, —C(O)CF₃, —C(O)N(H)R⁷⁰, —C(S)N(H)R⁷⁰, —NHC(O)NHR⁷⁰, or —NHC(S)NHR⁷⁰.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), R⁵is —ONH₂.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl- and R⁵is —ONH₂.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₃alkyl- and R⁵is —ONH₂and R⁴is halogen, nitro, —OR, or —CF₃.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₃alkyl- and R⁵is —ONH₂, R⁴is halogen, nitro, —OR, —CF₃and n=1, 2 or 3.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and R⁴is —C(H)(R^N)ONH₂.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and R⁴is —C(H)(R⁸)ONH₂.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl- optionally substituted with one —OR or —N(R^N)₂; and R⁵is —C(O)N(H)R⁷⁰or —C(S)N(H)R⁷⁰, wherein R⁷⁰is phenyl substituted with one or two groups which are each independently halogen, C₁-C₆alkyl, —COOH, —NH₂, —SH, or —OH.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl- optionally substituted with one —OR or —N(R^N)₂; and R⁵is —C(O)N(H)R⁷⁰or —C(S)N(H)R⁷⁰, wherein R⁷⁰is phenyl substituted with one or two groups which are each independently —NH₂, —SH, or —OH.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl-; and R⁵is —N(H)C(S)SR⁸.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl-; and R⁵is —N(H)C(S)SR⁸, wherein R⁸is -L²-G⁴, wherein L²is —C₁-C₆alkyl- optionally substituted with one or more groups which are each independently —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂; and G⁴is aryl or heteroaryl, each optionally substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl-; and R⁵is —N(H)C(S)SR⁸, wherein R⁸is -L²-G⁴, wherein L²is —C₁-C₆alkyl- optionally substituted with one or more groups which are each independently —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂; and G⁴is phenyl optionally substituted with one or more groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl-; and R⁵is —N(H)C(S)SR⁸, wherein R⁸is -L²-G⁴, wherein L²is —C₁-C₆alkyl- optionally substituted with one or more groups which are each independently —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂; and G⁴is phenyl substituted with one or two groups which are each independently halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, or C₁-C₆alkyl.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl-; and R⁵is —N(H)C(S)SR⁸, wherein R⁸is -L²-G⁴, wherein L²is —C₁-C₆alkyl- optionally substituted with one or more groups which are each independently —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂; and G⁴is a saturated or unsaturated heterocyclyl, each optionally substituted with one or more groups which are each independently ═R^D, halogen, —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —OC(O)R, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, heteroaryl, or heterocyclyl.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹-R⁵, wherein L¹is —C₁-C₆alkyl-; and R⁵is —N(H)C(S)SR⁸, wherein R⁸is -L²-G⁴, wherein L²is —C₁-C₆alkyl- optionally substituted with one or more groups which are each independently —OR, —N(R^N)₂, —C(O)OR, —C(O)N(R^N)₂; and G⁴is cyano, —N(R^N)₂, —NR^N(OH), —OR, —ONH₂, —C(O)OR, —C(O)N(R^N)₂, —C(O)R, —C(O)N(H)OH, —N(H)C(O)NH₂, or —P(O)(OR)₂.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -Q-L¹-R⁵, wherein Q is —C(O)—, —S(O)—, —S(O)₂—, —C(O)N(R^N)—, —C(O)O—, —C(O)S—, —OC(O)—, —N(R^N)C(O)—, —O—, —S—, —N(R^N)—, —CH(R)O—, —CH(R)S—, or —CH(R)N(R^N)—.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -Q-L¹-R⁵, wherein Q is —C(O)— or —S(O)₂—.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -Q-L¹-R⁵, wherein Q is —C(O)N(R^N)—.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -Q-L¹-R⁵, wherein Q is —O—, —S—, or —N(R^N)—.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -Q-L¹-R⁵, wherein Q is —CH(R)O—, —CH(R)S—, or —CH(R)N(R^N)—.

In another embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹⁰-R⁵⁰.

In an embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹⁰-R⁵⁰, wherein L¹⁰is a bond and R⁵⁰is a group of the formula,

embedded image

In another embodiment of the seventh aspect, the compound is according to formulae (VII), (VIIa) or (VIIb), and G¹is -L¹⁰-R⁵⁰, wherein L¹⁰is —C₁-C₆alkyl- and R⁵⁰is a group of the formula,

embedded image

In a eighth aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of Formula (VIII); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (VIII); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (VIII); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (VIII); (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (VIII); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (VIII),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

bond a is a single or double bond;

Y is ═O, ═S, or ═N(R¹⁰), wherein

R¹⁰is (i) hydrogen, hydroxyl, C₁-C₆alkoxy, amino, or cyano; or (ii) C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, phenyl, or benzyl, wherein each group is optionally substituted with one or more groups which are independently halogen, hydroxyl, C₁-C₆alkoxy, amino, carboxy, and carbamoyl; or (iii) formyl, —C(O)C₁-C₆alkyl, —C(O)OC₁-C₆alkyl, —C(O)N(H)C₁-C₆alkyl, or —S(O)₂C₁-C₆alkyl;

Z is —O—, —S—, or —N(R²⁰)—, wherein

R²⁰is hydrogen, C₁-C₆alkyl, —C(O)R, —C(O)OR, —C(O)N(R)₂, —S(O)R, or —S(O)₂R;

R¹is —C₁-C₆alkyl-COOR, or aryl optionally substituted with halogen;

R^1ais hydrogen, —COOR, or —C(O)N(R)₂;

R²is hydrogen, —C(O)R, or hydroxyl;

R³is hydrogen or hydroxyl; and

each R is independently hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl, or arylC₁-C₆alkyl, wherein each of group is optionally substituted with one or more groups which are independently halogen, hydroxyl, C₁-C₆alkoxy, amino, carboxy, and carbamoyl.

In an embodiment of the eighth aspect, the compound is according to formulae (VIIIa),

embedded image

and the remaining variables are as defined for formula (VIII).

In a ninth aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of Formula (IX); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (IX); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (IX); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (IX); (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (IX); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (IX),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

R is hydrogen or -L¹-R¹, wherein

R¹is hydrogen, cyano, nitro, —NH₂, —NH(OH), —OH, —ONH₂, —C(O)OR, —C(O)N(H)R, —C(S)N(H)R, —C(O)R, —C(═R^D)NH₂, —C(O)N(H)OH, —N(H)C(O)R, —N(H)C(S)R, —N(H)C(O)OR, —N(OH)C(O)R, —OC(O)NH₂, —C(O)CF₃, —C(O)CH₃, —S(O)R, —S(O)₂R, —S(O)OR, —S(O)₂OR, —S(O)N(R)₂, —S(O)₂N(R)₂, —N(H)S(O)R, —N(H)S(O)₂R, —P(O)(OR)₂, —NHC(O)NHR, —NHC(S)NHR, —SC(S)N(R)₂, or —N(R)C(S)SR,

each R^Dis independently ═O, ═S, ═N(R^N), ═N(OR), ═N(NH₂), or ═N(CN); and

In an tenth aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of Formula (Xa, Xb, or Xc); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (Xa, Xb, or Xc); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (Xa, Xb, or Xc); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of Formula (Xa, Xb, or Xc); (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (Xa, Xb, or Xc); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of Formula (Xa, Xb, or Xc),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

R¹is, when present, hydrogen or C₁-C₆alkyl, and

R is -L¹-R¹, wherein

R¹is hydrogen, cyano, nitro, —NH₂, —NH(OH), —OH, —ONH₂, —C(O)OR, —C(O)N(H)R, —C(S)N(H)R, —C(O)R, —C(═R^D)NH₂, —C(O)N(H)OH, —N(H)C(O)R, —N(H)C(S)R, —N(H)C(O)OR, —N(OH)C(O)R, —OC(O)NH₂, —C(O)CF₃, —C(O)CH₃, —S(O)R, —S(O)OR, —S(O)N(R)₂, —N(H)S(O)R, —S(O)₂R, —S(O)₂OR, —S(O)₂N(R)₂, —N(H)S(O)₂R, —P(O)(OR)₂, —NHC(O)NHR, —NHC(S)NHR, —SC(S)N(R)₂, or —N(R)C(S)SR,

each R^Dis independently ═O, ═S, ═N(R^N), ═N(OR), ═N(NH₂), or ═N(CN); and

In an eleventh aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount any compound listed in Tables 1-11; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of any compound listed in Tables 1-11; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of any compound listed in Tables 1-11; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and any compound listed in Tables 1-11; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of any compound listed in Tables 1-11; and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of any compound listed in Tables 1-11.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 1.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 2.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 3.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 4.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 5.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 6.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 7.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 8.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 9.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 10.

In an embodiment of the eleventh aspect, the compound is any one compound listed in Table 11.

TABLE 1

Cmpd #
Structure
Name

00001

embedded image

phenethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00002

embedded image

4-methoxyphenethyl 2-(1H- indol-3- yl)ethylcarbamodithioate

00003

embedded image

4-fluorophenethyl 2-(1H-indol- 3-yl)ethylcarbamodithioate

00004

embedded image

4-bromophenethyl 2-(1H-indol- 3-yl)ethylcarbamodithioate

00006

embedded image

2-phenylpropyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00007

embedded image

3-bromophenethyl 2-(1H-indol- 3-yl)ethylcarbamodithioate

00008

embedded image

3-chlorophenethyl 2-(1H-indol- 3-yl)ethylcarbamodithioate

00009

embedded image

4-methylphenethyl 2-(1H-indol- 3-yl)ethylcarbamodithioate

00010

embedded image

3-methoxyphenethyl 2-(1H- indol-3- yl)ethylcarbamodithioate

00012

embedded image

2-fluorophenethyl 2-(1H-indol- 3-yl)ethylcarbamodithioate

00020

embedded image

3-methylphenethyl 2-(1H-indol- 3-yl)ethylcarbamodithioate

00021

embedded image

2-chlorophenethyl 2-(1H-indol- 3-yl)ethylcarbamodithioate

00030

embedded image

2-(1H-indol-3-yl)ethyl 2-(1H- indol-3- yl)ethylcarbamodithioate

00047

embedded image

2-(3-methylnaphthalen-2- yl)ethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00053

embedded image

2-(2,3- dihydrobenzo[b][l,4]dioxin-6- yl)ethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00062

embedded image

naphthalen-2-ylmethyl 2-(2,3- dihydrobenzofuran-3- yl)ethylcarbamodithioate

00078

embedded image

3-((1H-indol-3-yl)methyl)-2- thioxothiazolidin-4-one

00080

embedded image

3-((1H-indol-3- yl)methyl)oxazolidine-2-thione

00239

embedded image

2-(benzo[b]thiophen-3-yl)acetic acid

00288

embedded image

2-(4-chloro-1H-indol-3- yl)acetamide

00293

embedded image

2-(indolin-7-yl)acetic acid

00307

embedded image

2-(benzo[b]thiophen-4-yl)acetic acid

00325

embedded image

3-(5-amino-1H-indol-3- yl)propanoic acid

00327

embedded image

3-(2-hydroxyethyl)-1H-indol-5- ol

00335

embedded image

2-hydroxy-2-(1H-indol-3- yl)acetic acid

0352

embedded image

5-amino-1H-indole-3- carboxylic acid

00386

embedded image

N-hydroxy-3-(1H-indol-3- yl)propanamide

00388

embedded image

N-hydroxy-2-(1H-indol-3- yl)acetamide

00390

embedded image

N-hydroxy-2-(9H-pyrido[3,4- b]indol-9-yl)acetamide

00391

embedded image

N-hydroxy-2-(8H- isothiazolo[5,4-b]indol-8- yl)acetamide

00392

embedded image

N-((8H-isothiazolo[5,4-b]indol- 8-yl)methyl)-N- hydroxyacetamide

00552

embedded image

1-(2(1H-indol-3-yl)ethyl)-3- hydroxy-2-methylpyridin- 4(1H)-one

00553

embedded image

1-(3-(1H-indol-3-yl)propyl)-3- hydroxy-2-methylpyridin- 4(1H)-one

00554

embedded image

1-((1H-indol-3-yl)methyl)-3- hydroxy-2-methylpyridin- 4(1H)-one

00555

embedded image

1-(2-(benzo[b]thiophcn-3- yl)ethyl)-3-hydroxy-2- methylpyridin-4(1H)-one

00562

embedded image

1-(2-(1H-indol-3-yl)ethyl)-3- hydroxypyridin-4(1H)-one

00563

embedded image

1-(3-(1H-indol-3-yl)propyl)-3- hydroxypyridin-4(1H)-one

00564

embedded image

1-((1H-indol-3-yl)methyl)-3- hydroxypyridin-4(1H)-one

00565

embedded image

1-(3-(1H-indol-3-yl)propyl)-3- (thiazol-2-yl)thiourea

00566

embedded image

5-(2-(1H-indol-3-yl)ethyl)-1- hydroxypyridin-2(1H)-one

00568

embedded image

1-((1H-indol-3-yl)methyl)-3- (thiazol-2-yl)thiourea

00571

embedded image

N-(3-(1H-indol-3-yl)propyl)-N- hydroxyacetamide

00577

embedded image

N-(3-(1H-indol-3-yl)propyl)-2- hydroxybenzothioamide

00588

embedded image

N-(2-aminophenyl)-4-(1H- indol-3-yl)butanamide

00589

embedded image

1-(1H-indol-3-yl)-2- (methylamino)ethanol

00590

embedded image

2-amino-1-(5-methoxy-1H- indol-3-yl)ethanol

00592

embedded image

N-(2-aminophenyl)-3-(1H- indol-3-yl)propanamide

00596

embedded image

N-((1H-indol-3- yl(methyl)benzothioamide

00601

embedded image

5-(2-(1H-indol-3- yl)ethylidene)pyrimidine- 2,4,6(1H,3H,5H)-trione

00603

embedded image

N-(2-(1H-indol-3-yl)ethyl)-N- hydroxyacetamide

00604

embedded image

1,1,1-trifluoro-5-(1H-indol-3- yl)pentan-2-one

00606

embedded image

2-(1H-indol-3-yl)ethanol

00611

embedded image

N-((1H-indol-3-yl)methyl)-N- hydroxyacetamide

00613

embedded image

6-(3-(1H-indol-3- yl)propyl)quinolin-8-ol

00630

embedded image

5-(3-(1H-indol-3- yl)propylidene)pyrimidine- 2,4,6(1H,3H,5H)-trione

00632

embedded image

N-(2-(benzo[b]thiophen-3- yl)ethyl)-2- hydroxybenzothioamide

00636

embedded image

1-(2-(benzo[b]thiophen-3- yl)ethyl)-3-hydroxypyridin- 4(1H)-one

00637

embedded image

1,1,1-trifluoro-4-(1H-indol-3- yl)butan-2-one

00644

embedded image

N-(2-(1H-indol-3-yl)ethyl)-2- hydroxybenzothioamide

00646

embedded image

N-((1H-indol-3-yl)methyl)-2- hydroxybenzothioamide

00655

embedded image

5-((1H-indol-3- yl)methyl)quinolin-8-ol

00660

embedded image

(E)-3-(1H-indol-3- yl)acrylimidamide

00667

embedded image

5-(2-(1H-indol-3- yl)ethylidene)-2- thioxodihydropyrimidine- 4,6(1H,5H)-dione

00672

embedded image

N-(2-(benzo[b]thiophen-3- yl)ethyl)-2- hydroxybenzothioamide

00673

embedded image

N-(3-(1H-indol-3- yl)propyl)benzothioamide

00695

embedded image

(E)-4-(1H-indol-3-yl)but-2- enimidamide

00717

embedded image

4-(indolin-1-yl)butan-2-one

00725

embedded image

1-(2-(1H-indol-3-yl)ethyl)-3- phenylthiourea

00729

embedded image

(E)-5-(1H-indol-3-yl)pent-2- enimidamide

00737

embedded image

3-(2,3-dioxoindolin-1- yl)propanoic acid

00739

embedded image

N-(2-aminophenyl)-3- (benzo[b]thiophen-3- yl)propanamide

00741

embedded image

(E)-3-(9H-pyrido[3,4-b]indol-9- yl)acrylimidamide

00745

embedded image

3-(5-methyl-1H-indol-3- yl)propan-1-amine

00749

embedded image

5-(3-(1H-indol-3- yl)propylidene)-2- thioxodihydropyrimidine- 4,6(1H,5H)-dione

00758

embedded image

2-(5-methoxy-1H-indol-3- yl)acetic acid

00764

embedded image

N-(2-(5-bromo-1H-indol-3- yl)ethyl)hydroxylamine

00789

embedded image

2-(5-methylbenzo[b]thiophen- 3-yl)acetic acid

00796

embedded image

2-(5-chlorobenzo[b]thiophen-3- yl)acetic acid

00813

embedded image

N-(2-(benzo[b]thiophen-3- yl)ethyl)-N-hydroxyacetamide

00819

embedded image

2-(1H-indol-1-yl)acetamide

00820

embedded image

2-(3-(hydroxymethyl)-1H- indol-1-yl)acetic acid

00840

embedded image

2-(5-bromo-1H-indol-3- yl)acetic acid

00843

embedded image

2-(5-bromo-1H-indol-3- yl)acetamide

00850

embedded image

(4S,5R)-3-((1H-indol-3- yl)methyl)-4-methyl-5- phenyloxazolidine-2-thione

00852

embedded image

2-(1-methyl-1H-indol-3- yl)acetic acid

00872

embedded image

4-(benzo[b]thiophen-3-yl)- 1,1,1-trifluorobutan-2-one

00882

embedded image

5-((1H-indol-3- yl)methylene)pyrimidine- 2,4,6(1H,3H,5H)-trione

00888

embedded image

5-(2-(1H-indol-3- yl)ethyl)quinolin-8-ol

00894

embedded image

2-(5-bromo-1H-indol-3- yl)ethanol

00898

embedded image

N-(2-aminophenyl)-2-(3- (thiazol-2-yl)-1H-indol-1- yl)acetamide

00924

embedded image

3-((1H-indol-3-yl)methyl)-4,5- dimethylthiazole-2(3H)-thione

00931

embedded image

N-(2-aminophenyl)-2-(8H- isothiazolo[5,4-b]indol-8- yl)acetamide

00940

embedded image

N-(1-(9H-pyrido[3,4-b]indol-9- yl)ethyl)-N-hydroxyacetamide

00949

embedded image

5-(2-(benzo[b]thiophen-3- yl)ethyl)quinolin-8-ol

00950

embedded image

N-(2-(benzo[b]thiophen-3- yl)ethyl)benzothioamide

00952

embedded image

(S)-3-((1H-indol-3-yl)methyl)- 4-isopropylthiazolidine-2- thione

00953

embedded image

2-(3-formyl-1H-indol-1- yl)acetamide

00957

embedded image

5-(2-(benzo[b]thiophen-3- yl)ethylidene)pyrimidine- 2,4,6(1H,3H,5H)-trione

00963

embedded image

(E)-3-(1H-indol-3- yl)acrylonitrile

00989

embedded image

5-(2-(benzo[b]thiophen-3- yl)ethylidene)-2- thioxodihydropyrimidine- 4,6(1H,5H)-dione

00998

embedded image

N-((8H-isothiazolo[5,4-b]indol- 8-yl)methyl)-2- hydroxybenzothioamide

01001

embedded image

2-(3-propionyl-1H-indol-1- yl)acetamide

01007

embedded image

1-(2-(benzo[b]thiophen-3- yl)ethyl)-3-(thiazol-2- yl)thiourea

01009

embedded image

1,1,1-trifluoro-3-(9H- pyrido[3,4-b]indol-9-yl)propan- 2-one

01015

embedded image

5-((1H-indol-3-yl)methylene)- 2-thioxodihydropyrimidine- 4,6(1H,5H)-dione

01017

embedded image

N-hydroxy-2-(3-(thiazol-2-yl)- 1H-indol-1-yl)acetamide

01027

embedded image

(E)-4-(benzo[b]thiophen-3- yl)but-2-enimidamide

01043

embedded image

1-(2-(benzo[b]thiophen-3- yl)ethyl)-3-phenylthiourea

01048

embedded image

1-((8H-isothiazolo[5,4-b]indol- 8-yl)methyl)-3-phenylthiourea

01060

embedded image

2-(6-cyano-1H-indol-1- yl)acetamide

01063

embedded image

1-(benzo[b]thiophen-3- ylmethyl)urea

01087

embedded image

N-((9H-pyrido[3,4-b]indol-9- yl)methyl)benzothioamidc

01091

embedded image

methyl 2-(1-methyl-1H-indol-3- yl)ethylcarbamodithioate

01094

embedded image

1-((9H-pyrido[3,4-b]indol-9- yl)methyl)-3-hydroxypyridin- 4(1H)-one

01114

embedded image

5-((3-(thiazol-2-yl)-1H-indol-1- yl)methyl)quinolin-8-ol

01119

embedded image

2-(3-cyano-1H-indol-1- yl)acetamide

01120

embedded image

1-((8H-isothiazolo[5,4-b]indol- 8-yl)methyl)-3-(thiazol-2- yl)thiourea

01125

embedded image

1-hydroxy-5-((3-(thiazol-2-yl)- 1H-indol-1-yl)methyl)pyridin- 2(1H)-one

01127

embedded image

N-(2-aminophenyl)-2-(9H- pyrido[3,4-b]indol-9- yl)acetamide

01128

embedded image

(E)-4-(benzo[b]thiophen-3- yl)but-2-enenitrile

01133

embedded image

N-((8H-isothiazolo[5,4-b]indol- 8-yl)methyl)benzothioamide

01135

embedded image

5-((8H-isothiazolo[5,4-b]indol- 8-yl)methyl)quinolin-8-ol

01143

embedded image

2-hydroxy-N-((3-(thiazol-2-yl)- 1H-indol-1- yl)methyl)benzothioamide

01153

embedded image

2-(3-formyl-2-methyl-1H-indol- 1-yl)acetamide

01165

embedded image

3-hydroxy-1-((3-(thiazol-2-yl)- 1H-indol-1-yl)methyl)pyridin- 4(1H)-one

01169

embedded image

(E)-3-(9H-pyrido[3,4-b]indol-9- yl)acrylonitrile

01183

embedded image

1-((8H-isothiazolo[5,4-b]indol- 8-yl)methyl)-3-hydroxypyridin- 4(1H)-one

01185

embedded image

(E)-3-(3-(thiazol-2-yl)-1H- indol-1-yl)acrylonitrile

01188

embedded image

N-hydroxy-N-((3-(thiazol-2-yl)- 1H-indol-1- yl)methyl)acetamide

01190

embedded image

4-((8H-isothiazolo[5,4-b]indol- 8-yl(methyl)-1-hydroxypyridin- 2(1H)-one

01200

embedded image

5-((9H-pyrido[3,4-b]indol-9- yl)methyl)-1-hydroxypyridin- 2(1H)-one

01206

embedded image

methyl 2-(1-(2-methoxyethyl)- 1H-indol-3- yl)ethylcarbamodithioate

01214

embedded image

methyl 2-(1-benzyl-1H-indol-3- yl)ethylcarbamodithioate

01219

embedded image

N-((3-(thiazol-2-yl)-1H-indol- 1-yl)methyl)benzothioamide

01228

embedded image

methyl 2-(1-isopropyl-1H- indol-3-yl)- ethylcarbamodithioate

01230

embedded image

5-((8H-isothiazolo[5,4-b]indol- 8-yl)methylene)pyrimidine- 2,4,6(1H,3H,5H)-trione

01232

embedded image

5-((3-(thiazol-2-yl)-1H-indol-1- yl)methylene)pyrimidine- 2,4,6(1H,3H,5H)-trione

01233

embedded image

(E)-3-(3-(thiazol-2-yl)-1H- indol-1-yl)acrylimidamide

01235

embedded image

(E)-3-(8H-isothiazolo[5,4- b]indol-8-yl)acrylimidamide

01238

embedded image

1,1,1-trifluoro-3-(3-(thiazol-2- yl)-1H-indol-1-yl)propan-2-one

01241

embedded image

5-((3-(thiazol-2-yl)-1H-indol-1- yl)methylene)-2- thioxodihydropyrimidine- 4,6(1H,5H)-dione

01244

embedded image

1,1,1-trifluoro-3-(8H- isothiazolo[5,4-b]indol-8- yl)propan-2-one

01246

embedded image

5-((2-((1Z,3Z)-penta-1,3- dienyl)-1H-pyrrolo[2,3- c]pyridin-1-yl)methyl)quinolin- 8-ol

01247

embedded image

1-(thiazol-2-yl)-3-((3-(thiazol- 2-yl)-1H-indol-1- yl)methyl)thiourea

01249

embedded image

(E)-3-(8H-isothiazolo[5,4- b]indol-8-yl)acrylonitrile

01254

embedded image

5-((8H-isothiazolo[5,4-b]indol- 8-yl)methylene)-2- thioxodihydropyrimidine- 4,6(1H,5H)-dione

01256

embedded image

methyl 2-(1-cyclopentyl-1H- indol-3-yl)- ethylcarbamodithioate

01258

embedded image

-((9H-pyrido[3,4-b]indol-9- yl)methyl)-3-(thiazol-2- yl)thiourea

01259

embedded image

1-((9H-pyrido[3,4-b]indol-9- yl)methyl)-3-phenylthiourea

01260

embedded image

(S)-2-amino-3-((2R,3R)-2- hydroperoxyindolin-3- yl)propanoic acid

01261

embedded image

(S)-2-amino-3-((2R,3S)-2- hydroperoxyindolin-3- yl)propanoic acid

01262

embedded image

(S)-2-amino-3-((2S,3R)-2- hydroperoxyindolin-3- yl)propanoic acid

01263

embedded image

(S)-2-amino-3-((2S,3S)-2- hydroperoxyindolin-3- yl)propanoic acid

01264

embedded image

(S)-2-amino-3-((2S,3S)-2- cyanoindolin-3-yl)propanoic acid

01265

embedded image

(S)-2-amino-3-((2R,3R)-2- cyanoindolin-3-yl)propanoic acid

01266

embedded image

(S)-2-amino-3-((2S,3R)-2- cyanoindolin-3-yl)propanoic acid

01267

embedded image

(S)-2-amino-3-((2R,3S)-2- cyanoindolin-3-yl)propanoic acid

01268

embedded image

(S)-2-amino-3-((R)-3- cyanoindolin-3-yl propanoic acid

01269

embedded image

(S)-2-amino-3-((S)-3- cyanoindolin-3-yl)propanoic acid

01270

embedded image

(S)-2-amino-3-((S)-3- hydroperoxyindolin-3- yl)propanoic acid

01271

embedded image

(S)-2-amino-3-((R)-3- hydroperoxyindolin-3- yl)propanoic acid

01274

embedded image

2-amino-3-(2- (hydroxymethyl)indolin-3- yl)propanoic acid

01275

embedded image

2-amino-3-(3- (hydroxymethyl)indolin-3- yl)propanoic acid

01277

embedded image

(2S)-2-amino-3-(2,3- dihydroxyindolin-3- yl)propanoic acid

01278

embedded image

(2S)-2-amino-3-(3-hydroxy-2- oxoindolin-3-yl)propanoic acid

01279

embedded image

2-amino-3-(2-(hydroxyamino)- 1H-indol-3-yl)propanoic acid

01280

embedded image

2-amino-3-(2-(hydroxyamino)- 1-methyl-1H-indol-3- yl)propanoic acid

01281

embedded image

2-amino-3-(2- (hydroxyamino)indolin-3- yl)propanoic acid

01282

embedded image

2-amino-3-(2-(hydroxyamino)- 1-methylindolin-3-yl)propanoic acid

01283

embedded image

(Z)-2-amino-3-(2- (hydroxyimino)indolin-3- yl)propanoic acid

01284

embedded image

(Z)-2-amino-3-(2- (hydroxyimino)-1- methylindolin-3-yl)propanoic acid

01285

embedded image

2-amino-3-(2-(aminooxy)-1H- indol-3-yl(propanoic acid

01286

embedded image

2-amino-3-(2-(aminooxy)-1- methyl-1H-indol-3- yl)propanoic acid

01287

embedded image

2-amino-3-(2- (aminooxy)indolin-3-yl)- propanoic acid

01288

embedded image

2-amino-3-(2-(aminooxy)-1- methylindolin-3-yl)propanoic acid

01291

embedded image

2-amino-3-(2- (methoxymethoxy)-1H-indol-3- yl)propanoic acid

01292

embedded image

2-amino-3-(2- (methoxymethoxy)-1-methyl- 1H-indol-3-yl)propanoic acid

01293

embedded image

N-hydroxy-3-(1H-indol-2- yl)propanamide

01294

embedded image

N-hydroxy-3-(indolin-2- yl)propanamide

01295

embedded image

N-(2-(1H-indol-2-yl)ethyl)-N- hydroxyacetamide

01296

embedded image

N-hydroxy-N-(2-(indolin-2- yl)ethyl)acetamide

01298

embedded image

methyl 3-(indolin-2-yl)propyl- carbamodithioate

01299

embedded image

N-hydroxy-3-(1H-indol-1- yl)propanamide

01300

embedded image

N-hydroxy-3-(indolin-1- yl)propanamide

01301

embedded image

N-(2-(1H-indol-1-yl)ethyl)-N- hydroxyacetamide

01302

embedded image

N-hydroxy-N-(2-(indolin-1- yl)ethyl)acetamide

01305

embedded image

3-(1H-indol-3- yl)propane(thioperoxoic)O- acid

01306

embedded image

SO-methyl 3-(1H-indol-3- yl)propane(thioperoxoate)

01307

embedded image

SO-2-(1H-indol-3-yl)ethyl ethane(thioperoxoate)

01308

embedded image

S-(3-(1H-indol-3- yl)propanoyl)- thiohydroxylamine

01309

embedded image

N-(2-(1H-indol-3-yl)ethyl)-S- acetylthiohydroxylamine

01310

embedded image

dimethyl 4-(1H-indol-3-yl)-2- oxobutylphosphonate

01361

embedded image

(S)-2-amino-3-((2R,3R)-2-(2- hydroxyethyl)indolin-3- yl)propanoic acid

01362

embedded image

(2S)-2-amino-3-((3S)-2,3- dihydroxyindolin-3- yl)propanoic acid

01364

embedded image

(S)-2-amino-3-((2R,3S)-2- (hydroxylmethyl)indolin-3- yl)propanoic acid

01367

embedded image

1-(2-(1H-indol-3-yl)ethyl)-5- hydroxy-2-methylpyridin- 4(1H)-one

01370

embedded image

(S)-2-amino-3-((S)-3- (hydroxylmethyl)indolin-3- yl)propanoic acid

01371

embedded image

(S)-2-amino-3-((2R,3R)-2- (hydroxylmethyl)indolin-3- yl)propanoic acid

01372

embedded image

(S)-2-amino-3-((2S,3R)-2- (hydroxylmethyl)indolin-3- yl)propanoic acid

01373

embedded image

(S)-2-amino-3-((2R,3S)-2-(2- hydroxyethyl)indolin-3- yl)propanoic acid

01374

embedded image

(S)-2-amino-3-((2S,3S)-2- (hydroxylmethyl)indolin-3- yl)propanoic acid

01375

embedded image

(S)-2-amino-3-((2S,3R)-2-(2- hydroxyethyl)indolin-3- yl)propanoic acid

01376

embedded image

(S)-2-amino-3-((2S,3S)-2-(2- hydroxyethyl)indolin-3- yl)propanoic acid

01378

embedded image

(S)-2-amino-3-((S)-3-(2- hydroxyethyl)indolin-3- yl)propanoic acid

01379

embedded image

(S)-2-amino-3-((R)3-(2- hydroxyethyl)indolin-3- yl)propanoic acid

01382

embedded image

(S)-2-amino-3-((S)-3-hydroxy- 2-oxoindolin-3-yl)propanoic acid

01383

embedded image

(S)-2-amino-3-((R)3-hydroxy- 2-oxoindolin-3-yl)propanoic acid

01387

embedded image

1-(3-(1H-indol-3-yl)propyl)-5- hydroxy-2-methylpyridin- 4(1H)-one

01391

embedded image

2-amino-3-(1H-indol-2- yl)propanoic acid

01392

embedded image

naphthalen-2-ylmethyl (2,3- dihydrobenzofuran-3- yl)methylcarbamodithioate

01403

embedded image

2-amino-3-(indolin-2- yl)propanoic acid

01418

embedded image

2-amino-3-(3-(hydroxymethyl)- 1-methylindolin-3-yl)propanoic acid

01419

embedded image

2-amino-3-(3-(hydroxymethyl)- 3H-indol-3-yl)propanoic acid

01424

embedded image

2-(7-methyl-2-oxo-2H- chromcn-3-yl)ethyl 2-(1H- indol-3- yl)ethylcarbamodithioate

01438

embedded image

2-amino-3-(1-hydroxy-2- oxoindolin-3-yl)propanoic acid

01443

embedded image

1-((1H-indol-3-yl)methyl)-5- hydroxy-2-methylpyridin- 4(1H)-one

01444

embedded image

2-amino-3-(1H-indol-1- yl)propanoic acid

01445

embedded image

2-amino-3-(indolin-1- yl)propanoic acid

01446

embedded image

methyl 3-(1H-indol-1- yl)propylcarbamodithioate

01447

embedded image

methyl 3-(indolin-1-yl)propyl- carbamodithioate

TABLE 2

Cmpd #
Structure
Name

00523

embedded image

ethyl 1,1-dimethyl-2,3,4,9- tetrahydro-1H-pyrido[3,4- b]indole-3-carboxylate

00525

embedded image

1-(pentan-3-yl)-2,3,4,9- tetrahydro-1H-pyrido[3,4- b]indole-3-carboxylic acid

00526

embedded image

3-methyl-2,3,4,9-tetrahydro- 1H-pyrido[3,4-b]indole-3- carboxylic acid

00527

embedded image

(S)-methyl 2,3,4,9- tetrahydro-1H-pyrido[3,4- b]indole-3-carboxylate

00528

embedded image

(S)-ethyl 2,3,4,9-tetrahydro- 1H-pyrido[3,4-b]indole-3- carboxylate

00530

embedded image

(S)-1-methyl-4,9-dihydro- 3H-pyrido[3,4-b]indole-3- carboxylic acid

00531

embedded image

(1R,3R)-methyl 1- (benzo[d][1,3]dioxol-5-yl)- 2,3,4,9-tetrahydro-1H- pyrido[3,4-b]indole-3- carboxylate

00532

embedded image

methyl 1-p-tolyl-2,3,4,9- tetrahydro-1H-pyrido[3,4- b]indole-3-carboxylate

00533

embedded image

1-(3- (trifluoromethyl)phenyl)- 2,3,4,9-tetrahydro-1H- pyrido[3,4-b]indole-3- carboxylic acid

00535

embedded image

1-(2-bromo-5-(pyridin-2- ylmethoxy)phenyl)-2,3,4,9- tetrahydro-1H-pyrido[3,4- b]indole-3-carboxylic acid

00539

embedded image

3,4-dihydropyrano[3,4- b]indol-1(9H)-one

00541

embedded image

l-methyl-4,9-dihydro-3H- pyrido[3,4-b]indol-6-ol

00545

embedded image

1-(3,4-dimethoxyphenyl)-6- methoxy-2,3,4,9-tetrahydro- 1H-pyrido[3,4-b]indole

00546

embedded image

1-phenyl-4,9-dihydro-3H- pyrido[3,4-b]indole

00549

embedded image

3-allyl-2- mercaptobenzofuro[3,2- d]pyrimidin-4(3H)-one

00550

embedded image

2-(4-oxobenzofuro[3,2- d]pyrimidin-3(4H)-yl)acetic acid

01272

embedded image

2-amino-3-(2,2a,3,7b- tetrahydrooxeto[3,2-b]indol- 7b-yl)propanoic acid

01273

embedded image

2-amino-3-(2,2a,7,7a- tetrahydrooxeto[2,3-b]indol- 2a-yl)propanoic acid

01276

embedded image

3a,8a-dihydroxy- 1,2,3,3a,8,8a- hexahydropyrrolo[2,3- b]indole-2-carboxylic acid

01289

embedded image

2,3,4,9-tetrahydro- [1,2]oxazino[6,5-b]indole-3- carboxylic acid

01290

embedded image

9-methyl-2,3,4,9-tetrahydro- [1,2]oxazino[6,5-b]indole-3- carboxylic acid

01311

embedded image

dimethyl 2-oxo-2,3,4,9- tetrahydro-1H-carbazol-1- ylphosphonate

01365

embedded image

(2S)-2-amino-3-((7bS)-3,7b- dihydro-2aH- [1,2]dioxeto[3,4-b]indol-7b- yl)propanoic acid

01366

embedded image

3,3a,8,8a-tetrahydro-2H- furo[2,3-b]indole

01368

embedded image

(S)-2-amino-3-((3aR,8bS)- 3,3a,4,8b-tetrahydro-1H- furo[3,4-b]indol-8b- yl)propanoic acid

01369

embedded image

(S)-2-amino-3-((3aS,8aS)- 3,3a,8,8a-tetrahydro-2H- furo[2,3-b]indol-3a- yl)propanoic acid

01380

embedded image

(S)-2-amino-3-((3aS,8bS)- 4,8b-dihydro-3aH- [1,3]dioxolo[4,5-b]indol-8b- yl)propanoic acid

01381

embedded image

(2S,3aR,8aS)-3a,8a- dihydroxy-1,2,3,3a,8,8a- hexahydropyrrolo[2,3- b]indole-2-carboxylic acid

01385

embedded image

(2S,3aS,8aR)-3a,8a- dihydroxy-1,2,3,3a,8,8a- hexahydropyrrolo[2,3- b]indole-2-carboxylic acid

01388

embedded image

sodium 2-oxo-1,2- dihydrobenzofuro[2,3-d]- pyrimidin-4-olate

01390

embedded image

(2S)-2-amino-2- (2,3,4,4a,9,9a- hexahydropyrano[2,3- b]indol-4-yl)acetic acid

01410

embedded image

3,3a,8,8a-tetrahydro-2H- furo[2,3-b]indol-2-one

01413

embedded image

(2S)-2-amino-2-(3,3a,8,8a- tetrahydro-2H-furo[2,3- b]indol-3-yl)acetic acid

01425

embedded image

(2S)-2-amino-2-((3aR,8aS)- 3a-hydroxy-3,3a,8,8a- tetrahydro-2H-furo[2,3- b]indol-3-yl)acetic acid

01427

embedded image

(2S)-2-amino-2-((4aR,9aS)- 4a-hydroxy-2,3,3,4a,9,9a- hexahydropyrano[2,3- b]indol-4-yl)acetic acid

01429

embedded image

6-methoxy-4,9-dihydro-1H- pyrido[3,4-b]indol-3(2H)- one

01430

embedded image

(2R)-2-amino-2- (l,3,4,4a,5,9b- hexahydrothiopyrano[4,3- b]indol-1-yl)acetic acid

01431

embedded image

6-methoxy-4,9-dihydro-1H- pyrido[3,4-b]indol-3(2H)- one

01432

embedded image

4,9-dihydro-1H-pyrido[3,4- b]indole-1,3(2H)-dione

01433

embedded image

pyrano[3,4-b]indole- 1,3(4H,9H)-dione

01434

embedded image

(3S)-3-amino-3,3a,8,8a- tetrahydro-2H-furo[2,3- b]indol-2-one

01448

embedded image

(S)-2-amino-3-((3aS,8bS)- 3,3a,4,8b-tetrahydro-2H- furo[3,2-b]indol-8b- yl)propanoic acid

01449

embedded image

2,3,4,4a,5,9b- hexahydropyrano[3,2- b]indole

01458

embedded image

(S)-2-amino-3-((2aS,7bS)- 2,2a,3,7b- tetrahydrooxeto[3,2-b]indol- 7b-yl)propanoic acid

01459

embedded image

2,3,4,4a,9,9a- hexahydropyrano[2,3- b]indole

01460

embedded image

(2S)-2-amino-2- (1,3,4,4a,5,9b- hexahydropyrano[4,3- b]indol-1-yl)acctic acid

01461

embedded image

1,3,4,4a,5,9b- hexahydropyrano[4,3- b]indole

01470

embedded image

2,3,4,9-tetrahydro-1H- pyrido[3,4-b]indol-1-one

01479

embedded image

(S)-2-amino-3-((2aR,7aS)- 2,2a,7,7a- tetrahydrooxeto[2,3-b]indol- 2a-yl)propanoic acid

01490

embedded image

1,3,4,4a,5,9b- hexahydrothiopyrano[4,3- b]indole

TABLE 3

Cmpd #
Structure
Name

01363

embedded image

(2S,4S)-4-amino-3H- spiro[furan-2,3′-indoline]- 2′,5(4H)-dione

01377

embedded image

(2R,4S)-4-amino-3H- spiro[furan-2,3′-indoline]- 2′,5(4H)-dione

01402

embedded image

4,5-dihydro-2H-spiro[furan- 3,3′-indole]-5-carboxylic acid

01414

embedded image

1′-hydroxyspiro[indole-3,3′- pyrrolidine]-5′-carboxylic acid

01417

embedded image

4′,5′-dihydro-2′H- spiro[indole-3,3′-thiophene]- 5′-carboxylic acid

01439

embedded image

(S)-2′-thioxospiro[indoline- 3,5′-oxazolidin]-2-one

01451

embedded image

(S)-2′-thioxospiro[indoline- 3,5′-thiazolidin]-2-one

01452

embedded image

1′-hydroxyspiro[indoline- 3,3′-pyrrolidine]-5′- carboxylic acid

01455

embedded image

spiro[indoline-3,3′- pyrrolidin]-2-one

01456

embedded image

4,5-dihydro-2H-spiro[furan- 3,3′-indolin]-2′-one

01457

embedded image

spiro[indoline-3,2′-oxiran]- 2-one

01462

embedded image

3H-spiro[furan-2,3′- indoline]

01463

embedded image

1″,2″- dihydrodispiro[cyclopentane- 1,2′-oxirane-3′,3″-indole]

01464

embedded image

(S)-spiro[indoline-3,5′- oxazolidine]-2,2′-dione

01471

embedded image

l-methyl-4′,5′-dihydro-2′H- spiro[indoline-3,3′- thiophene]-5′-carboxylic acid

01472

embedded image

1′-methyl-4,5-dihydro-2H- spiro[furan-3,3′-indoline]-5- carboxylic acid

01473

embedded image

1,1′-dimethylspiro[indoline- 3,3′-pyrrolidine]-5′- carboxylic acid

01474

embedded image

1′-hydroxy-1- methylspiro[indoline-3,3′- pyrrolidine]-5′-carboxylic acid

01475

embedded image

4′,5′-dihydro-2′H- spiro[indoline-3,3′- thiophene]-5′-carboxylic acid

01476

embedded image

4,5-dihydro-2H-spiro[furan- 3,3′-indoline]-5-carboxylic acid

01489

embedded image

1′-methylspiro[indole-3,3′- pyrrolidine]-5′-carboxylic acid

01491

embedded image

1′-methylspiro[indoline-3,3′- pyrrolidine]-5′-carboxylic acid

TABLE 4

Cmpd #
Structure
Name

00218

embedded image

4,5-bis (2-hydroxyethylthio)- 1,3-dithiol-2-one

00738

embedded image

3-(3-methyl-2-oxo-2,3- dihydro-1H- benzo[d]imidazol-1- yl)propanoic acid

01069

embedded image

4,5-dihydroxy-1,3- bis(hydroxylmethyl)- imidazolidin-2-one

01110

embedded image

4,5-dihydroxy-1,3- bis(methoxymethyl)- imidazolidin-2-one

01129

embedded image

4,5-bis (2-aminoethylthio)- 1,3-dithiole-2-thione

01160

embedded image

4-hydroxy-1,3- bis(hydroxymethyl) -5- methoxyimidazolidin- 2-one

01181

embedded image

1-ethyl-3-propyl-1H- benzo[d]imidazol- 2(3H)- imine

01192

embedded image

3,3′-(2-oxo- 1,3-dithiole-4,5- diyl)bis- (sulfanediyl) dipropanenitrile

01202

embedded image

1-tert-butyl- 4,5-dihydroxy- 3-methylimidazolidin- 2-one

01222

embedded image

4,5-dihydroxy-1- (hydroxymethyl)-3- (methoxymethyl) imidazolidin- 2-one

01237

embedded image

4,6-diethyldihydro- 3aH- [1,3]dioxolo [4,5-d]imidazol- 5(4H)-one

01242

embedded image

6-hydroxy-6,7- dihydro-5H- [1,3]dithiolo[4,5- b][1,4]dithiepin- 2-one

01245

embedded image

6,7-dihydro-5H- [1,3]dithiolo[4,5-b] [1,4]dithiepin-2-one

01251

embedded image

5,6,7,8-tetrahydro- [1,3]dithiolo[4,5- b][1,4]dithiocine- 2-thione

01252

embedded image

5,6-dihydro- [1,3]dithiolo[4,5- b][1,4]dithiin-2-one

01420

embedded image

1-butyl-3- hydroxy-1H- benzo[d]imidazol- 2(3H)-one

01421

embedded image

1-hydroxy-3- methyl-1H- benzo[d]imidazol- 2(3H)-one

01422

embedded image

1,3-dihydroxy- 1H- benzo[d]imidazol- 2(3H)-one

TABLE 5

Cmpd #
Structure
Name

00157

embedded image

(E)-5-(thiophen-2- ylmethylene)-2- thioxoimidazolidin-4-one

00209

embedded image

2-(3,5-dimethyl-4-nitro-1H- pyrazol-1-yl)acetamide

00214

embedded image

N-benzyl-3-nitro-1H- pyrazole-5-carboxamide

00217

embedded image

(2-(allylthio)-1-(3- fluorobenzyl)-1H-imidazol- 5-yl)methanol

00219

embedded image

(E)-2-(1-(thiophen-2- yl)ethylideneaminooxy) acetamide

00224

embedded image

(1,3-dimethyl-1H- thieno[2,3-c]pyrazol-5- yl)methanol

00225

embedded image

2-(1H- benzo[d][1,2,3]triazol-1- yl)acetamide

00233

embedded image

2-(thiophen-2- ylsulfonyl)acetamide

00240

embedded image

2-(2-hydroxy-1H- benzo[d]imidazol-1-yl)- acetamide

00268

embedded image

3-(2-amino-2- oxoethyl)benzo[d]thiazol-3- ium chloride

00379

embedded image

3,3′-bithiophene-4,4′- diyldimethanol

00593

embedded image

2-(2-phenylthiophen-3- yl)acetic acid

00599

embedded image

3-amino-3-(5- methylthiophen-2- yl)propanoic acid

00602

embedded image

3-amino-3-(5-methylfuran- 2-yl)propanoic acid

00621

embedded image

4-amino-3-(5- chlorothiophen-2- yl)butanoic acid

00649

embedded image

N-(2-mercaptophenyl)furan- 2-carboxamide

00650

embedded image

3-(thiophen-2-yl)propanoic acid

00668

embedded image

2-(2-(allylthio)-1H- benzo[d]imidazol-1- yl)acetic acid

00671

embedded image

N-(2-amino-5- methoxyphenyl)furan-2- carboxamide

00697

embedded image

2-(1H- benzo[d][1,2,3]triazol-1-yl)- 2-hydroxyacetic acid

00722

embedded image

N-(5-methoxy-2- methylphenyl)thiophene-2- carboxamide

00753

embedded image

3-(1-methyl-1H-pyrazole-5- carboxamido)propanoic acid

00761

embedded image

N-(5-chloro-2- methylphenyl)thiophene-2- carboxamide

00781

embedded image

2-(1-benzyl-1H-imidazol-2- ylthio)acetic acid

00791

embedded image

2-hydroxy-N- ((4-phenyl-1H-imidazol-1- yl)methyl)benzothioamide

00828

embedded image

(1-pentyl-1H- benzo[d]imidazol-2- yl)methanol

00835

embedded image

2-(thiophen-2- ylthio)acetamide

00836

embedded image

3-nitro-N-(pyridin-2-yl)-1H- pyrazole-5-carboxamide

00855

embedded image

2-(2-methyl-4,5,6,7- tetrahydro-2H-indazol-3- yl)acetic acid

00857

embedded image

2-(2-methyl-4-nitro-1H- imidazol-1-yl)acetamide

00861

embedded image

methyl 3-amino-3- (thiophen-2-yl)propanoate

00867

embedded image

N-(3-methylpyridin-4- yl)thiophene-2-carboxamide

00868

embedded image

2-(thieno[2,3-d]pyrimidin-4- ylamino)ethanol

00870

embedded image

5-((4-phenyl-1H-imidazol- l-yl)methyl)quinolin-8-ol

00874

embedded image

2-(2-(hydroxymethyl)-1H- benzo[d]imidazol-1- yl)ethanol

00883

embedded image

N-(2-aminophenyl)-4- phenyl-1H-imidazole-1- carboxamide

00887

embedded image

1,2-diamino-3-(2- hydroxyethyl)-1H- benzo[d]imidazol-3-ium chloride

00891

embedded image

(1-isobutyl-1H- benzo[d]imidazol-2-yl)- methanol

00892

embedded image

2-(5-methyl-3-nitro-1H- pyrazol-1-yl)acetamide

00897

embedded image

5-nitro-N-(pyridin-2- yl)furan-2-carboxamide

00906

embedded image

1-(1-(2-methylallyl)-1H- benzo[d]imidazol-2- yl)ethanol

00910

embedded image

1-(1-methyl-1H- benzo[d]imidazol-2- yl)ethanamine

00913

embedded image

3-(3,5-dimethyl-4-nitro-1H- pyrazol-1-yl)propanoic acid

00916

embedded image

6-(2-hydroxyethylamino)-1- methyl-1H-pyrazolo[3,4- d]pyrimidin-4(5H)-one

00918

embedded image

(E)-2-(1-(thiophen-2- yl)ethylideneaminooxy)acetic acid

00921

embedded image

2-(5-methyl-4-nitro-1H- pyrazol-1-yl)acetic acid

00927

embedded image

(1-(2-methylallyl)-1H- benzo[d]imidazol-2- yl)methanol

00930

embedded image

(1-(2-ethoxyethyl)-1H- benzo[d]imidazol-2- yI)methanol

00944

embedded image

2-(6-amino-9H-purin-9- yl)ethanol

00959

embedded image

3-(1-benzyl-1H-imidazol-2- ylthio)propanenitrile

00961

embedded image

(1-allyl-1H- benzo[d]imidazol-2-yl)- methanol

00965

embedded image

(1-propyl-1H- benzo[d]imidazol-2-yl)- methanol

00977

embedded image

2-(5-amino-2- (hydroxymethyl)-1H-benzo- [d]imidazol-1-yl)ethanol

00979

embedded image

1-(1-allyl-1H- benzo[d]imidazol-2-yl)- ethanol

00981

embedded image

2-(2-propyl-1H- benzo[d]imidazol-1-yl)- acetamide

00999

embedded image

2-(2-methyl-1H- benzo[d]imidazol-1-yl)- ethanol

01004

embedded image

(E)-3-(4-phenyl-1H- imidazol-1-yl)acrylonitrile

01008

embedded image

N-((4-phenyl-1H-imidazol- 1-yl )methyl)benzothioamide

01012

embedded image

(1-(prop-2-ynyl)-1H- benzo[d]imidazol-2- yl)methanol

01018

embedded image

2-(1-propyl-1H- benzo[d]imidazol-2-yl)- acetic acid

01021

embedded image

2-(1H-benzo[d]imidazol-1- yl)ethanol

01034

embedded image

2-(5-methyl-3,4-dinitro-1H- pyrazol-1-yl)acetic acid

01045

embedded image

5-((4-phenyl-1H-imidazol- 1-yl)methylene)pyrimidine- 2,4,6(1H,3H,5H)-trione

01057

embedded image

2-(3-(difluoromethyl)-5- methyl-4-nitro-1H-pyrazol- 1-yl)acetic acid

01064

embedded image

N-(5-methylisoxazol-3- yl)thiophene-2-carboxamide

01071

embedded image

2-(1H-benzo[d]imidazol-1- yl)acetamide

01078

embedded image

2-(2-(methylamino)-1H- benzo[d]imidazol-1- yl)ethanol

01115

embedded image

2-(methyl(7- methylthieno[3,2- d]pyrimidin-4- yl)amino)ethanol

01124

embedded image

2-(ethyl(1-methyl-1H- pyrazolo[3,4-d]pyrimidin-4- yl)amino)ethanol

01142

embedded image

5-((4-phenyl-1H-imidazol- 1-yl)methylene)-2- thioxodihydropyrimidine- 4,6(1H,5H)-dione

01146

embedded image

2-(1H-imidazol-5-yl)ethyl carbamimidothioate

01147

embedded image

2-(4-chloro-5-methyl-3- nitro-1H-pyrazol-1- yl)acetamide

01159

embedded image

1 -phenyl-3-((4-phenyl-1H- imidazol-1- yl)methyl)thiourea

01171

embedded image

9-(2-hydroxyethyl)-3H- purine-6(9H)-thione

01173

embedded image

1-((4-phenyl-1H-imidazol- 1-yl)methyl)-3-(thiazol-2- yl)thiourea

01179

embedded image

2-(4-cyano-5-methyl-3- nitro-1H-pyrazol-1- yl)acetamide

01191

embedded image

(1-methyl-3- (trifluoromethyl)-1H-thieno- [2,3-c]pyrazol-5- yl)methanol

01205

embedded image

2-(4-acetyl-5-methyl-1H- 1,2,3-triazol-1-yl)acetamide

01225

embedded image

2-(4-bromo-5-methyl-3- nitro-1H-pyrazol-1- yl)acetamide

01234

embedded image

(2,2′-dibromo-3,3′- bithiophene-4,4′-diyl)- dimethanol

01255

embedded image

3-(carboxymethyl)-2,4- dimethylbenzo[d]thiazol-3- ium chloride

01440

embedded image

N-hydroxy-4-(4,5,6,7- tetrahydro-1H-indol-3- yl)butanamide

01442

embedded image

N-hydroxy-N-(3-(4,5,6,7- tetrahydro-1H-indol-3- yl)propyl)acetamide

TABLE 6

Cmpd #
Structure
Name

00155

embedded image

(E)-5-((4,6- dimethylpyrimidin-2- ylamino)methylene)-2- thioxoimidazolidin-4-one

00220

embedded image

2-(quinazolin-4- ylthio)acetamide

00662

embedded image

2-(quinolin-4- ylamino)acetic acid

00678

embedded image

N-(3-hydroxyphenyl) nicotinamide

00687

embedded image

5-oxo-5-(pyridin-3- ylamino)pentanoic acid

00699

embedded image

3-(nicotinamido)propanoic acid

00732

embedded image

3-(2-chloronicotinamido) propanoic acid

00766

embedded image

N-(2-hydroxyphenyl) nicotinamide

00767

embedded image

N-(5-amino-2- methylphenyl)nicotinamide

00772

embedded image

2-(quinolin-2-yl)ethanol

00787

embedded image

2-(quinazolin-4- ylamino)ethanol

00809

embedded image

N-(2-chloropyridin-3- yl)isonicotinamide

00834

embedded image

N-(6-methylpyridin-2- yl)nicotinamide

00902

embedded image

N-(2,5- dichlorophenyl)isonicotinamide

00929

embedded image

(R)-1-(2-amino-4- methylquinolin-3-yl)ethanol

00955

embedded image

1-(quinazolin-4- ylthio)propan-2-one

00960

embedded image

2-(4-nitropyridin-3- ylamino)ethanol

00967

embedded image

4-(hydroxymethyl)quinolin-3-ol

01011

embedded image

2-(quinazolin-4- yloxy)acetamide

01016

embedded image

1-(2-amino-2- oxoethyl)quinolinium chloride

01066

embedded image

N-(4H-1,2,4-triazol-4- yl)isonicotinamide

01089

embedded image

2-chloro-N-(4H-1,2,4- triazol-4-yl)nicotinamide

01141

embedded image

5-(pyridin-4- ylmethyl)thiazolidine- 2,4-dione

01199

embedded image

3-amino-1-(2-amino-2- oxoethyl)quinolinium chloride

TABLE 7

Cmpd #
Structure
Name

00077

embedded image

3-benzyl-1,3-thiazinane-2- thione

00079

embedded image

3-benzyl-2- thioxothiazolidin-4-one

00081

embedded image

3-benzyloxazolidine-2- thione

00138

embedded image

2-amino-3- (benzylcarbamothioylthio)- propanoic acid

00140

embedded image

2-amino-3-(3-phenylpropyl- carbamo- thioylthio)propanoic acid

00148

embedded image

(Z)-5-(benzo[d][1,3]dioxol- 5-ylmethylene)-2- thioxothiazolidin-4-one

00150

embedded image

(Z)-5-(4- (dimethylamino)benzylidene)- 2-thioxo-1,3-thiazinan-4- one

00154

embedded image

(E)-5-((4-oxo-4H-chromen- 3-yl)methylene)-2- thioxoimidazolidin-4-one

00221

embedded image

5-(4-fluorobenzyl)-2- iminothiazolidin-4-one

00261

embedded image

3-(2,5- dimethylphenyl)butanoic acid

00262

embedded image

5-(4- hydroxybenzyl)imidazolidine- 2,4-dione

00282

embedded image

3-(3-nitrophenyl)butanoic acid

00291

embedded image

2-(2-methyl-1-oxo-1,2- dihydroisoquinolin-4- yl)acetic acid

00292

embedded image

2-(4-hydroxy-3- methoxyphenyl)- acetimidamide

00313

embedded image

3-(4-fluorophenyl)-3- oxopropanoic acid

00317

embedded image

O-(3- nitrobenzyl)hydroxylamine

00346

embedded image

2-(6- propylbenzo[d][1,3]dioxol- 5-yl)acetic acid

00360

embedded image

N-(3,4-dichlorophenyl)-3- hydroxypropanamide

00389

embedded image

1-hydroxy-4- phenethylpyridin-2(1H)-one

00394

embedded image

2-(4-iminoquinolin-1(4H)- yl)acetamide

00567

embedded image

3-amino-3-(naphthalen-1- yl)propanoic acid

00572

embedded image

(Z)-2-(3- hydroxybenzylidene)- hydrazinecarboximidamide

00587

embedded image

(Z)-2-(4-hydroxy-3- methoxybenzylidene)- hydrazinecarboximidamide 2-(2-(1H-pyrrol-1- yl)phenyl)acetate

00591

embedded image

1-(naphthalen-2-ylmethyl)- 3-(thiazol-2-yl)thiourea

00607

embedded image

2-hydroxy-N-(naphthalen-2- ylmethyl)benzothioamide

00616

embedded image

(E)-2-(2-hydroxy-5- nitrobenzylidene)- hydrazinecarboximidamide

00620

embedded image

1-(benzhydryloxy)guanidine

00627

embedded image

4-fluoro-N-(2- mercaptophenyl)benzamide

00634

embedded image

2-hydroxy-N- phenethylbenzothioamide

00656

embedded image

N-benzyl-2- hydroxybenzothioamide

00657

embedded image

1-(naphthalen-2-ylmethyl)- 3-phenylthiourea

00664

embedded image

5-benzylquinolin-8-ol

00665

embedded image

(Z)-2-(4-hydroxy-3- iodobenzylidene)- hydrazinecarboximidamide

00683

embedded image

3-(4- fluorobenzamido)propanoic acid

00686

embedded image

N-(5-methoxy-2- methylphenyl)benzamide

00688

embedded image

1-phenethyl-3-(thiazol-2- yl)thiourea

00689

embedded image

5-oxo-5-phenylpentanoic acid

00691

embedded image

3-(2,4- difluorophenoxy)propanoic acid

00698

embedded image

5-benzyl-1-hydroxypyridin- 2(1H)-one

00711

embedded image

3-(2,5- dimethoxyphenylamino) propanoic acid

00720

embedded image

3-(2- chlorobenzamido)propanoic acid

00721

embedded image

2-(benzoylthio)acetic acid

00724

embedded image

4-amino-3-(3,4- dihydroxyphenyl)butanoic acid

00744

embedded image

(E)-2-(2-hydroxy-3- nitrobenzylidene) hydrazinecarboxamide

00748

embedded image

(1E,2E)-N′-hydroxy-2-(3- nitro-benzylidene) hydrazinecarboximidamide

00752

embedded image

3-(2,3- dihydrobenzo[b][1,4]dioxin- 6-yloxy)propanoic acid

00755

embedded image

2-amino-1- (benzo[d][1,3]dioxol-5-yl)- ethanol

00760

embedded image

O-(4- carboxybenzyl)hydroxylamine

00762

embedded image

O-(3- fluorobenzyl)hydroxylamine

00773

embedded image

3-(4- chlorophenoxy)propanoic acid

00774

embedded image

O-(4- fluorobenzyl)hydroxylamine

00775

embedded image

2-(2- carbamoylphenoxy)acetic acid

00778

embedded image

2-amino-1-(4- methoxyphenyl)ethanol

00786

embedded image

3-(naphthalen-2- ylmethyl)oxazolidine-2- thione

00788

embedded image

3-amino-N-(4- methylpyridin-2-yl)- benzamide

00801

embedded image

(E)-N′-hydroxy-2-(2- phenoxyphenyl)- acetimidamide

00808

embedded image

2-amino-1-(2-chloro-3,4- dimethoxyphenyl)ethanol

00810

embedded image

N-(5-amino-2- chlorophenyl)benzamide

00811

embedded image

O-(2- nitrobenzyl)hydroxylamine

00827

embedded image

N-hydroxy-2-(naphthalen-2- yl)acetamide

00830

embedded image

3-(naphthalen-2-ylmethyl)- 2-thioxothiazolidin-4-one

00848

embedded image

N-(2,5- dimethylphenyl) hydrazinecarboximidamide

00849

embedded image

2-(2,5- dimethoxyphenyl)acetimidamide

00862

embedded image

N-benzyl-N- hydroxyacetamide

00864

embedded image

N-benzylbenzothioamide

00869

embedded image

O-(2- fluorobenzyl)hydroxylamine

00880

embedded image

5-(naphthalen-2- ylmethyl)quinolin-8-ol

00889

embedded image

N-hydroxy-2- phenylacetamide

00890

embedded image

5-(3- aminobenzyl)thiazolidine- 2,4-dione

00895

embedded image

3-fluoro-N-(4H-1,2,4- triazol-4-yl)benzamide

00900

embedded image

2-(4- hydroxyphenyl)acetimidamide

00914

embedded image

O-(3,4- dichlorobenzyl)hydroxylamine

00917

embedded image

N-(2- hydroxyethyl)benzo[d][1,3] dioxole-5-carboxamide

00920

embedded image

N-benzyl-1H-imidazole-4- carboxamide

00922

embedded image

N-(2,6- dimethylphenyl)hydrazine- carboximidamide

00934

embedded image

O-(4- (trifluoromethyl)benzyl)- hydroxylamine

00945

embedded image

5-(4-nitrophenylamino)-5- oxopentanoic acid

00947

embedded image

(4S,5R)-4-methyl-3- (naphthalen-2-ylmethyl)-5- phenyloxazolidine-2-thione

00951

embedded image

4,5-dimethyl-3-(naphthalen- 2-ylmethyl)thiazole-2(3H)- thione

00964

embedded image

N-o- tolylhydrazinecarboximidamide

00969

embedded image

1-(2,5-dimethylbenzyl)urea

00970

embedded image

O-(4- methoxybenzyl)hydroxylamine

00974

embedded image

(Z)-2-(benzhydryloxy)-N′- hydroxyacetimidamide

00976

embedded image

(Z)-2-(4-hydroxy-3- nitrobenzylidene)- hydrazinecarboxamide

00978

embedded image

N-hydroxy-N- phenethylacetamide

00982

embedded image

5-(2- phenylethylidene)pyrimidine- 2,4,6(1H,3H,5H)-trione

00990

embedded image

5-phenethylquinolin-8-ol

00994

embedded image

(Z)-2-(4-hydroxy-3- methoxy-5- nitrobenzylidene) hydrazinecarboxamide

00995

embedded image

3-(naphthalen-2-ylmethyl)- 1,3-thiazinane-2-thione

00996

embedded image

1-phenethyl-3- phenylthiourea

01013

embedded image

5-(2-chlorophenyl)-2- iminothiazolidin-4-one

01014

embedded image

O-(4- nitrobenzyl)hydroxylamine

01028

embedded image

5-(2,4- dimethylphenylamino)-5- oxopentanoic acid

01031

embedded image

(2-amino-6- nitrophenyl)methanol

01033

embedded image

O-(4- chlorobenzyl)hydroxylamine

01039

embedded image

2-(5-chloro-2- nitrophenylamino)ethanol

01051

embedded image

(E)-3-(naphthalen-2- yl)acrylonitrile

01056

embedded image

1-ethyl-1-phenylguanidine

01059

embedded image

1-(2-methoxybenzyl)urea

01062

embedded image

5-(2-phenylethylidene)-2- thioxodihydropyrimidine- 4,6(1H,5H)-dione

01065

embedded image

4-nitrobenzyl carbamate

01070

embedded image

N1-(4-nitrobenzyl)ethane- 1,2-diamine

01076

embedded image

N-phenethylbenzothioamide

01077

embedded image

2-(2- fluorophenyl)acetimidamide

01081

embedded image

(S)-4-isopropyl-3- (naphthalen-2-ylmethyl)- thiazolidine-2-thione

01083

embedded image

(E)-2-hydrazono-5-(4- methoxybenzyl)thiazolidin- 4-one

01088

embedded image

2-(2,4- difluorophenyl)acetimidamide

01099

embedded image

2-imino-5-(2- methylbenzyl)thiazolidin-4- one

01100

embedded image

(E)-4-phenylbut-2- enimidamide

01101

embedded image

1-benzyl-3-phenylthiourea

01107

embedded image

N- (benzyl)imidodicarbonimidic diamide

01116

embedded image

5-benzyl-2- iminothiazolidin-4-one

01131

embedded image

1-(2-chlorobenzyl)urea

01138

embedded image

4-((2-aminoethoxy)(o- tolyl)methyl)phenol

01139

embedded image

2-(2-oxo-2H-chromen-4- yl)acetic acid

01140

embedded image

5-benzylidenepyrimidine- 2,4,6(1H,3H,5H)-trione

01144

embedded image

N-(2-trifluromethyl-4- chloro)imidodicarbonimidic diamide

01145

embedded image

(Z)-ethyl 2-acetamido-3-(4- fluorophenyl)acrylate

01149

embedded image

(E)-3-(naphthalen-2- yl)acrylimidamide

01151

embedded image

5-(4- methylbenzyl)thiazolidine- 2,4-dione

01156

embedded image

N-(2-bromo-4- fluoro)imidodicarbonimidic diamide

01168

embedded image

5-(2-chlorobenzyl)-2- iminothiazolidin-4-one

01170

embedded image

1-phenethylguanidine

01174

embedded image

(2-amino-4- nitrophenyl)methanol

01177

embedded image

N-(2-methyl-3- chloro)imidodicarbonimidic diamide

01193

embedded image

1,1,1-trifluoro-3- phenylpropan-2-one

01197

embedded image

5-benzylidene-2- thioxodihydropyrimidine- 4,6(1H,5H)-dione

01209

embedded image

(E)-2-amino-2-oxoethyl 2- acetamido-3-phenylacrylate

01210

embedded image

cinnamimidamide

01217

embedded image

N-(2,6- dimethyl)imidodicarbonimidic diamide

01218

embedded image

5-(naphthalen-2- ylmethylene)-2-thioxodi- hydropyrimidine- 4,6(1H,5H)-dione

01229

embedded image

N-(2-methyl-6- chloro)imidodicarbonimidic diamide

01231

embedded image

N-(2,6- difluorophenyl) imidodicarbonimidic diamide

01248

embedded image

cinnamonitrile

TABLE 8

Cmpd #
Structure
Name

00347

embedded image

2-(2-chlorophenyl)-5-imino- 2,5-dihydrofuran-3,4-diol

00356

embedded image

1-(3,4-dihydroxy-5- (hydroxymethyl)- tetrahydrofuran-2-yl)-5- fluoro-1H-imidazole-4- carboxamide

00871

embedded image

2-(2-fluoro-1H-imidazol-1- yl)-5-(hydroxyl- methyl)tetrahydrofuran-3,4- diol

01042

embedded image

2-(5-fluoro-1H-imidazol-1- yl)-5- (hydroxymethyl) tetrahydrofuran- 3,4-diol

01111

embedded image

4-acetyl-5-(2-fluorophenyl)- 3-hydroxy-1H-pyrrol-2(5H)- one

01150

embedded image

4-acetyl-3-hydroxy-5- phenylfuran-2(5H)-one

01163

embedded image

4-acetyl-5-(2-chlorophenyl)- 3-hydroxy-1H-pyrrol-2(5H)- one

01187

embedded image

4-acetyl-5-(2-fluorophenyl)- 3-hydroxyfuran-2(5H)-one

01198

embedded image

4-acetyl-5-(2-chlorophenyl)- 3-hydroxyfuran-2(5H)-one

01226

embedded image

4-acetyl-5-(2-fluorophenyl)- 3-hydroxy-1-methyl-1H- pyrrol-2(5H)-one

01240

embedded image

4-acetyl-5-(2-chlorophenyl)- 3-hydroxy-1-methyl-1H- pyrrol-2(5H)-one

TABLE 9

Cmpd #
Structure
Name

01465

embedded image

imidazo[5,1- a]isoquinoline

01469

embedded image

3-butylimidazo[5,1- a]isoquinoline

01481

embedded image

2-amino-2- (imidazo[5,1- a]isoquinolin-3- yl)acetic acid

01482

embedded image

N-hydroxy-2- (imidazo[5,1- a]isoquinolin-3- yl)acetamide

01483

embedded image

N- hydroxyimidazo[5,1- a]isoquinoline-3- carboxamide

TABLE 10

Cmpd #
Structure
Name

01386

embedded image

2-amino-6-butyl-6,7- dihydroquinazoline- 4,5,8(3H)-trione

01394

embedded image

2-amino-6-butyl-6,7- dihydroquinazoline- 4,5,8(3H)-trione

01395

embedded image

2-amino-6-butyl-3-methyl- 6,7-dihydroquinazoline- 4,5,8(3H)-trione

01396

embedded image

2-amino-3-methyl-6-propyl- 6,7-dihydroquinazoline- 4,5,8(3H)-trione

01398

embedded image

2-amino-3-(2-amino-3- methyl-4,5,8-trioxo- 3,4,5,6,7,8- hexahydroquinazolin- 6-yl)propanoic acid

01400

embedded image

2-(2-amino-3-methyl-4,5,8- trioxo-3,4,5,6,7,8- hexahydroquinazolin-6-yl)- N-hydroxyacetamide

01401

embedded image

2-(2-amino-4,5,8-trioxo- 3,4,5,6,7,8- hexahydroquinazolin-6- yl)-N-hydroxyacetamide

01406

embedded image

2-amino-3-(2-amino-4-oxo- 4,4a,5,8-tetrahydropteridin- 6-yl)propanoic acid

01411

embedded image

2-amino-6-propyl-6,7- dihydroquinazoline- 4,5,8(3H)-trione

01478

embedded image

2-amino-3-(2-amino-4-oxo- 4,4a,5,8-tetrahydropteridin- 6-yl)propanoic acid

01480

embedded image

2-(2-amino-4-oxo-3,4- dihydropteridin-6-yl)-N- hydroxyacetamide

01484

embedded image

2-amino-6-butylpteridin- 4(3H)-one

01485

embedded image

2-amino-6-butyl-4a,5- dihydropteridin-4(8H)-one

01486

embedded image

2-amino-6-propylpteridin- 4(3H)-one

01487

embedded image

2-amino-6-butyl-4a,5- dihydropteridin-4(8H)-one

01488

embedded image

2-amino-3-(2-amino-4-oxo- 3,4-dihydropteridin-6- yl)propanoic acid

TABLE 11

Cmpd #
Structure
Name

00027

embedded image

methyl 6-(1H-indol-3- yl)hexylcarbamodithioate

00028

embedded image

methyl 1-(1H-indol-3-yl)-2- methylpropan-2- ylcarbamodithioate

00063

embedded image

naphthalen-2-ylmethyl 2- (chroman-3- yl)ethylcarbamodithioate

00064

embedded image

naphthalen-2-ylmethyl thiochroman-3- ylcarbamodithioate

00141

embedded image

isopropyl 2-(benzylthio- carbonothioylamino)acetate

00142

embedded image

p-tolyl phenylcarbamodithioate

00144

embedded image

2,4-dinitrophenyl cyclohexylcarbamodithioate

00145

embedded image

2-bromobenzyl sulpholan-2- yl carbamodithioate

00146

embedded image

2-bromo-4-nitrobenzyl sulpholan-2-yl carbamodithioate

00147

embedded image

ethyl pyridin-2- ylcarbamodithioate

00149

embedded image

(E)-5-(1-acetyl-2- oxoindolin-3-ylidene)-2- thioxothiazolidin-4-one

00151

embedded image

(5-oxo-1-phenyl-2- thioxoimidazolidin-4- yl)methyl phenylcarbamodithioate

00152

embedded image

4,6-diphenyl-1,3,5- thiadiazinane-2-thione

00167

embedded image

naphthalene-1,2-dione

00168

embedded image

naphthalen-1-ol

00210

embedded image

3-(1H-pyrrol-1- yl)thiophene-2-carboxylic acid

00215

embedded image

3-imino-3-(2- iminopiperidin-1-yl)- propanamide

00216

embedded image

1-(2-(2,4- difluorophenyl)thiazolidin- 3-yl)ethanone

00222

embedded image

2-(benzylthio)pyrimidine- 4,6-diol

00226

embedded image

2-([1,2,4]triazolo[4,3- a]pyridin-3-ylthio)acetamide

00230

embedded image

2-amino-5-(2- chlorophenyl)thiazole-4- carboxylic acid

00252

embedded image

2,4-bis(allyloxy)-1- ethylbenzene

00254

embedded image

1H-indole-2,3-dicarboxylic acid

00256

embedded image

2-(5-nitro-1H-indol-3- yl)ethanamine

00267

embedded image

3-(3-oxo-2,3-dihydro-1H- indazol-1-yl)propanoic acid

00269

embedded image

4-oxo-4-(pyrrolidin-1- yl)butanoic acid

00271

embedded image

3-amino-N,N- diethylbenzamide

00272

embedded image

ethyl 3,5-dihydroxybenzoate

00281

embedded image

decahydronaphthalene-2,3- diol

00289

embedded image

1-(3,3- dimethylbicyclo[2.2.1]hepta n-2-yl)ethanone

00300

embedded image

2,6-dihydroxypyrimidin-4- ylphosphonic acid

00305

embedded image

2-(hydroxymethyl)-6-(1- methylhydrazinyl)- tetrahydro-2H-pyran-3,4,5- triol

00309

embedded image

7-amino-8- hydroxyquinoline-5-sulfinic acid

00310

embedded image

2-methyl-2- phenylhydrazinecarboxamide

00311

embedded image

N′-(2- aminophenyl)formohydrazide

00312

embedded image

2-oxo-2-(2- phenylhydrazinyl)acetamide

00319

embedded image

6-hydroxypyridine-2,3- dicarboxylic acid

00320

embedded image

2,7-dihydroxyquinoline-5,8- dione

00324

embedded image

N,N-dimethyl-2-oxo-2- phenylacetamide

00332

embedded image

N-ethyl-N- phenylcarbamimidoyl cyanide

00334

embedded image

1H-pyrazolo[3,4- d]pyrimidin-4(2H)-one

00337

embedded image

4-hydroxy-7- methylpyrano[4,3-b]pyran- 2,5-dione

00342

embedded image

6,7-dihydroxy-4- methylchroman-2-one

00343

embedded image

6,7-dihydroxy-2-oxo-2H- chromene-4-carboxylic acid

00345

embedded image

6- (benzyl(methyl)amino)pyrimidine- 2,4-diol

00348

embedded image

1-methyl-4-(2- methylhydrazinyl)-1H- pyrazolo[3,4-d]pyrimidine

00352

embedded image

5-amino-1H-indole-3- carboxylic acid

00363

embedded image

(6Z,8Z)-4-hydroxy-5H- benzo[7]annulen-5-one

00364

embedded image

(E)-acenaphthylen-1(2H)- ylidenehydrazine

00366

embedded image

2,3,4,5-tetrahydro-1H- benzo[d]azepin-1-ol

00367

embedded image

6,7,8,9-tetrahydro-5H- benzo[7]annulene-2,9-diol

00368

embedded image

1-methyl-2,3-dihydro-1H- indene-4,7-diol

00378

embedded image

4-hydroxy-3-methyl-1- phenyl-1H-pyrazol-5(4H)- one

00380

embedded image

2,3-diphenyl-2,5- dihydrofuran

00382

embedded image

2-(2-hydroxy-7,7-dimethyl- 3-oxobicyclo[2.2.1]heptan- 1-yl)acetic acid

00385

embedded image

5,5- dimethylbicyclo[2.1.1]hexane- 2-carboxylic acid

00396

embedded image

1-(iminomethyl)naphthalen- 2-ol

00398

embedded image

6,7-dihydroxy-4- methylquinolin-2(1H)-one

00464

embedded image

2-((3-methyl-1,4-dioxo-1,4- dihydronaphthalen-2- yl)methyl)isoindoline-1,3- dione

00477

embedded image

3,3′-methylenebis(2- hydroxynaphthalene-1,4- dione)

00507

embedded image

2,5-dioxopyrrolidin-1-yl 4- (7-oxo-7H-furo[3,2- g]chromen-9- yloxy)butanoate

00515

embedded image

2- hydroxybenzo[d]naphtho[2,3- b]furan-6,11-dione

00516

embedded image

chrysene-1,4-dione

00561

embedded image

N-((1H-indol-3-yl)methyl)- 2-(2-thioxo-2,3- dihydrothiazol-4- yl)acetamide

00578

embedded image

4-amino-4-oxo-2- phenylbutanoic acid

00586

embedded image

N1-((1H-indol-3- yl)methyl)ethane-1,2- diamine

00605

embedded image

3,6-dihydroxy-2- methylbenzoic acid

00608

embedded image

5-phenylthiazole-4- carboxylic acid

00610

embedded image

4-(pyridin-3-yl)-1H-pyrrole- 3-carboxylic acid

00622

embedded image

3-((1H-indol-3- yl)methylthio)-2-methyl- 1,2-dihydro-1,2,4-triazine- 5,6-dione

00623

embedded image

N-o- tolylhydrazinecarbothioamide

00628

embedded image

2-(benzylamino)phenol

00645

embedded image

3-(3-oxo-1H-indazol-2(3H)- yl)propanoic acid

00658

embedded image

2-(2-methylfuran-3- carboxamido)pentanedioic acid

00663

embedded image

6-chloro-2-(3- fluorobenzylthio)pyrimidin- 4-amine

00669

embedded image

(Z)-N′-hydroxy-1H-indole- 3-carboximidamide

00670

embedded image

6,8-dihydroxy-3-methyl-1H- isochromen-1-one

00675

embedded image

N-(4-fluorobenzyl)-2,5- dimethoxyaniline

00681

embedded image

2-cyclobutoxybenzamide

00682

embedded image

2-methyl-3-(naphthalen-2- ylmethylthio)-1,2-dihydro- 1,2,4-triazine-5,6-dione

00685

embedded image

2-(benzylthio)-6- methylpyrimidin-4-amine

00690

embedded image

2-(5-phenyl-1H-tetrazol-1- yl)acetamide

00692

embedded image

6-chloro-2-(2- fluorobenzylthio)pyrimidin- 4-amine

00700

embedded image

2-(1H-pyrrol-1- yl)benzohydrazide

00701

embedded image

N-(naphthalen-2-ylmethyl)- 2-(2-thioxo-2,3- dihydrothiazol-4- yl)acetamide

00705

embedded image

2-(benzylthio)-6- chloropyrimidin-4-amine

00707

embedded image

4-phenylisoxazole-3,5-diol

00714

embedded image

4-(indolin-3-yl)-4- oxobutanoic acid

00716

embedded image

(2E,4E,6Z)-2-(furan-2- ylmethylamino)-5- nitrocyclohepta-2,4,6- trienone

00718

embedded image

2-(5-bromo-1H-indol-3- yl)ethanamine

00727

embedded image

4-oxo-4-(5-oxo-1,4- diazepan-1-yl)butanoic acid

00740

embedded image

3- (nitroso(phenyl)amino)propanoic acid

00746

embedded image

N-benzyl-5-methylpyrazine- 2-carboxamide

00750

embedded image

4-(4-(2- hydroxyethyl)piperazin-1- yl)-4-oxobutanoic acid

00751

embedded image

3-(cyclohexa-1,5- dienylmethylthio)-2-methyl- 1,2-dihydro-1,2,4-triazine- 5,6-dione

00757

embedded image

benzofuran-2,3-dicarboxylic acid

00759

embedded image

pyrrolidin-1-yl(o- tolyl)methanone

00768

embedded image

2-(1H-inden-3-yl)acetic acid

00770

embedded image

N-(2- nitrophenyl) hydrazinecarbothioamide

00777

embedded image

3-([1,2,4]triazolo[4,3- a]pyridin-3-yl)propan-1- amine

00782

embedded image

5-methoxy-4-oxo-4H-pyran- 2-carboxylic acid

00783

embedded image

2-(2- bromoethoxy)benzamide

00784

embedded image

7-ethyl-2,3- dihydrobenzo[b][1,4]dioxine- 6-carboxylic acid

00793

embedded image

2-(3- chlorobenzylthio)pyrimidine- 4,6-diol

00797

embedded image

N-ethyl-N- phenylcarbamimidothioic acid

00799

embedded image

6-amino-2-(thiophen-2- ylmethylthio)pyrimidin-4-ol

00803

embedded image

6-amino-2- (benzylthio)pyrimidin-4-ol

00805

embedded image

1-butyl-2-hydrazinyl-1H- benzo[d]imidazole

00806

embedded image

2-(1-methyl-1H-indol-3- ylthio)acetic acid

00807

embedded image

3-methyl-N′-phenyl-1H- pyrazole-5-carbohydrazide

00812

embedded image

4-oxo-4-(piperazin-1- yl)butanoic acid

00814

embedded image

6-amino-2-(pyridin-3- ylmethylthio)pyrimidin-4-ol

00815

embedded image

2-(phthalazin-1-ylthio)acetic acid

00821

embedded image

4-oxo-4-(piperidin-1- yl)butanoic acid

00822

embedded image

1,2,3,4-tetrahydroquinoline- 8-carboxylic acid

00824

embedded image

5-nitro-N-phenylfuran-2- carboxamide

00837

embedded image

N,2-dihydroxybenzamide

00856

embedded image

3-hydroxy-5-nitrobenzoic acid

00858

embedded image

2-amino-3-nitrobenzoic acid

00875

embedded image

1,3-dimethyl-1H-thieno[2,3- c]pyrazole-5-carboxylic acid

00877

embedded image

1-phenyl-2-(pyridin-4- yl)ethanone

00881

embedded image

1-(5-amino-2,4- dihydroxyphenyl)propan-1- one

00886

embedded image

4-phenyl-1,2,5-oxadiazol-3- ol

00896

embedded image

(E)-N′-(2-(1H-imidazol-4- yl)ethyl)formohydrazonamide

00899

embedded image

1-ethyl-1H- benzo[d]imidazole-2- sulfonic acid

00901

embedded image

5-(diethylamino)-2- hydroxybenzoic acid

00903

embedded image

4-hydroxypyridine-2,6- dicarboxylic acid

00905

embedded image

2-hydroxybenzo[d]thiazole- 5,7-dicarboxylic acid

00909

embedded image

2-hydroxy-5- thioureidobenzoic acid

00912

embedded image

2-(1-methyl-1H-indol-3- ylthio)acetamide

00915

embedded image

1-benzoylpiperidine-3- carboxylic acid

00919

embedded image

3-methyl-4-phenyl-1,2,3- oxadiazol-3-ium-5-olate

00932

embedded image

1-propyl-1H- benzo[d]imidazol-2-amine

00935

embedded image

N,N-dimethyl-4-phenyl-1H- pyrazol-3-amine

00938

embedded image

(E)-2-oxo-2-(2-(1- (thiophen-2-yl)- ethylidene)hydrazinyl)acetamide

00939

embedded image

2-amino-3,4- dimethoxybenzoic acid

00943

embedded image

(2- methoxyphenyl)(morpholino) methanone

00946

embedded image

1-(2-isopropylphenyl)urea

00954

embedded image

2-(4-amino-4H-1,2,4- triazol-3-ylthio)acetamide

00958

embedded image

8-methoxyquinoline-2,4-diol

00966

embedded image

(1-allyl-1H-indol-3- yl)methanol

00973

embedded image

N-(pentan-2-yl)thiophene-2- carboxamide

00975

embedded image

2-fluoro-N-(furan-2- ylmethyl)-4-nitroaniline

00980

embedded image

1-((2R,4S,5S,E)-3- (chloromethylene)-4,5- dihydroxytetrahydrofuran-2- yl)pyrimidine-2,4(1H,3H)- dione

00983

embedded image

N-(2,5- dichlorophenyl)pyrazine-2- carboxamide

00984

embedded image

methyl ethyl(phenyl) carbamimidothioate

00988

embedded image

4-formamido-3-phenyl- 1,2,5-oxadiazole 2-oxide

00991

embedded image

(1H-imidazol-2- yl)(thiophen-2- yl)methanone

00993

embedded image

(2- ethoxyphenyl)(morpholino) methanone

00997

embedded image

4- ((methylamino)methyl)quinolin- 2(1H)-one

01000

embedded image

(3-methyl-4-phenyl-1,2,3- oxadiazol-3-ium-5-yl)amide

01003

embedded image

(E)-4- ((hydroxyimino)methyl)-3- phenyl-1,2,5-oxadiazole 2- oxide

01010

embedded image

5-methoxy-1,2- dihydrocyclobutabenzene-1- carboxylic acid

01019

embedded image

N- allylbenzo[d][1,3]dioxole-5- carboxamide

01020

embedded image

2-hydroxy-5-(N- methylsulfamoyl)benzamide

01022

embedded image

1-ethyl-1H- benzo[d]imidazol-2(3H)-one

01024

embedded image

2,3- dihydrobenzo[b][1,4]dioxine- 5-carboxamide

01026

embedded image

1,3-bis(allyloxy)benzene

01029

embedded image

1-isopropyl-1H- benzo[d]imidazol-2(3H)-one

01030

embedded image

N-benzyl-1H-1,2,4-triazole- 5-carboxamide

01036

embedded image

1-(2,3-dihydro-1H-inden-1- yl)guanidine

01037

embedded image

2-(1-(methylamino)ethyl)-3- propylquinazolin-4(3H)-one

01038

embedded image

1H-pyrazole-1,4,5- tricarboxylic acid

01040

embedded image

2-(4-(pyridin-2-yl)-4H- 1,2,4-triazol-3-ylthio)acetic acid

01041

embedded image

N- propylbenzo[d][1,3]dioxole- 5-carboxamide

01044

embedded image

allyl 2-(allyloxy)benzoate

01046

embedded image

methyl 2,3-dihydroxy-1- naphthoate

01052

embedded image

2-chloro-N-(3- methoxypropyl)-N-phenyl- acetamide

01058

embedded image

2-(4- chlorophenylcarbonothioyl) hydrazinecarboxamide

01061

embedded image

(E)-N′- butylidenebenzohydrazide

01067

embedded image

2-(pyrrolidin-1-yl)thiazol- 4(5H)-one

01068

embedded image

N-allylthiophene-2- carboxamide

01072

embedded image

1,2,3,4- tetrahydroisoquinoline- 6,7-diol

01073

embedded image

N-(2-oxo-2H-chromen-3- yl)acetamide

01074

embedded image

2-(2-methylindolizin-3-yl)- 2-oxoacetic acid

01075

embedded image

1-methylisoquinoline-6,7- diol

01079

embedded image

2-benzo[4,5]thiazolo[2,3- c][l,2,4]triazol-3-ylsulfanyl- acetamide

01080

embedded image

2,4- bis(allyloxy)benzaldehyde

01082

embedded image

3-(cyclohexa-1,5- dienylmethyl)oxazolidine-2- thione

01090

embedded image

(E)-N′-butylidenethiophene- 2-carbohydrazide

01092

embedded image

pyrrolo[1,2-a]quinoxalin- 4(5H)-one

01093

embedded image

l-((2R,3R,4S,5S,6R)-3,4,5- trihydroxy-6- (hydroxymethyl)tetrahydro- 2H-pyran-2-yl)thiourea

01096

embedded image

N-(3-methoxypropyl)-2- methylfuran-3-carboxamide

01098

embedded image

1-(furan-2- carbonyl)piperidine-3- carboxylic acid

01104

embedded image

(E)-N′- butylidenepicolinohydrazide

01105

embedded image

(E)-4-chloro-N′- propylidenebenzohydrazide

01106

embedded image

5,8-dihydroxy-3,4- dihydronaphthalen-2(1H)- one

01108

embedded image

3,4-dihydro- [1,4]diazepino[3,2,1- hi]indol-2(1H)-one

01109

embedded image

N,N-diethyl-3,5- dimethoxybenzamide

01113

embedded image

1H-benzo[d][1,2,3]triazole- 1-carboximidamide

01118

embedded image

2-amino-2-oxoethyl 2- (methylthio)nicotinate

01121

embedded image

3-(2-oxoazepan-1- yl)propanamide

01123

embedded image

(Z)-4,5,8,9-tetrahydro-2H- pyrrolo[1,2-a][1,3]diazepin- 7(3H)-one

01126

embedded image

2-(allyloxy)-3- methylbenzamide

01130

embedded image

quinoline-3,4-dicarboxylic acid

01134

embedded image

3-(cyclohexa-1,5- dienylmethyl)-2- thioxothiazolidin-4-one

01137

embedded image

2-(benzylthio)-6- methylpyrimidin-4-ol

01148

embedded image

2-methyl-3- (methylamino)quinazolin- 4(3H)-one

01152

embedded image

(4S,5R)-3-(cyclohexa-1,5- dienylmethyl)-4-methyl-5- phenyloxazolidine-2-thione

01154

embedded image

(Z)-2-hydrazono-2-(pyridin- 2-yl)ethanol

01158

embedded image

(E)-N′-((E)-but-2- enylidene)thiophene-2- carbohydrazide

01161

embedded image

3-hydroxy-5-(thiophen-2- yl)cyclohex-2-enone

01164

embedded image

4-(pyrrolidin-1-yl)-1H- imidazol-2(5H)-one

01167

embedded image

4-hydroxy-2-mercapto-5- methyl-7H-pyrano[2,3- d]pyrimidin-7-one

01175

embedded image

4-ethoxy-3-phenyl-1,2,5- oxadiazole 2-oxide

01178

embedded image

4-amino-1-naphthoic acid

01180

embedded image

7-chloro-3- methylbenzofuran-2- carboxylic acid

01182

embedded image

4-hydroxy-2,5-dimethyl-7H- pyrano[2,3-d]pyrimidin-7- one

01184

embedded image

2-(piperidin-1-yl)thiazol- 4(5H)-one

01189

embedded image

4-amino-1-butyl-5,6- dihydropyrimidin-2(1H)-one

01194

embedded image

2-(5,6,7,8-tetrahydro- [1,2,4]triazolo[4,3- a]pyridin-3-yl)acetonitrile

01195

embedded image

5,7-dimethylpyrido[2,3- d]pyrimidine-2,4-diol

01196

embedded image

1,10b-dihydropyrazolo[ 1,5- c]quinazolin-5(6H)-one

01204

embedded image

4,7,8-trihydroxy-1-oxo- 1,2,3,4-tetrahydro- isoquinoline

01207

embedded image

2-methoxy-4,7- dimethylpyrido[2,3-d]- pyrimidin-5(8H)-one

01212

embedded image

(E)-6-((9H-pyrido[3,4- b]indol-9-yl)- methylene)piperazine-2,3,5- trione

01213

embedded image

4-oxo-2,3,4,5-tetrahydro- 1H-benzo[b][1,4]diazepine- 1-carboxamide

01215

embedded image

(E)-3-((9H-pyrido[3,4- b]indol-9-yl)methylene)-6- thioxopiperazine-2,5-dione

01220

embedded image

2-mercapto-5,7- dimethylpyrido[2,3- d]pyrimidin-4(3H)-one

01224

embedded image

2,4,7-trimethylpyrido[2,3- d]pyrimidin-5(8H)-one

01236

embedded image

3,4- dichlorobenzo[b]thiophene- 2-carboxylic acid

01239

embedded image

2-(benzylthio)-4,5- diphenylthiazole

01243

embedded image

2-((1H-indol-3- yl)methylthio)-4,5- diphenylthiazole

01250

embedded image

2,2′,4,4′-tetramethyl-3,3′- bithiophene

01253

embedded image

N-allyl-N-((1-(2- fluorophenyl)-1H-pyrrol-2- yl)methyl)prop-2-en-1- amine

01257

embedded image

4,4′-dibromo-2,2′-dimethyl- 3,3′-bithiophene

01360

embedded image

methyl 2-(1H-indol-3- yl)propylcarbamodithioate

01384

embedded image

3,4-dihydro-1H- [1,4]oxazino[4,3-a]indole

01389

embedded image

potassium 1,4-dioxo-1,4- dihydronaphthalene-2- sulfonate

01393

embedded image

8-butyl-2,2,4,4- tetramethylphenazine- 1,3(2H,4H)-dione

01397

embedded image

1H-naphtho[1,2-d]imidazol- 9-ol

01399

embedded image

naphthalen-2-ylmethyl 2- (thiochroman-3- yl)ethylcarbamodithioate

01404

embedded image

naphthalen-2-ylmethyl chroman-3- ylmethylcarbamodithioate

01407

embedded image

8-butyl-2,2,4,4-tetramethyl- 5,10-dihydrophenazine- 1,3(2H,4H)-dione

01408

embedded image

2,2,4,4- tetramethylphenazine- 1,3(2H,4H)-dione

01409

embedded image

2,2,4,4-tetramethyl-5,10- dihydrophenazine- 1,3(2H,4H)-dione

01412

embedded image

3-hydroxy-2- methylquinazolin-4(3H)-one

01415

embedded image

(2S)-2-amino-3-(3,4,10,10a- tetrahydro-1H- [1,4]oxazino[4,3-a]indol-10- yl)propanoic acid

01416

embedded image

3-hydroxyquinazoline- 2,4(1H,3H)-dione

01423

embedded image

3-butyl-1-hydroxyindolin-2- one

01435

embedded image

2-butyl-3- hydroxyquinazolin-4(3H)- one

01436

embedded image

naphthalen-2-ylmethyl 3-(2- oxobenzo[d]oxazol-3(2H)- yl)propylcarbamodithioate

01450

embedded image

1H-naphtho[l,2- d]imidazole-1,9-diol

01453

embedded image

(1aR,1bS,6bR,6cS)- 1b,2,6b,6c-tetrahydro-1aH- oxireno[3,4]cyclobuta[1,2- b]indole

01454

embedded image

3,4,10,10a-tetrahydro-1H- [1,4]oxazino[4,3-a]indole

01467

embedded image

11- hydroxybenzo[g]furo[3,2- b]quinoxaline- 5,10(4H,11H)-dione

In a twelfth aspect, the compounds as provided as listed in Table 12.

TABLE 12

Cmpd #
Structure
Name

00001

embedded image

phenethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00002

embedded image

4-methoxyphenethyl 2-(1H-indol- 3-yl)ethylcarbamodithioate

00003

embedded image

4-fluorophenethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00004

embedded image

4-bromophenethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00006

embedded image

2-phenylpropyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00007

embedded image

3-bromophenethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00008

embedded image

3-chlorophenethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00009

embedded image

4-methylphenethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00010

embedded image

3-methoxyphenethyl 2-(1H-indol- 3-yl)ethylcarbamodithioate

00023

embedded image

(6,7-Dimethoxy-2-oxo-2H- chromen-4-yl)methyl 2-(1H-indol- 3-yl)ethyl-carbamodithioate

00030

embedded image

2-(1H-indol-3-yl)ethyl 2-(1H- indol-3-yl)ethylcarbamodithioate

00038

embedded image

(2-Methylquinolin-6-yl)methyl 2- (1H-indol-3- yl)ethylcarbamodithioate

00047

embedded image

2-(3-methylnaphthalen-2-yl)ethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00049

embedded image

4-((2-(1H-indol-3- yl)ethylcarbamothioylthio) methyl)-2-oxo-2H-chromen-7-yl acetate

00050

embedded image

Benzo[d][l,3]dioxol-5-ylmethyl 2- (1H-indol-3- yl)ethylcarbamodithioate

00052

embedded image

Benzo[d]isoxazol-3-ylmethyl 2- (1H-indol-3- yl)ethylcarbamodithioate

00053

embedded image

2-(2,3- dihydrobenzo[b][1,4]dioxin-6- yl)ethyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00065

embedded image

(6-Bromobenzo[d][1,3]dioxol-5- yl)methyl 2-(1H-indol-3- yl)ethylcarbamodithioate

00066

embedded image

Methyl 2,4- dimethylphenethyl-carbamodithioate

00069

embedded image

Methyl 2-(pyridin-4- yl)ethylcarbamodithioate

00786

embedded image

3-(naphthalen-2- ylmethyl)oxazolidine-2-thione

00830

embedded image

3-(naphthalen-2-ylmethyl)-2- thioxothiazolidin-4-one

In a thirteenth aspect is provided a compound of the formula (XIII),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

L¹is —C₂-C₆alkyl-;

X is ═O or ═S;

ring D is an aryl or heteroaryl group, each optionally substituted with one to four R groups;

R¹is -L²-R², wherein L²is —C₂-C₆alkyl-; and R²is (i) hydrogen; (ii) aryl optionally substituted with one to four R groups; or (iii) heteroaryl optionally substituted with one to four R groups; and

each R is independently halogen, cyano, nitro, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, —OR³, —SR³, —N(R³)₂, —OC(O)R³, —C(O)OR³, —C(O)N(R³)₂, —N(R³)C(O)R³, —S(O)R³, or —S(O)₂R³, wherein each R³is independently hydrogen or C₁-C₆alkyl;

provided that when ring D is an aryl or unsubstituted indol-3-yl, benzofuran-3-yl, or benzothien-3-yl group, and L¹is —C₂-C₃alkyl-, then (a) R²is not hydrogen.

In an embodiment of the thirteenth aspect, the compound is according to formula (XIII), wherein ring D is aryl.

In an embodiment of the thirteenth aspect, the compound is according to formula (XIII), wherein ring D is heteroaryl.

In an embodiment of the thirteenth aspect, the compound is according to formula (XIII), wherein ring D is phenyl, naphthyl, azulenyl, indolyl, benzothienyl, benzofuranyl, pyridyl, pyrazinyl, pyrimidinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, quinolinyl, or quinazolinyl, each optionally substituted with one to four R groups.

In an embodiment of the thirteenth aspect, the compound is according to formula (XIII), wherein ring D is phenyl or naphthyl, each optionally substituted with one to four R groups.

In an embodiment of the thirteenth aspect, the compound is according to formula (XIII), wherein ring D is indolyl, benzothienyl, benzofuranyl, pyridyl, pyrazinyl, pyrimidinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, quinolinyl, or quinazolinyl, each optionally substituted with one to four R groups.

In an embodiment of the thirteenth aspect, the compound is according to formula (XIII), wherein ring D is indolyl, benzothienyl, benzofuranyl, quinolinyl, or quinazolinyl, each optionally substituted with one to four R groups.

In an embodiment of the thirteenth aspect, the compound is according to formula (XIII), wherein ring D is indolyl, benzothienyl, or benzofuranyl, each optionally substituted with one to four R groups.

In an embodiment of the thirteenth aspect, the compound is according to formula (XIII), wherein X is ═S.

In an embodiment of the thirteenth aspect, the compound is according to formula (XIII), wherein X is ═O.

In an embodiment of the thirteenth aspect, the compound is according to one of formulae (XIIIa-c),

embedded image

In an embodiment of the thirteenth aspect, the compound is according to one of formulae (XIII and XIIIa-c), wherein L¹is —CH₂CH₂—.

In an embodiment of the thirteenth aspect, the compound is according to one of formulae (XIII and XIIIa-c), wherein L²is —CH₂CH₂—.

In an embodiment of the thirteenth aspect, the compound is according to one of formulae (XIII and XIIIa-c), wherein L¹and L²are both is —CH₂CH₂—.

In an embodiment of the thirteenth aspect, the compound is a compound listed in Table 12.

In a fourteenth aspect, methods are provided for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount a compound of formula (XXI); (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (XXI); (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (XXI); (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound of formula (XXI), (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (XXI); and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound of formula (XXI),

embedded image

and pharmaceutically acceptable salts thereof, wherein

ring A is aryl, heteroaryl, C₅-C₁₀cycloalkyl, or heterocyclyl, each optionally substituted with one or more R^Agroups, wherein

each R^Ais independently halogen, cyano, nitro, —N(R^A1)₂, —OR^A1, —ON(R^A1)₂, —N(R^A1)N(R^A1)₂, —SR^A1, —C(O)R^A1, —C(O)OR^A1, —C(O)N(R^A1)₂, —S(O)R^A1, —S(O)OR^A1, —S(O)N(R^A1)₂, —S(O)₂R^A1, —S(O)₂OR^A1, —S(O)₂N(R^A1)₂, —OC(O)R^A1, —OC(O)OR^A1, —OC(O)N(R^A1)₂, —N(R^A1)C(O)OR^A1, —N(R^A1)C(O)N(R^A1)₂, —C₁-C₆alkyl, —C₁-C₆haloalkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A1)₂, —OR^A1, —ON(R^A1)₂, —N(R^A1)N(R^A1)₂, —SR^A1, —C(O)R^A1, —C(O)OR^A1, —C(O)N(R^A1)₂, —S(O)R^A1, —S(O)OR^A1, —S(O)N(R^A1)₂, —S(O)₂R^A1, —S(O)₂OR^A1, —S(O)₂N(R^A1)₂, —OC(O)R^A1, —OC(O)OR^A1, —OC(O)N(R^A1)₂, —N(R^A1)C(O)OR^A1, or —N(R^A1)C(O)N(R^A1)₂, wherein

each R^A1is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more halogen, cyano, nitro, —N(R^A2)₂, —OR^A2, —ON(R^A2)₂, —N(R^A2)N(R^A2)₂, —SR^A2, —C(O)R^A2, —C(O)OR^A2, —C(O)N(R^A2)₂, —S(O)R^A2, —S(O)OR^A2, —S(O)N(R^A2)₂, —S(O)₂R^A2, —S(O)₂OR^A2, —S(O)₂N(R^A2)₂, —OC(O)R^A2, —OC(O)OR^A2, —OC(O)N(R^A2)₂, —N(R^A2)C(O)OR^A2, or —N(R^A2)C(O)N(R^A2)₂, wherein

each R^A2is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl; and

L is a bond or —X-L¹-, wherein

X is bonded to A, and is a bond, —O—, —S—, —N(R^X)—, —C(Y)—, —S(O)—, —S(O)₂—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(R^X)—, —N(R^X)C(O)O—, —C(O)N(R^X)—, —N(R^X)C(O)—, —N(R^X)C(O)N(R^X)—, —S(O)O—, —OS(O)—, —S(O)N(R^X)—, —N(R^X)S(O)—, —S(O)₂O—, —OS(O)₂—, —S(O)₂N(R^X)—, —N(R^X)S(O)₂—, —C₁-C₃alkylO—, —C₁-C₃alkylS—, —C₁-C₃alkylN(R^X)—, —C₁-C₃alkylC(Y)—, —C₁-C₃alkylS(O)—, —C₁-C₃alkylS(O)₂—, —C₁-C₃alkylC(O)O—, —C₁-C₃alkylO—C(O)—, —C₁-C₃alkylOC(O)O—, —C₁-C₃alkylN(R^X)C(O)O—, —C₁-C₃alkylOC(O)N(R^X)—, —C₁-C₃alkyl-C(O)N(R^X)—, —C₁-C₃alkylN(R^X)C(O)—, —C₁-C₃alkylN(R^X)C(O)N(R^X)—, —C₁-C₃alkylS(O)O—, —C₁-C₃alkylOS(O)—, —C₁-C₃alkylS(O)N(R^X)—, —C₁-C₃alkylN(R^X)S(O)—, —C₁-C₃alkylS(O)₂O—, —C₁-C₃alkylOS(O)₂—, —C₁-C₃alkylS(O)₂N(R^X)—, or —C₁-C₃alkylN(R^X)S(O)₂—, wherein

each R^Xis independently hydrogen or —C₁-C₆alkyl;

Y is ═O, ═S, or ═NH; and

L¹is —C₁-C₆alkyl-, or —C₂-C₆alkenyl-, wherein the alkyl and alkenyl are each optionally substituted with one or two R^Lgroups, wherein

each R^Lis independently halogen, cyano, nitro, —N(R^L1)₂, —OR^L1, —ON(R^L1)₂, —N(R^L1)N(R^L1)₂, —N(R^L1)C(O)R^L1, —SR^L1, —C(O)R^L1, —C(O)OR^L1, —C(O)N(R^L1)₂, —S(O)R^L1, —S(O)OR^L1, —S(O)N(R^L1)₂, —S(O)₂R^L1, —S(O)₂OR^L1, —S(O)₂N(R^L1)₂, —OC(O)R^L1, —OC(O)OR^L1, —OC(O)N(R^L1)₂, —N(R^L1)C(O)OR^L1, —N(R^L1)C(O)N(R^L1)₂, —C₁-C₆alkyl, —C₁-C₆haloalkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, —C₁-C₆alkylC₃-C₈cycloalkyl, -heterocyclyl, or —C₁-C₆alkylheterocyclyl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or two halogen, cyano, nitro, —N(R^L1)₂, —OR^L1, —ON(R^L1)₂, —N(R^L1)N(R^L1)₂, —SR^L1, —C(O)R^L1, —C(O)OR^L1, —C(O)N(R^L1)₂, —S(O)R^L1, —S(O)OR^L1, —S(O)N(R^L1)₂, —S(O)₂R^L1, —S(O)₂OR^L1, —S(O)₂N(R^L1)₂, —OC(O)R^L1, —OC(O)OR^L1, —OC(O)N(R^L1)₂, —N(R^L1)C(O)R^L1, —N(R^L1)C(O)OR^L1, or —N(R^L1)C(O)N(R^L1)₂, wherein

each R^L1is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more halogen, cyano, nitro, —N(R^L2)₂, —OR^L2, —ON(R^L2)₂, —N(R^L2)N(R^L2)₂, —SR^L2, —C(O)R^L2, —C(O)OR^L2, —C(O)N(R^L2)₂, —S(O)R^L2, —S(O)OR^L2, —S(O)N(R^L2)₂, —S(O)₂R^L2, —S(O)₂OR^L2, —S(O)₂N(R^L2)₂, —OC(O)R^L2, —OC(O)OR^L2, —OC(O)N(R^L2)₂, —N(R^L2)C(O)OR^L2, or —N(R^L2)C(O)N(R^L2)₂, wherein

each R^L2is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl.

A preferred subgenus of the fourteenth aspect includes compounds in which ring A is substituted with at least one R^A. Preferably, ring A is substituted with one or two R^A. More preferably, ring A is substituted with two R^A.

Another preferred subgenus of the fourteenth aspect includes compounds in which ring A is aryl, heteroaryl, or heterocyclyl, each optionally substituted with one or more R^Agroups.

Another preferred subgenus of the fourteenth aspect includes compounds in which ring A is aryl, heteroaryl, or heterocyclyl, each optionally substituted with one or more R^Agroups, provided that ring A is not piperidinyl. Compounds of this subgenus are preferably used for treating cancer, infectious disease, trauma, and age-related cataracts as described herein below, although they are also suitable for the other uses described in the “Methods of Use” section hereinbelow.

Another preferred subgenus of the fourteenth aspect includes compounds in which ring A is aryl or heteroaryl optionally substituted with one or more R^Agroups. Preferably, ring A is aryl or heteroaryl, each substituted with one or two R^Agroups.

Another preferred subgenus of the fourteenth aspect includes compounds in which ring A is aryl optionally substituted with one or more R^Agroups. Preferably, ring A is phenyl or naphthyl, each substituted with one or two R^Agroups. More preferably, ring A is phenyl substituted with one or two R^Agroups. Even more preferably, ring A is phenyl substituted with one or two R^Agroups, wherein at least one R^Agroup is meta- or ortho- to L.

Another preferred subgenus of the fourteenth aspect includes compounds in which ring A is indolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzooxazolinyl, benzimidazolidinyl, benzothioxazolinyl, cromanyl, 2,3-dihydrobenzo[b][1,4]dioxanyl, benzo[d][1,3]dioxolyl, tetrahydronaphthyl, indenyl, or dihydroindenyl, each optionally substituted with one or more R^Agroups, or preferably, each substituted with one or two R^Agroups.

Another preferred subgenus of the fourteenth aspect includes compounds in which ring A is tetrahydroquinolinyl, 4,5,6,7-tetrahydrobenzimidazolyl, 4,5,6,7-tetrahydrobenzothienyl, 4,5,6,7-tetrahydrobenzo-furanyl, 4,5,6,7-tetrahydroindolyl, 4,5,6,7-tetrahydrobenzoxazolyl, 4,5,6,7-tetrahydrobenzo-thioxazolyl, each optionally substituted with one or more R^Agroups, or preferably, each substituted with one or two R^Agroups.

Another preferred subgenus of the fourteenth aspect includes compounds in which ring A is heteroaryl optionally substituted with one or more R^Agroups, or preferably, each substituted with one or two R^Agroups. Preferably, ring A is pyrrolyl, furanyl, thienyl, benzothienyl, indolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothioxazolyl, benzotriazolyl, quinolinyl, or quinazolinyl, each optionally substituted with one or more R^Agroups, or preferably, each substituted with one or two R^Agroups. More preferably, ring A is pyridinyl, pyrimidinyl, pyrazinyl, or 1,3,5-triazinyl, each optionally substituted with one or more R^Agroups, or preferably, each substituted with one or two R^Agroups. In an alternative embodiment, ring A is benzothienyl, indolyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothioxazolyl, or benzotriazolyl, each optionally substituted with one or more R^Agroups, or preferably, each substituted with one or two R^Agroups. Preferably, ring A is benzothienyl, indolyl, or benzofuranyl, each optionally substituted with one or more R^Agroups, or preferably, each substituted with one or two R^Agroups.

Another preferred subgenus of the fourteenth aspect includes compounds in which ring A is C₅-C₁₀cycloalkyl substituted with one or two R^Agroups. Preferably, ring A is C₅-C₇cycloalkyl substituted with one or two R^Agroups.

In a preferred subgenus of any of the preceding subgenera of the fourteenth aspect,

(a) at least one R^Ais halogen, cyano, nitro, —N(R^A11)², —OR^A11, —ON(R^A11)₂, —N(R^A11)N(R^A11)₂, —SR^A11, —C(O)OR^A11, —C(O)OR^A11, —C(O)N(R^A11)₂, —S(O)R^A11, —S(O)OR^A11, —S(O)N(R^A11)₂, —S(O)₂R^A11, —S(O)₂OR^A11, —S(O)₂N(R^A11)₂, —OC(O)R^A11, —OC(O)OR^A11, —OC(O)OR^A11, —OC(O)N(R^A11)₂, —N(R^A11)C(O)OR^A11, or —N(R^A11)C(O)N(R^A11)₂, each R^A11is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^A12)², —OR^A12, —ON(R^A12)₂, —N(R^A12)N(R^A12)₂, —SR^A12, —C(O)OR^A12, —C(O)OR^A12, —C(O)N(R^A12)₂, —S(O)R^A12, —S(O)OR^A12, —S(O)N(R^A12)₂, —S(O)₂R^A12, —S(O)₂OR^A12, —S(O)₂N(R^A12)₂, —OC(O)R^A12, —OC(O)OR^A12, —OC(O)OR^A12, —OC(O)N(R^A12)₂, —N(R^A12)C(O)OR^A12, or —N(R^A12)C(O)N(R^A12)₂, wherein each R^A12is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl.

(b) at least one R^Ais halogen, cyano, nitro, —NH₂, —OH, —ONH₂, —NHNH₂, —C(O)OH, or —C(O)NH₂.

(d) at least one R^Ais —N(R^A11)₂or —OR^A11, wherein each R^A11is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, or —C₁-C₆alkylheteroaryl, wherein each alkyl, aryl, alkylaryl, heteroaryl, and alkylheteroaryl is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^A12)², —OR^A12, —ON(R^A12)₂, —N(R^A12)N(R^A12)₂, —SR^A12, —C(O)OR^A12, —C(O)OR^A12, —C(O)N(R^A12)₂, —S(O)R^A12, —S(O)OR^A12, —S(O)N(R^A12)₂, —S(O)₂R^A12, —S(O)₂OR^A12, —S(O)₂N(R^A12)₂, —OC(O)R^A12, —OC(O)OR^A12, —OC(O)N(R^A12)₂, —N(R^A12)C(O)OR^A12, or —N(R^A12)C(O)N(R^A12)₂, wherein each R^A12is independently hydrogen, or —C₁-C₆alkyl;

(e) at least one R^Ais —NHR^A11or —OR^A11, wherein R^A11is phenyl or pyridinyl, each optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^A12)², —OR^A12, —ON(R^A12)₂, —N(R^A12)N(R^A12)₂, —SR^A12, —C(O)R^A12, —C(O)OR^A12, —C(O)N(R^A12)₂, —S(O)₂R^A12, —S(O)₂OR^A12, —S(O)₂N(R^A12)₂, —OC(O)R^A12, —OC(O)OR^A12, —OC(O)N(R^A12)₂, —N(R^A12)C(O)OR^A12, or —N(R^A12)C(O)N(R^A12)₂, —C₁-C₆alkyl, -aryl, or -heteroaryl, wherein each R^A12is independently hydrogen, —C₁-C₆alkyl

(f) at least one R^Ais —NHR^A11, wherein R^A11is phenyl or pyridinyl, each optionally substituted with one or two groups which are each independently halogen, cyano, nitro, —N(R^A12)², —OR^A12, —ON(R^A12)₂, —N(R^A12)N(R^A12)₂, —SR^A12, —C(O)R^A12, —C(O)OR^A12, —C(O)N(R^A12)₂, —S(O)₂R^A12, —S(O)₂OR^A12, —S(O)₂N(R^A12)₂, —OC(O)R^A12, —OC(O)OR^A12, —OC(O)N(R^A12)₂, —N(R^A12)C(O)OR^A12, or —N(R^A12)C(O)N(R^A12)₂, —C₁-C₆alkyl, -aryl, or -heteroaryl, wherein each R^A12is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkyl. Even more preferably, only one R^Ais present and R^Ais —NHR^A11, wherein R^A11is phenyl or pyridinyl, each optionally substituted with one or two groups which are each independently halogen, cyano, nitro, —N(R^A12)², —OR^A12, —ON(R^A12)₂, —N(R^A12)N(R^A12)₂, —SR^A12, —C(O)R^A12, —C(O)OR^A12, —C(O)N(R^A12)₂, —S(O)₂R^A12, —S(O)₂OR^A12, —S(O)₂N(R^A12)₂, —OC(O)R^A12, —OC(O)OR^A12, —OC(O)N(R^A12)₂, —N(R^A12)C(O)OR^A12, or —N(R^A12)C(O)N(R^A12)₂, —C₁-C₆alkyl, -aryl, or -heteroaryl, wherein each R^A12is independently hydrogen, —C₁-C₆alkyl;

(g) at least one R^Ais —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, or —C₁-C₆alkylheteroaryl, wherein each alkyl, aryl, alkylaryl, heteroaryl, and alkylheteroaryl, is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)R^A21, —S(O)OR^A21, —S(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl;

(h) at least one R^Ais -aryl or -heteroaryl, each optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, -heteroaryl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl.

(i) only one R^Ais present and R^Ais -aryl or -heteroaryl, each optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, -heteroaryl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl;

(j) one of two R^Aare present and one R^Ais phenyl optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, -heteroaryl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl;

(k) one or two R^Aare present, one R^Ais phenyl optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, -heteroaryl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl, where the optionally substituted phenyl is ortho or meta to L;

(l) one or two R^Aare present, one R^Ais phenyl optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, -heteroaryl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl, where the optionally substituted phenyl is ortho to L;

(m) at least one R^Ais —C₁-C₆alkyl optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)R^A21, —S(O(OR^A21, —S(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl.

(n) at least one R^Ais —C₁-C₆alkyl optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)R^A21, —S(O)OR^A21, —S(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen or —C₁-C₆alkyl;

(o) at least one R^Ais —C₁-C₆alkyl substituted with one or two groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)R^A21, —S(O)OR^A21, —S(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen or —C₁-C₆alkyl; or

(p) only one R^Ais present and R^Ais —C₁-C₆alkyl substituted with one or two groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)R^A21, —S(O)OR^A21, —S(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen or —C₁-C₆alkyl.

A preferred subgenus of any of the preceding subgenera includes compounds in which L is

(a) a bond;

(b) —X-L¹, wherein L¹is -linear C₁-C₆alkyl- optionally substituted with one or two R^Lgroups

(d) -linear C₁-C₆alkyl- substituted with one R^Lgroup;

(e) -linear C₁-C₃alkyl- substituted with one R^Lgroup;

(f). -linear C₁-C₆alkyl-,

(g) —CH(R^L)— or

(h) —CH₂—.

A preferred subgenus of any of the preceding subgenera includes compounds in which X is

(a) a bond;

(b) —O—, —S—, or —N(R^X)—;

(d) —C(Y)—, —S(O)—, —S(O)₂, —OC(O)—, —N(R^X)C(O)—, —N(R^X)S(O)—, —OS(O)₂, or —N(R^X)S(O)₂—;

(e) —C(O)—, —C(═NH)—, or —N(H)C(O)—;

(f) —C₁-C₃alkylOC(O)—, —C₁-C₃alkylN(R^X)C(O)—, —C₁-C₃alkylN(R^X)S(O)—, —C₁-C₃alkylOS(O)₂, or —C₁-C₃alkylN(R^X)S(O)₂—;

(g) —C₁-C₃alkylN(R^X)C(O)—; or

(h) —C₁-C₂alkylN(H)C(O)—.

A preferred subgenus of any of the preceding subgenera includes compounds in which

(a) at least one R^Lis —C₁-C₆alkyl optionally substituted with one or two groups which are each independently halogen, cyano, nitro, —N(R^L11)₂, —OR^L11, —ON(R^L11)₂, —N(R^L11)N(R^L11)₂, —SR^L11, —C(O)R^L11, —C(O)OR^L11, —C(O)N(R^L11)₂, —S(O)R^L11, —S(O)OR^L11, —S(O)N(R^L11)₂, —S(O)₂R^L11, —S(O)₂OR^L11, —S(O)₂N(R^L11)₂, —OC(O)R^L11, —OC(O)OR^L11, —OC(O)N(R^L11)₂, —N(R^L11)C(O)OR^L11, or —N(R^L11)C(O)—N(R^L11)₂, wherein each R^L11is independently hydrogen or —C₁-C₆alkyl;

(b) at least one R^Lis —C₁-C₆alkyl-OR^L21, —C₁-C₆alkyl-NH—R^L21, —C₁-C₆alkyl-NHC(O)R^L21, —C₂-C₆alkenyl-OR^L21, —C₂-C₆alkenyl-NH—R^L21, or —C₂-C₆alkenyl-NHC(O)R^L21, wherein each R^L21is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, or —C₁-C₆alkylheteroaryl, wherein each alkyl, aryl, alkylaryl, heteroaryl, cycloalkyl, and alkylheteroaryl, is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^L22)₂, —OR^L22, —ON(R^L22)₂, —N(R^L22)N(R^L22)₂, —SR^L22, —C(O)R^L22, —C(O)OR^L22, —C(O)N(R^L22)₂, —S(O)R^L22, —S(O)OR^L22, —S(O)N(R^L22)₂, —S(O)₂R^L22, —S(O)₂OR^L22, —S(O)₂N(R^L22)₂, —OC(O)R^L22, —OC(O)OR^L22, —OC(O)N(R^L22)₂, —N(R^L22)C(O)OR^L22, or —N(R^L22)C(O)N(R^L22)₂, wherein each R^L22is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl;

(c) at least one R^Lis —N(R^L21)₂, —OR^L21, —ON(R^L21)₂, —N(R^L21)N(R^L21)₂, —C(O)R^L21, —C(O)OR^L21, —C(O)N(R^L21)₂, —OC(O)R^L21, —OC(O)OR^L21, —OC(O)N(R^L21)₂, —N(R^L21)C(O)OR^L21, or —N(R^L21)C(O)N(R^L21)₂, wherein each R^L21is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, or —C₁-C₆alkylheteroaryl, wherein each alkyl, aryl, alkylaryl, heteroaryl, cycloalkyl, and alkylheteroaryl, is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^L22)₂, —OR^L22, —ON(R^L22)₂, —N(R^L22)N(R^L22)₂, —SR^L22, —C(O)R^L22, —C(O)OR^L22, —C(O)N(R^L22)₂, —S(O)R^L22, —S(O)OR^L22, —S(O)N(R^L22)₂, —S(O)₂R^L22, —S(O)₂OR^L22, —S(O)₂N(R^L22)₂, —OC(O)R^L22, —OC(O)OR^L22, —OC(O)N(R^L22)₂, —N(R^L22)C(O)OR^L22, or —N(R^L22)C(O)N(R^L22)₂, wherein each R^L22is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl;

or (d) at least one R^Lis —N(R^L21)₂or —OR^L21, wherein each R^L21is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, or —C₁-C₆alkylheteroaryl, wherein each alkyl, aryl, alkylaryl, heteroaryl, and alkylheteroaryl, is optionally substituted with one or more halogen, cyano, nitro, —N(R^L22)₂, —OR^L22, —ON(R^L22)₂, —C(O)OR^L22, or —C(O)N(R^L22)₂, wherein each R^L22is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl.

Another preferred genus of the fourteenth aspect includes compounds in which the compound of formula (XXI) is according to one of the formulas (XXII)-(XXIX),

embedded image

wherein m is 0, 1, 2, or 3; and n is 0, 1, 2, 3, 4, or 5.

A preferred subgenus of any of the formulas (XXV)-(XXVII) includes compounds in which n is 1, 2, 3, 4, or 5. Preferably, n is 1 or 2. More preferably, n is 1.

A preferred subgenus of any of the formulas (XXII), (XXV), and (XXVIII), includes compounds in which m is 1.

A preferred subgenus of any of the formulas (XXII)-(XXIV), includes compounds in which ring A indolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzooxazolinyl, benzimidazolidinyl, benzothioxazolinyl, cromanyl, 2,3-dihydrobenzo[b][1,4]dioxanyl, benzo[d][1,3]dioxolyl, tetrahydronaphthyl, indenyl, or dihydroindenyl, each optionally substituted with one or more R^Agroups, and preferably, substituted with one or two R^Agroups.

Another preferred subgenus of any of the formulas (XXII)-(XXIV), includes compounds in which ring A is

(a) heteroaryl optionally substituted with one or more R^Agroups, and preferably, substituted with one or two R^Agroups.

(b) pyrrolyl, furanyl, thienyl, imidazolyl, benzothienyl, indolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothioxazolyl, benzotriazolyl, quinolinyl, or quinazolinyl, each optionally substituted with one or more R^Agroups, and preferably, substituted with one or two R^Agroups;

(c) pyridinyl, pyrimidinyl, pyrazinyl, or 1,3,5-triazinyl, each optionally substituted with one or more R^Agroups, and preferably, substituted with one or two R^Agroups;

(d) benzothienyl, indolyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothioxazolyl, or benzotriazolyl, each optionally substituted with one or more R^Agroups, and preferably, substituted with one or two R^Agroups; or

(e) benzothienyl, indolyl, or benzofuranyl, each optionally substituted with one or more R^Agroups, and preferably, substituted with one or two R^Agroups.

Another preferred subgenus of any of formulas (XXII)-(XXIV), includes compounds in which ring A is tetrahydroquinolinyl, 4,5,6,7-tetrahydrobenzimidazolyl, 4,5,6,7-tetrahydrobenzothienyl, 4,5,6,7-tetrahydrobenzo-furanyl, 4,5,6,7-tetrahydroindolyl, 4,5,6,7-tetrahydrobenzoxazolyl, 4,5,6,7-tetrahydrobenzo-thioxazolyl, each optionally substituted with one or more R^Agroups, and preferably, substituted with one or two R^Agroups.

Another preferred subgenus of any of formulas (XXII)-(XXIV), includes compounds in which ring A is C₅-C₁₀cycloalkyl substituted with one or two R^Agroups. Preferably, ring A is C₅-C₇cycloalkyl substituted with one or two R^Agroups.

A preferred subgenus of any of the preceding subgenera of formulas (XXII)-(XXXIII), includes compounds in which

(a) at least one R^Ais halogen, cyano, nitro, —N(R^A11)₂, —OR^A11, —ON(R^A11)₂, —N(R^A11)N(R^A11)₂, —SR^A11, —C(O)R^A11, —C(O)OR^A11, —C(O)N(R^A11)₂, —S(O)R^A11, —S(O)OR^A11, —S(O)N(R^A11)₂, —S(O)₂R^A11, —S(O)₂OR^A11, —S(O)₂N(R^A11)₂, —OC(O)R^A11, —OC(O)OR^A11, —OC(O)N(R^A11)₂, —N(R^A11)C(O)OR^A11, or —N(R^A11)C(O)N(R^A11)₂, wherein each R^A11is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^A12)₂, —OR^A12, —ON(R^A12)₂, —N(R^A12)N(R^A12)₂, —SR^A12, —C(O)R^A12, —C(O)OR^A12, —C(O)N(R^A12)₂, —S(O)R^A12, —S(O)OR^A12, —S(O)N(R^A12)₂, —S(O)₂R^A12, —S(O)₂OR^A12, —S(O)₂N(R^A12)₂, —OC(O)R^A12, —OC(O)OR^A12, —OC(O)N(R^A12)₂, —N(R^A12)C(O)OR^A12, or —N(R^A12)C(O)N(R^A12)₂, wherein each R^A12is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl.

(b) at least one R^Ais halogen, cyano, nitro, —NH₂, —OH, —ONH₂, —NHNH₂, —C(O)OH, or —C(O)NH₂;

(d) at least one R^Ais —N(R^A11)₂or —OR^A11, wherein each R^A11is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, or —C₁-C₆alkylheteroaryl, wherein each alkyl, aryl, alkylaryl, heteroaryl, and alkylheteroaryl is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^A12)₂, —OR^A12, —ON(R^A12)₂, —N(R^A12)N(R^A12)₂, —SR^A12, —C(O)R^A12, —C(O)OR^A12, —C(O)N(R^A12)₂, —S(O)R^A12, —S(O)OR^A12, —S(O)N(R^A12)₂, —S(O)₂R^A12, —S(O)₂OR^A12, —S(O)₂N(R^A12)₂, —OC(O)R^A12, —OC(O)OR^A12, —OC(O)N(R^A12)₂, —N(R^A12)C(O)OR^A12, or —N(R^A12)C(O)N(R^A12)₂, wherein herein each R^A12is independently hydrogen or —C₁-C₆alkyl;

(e) at least one R^Ais —NHR^A11or —OR^A11, wherein R^A11is phenyl or pyridinyl, each optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^A12)₂, —OR^A12, —ON(R^A12)₂, —N(R^A12)N(R^A12)₂, —SR^A12, —C(O)R^A12, —C(O)OR^A12, —C(O)N(R^A12)₂, —S(O)₂R^A12, —S(O)₂OR^A12, —S(O)₂N(R^A12)₂, —OC(O)R^A12, —OC(O)OR^A12, —OC(O)N(R^A12)₂, —N(R^A12)C(O)OR^A12, or —N(R^A12)C(O)N(R^A12)₂, —C₁-C₆alkyl, -aryl, or -heteroaryl, wherein each R^A12is independently hydrogen or —C₁-C₆alkyl;

(g) only one R^Ais present and R^Ais —NHR^A11, wherein R^A11is phenyl or pyridinyl, each optionally substituted with one or two groups which are each independently halogen, cyano, nitro, —N(R^A12)₂, —OR^A12, —ON(R^A12)₂, —N(R^A12)N(R^A12)₂, —SR^A12, —C(O)R^A12, —C(O)OR^A12, —C(O)N(R^A12)₂, —S(O)₂R^A12, —S(O)₂OR^A12, —S(O)₂N(R^A12)₂, —OC(O)R^A12, —OC(O)OR^A12, —OC(O)N(R^A12)₂, —N(R^A12)C(O)OR^A12, or —N(R^A12)C(O)N(R^A12)₂, —C₁-C₆alkyl, -aryl, or -heteroaryl, wherein each R^A12is independently hydrogen or —C₁-C₆alkyl;

(h) at least one R^Ais —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, or —C₁-C₆alkylheteroaryl, wherein each alkyl, aryl, alkylaryl, heteroaryl, and alkylheteroaryl, is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)R^A21, —S(O)OR^A21, —S(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl;

(i) at least one R^Ais -aryl or -heteroaryl, each optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, -heteroaryl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, C₁-C₆haloalkyl; -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl;

(j) only one R^Ais present and R^Ais -aryl or -heteroaryl, each optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, -heteroaryl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl;

(k) one R^Ais —C₁-C₆alkyl optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)R^A21, —S(O)OR^A21, —S(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl;

(l) at least one R^Ais —C₁-C₆alkyl optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)R^A21, —S(O)OR^A21, —S(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen or —C₁-C₆alkyl;

(m) at least one R^Ais —C₁-C₆alkyl substituted with one or two groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)R^A21, —S(O)OR^A21, —S(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen or —C₁-C₆alkyl; or

(n) only one R^Ais present and R^Ais —C₁-C₆alkyl substituted with one or two groups which are each independently halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A21)₂, —OR^A21, —ON(R^A21)₂, —N(R^A21)N(R^A21)₂, —SR^A21, —C(O)R^A21, —C(O)OR^A21, —C(O)N(R^A21)₂, —S(O)R^A21, —S(O)OR^A21, —S(O)N(R^A21)₂, —S(O)₂R^A21, —S(O)₂OR^A21, —S(O)₂N(R^A21)₂, —OC(O)R^A21, —OC(O)OR^A21, —OC(O)N(R^A21)₂, —N(R^A21)C(O)OR^A21, or —N(R^A21)C(O)N(R^A21)₂, wherein each R^A21is independently hydrogen or —C₁-C₆alkyl.

A preferred subgenus of any of the preceding subgenera of formulas (XXII)-(XXXIII), includes compounds in which

(a) X is a bond;

(b) X is —O—, —S—, or —N(R^X)—;

(d) X is —C(Y)—, —S(O)—, —S(O)₂—, —OC(O)—, —N(R^X)C(O)—, —N(R^X)S(O)—, —OS(O)₂—, or —N(R^X)S(O)₂—;

(e) X is —C(O)—, —C(═NH)—, or —N(H)C(O)—;

(f) X is —C₁-C₃alkylOC(O)—, —C₁-C₃alkylN(R^X)C(O)—, —C₁-C₃alkylN(R^X)—S(O)—, —C₁-C₃alkylOS(O)₂—, or —C₁-C₃alkylN(R^X)S(O)₂—;

(g) X is —C₁-C₃alkylN(R^X)C(O)—; or

(h) X is —C₁-C₂alkylN(H)C(O)—.

A preferred subgenus of any of the preceding subgenera of formulas (XXII), (XXV), and (XXVIII), includes compounds in which

(a) m is 1, 2, or 3, and X is —C(Y)—, —S(O)—, —S(O)₂—, —OC(O)—, —N(R^X)C(O)—, —N(R^X)S(O)—, —OS(O)₂—, or —N(R^X)S(O)₂—;

(b) m is 1 or 2, and X is —C(O)—, —C(═NH)—, or —N(H)C(O)—;

(d) m is 1 or 2, and X is —O—;

(e) m is 1, 2, or 3, and X is —C₁-C₃alkylOC(O)—, —C₁-C₃alkylN(R^X)C(O)—, —C₁-C₃alkylN(R^X)S(O)—, —C₁-C₃alkylOS(O)₂—, or —C₁-C₃alkylN(R^X)S(O)₂—;

(f) m is 1, 2, or 3, and X is —C₁-C₃alkylN(R^X)C(O)—; or

(g) m is 1 or 2, and X is —C₁-C₂alkylN(H)C(O)—.

A preferred subgenus of any of the preceding subgenera of formulas (XXII)-(XXXIII), includes compounds in which

(a) one R^Lis —C₁-C₆alkyl optionally substituted with one or two groups which are each independently halogen, cyano, nitro, —N(R^L11)₂, —OR^L11, —ON(R^L11)₂, —N(R^L11)N(R^L11)₂, —SR^L11, —C(O)R^L11, —C(O)OR^L11, —C(O)N(R^L11)₂, —S(O)R^L11, —S(O)OR^L11, —S(O)N(R^L11)₂, —S(O)₂R^L11, —S(O)₂OR^L11, —S(O)₂N(R^L11)₂, —OC(O)R^L11, —OC(O)OR^L11, —OC(O)N(R^L11)₂, —N(R^L11)C(O)OR^L11, or —N(R^L11)C(O)N(R^L11)₂, wherein each R^L11is independently hydrogen or —C₁-C₆alkyl;

(b) one R^Lis —C₁-C₆alkyl-OR^L21, —C₁-C₆alkyl-NH—R^L21, —C₁-C₆alkyl-NHC(O)R^L21, —C₂-C₆alkenyl-OR^L21, —C₂-C₆alkenyl-NH—R^L21, or —C₂-C₆alkenyl-NHC(O)R^L21, wherein each R^L21is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, or —C₁-C₆alkylheteroaryl, wherein each alkyl, aryl, alkylaryl, heteroaryl, cycloalkyl, and alkylheteroaryl, is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^L22)₂, —OR^L22, —ON(R^L22)₂, —N(R^L22)N(R^L22)₂, —SR^L22, —C(O)R^L22, —C(O)OR^L22, —C(O)N(R^L22)₂, —S(O)R^L22, —S(O)OR^L22, —S(O)N(R^L22)₂, —S(O)₂R^L22, —S(O)₂OR^L22, —S(O)₂N(R^L22)₂, —OC(O)R^L22, —OC(O)OR^L22, —OC(O)N(R^L22)₂, —N(R^L22)C(O)OR^L22, or —N(R^L22)C(O)N(R^L22)₂, wherein each R^L22is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl;

(c) one R^Lis —N(R^L21)₂, —OR^L21, —ON(R^L21)₂, —N(R^L21)N(R^L21)₂, —C(O)R^L21, —C(O)OR^L21, —C(O)N(R^L21)₂, —OC(O)R^L21, —OC(O)OR^L21, —OC(O)N(R^L21)₂, —N(R^L21)C(O)OR^L21, or —N(R^L21)C(O)N(R^L21)₂, wherein each R^L21is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, or —C₁-C₆alkylheteroaryl, wherein each alkyl, aryl, alkylaryl, heteroaryl, and alkylheteroaryl, is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^L22)₂, —OR^L22, —ON(R^L22)₂, —N(R^L22)N(R^L22)₂, —SR^L22, —C(O)R^L22, —C(O)OR^L22, —C(O)N(R^L22)₂, —S(O)R^L22, —S(O)OR^L22, —S(O)N(R^L22)₂, —S(O)₂R^L22, —S(O)₂OR^L22, —S(O)₂N(R^L22)₂, —OC(O)R^L22, —OC(O)OR^L22, —OC(O)N(R^L22)₂, —N(R^L22)C(O)OR^L22, or —N(R^L22)C(O)N(R^L22)₂, wherein each R^L22is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl; or

(d) one R^Lis —N(R^L21)₂or —OR^L21, wherein each R^L21is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, or —C₁-C₆alkylheteroaryl, wherein each alkyl, aryl, alkylaryl, heteroaryl, and alkylheteroaryl, is optionally substituted with one or more halogen, cyano, nitro, —N(R^L22)₂, —OR^L22, —ON(R^L22)₂, —C(O)OR^L22, or —C(O)N(R^L22)₂, wherein each R^L22is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl.

In our study of the activities of the foregoing compounds, we made the following observations and conclusions:

(1) The —O— in the aminoxy group is essential.

(2) A primary —NH₂group in aminoxy group is required for activity;

(3) The order of R—O—NH₂is essential

(4) Substitution of the 3-NO₂group by 3-Cl; 3-Br; 3-I; 3,5-Cl; increases activity ˜3-fold.

(5) The preferred position for phenyl substitution with small groups is in meta, followed by ortho and para.

(6) Multiple substitutions on the phenyl ring are accepted.

(7) Mono or bicyclic heterocycles, aromatic or non-aromatic can substitute the phenyl ring.

(8) Substitutions of the phenyl ring with another phenyl ring (substituted in para with Cl, —OCH₃or —CH₃) is accepted in ortho and in meta. The preferred position of substitution on the main phenyl ring depends on the secondary substituents in the secondary phenyl ring.

(9) A secondary aromatic ring can be linked to the main phenyl ring either directly, or through a linker. The longer the linker, the lesser the activity, though the activity is greatly affected by the nature of the substituents on the secondary phenyl ring.

(10) Several aromatic heterocycles can be joined to the C6 position of the main phenyl ring, alone or in combination with 3-Cl substitution on the main phenyl ring.

(11) Rigidification of the aminoxy group into a co-planar or non co-planar structure with the phenyl ring, generally diminishes compound activity.

(12) Increasing linker length decreases activity.

(13) Linker L substitutions with R^Lgroups are accepted.

(14) Substitutions of the benzylic position with ester and amides are well tolerated and increase activity compared to the unsubstituted parent compound.

(15) Substitution of the benzylic carbon with a phenyl group via a C0-C3 carbon or ether linker maintains the activity with respect to the unsubstituted benzylic carbon. On the contrary, substitution with a non-aromatic ring such as cyclohexyl or N-morpholino generally reduces the activity (especially for the N-morpholino).

(16) The length of the R^Lgroups have an influence on the activity. A C0 linker results in the highest activity, followed by a C2 linker and then by a C1 linker, for both aromatic or non-aromatic rings.

(17) Inclusion of an ether linker in R^Lincreases the activity compared to the corresponding alkyl linker.

The foregoing points are presented as a general guide of preferred characteristics of the compounds of the invention only and are not intended and should not be construed as limiting all aspects or embodiments of the compounds.

In a fifteenth aspect, the invention provides a pharmaceutical composition comprising a compound described in any of the preceding aspects (and any embodiment thereof), and a pharmaceutically acceptable carrier, diluent, or excipient, provided the compound is not 2-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)-1-(aminooxy)ethane. Such compositions are substantially free of non-pharmaceutically acceptable components, i.e., contain amounts of non-pharmaceutically acceptable components lower than permitted by US regulatory requirements at the time of filing this application. In some embodiments of this aspect, if the compound is dissolved or suspended in water, the composition further optionally comprises an additional pharmaceutically acceptable carrier, diluent, or excipient.

In a sixteenth aspect, the invention provides a use of compounds of described in any of the preceding aspects (and any embodiment thereof), as defined above, for the preparation of a medicament for the treatment of medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase. Medical conditions contemplated in this sixteenth aspect include all the conditions described herein.

In a seventeenth aspect, the invention provides a use of compounds of described in any of the preceding aspects (and any embodiment thereof), as defined above, for the preparation of a medicament to stimulate T cell proliferation or to reverse an immunologic state of anergy or immunosuppression.

In an embodiment of the seventeenth aspect, the anergy or immunosuppression is caused by expression of the enzyme indoleamine-2,3-dioxygenase.

In a eighteenth aspect, the invention provides a the use of compounds of described in any of the preceding aspects (and any embodiment thereof), as defined above, for the preparation of a medicament for the treatment of immunosuppression associated with cancer, infectious diseases, or viral infections.

In one embodiment of the eighteenth aspect, the invention provides the use of compounds of described in any of the preceding aspects (and any embodiment thereof), as defined above, for the preparation of a medicament for the treatment of tumor-specific immunosuppression associated with cancer. Preferably, the cancer is cancer of the colon, pancreas, breast, prostate, lung, brain, ovary, cervix, testes, renal, or head and neck, lymphoma, leukemia, melanoma, and the like.

In another embodiment of the eighteenth aspect, the invention the use of compounds described in any of the preceding aspects (and any embodiment thereof), as defined above, and embodiments thereof as defined above, for the preparation of a medicament for the treatment of infectious diseases. Preferably, the infections disease is tuberculosis or Leishmaniasis.

In another embodiment of the eighteenth aspect, the invention provides the use of compounds described in any of the preceding aspects (and any embodiment thereof), as defined above, and embodiments thereof as defined above, for the preparation of a medicament for the treatment of infectious diseases where the infectious disease is a viral infection. Preferably, the viral infection is selected from the group consisting of: hepatitis C virus (HCV), human papilloma virus (HPV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella zoster virus, poliovirus, coxsackie virus, and human immunodeficiency virus (HIV). More preferably, the viral infection is human immunodeficiency virus (HIV).

In a nineteenth aspect, the invention provides pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent, or carrier and a compound of the formula (XL),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

ring A is phenyl, tetrahydronaphthyl, quinolinyl, indolyl, benzothienyl, benzothiazolyl, benzodioxanyl, benzopyranyl, benzofuranyl, pyridyl or pyrimidinyl, each optionally substituted with one or more R^Agroups, wherein

each R^Ais independently halogen, cyano, nitro, —N(R^A1)₂, —OR^A1, —N(R^A1)N(R^A1)₂, —SR^A1, —C(O)R^A1, —C(O)OR^A1, —C(O)N(R^A1)₂, —S(O)R^A1, —S(O)OR^A1, —S(O)N(R^A1)₂, —S(O)₂R^A1, —S(O)₂OR^A1, —S(O)₂N(R^A1)₂, —OC(O)R^A1, —OC(O)OR^A1, —OC(O)N(R^A1)₂, —N(R^A1)C(O)OR^A1, —N(R^A1)S(O)₂R^A1, —N(R^A1)C(O)OR^A1, —N(R^A1)C(O)N(R^A1)₂, —C₁-C₆alkyl, —C₁-C₆haloalkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^A1)₂, —OR^A1, —N(R^A1)N(R^A1)₂, —SR^A1, —C(O)R^A1, —C(O)OR^A1, —C(O)N(R^A1)₂, —S(O)R^A1, —S(O)OR^A1, —S(O)N(R^A1)₂, —S(O)₂R^A1, —S(O)₂OR^A1, —S(O)₂N(R^A1)₂, —OC(O)R^A1, —OC(O)OR^A1, —OC(O)N(R^A1)₂, —N(R^A1)C(O)OR^A1, or —N(R^A1)C(O)N(R^A1)₂, wherein

each R^A1is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more halogen, cyano, nitro, —N(R^A2)₂, —OR^A2, —N(R^A2)N(R^A2)₂, —SR^A2, —C(O)R^A2, —C(O)OR^A2, —C(O)N(R^A2)₂, —S(O)R^A2, —S(O)OR^A2, —S(O)N(R^A2)₂—S(O)₂R^A2, —S(O)₂OR^A2, —S(O)₂N(R^A2)₂, —OC(O)R^A2, —OC(O)OR^A2, —OC(O)N(R^A2)₂, —N(R^A2)C(O)OR^A2, or —N(R^A2)C(O)N(R^A2)₂, wherein

each R^A2is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl; and

L is a bond or —C(H)(R^L)—, wherein

R^Lis hydrogen, halogen, cyano, nitro, —N(R^L1)₂, —OR^L1, —ON(R^L1)₂, —N(R^L1)N(R^L1)₂, —N(R^L1)C(O)R^L1, —N(R^L1)S(O)₂R^L1, —SR^L1, —C(O)R^L1, —C(O)OR^L1, —C(O)N(R^L1)₂, —S(O)R^L1, —S(O)OR^L1, —S(O)N(R^L1)₂, —S(O)₂R^L1, —S(O)₂OR^L1, —S(O)₂N(R^L1)₂, —OC(O)R^L1, —OC(O)OR^L1, —OC(O)N(R^L1)₂, —N(R^L1)C(O)OR^L1, —N(R^L1)C(O)N(R^L1)₂, —C₁-C₆alkyl, —C₁-C₆haloalkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, —C₁-C₆alkyl(C₃-C₈)cycloalkyl, -heterocyclyl, or —C₁-C₆alkylheterocyclyl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, heterocyclyl, and alkylheterocyclyl is optionally substituted with one halogen, cyano, nitro, —N(R^L1)₂, —N(R^L1)C(O)R^L1, —OR^L1, —N(R^L1)N(R^L1)₂, —SR^L1, —C(O)R^L1, —C(O)OR^L1, —C(O)N(R^L1)₂, —S(O)R^L1, —S(O)OR^L1, —S(O)N(R^L1)₂, —S(O)₂R^L1, —S(O)₂OR^L1, —S(O)₂N(R^L1)₂, —OC(O)R^L1, —OC(O)OR^L1, —OC(O)N(R^L1)₂, —N(R^L1)C(O)OR^L1, or —N(R^L1)C(O)N(R^L1)₂, wherein

each R^L1is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, —C₁-C₆alkyl(C₃-C₈)cycloalkyl, or -heterocyclyl, wherein alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, and heterocyclyl, is optionally substituted with one or more groups which are each independently halo en cyano nitro, —N(R^L11)₂, —OR^L11, —ON(R^L11)₂, —N(R^L11)N(R^L11)₂, —SR^L11, —C(O)R^L11, —C(O)OR^L11, —C(O)N(R^L11)₂, —S(O)R^L11, —S(O)OR^L11, —S(O)N(R^L11)₂—S(O)₂R^L11, —S(O)₂OR^L11, —S(O)₂N(R^L11)₂, —OC(O)R^L11, —OC(O)OR^L11, —OC(O)N(R^L11)₂, —N(R^L11)C(O)OR^L11, —N(R^L11)C(O)N(R^L11)₂, wherein each R^L11is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl,

provided that

(i) when ring A is phenyl and R^Lis hydrogen, then ring A is substituted with at least one R^A;

(ii) when ring A is phenyl and R^Lis hydrogen, —COOH, unsubstituted C₁-C₆alkyl, —C₁-C₆alkyl-COOH, or unsubstituted phenyl, then ring A is substituted with at least one R^Athat is not halogen, hydroxy, trifluoromethyl, C₁-C₅alkyl, C₁-C₄alkoxy, nitro, amino, C₁-C₄alkylthio, benzyloxy, or —OC(O)R^L1;

(iii) when ring A is phenyl and R^Lis hydrogen, then R^Ais not hydroxy, —C(O)N(H)(isopropyl), or —CH₂C(O)OR^A1;

(iv) when ring A is phenyl and L is a bond, then ring A is substituted with at least one R^Athat is not halogen, nitro, trifluoromethyl, or methyl.

In one embodiment of the nineteenth aspect, the compound is according to formula (XLI),

embedded image

or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, or 3.

In another embodiment of the nineteenth aspect, the compound is according to formula (XLII),

embedded image

or a pharmaceutically acceptable salt thereof, wherein

n is 0, 1, or 2; and

R^Bis aryl or heteroaryl, each optionally substituted with one or more halogen, cyano, nitro, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, -heterocyclyl, —N(R^B1)₂, —OR^B1, —N(R^B1)N(R^B1)₂, —SR^B1, —C(O)R^B1, —C(O)OR^B1, —C(O)N(R^B1)₂, —S(O)R^B1, —S(O)OR^B1, —S(O)N(R^B1)₂, —S(O)₂R^B1, —S(O)₂OR^B1, —S(O)₂N(R^B1)₂, —OC(O)R^B1, —OC(O)OR^B1, —OC(O)N(R^B1)₂, —N(R^B1)C(O)OR^B1, or —N(R^B1)C(O)N(R^B1)₂, wherein

each R^B1is independently hydrogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, or -heterocyclyl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more halogen, cyano, nitro, —N(R^B2)₂, —OR^B2, —N(R^B2)N(R^B2)₂, —SR^B2, —C(O)R^B2, —C(O)OR^B2, —C(O)N(R^B2)₂, —S(O)R^B2, —S(O)OR^B2, —S(O)N(R^B2)₂, —S(O)₂R^B2, —S(O)₂OR^B2, —S(O)₂N(R^B2)₂, —OC(O)R^B2, —OC(O)OR^B2, —OC(O)N(R^B2)₂, —N(R^B2)C(O)OR^B2, or —N(R^B2)C(O)N(R^B2)₂, wherein

each R^B2is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl.

In another embodiment of the nineteenth aspect, the compound is according to formula (XLII),

embedded image

or a pharmaceutically acceptable salt thereof.

In an embodiment of formulae (XLII) and (XLIII), R^Bis phenyl optionally substituted with one or more halogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —N(R^B1)₂, —OR^B1, or —C(O)OR^B1, wherein each R^B1is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, wherein each R^B2is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl.

In another embodiment of formulae (XLII) and (XLIII), R^Bis phenyl optionally substituted with one halogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —N(R^B1)₂, —OR^B1, or —C(O)OR^B1, wherein each R^B1is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, wherein each R^B2is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl.

In an embodiment of formulae (XLII) and (XLIII), R^Bis thienyl, pyrimidinyl, indolyl, or pyridyl.

In another embodiment of the nineteenth aspect, the compound is according to formula (XLIV),

embedded image

or a pharmaceutically acceptable salt thereof.

In an embodiment of formulae (XLIV), R^Bis phenyl optionally substituted with one or more halogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —N(R^B1)², —OR^B1, or —C(O)OR^B1, wherein each R^B1is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, wherein each R^B2is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl.

In another embodiment of formulae (XLIV), R^Bis phenyl optionally substituted with one halogen, —C₁-C₆alkyl, —C₁-C₆haloalkyl; —N(R^B1)², —OR^B1, or —C(O)OR^B1, wherein each R^B1is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, wherein each R^B2is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl.

In another embodiment of formulae (XLIV), R^Bis thienyl, pyrimidinyl, indolyl, or pyridyl.

In any of formulae (XL)-(XLIV), and any of the preceding embodiments thereof, RL is one of the following:

(a) R^Lis hydrogen;

(b) —C₁-C₆alkyl-OR^L21, —C₁-C₆alkyl-NH—R^L21, —C₁-C₆alkyl-NHC(O)R^L21, —C₂-C₆alkenyl-OR^L21, —C₂-C₆alkenyl-NH—R^L21or —C₂-C₆alkenyl-NHC(O)R^L21wherein each R^L21is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, —C₁-C₆alkyl(C₃-C₈)cycloalkyl, or -heterocyclyl, wherein alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, and heterocyclyl, is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^L22)₂, —OR^L22, —ON(R^L22)₂—N(R^L22)N(R^L22)₂, —SR^L22, —C(O)R^L22, —C(O)OR^L22, —C(O)N(R^L22)₂, —S(O)R^L22, —S(O)OR^L22, —S(O)N(R^L22)₂, —S(O)₂R^L22, —S(O)₂OR^L22, —S(O)₂N(R^L22)₂, —OC(O)R^L22, —OC(O)OR^L22, —OC(O)N(R^L22)₂, —N(R^L22)C(O)OR^L22, or —N(R^L22)C(O)N(R^L22)₂, wherein each R^L22is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl;

(c) —C₁-C₆alkyl-OR^L21, —C₁-C₆alkyl-NH—R^L21, or —C₁-C₆alkyl-NHC(O)R^L21, wherein each R^L21is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, —C₁-C₆alkyl(C₃-C₈)cycloalkyl, or -heterocyclyl, wherein alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, and heterocyclyl, is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^L22)₂, —OR^L22, —ON(R^L22)₂, —N(R^L22)N(R^L22)₂, —SR^L22, —C(O)R^L22, —C(O)OR^L22, —C(O)N(R^L22)₂, —S(O)R^L22, —S(O)OR^L22, —S(O)N(R^L22)₂, —S(O)₂R^L22, —S(O)₂OR^L22, —S(O)₂N(R^L22)₂, —OC(O)R^L22, —OC(O)OR^L22, —OC(O)N(R^L22)₂, —N(R^L22)C(O)OR^L22, or —N(R^L22)C(O)N(R^L22)₂, wherein each R^L22is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl;

(d) —C₂-C₆alkenyl-OR^L21, —C₂-C₆alkenyl-NH—R^L21, or —C₂-C₆alkenyl-NHC(O)R^L21, wherein each R^L21is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, —C₁-C₆alkyl(C₃-C₈)cycloalkyl, or -heterocyclyl, wherein alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, and heterocyclyl, is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^L22)₂, —OR^L22, —ON(R^L22)₂, —N(R^L22)N(R^L22)₂, —SR^L22, —C(O)R^L22, —C(O)OR^L22, —C(O)N(R^L22)₂, —S(O)R^L22, —S(O)OR^L22, —S(O)N(R^L22)₂, —S(O)₂R^L22, —S(O)₂OR^L22, —S(O)₂N(R^L22)₂, —OC(O)R^L22, —OC(O)OR^L22, —OC(O)N(R^L22)₂, —N(R^L22)C(O)OR^L22, or —N(R^L22)C(O)N(R^L22)₂, wherein each R^L22is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl;

(e) —N(R^L21)₂, —OR^L21, —ON(R^L21)₂, —N(R^L21)N(R^L21)₂, —C(O)R^L21, —C(O)OR^L21, —C(O)N(R^L21)₂, —OC(O)R^L21, —OC(O)OR^L21, —OC(O)N(R^L21)₂, —N(R^L21)C(O)OR^L21, or —N(R^L21)C(O)N(R^L21)₂, wherein each R^L21is independently hydrogen, —C₁-C₆alkyl, -aryl, —C₁-C₆alkylaryl, -heteroaryl, —C₁-C₆alkylheteroaryl, —C₃-C₈cycloalkyl, —C₁-C₆alkyl(C₃-C₈)cycloalkyl, or -heterocyclyl, wherein alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, and heterocyclyl, is optionally substituted with one or more groups which are each independently halogen, cyano, nitro, —N(R^L22)₂, —OR^L22, —ON(R^L22)₂, —N(R^L22)N(R^L22)₂, —SR^L22, —C(O)R^L22, —C(O)OR^L22, —C(O)N(R^L22)₂, —S(O)R^L22, —S(O)OR^L22, —S(O)N(R^L22)₂, —S(O)₂R^L22, —S(O)₂OR^L22, —S(O)₂N(R^L22)₂, —OC(O)R^L22, —OC(O)OR^L22, —OC(O)N(R^L22)₂, —N(R^L22)C(O)OR^L22, or —N(R^L22)C(O)N(R^L22)₂, wherein each R^L22is independently hydrogen, —C₁-C₆alkyl, aryl, or —C₁-C₆alkylaryl;

(f) —C₁-C₂alkyl-N(R^L1)₂;

(g) —C₁-C₂alkyl-N(R^L1)C(O)R^L1;

(h) —C₁-C₂alkyl-OR^L1;

(i) —C₁-C₂alkyl-C(O)OR^L1;

(j) —C₁-C₂alkyl-C(O)N(R^L1)₂;

(k) —C₁-C₂alkyl-N(R^L1)C(O)OR^L1; or

(l) —C(O)N(R^L1)₂.

In a twentieth aspect, the invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient, diluent, or carrier and a compound in Table 15 (infra).

In a twenty-first aspect, the invention provides methods for treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a pharmaceutical composition of the nineteenth of twentieth aspects.

In an embodiment of the twenty-first aspect, the immunosuppression is associated with an infectious disease, or cancer.

In another embodiment of the twenty-first aspect, the immunosuppression is associated with an infectious disease and the infectious disease is a viral infection selected from the group consisting of: hepatitis C virus (HCV), human papilloma virus (HPV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), poliovirus, varicella zoster virus, coxsackie virus, human immunodeficiency virus (HIV).

In an embodiment of the twenty-first aspect, the immunosuppression is immunsupression associated with HIV-1 infection.

In another embodiment of the twenty-first aspect, the immunosuppression is associated with an infectious disease and the infectious disease is tuberculosis or Leishmaniasis.

In another embodiment of the twenty-first aspect, the immunosuppression is associated with a cancer.

In an embodiment of the twenty-first aspect, the immunosuppression is tumor-specific immunosuppression associated with cancer.

In another embodiment of the twenty-first aspect, the immunosuppression is associated with a cancer, wherein the cancer is colon, pancreas, breast, prostate, lung, brain, ovary, cervix, testes, renal, head, or neck cancer, or lymphoma, leukemia, or melanoma.

Definitions

Terms used herein may be preceded and/or followed by a single dash, “—”, or a double dash, “═”, to indicate the bond order of the bond between the named substituent and its parent moiety; a single dash indicates a single bond and a double dash indicates a double bond. In the absence of a single or double dash it is understood that a single bond is formed between the substituent and its parent moiety; further, substituents are intended to be read “left to right” unless a dash indicates otherwise. For example, C₁-C₆alkoxycarbonyloxy and —OC(O)C₁-C₆alkyl indicate the same functionality; similarly arylalkyl and -alkylaryl indicate the same functionality.

The term “alkenyl” as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

The term “linear alkenyl” as used herein means straight chain hydrocarbon containing from 2 to 10 carbons, unless otherwise specified, and containing at least one carbon-carbon double bond. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, and 3-decenyl.

The term “alkoxy” as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.

The term “alkyl” as used herein, means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. When an “alkyl” group is a linking group between two other moieties, then it may also be a straight or branched chain; examples include, but are not limited to —CH₂—, —CH₂CH₂—, —CH₂CH₂CHC(CH₃)—, —CH₂CH(CH₂CH₃)CH₂—.

The term “linear alkyl” as used herein, means a straight chain hydrocarbon containing from 1 to 10 carbon atoms, unless otherwise specified. Linear alkyl includes methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. When a “linear alkyl” group is a linking group between two other moieties, then it is also a straight chain; examples include, but are not limited to —CH₂—, —CH₂CH₂—, and —CH₂CH₂CH₂—.

The term “alkynyl” as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.

The term “aryl,” as used herein, means phenyl (i.e., monocyclic aryl), or a bicyclic ring system containing at least one aromatic ring containing only carbon atoms in the aromatic ring. The bicyclic aryl can be naphthyl, or a phenyl fused to a cycloalkyl, or a phenyl fused to a cycloalkenyl, or a phenyl fused to a heterocyclyl. The bicyclic aryl can be attached to the parent molecular moiety through any atom contained within the bicyclic aryl. Representative examples of the bicyclic aryl include, but are not limited to, dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl, tetrahydronaphthalenyl, 2,3-dihydrobenzofuranyl, or benzo[d][1,3]di-oxolyl.

The term “arylalkyl” and “-alkylaryl” as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl.

The term “carboxy” as used herein, means a —CO₂H group.

The term “cyano” as used herein, means a —CN group.

The term “cyanoalkyl” as used herein, means a cyano group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of cyanoalkyl include, but are not limited to, cyanomethyl, 2-cyanoethyl, and 3-cyanopropyl.

The term “cycloalkyl” as used herein, means a monocyclic, bicyclic, or tricyclic ring systems, where such groups can be saturated or unsaturated, but not aromatic. Monocyclic ring systems are exemplified by a saturated cyclic hydrocarbon group containing from 3 to 8 carbon atoms. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Bicyclic ring systems are exemplified by a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms. Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Tricyclic ring systems are exemplified by a bicyclic ring system in which two non-adjacent carbon atoms of the bicyclic ring are linked by a bond or an alkylene bridge of between one and three carbon atoms. Representative examples of tricyclic-ring systems include, but are not limited to, tricyclo[3.3.1.0^3,7]nonane and tricyclo[3.3.1.1^3,7]decane (adamantane).

The term “formyl” as used herein, means a —C(O)H group.

The term “halo” or “halogen” as used herein, means —Cl, —Br, —I or —F.

The term “haloalkyl” as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.

The term “heteroaryl,” as used herein, means a monocyclic heteroaryl or a bicyclic ring system containing at least one heteroaromatic ring. The monocyclic heteroaryl can be a 5 or 6 membered ring. The 5 membered ring consists of two double bonds and one, two, three or four nitrogen atoms and optionally one oxygen or sulfur atom. The 6 membered ring consists of three double bonds and one, two, three or four nitrogen atoms. The 5 or 6 membered heteroaryl is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the heteroaryl. Representative examples of monocyclic heteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and triazinyl. The bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, or a monocyclic heteroaryl fused to a cycloalkyl, or a monocyclic heteroaryl fused to a cycloalkenyl, or a monocyclic heteroaryl fused to a monocyclic heteroaryl. The bicyclic heteroaryl is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the bicyclic heteroaryl. Representative examples of bicyclic heteroaryl include, but are not limited to, benzimidazolyl, benzofuranyl, benzothienyl, benzoxadiazolyl, cinnolinyl, dihydroquinolinyl, dihydroisoquinolinyl, furopyridinyl, indazolyl, indolyl, isoquinolinyl, naphthyridinyl, quinolinyl, tetrahydroquinolinyl, and thienopyridinyl.

The term “heteroarylalkyl” and “-alkylheteroaryl” as used herein, means a heteroaryl, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heteroarylalkyl include, but are not limited to, fur-3-ylmethyl, 1H-imidazol-2-ylmethyl, 1H-imidazol-4-ylmethyl, 1-(pyridin-4-yl)ethyl, pyridin-3-ylmethyl, 6-chloropyridin-3-ylmethyl, pyridin-4-ylmethyl, (6-(trifluoromethyl)pyridin-3-yl)methyl, (6-(cyano)pyridin-3-yl)methyl, (2-(cyano)pyridin-4-yl)methyl, (5-(cyano)pyridin-2-yl)methyl, (2-(chloro)pyridin-4-yl)methyl, pyrimidin-5-ylmethyl, 2-(pyrimidin-2-yl)propyl, thien-2-ylmethyl, and thien-3-ylmethyl.

The term “heterocyclyl” as used herein, means a monocyclic heterocycle or a bicyclic heterocycle, where such groups can be saturated or unsaturated, but not aromatic. The monocyclic heterocycle is a 3, 4, 5, 6 or 7 membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S. The 3 or 4 membered ring contains 1 heteroatom selected from the group consisting of O, N and S. The 5 membered ring contains zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. The 6 or 7 membered ring contains zero, one or two double bonds and one, two or three heteroatoms selected from the group consisting of O, N and S. The monocyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle. Representative examples of monocyclic heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. The bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, or a monocyclic heterocycle fused to a cycloalkyl, or a monocyclic heterocycle fused to a cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle, or a monocyclic heterocycle fused to a monocyclic heteroaryl. The bicyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the bicyclic heterocycle. Representative examples of bicyclic heterocycle include, but are not limited to, 1,3-benzodioxolyl, 1,3-benzodithiolyl, 2,3-dihydro-1,4-benzo dioxinyl, 2,3-dihydro-1-benzofuranyl, 2,3-dihydro-1-benzothienyl, 2,3-dihydro-1H-indolyl, and 1,2,3,4-tetrahydroquinolinyl.

The term “hydroxy” as used herein, means an —OH group.

The term “hydroxyalkyl” as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.

The term “mercapto” as used herein, means a —SH group.

The term “nitro” as used herein, means a —NO₂group.

The term “saturated” as used herein means the referenced chemical structure does not contain any multiple carbon-carbon bonds. For example, a saturated cycloalkyl group as defined herein includes cyclohexyl, cyclopropyl, and the like.

The term “unsaturated” as used herein means the referenced chemical structure contains at least one multiple carbon-carbon bond, but is not aromatic. For example, a unsaturated cycloalkyl group as defined herein includes cyclohexenyl, cyclopentenyl, cyclohexadienyl, and the like.

As used herein, the term “cell” is meant to refer to a cell that is in vitro, ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal.

As used herein, the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, “contacting” the IDO enzyme with a compound includes the administration of a compound described herein to an individual or patient, such as a human, having IDO, as well as, for example, introducing a compound into a sample containing a cellular or purified preparation containing the IDO enzyme.

As used herein, the term “individual” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.

As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following:

(1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease;

(2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder; and

(3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.

As used here, the terms “treatment” and “treating” means (i) ameliorating the referenced disease state, for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing or improving the pathology and/or symptomatology) such as decreasing the severity of disease; or (ii) eliciting the referenced biological effect (e.g., IDO modulation or tryptophan degradation inhibition).

As used herein, the terms “catalytic pocket”, “catalytic site”, “active site” collectively and indistinctly refer to a region of the enzyme that contains amino acid residues responsible for the substrate binding (charge, hydrophobicity, steric hindrance) and catalytic amino acid residues which act as proton donors or acceptors or are responsible for binding a cofactor and participate in the catalisis of a chemical reaction.

As used herein, the phrase “pharmaceutically acceptable salt” refers to both pharmaceutically acceptable acid and base addition salts and solvates. Such pharmaceutically acceptable salts include salts of acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic, methanesulfonic, nitric, benzoic, citric, tartaric, maleic, hyrdoiodic, alkanoic such as acetic, HOOC—(CH₂)_n—COOH where n is 0-4, and the like. Non-toxic pharmaceutical base addition salts include salts of bases such as sodium, potassium, calcium, ammonium, and the like. Those skilled in the art will recognize a wide variety of non-toxic pharmaceutically acceptable addition salts.

Methods of Use

Compounds described herein can modulate activity of the enzyme indoleamine-2,3-dioxygenase (IDO). The term “modulate” is meant to refer to an ability to increase or decrease activity of an enzyme or receptor. Accordingly, compounds described herein can be used in methods of modulating IDO by contacting the enzyme with any one or more of the compounds or compositions described herein. In some embodiments, the compounds described herein can act as inhibitors of IDO. In further embodiments, the compounds described herein can be used to modulate activity of IDO in cell or in an individual in need of modulation of the enzyme by administering a modulating (e.g., inhibiting) amount of a compound described herein.

Further provided are methods of inhibiting the degradation of tryptophan and preventing the production of N-formylkynurenine in a system containing cells expressing IDO such as a tissue, living organism, or cell culture. In some embodiments methods of altering (e.g., increasing) extracellular tryptophan levels in a mammal comprise administering an effective amount of a compound of composition provided herein. Methods of measuring tryptophan levels and tryptophan degradation are routine in the art.

Further provided are methods of inhibiting immunosuppression such as IDO-mediated immunosuppression in a patient by administering to the patient an effective amount of a compound or composition recited herein. IDO-mediated immunosuppression has been associated with, for example, cancers, tumor growth, metastasis, infectious diseases (e.g., viral infection), viral replication, etc.

Further provided are methods for treating tumor-specific immunosuppression associated with cancer in a patient by administering to the patient an effective amount of a compound or composition recited herein. Example tumor-specific immunosuppression associated with cancers treatable by the methods herein include immunosuppression associated with cancer of the colon, pancreas, breast, prostate, lung, brain, ovary, cervix, testes, renal, head and neck, lymphoma, leukemia, melanoma, and the like.

For example, IDO-mediated immunosuppression associated with viral infection, is associated with a viral infection selected from the group consisting of: hepatitis C virus (HCV), human papilloma virus (HPV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), poliovirus, varicella zoster virus, coxsackie virus, human immunodeficiency virus (HIV).

Further provided are methods for treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, in a patient by administering to the patient an effective amount of a compound or composition recited herein.

In other examples, IDO-mediated immunosuppression associated with and infectious diseases is associated with tuberculosis or Leishmaniasis.

For example, a patient undergoing or having completed a course of chemotherapy and/or radiation therapy for the treatment of a disease state, such as a cancer, can benefit from administering to the patient a therapeutically effective amount of a compound or composition recited herein for inhibiting immunosuppression resulting from the disease state and/or treatment thereof.

Further provided are methods of treating diseases associated with activity or expression, including abnormal activity and/or overexpression, of IDO in an individual (e.g., patient) by administering to the individual in need of such treatment a therapeutically effective amount or dose of a compound described herein or a pharmaceutical composition thereof. Example diseases can include any disease, disorder or condition that is directly or indirectly linked to expression or activity of the IDO enzyme, such as over expression or abnormal activity. An IDO-associated disease can also include any disease, disorder or condition that can be prevented, ameliorated, or cured by modulating enzyme activity.

Examples of IDO-associated diseases include cancer, viral infection such as HIV infection, depression, neurodegenerative disorders such as Alzheimer's disease and Huntington's disease, trauma, age-related cataracts, organ transplantation (e.g., organ transplant rejection), and autoimmune diseases including asthma, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and systemic lupus erythematosusor. Example cancers treatable by the methods herein include cancer of the colon, pancreas, breast, prostate, lung, brain, ovary, cervix, testes, renal, head and neck, lymphoma, leukemia, melanoma, and the like.

Combination Therapy

One or more additional pharmaceutical agents for treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g., IL2, GM-CSF, etc.), and/or tyrosine kinase inhibitors can be used in combination with the compounds described herein for treatment of IDO-associated diseases, disorders or conditions (as noted above) or for enhancing the effectiveness of the treatment of a disease state or condition, such as cancer. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.

Suitable antiviral agents contemplated for use in combination with the compounds described herein can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.

Example suitable NRTIs include zidovudine (AZT); didanosine (ddI); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(−)—FTC]; beta-L-FD4 (also called beta-L-D4C and named beta-L-2′,3′-dicleoxy-5-fluoro-cytidene); DAPD, ((−)-beta-D-2,6,-diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinedione); and (+)-calanolide A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK-639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No. 11607.

Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (Cytoxan™), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.

Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.

Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (Taxol™), mithramycin, deoxyco-formycin, mitomycin-C, L-asparaginase, interferons (especially IFN-α), etoposide, and teniposide.

Other cytotoxic agents include navelbene, CPT-11, anastrazole, letrazole, capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine.

Also suitable are cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.

Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4,4-1BB and PD-1, or antibodies to cytokines (IL-10, TGF-β, etc.).

Other anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2, CCR4 and CCR6.

Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.

Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.

Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the “Physicians' Desk Reference” (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, N.J.), the disclosure of which is incorporated herein by reference as if set forth in its entirety.

Pharmaceutical Formulations and Dosage Forms

When employed as pharmaceuticals, the compounds described herein can be administered in the form of pharmaceutical compositions which is a combination of a compound described herein and a pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Also, pharmaceutical compositions can contain, as the active ingredient, one or more of the compounds described herein above in combination with one or more pharmaceutically acceptable carriers. In making the compositions described herein, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of a compound described herein.

The tablets or pills can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

The liquid forms in which the compounds and compositions can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.

The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.

The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

The therapeutic dosage of the compounds can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound described herein in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds described herein can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

The compounds described herein can also be formulated in combination with one or more additional active ingredients which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like.

Screening of IDO Inhibitory Compounds

Molecular Modeling Methods

Protein structure information, typically in the form of the atomic structure coordinates, can be used in a variety of computational or computer-based methods to design, screen for or identify compounds that bind to the catalytic site of IDO. Such information is useful to design improved analogues of known IDO inhibitors or to design novel classes of compounds based on the structure of reaction intermediates of IDO—complexed with its substrates oxygen and tryptophan.

In one embodiment, compounds whose structure mimics the reaction intermediates of tryptophan dioxygenation catalyzed by IDO can also be deduced from the proposed reaction mechanism.

In still another embodiment, the structure of the IDO catalytic domain and enzyme active site can be used to computationally screen small molecule databases for functional groups or compounds that can bind in whole, or in part, to IDO. In this screening, the quality of fit of such entities or compounds to the binding site may be judged by methods such as estimated interaction energy or by shape complementarity. See, for example, Meng et al., (1992), J. Comp. Chem., 13:505-524.

Compounds fitting the catalytic site serve as a starting point for an iterative design, synthesis and test cycle in which new compounds are selected and optimized for desired properties including affinity, efficacy, and selectivity. For example, the compounds can be subjected to additional modification, such as replacement or addition of R-group substituents of a core structure identified for a particular class of binding compounds, modeling or activity screening if desired, and then subjected to additional rounds of testing.

By “modeling” is intended to mean quantitative and qualitative analysis of molecular structure and/or function based on atomic structural information and interaction models of a receptor and a ligand agonist or antagonist. Modeling thus includes conventional numeric-based molecular dynamic and energy minimization models, interactive computer graphic models, modified molecular mechanics models, distance geometry and other structure-based constraint models. Modeling is performed using a computer running specialized software.

Molecular Docking

Identification of IDO protein structure complexed with the IDO inhibitor 4-phenylimidazole and identification of the catalytic site structure has made it possible to apply the principles of molecular recognition to evaluate a variety of compound structures which are complementary to the structure of the site. Accordingly, computer programs that employ various docking algorithms can be used to identify compounds that fit into the catalytic site of IDO and can interact with amino acids defining such catalytic pocket, or with its heme cofactor, thus preventing binding and/or processing of its natural substrate, tryptophan. Fragment-based docking can also be used to build molecules de novo inside the catalytic site by placing molecular fragments that have a complementary fit with the site, thereby optimizing intermolecular interactions and subsequently synthesizing molecules that contain several of the molecular fragments that interact with amino acids in the catalytic pocket. Techniques of computational chemistry can further be used to optimize the geometry of the bound conformations.

Docking may be accomplished using commercially available software such as GLIDE (available from Schrodinger, Inc., Portland, Oreg.); DOCK (Kuntz et al., (1982), J. Mol. Biol., 161:269-288, available from University of California, San Francisco, Calif.); AUTODOCK (Goodsell & Olsen, (1990), Proteins: Structure, Function, and Genetics 8:195-202, available from Scripps Research Institute, La Jolla, Calif.; GOLD (Jones, et al., (1995), J. Mol. Biol., 245:43-53, available from the Cambridge Crystallographic Data Centre, 12 Union Road. Cambridge, U.K.; QUANTA (available from Accelrys, a subsidiary of Pharmacopeia, Inc.); SYBYL, (available from Tripos, Inc., 1700 South Hanley Road, St. Louis, Mo.), and ICM (Abagayan, et al., available from MolSoft, L.L.C., 3366 North Torrey Pines Court, Suite 300, La Jolla, Calif.).

Docking is typically followed by energy minimization and molecular dynamics simulations of the docked molecule, using molecular mechanics force fields such as MM2 (see, e.g., Rev. Comp. Chem., 3, 81 (1991)), MM3 (Allinger, N. L., Bowen, J. P., and coworkers, University of Georgia; see, J. Comp. Chem., 17:429 (1996); available from Tripos, Inc., 1699 South Hanley Road, St. Louis, Mo.), CHARMM (see, e.g., B. R. Brooks, R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus, “CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations,” J. Comp. Chem., 4, 187-217, (1983)), a version of AMBER such as version 7, (Kollman, P. A., et al., School of Pharmacy, Department of Pharmaceutical Chemistry, University of California at San Francisco), and Discover (available from Accelrys, a subsidiary of Pharmacopeia, Inc.).

Constructing Molecules that Bind to IDO

A compound that binds to the catalytic site of IDO, thereby exerting a modulatory or other effect on its function, may be computationally designed and evaluated by means of a series of steps in which functional groups or other fragments are screened and selected for their ability to associate with the individual binding pockets or other areas of the IDO catalytic pocket. One of ordinary skill in the art may use one of several methods to screen functional groups and fragments for their ability to associate with IDO. Selected fragments or functional groups may then be positioned in a variety of orientations, or docked, within the catalytic pocket of IDO as described above.

Specialized computer programs may assist in the process of selecting fragments or functional groups, or whole molecules that can fit into and populate a binding site, or can be used to build virtual libraries of compounds. These include: GRID (Goodford, (1985), J. Med. Chem., 28:849-857, available from Oxford University, Oxford, UK); and MCSS (Miranker & Karplus, (1991), Proteins: Structure, Function and Genetics 11:29-34, available from Accelrys, a subsidiary of Pharmacopeia, Inc., as part of the Quanta package).

Once suitable functional groups or fragments have been selected, they can be assembled into a single compound or inhibitor. Assembly may be performed by visual inspection and by manual model building using software such as QUANTA or SYBYL, while observing the relationship of the fragments to each other in relation to a three-dimensional image of the structure coordinates of IDO catalytic pocket.

Alternatively, fragment assembly can be performed using the software CAVEAT (Bartlett et al., “CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules,” in Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Chem. Soc. 78:182-196, (1989); available from the University of California, Berkeley, Calif.); and HOOK (available from Accelrys, a subsidiary of Pharmacopeia, Inc., as part of the Quanta package).

In another embodiment, IDO inhibitor molecules may be designed as a whole or de novo using either an empty active site. Software programs for achieving this include: LUDI (Bohm, J. Comp. Aid. Molec. Design, 6:61-78, (1992), available from Accelrys, a subsidiary of Pharmacopeia, Inc.); LEGEND (Nishibata and Itai, Tetrahedron, 47:8985, (1991), available from Molecular Simulations, Burlington, Mass.); and LeapFrog (available from Tripos, Inc., 1699 South Hanley Road, St. Louis, Mo.).

Quantifying Potential of IDO Binding Molecules

Once a compound has been designed or selected by methods such as those described above, the efficiency with which that compound may bind to the catalytic site of IDO may be tested and optimized by computational evaluation. For example, a compound that has been designed or selected to function as an inhibitor (antagonist) preferably occupies a volume that overlaps with the volume occupied by the native substrate at the active site. An effective IDO inhibitor preferably displays a relatively small difference in energy between its bound and free states (i.e., it has a small deformation energy of binding). Thus, the most efficient inhibitors of IDO should preferably be designed with a deformation energy of binding of not greater than about 10 kcal/mol or, even more preferably, not greater than about 7 kcal/mol.

A compound selected or designed for binding to the IDO catalytic site may be further computationally optimized so that in its bound state it would lack repulsive electrostatic interactions with amino acids of the IDO catalytic pocket and it has favorable hydrogen bond formation, attractive electrostatic interactions with such amino acids. Such favorable or repulsive electrostatic interactions include charge-charge, dipole-dipole and charge-dipole interactions. Specifically, the sum of all electrostatic interactions between the inhibitor and the binding pocket when the inhibitor is bound to it preferably make a neutral or favorable contribution to the enthalpy of binding.

Specific computer software is available to evaluate compound deformation energy and electrostatic interaction. Examples of programs designed for such uses fall into approximately three levels of sophistication. The first level of approximation, molecular mechanics, is also the cheapest to compute and can most usefully be used to calculate deformation energies. Molecular mechanics programs find application for calculations on small organic molecules as well as polypeptides, nucleic acids, proteins, and most other biomolecules. Examples of programs which have implemented molecular mechanics force fields include: AMBER (Kollman, P. A., et al., School of Pharmacy, Department of Pharmaceutical Chemistry, University of California at San Francisco); CHARMM (see B. R. Brooks, R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus, “CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations,” J. Comp. Chem., 4, 187-217, (1983); A. D. MacKerell, Jr., B. Brooks, C. L. Brooks, III, L. Nilsson, B. Roux, Y. Won, and M. Karplus, “CHARMM: The Energy Function and Its Parameterization with an Overview of the Program,” in The Encyclopedia of Computational Chemistry, 1, 271-277, P. v. R. Schleyer et al., eds, John Wiley & Sons, Chichester, (1998)); and QUANTA/CHARMm (available from Accelrys, a subsidiary of Pharmacopeia, Inc.).

An intermediate level of sophistication comprises the so-called “semi-empirical” methods, which are relatively inexpensive to compute and are most frequently employed for calculating deformation energies of organic molecules. Examples of program packages that provide semi-empirical capability are MOPAC 2000 (Stewart, J. J. P., et al., available from Schrodinger, Inc., 1500 S.W. First Avenue, Suite 1180, Portland, Oreg.) and AMPAC (Holder, A., et al., available from Tripos, Inc., 1699 South Hanley Road, St. Louis, Mo.).

The highest level of sophistication is achieved by those programs that employ so-called ab initio quantum chemical methods and methods of density functional theory, for example: Gaussian 03, (available from Gaussian, Inc., Carnegie Office Park, Building 6, Suite 230. Carnegie, Pa.); and Q-Chem2.0 (“A high-performance ab initio electronic structure program,” J. Kong, et al., J. Comput. Chem., 21, 1532-1548, (2000)).

Virtual Screening

Databases containing the structural coordinates of thousands of small molecules can be computationally screened to identify molecules that are likely to bind to the catalytic site of IDO. In such screening, the quality of fit of molecules to the binding site in question may be evaluated by any of a number of methods that are familiar to one of ordinary skill in the art, including shape complementarity (see, e.g., DesJalais, et al., J. Med. Chem., 31:722-729, (1988)) or by estimated energy of interaction (Meng, et al., J. Comp. Chem., 13:505-524, (1992)).

In an method, potential binding compounds may be obtained by rapid computational screening. Such a screening comprises testing a large number, which may be hundreds, or may preferably be thousands, or more preferably tens of thousands, or even more preferably hundreds of thousands of molecules whose formulae are known and for which at least one conformation can be readily computed.

The databases of small molecules include any virtual or physical database, such as electronic and physical compound library databases. Preferably, the molecules are obtained from one or more molecular structure databases that are available in electronic form, for example, the “Available Chemicals Directory” (ACD), the MDL Drug Data Report and/or the Comprehensive Medicinal Chemistry Database (available from MDL Information Systems, Inc., 14600 Catalina Street, San Leandro, Calif.); the Cambridge Structural Database; the Fine Chemical Database (Rusinko, Chem. Des. Auto. News, 8:44-47 (1993)); the National Cancer Institute database and any proprietary database of compounds with known medicinal properties, as is found in large or small pharmaceutical companies.

The molecules in such databases are preferably stored as a connection table, with or without a 2D representation that comprises coordinates in just 2 dimensions, say x and y, for facilitating visualization on a computer display. The molecules are more preferably stored as at least one set of 3D coordinates corresponding to an experimentally derived or computer-generated molecular conformation. If the molecules are only stored as a connection table or a 2D set of coordinates, then it could be necessary to generate a 3D structure for each molecule before proceeding with a computational screen. Programs for converting 2D molecular structures or molecule connection tables to 3D structures include Converter (available from Accelrys, a subsidiary of Pharmacopeia, Inc.) and CONCORD (A. Rusinko III, J. M. Skell, R. Balducci, C. M. McGarity, and R. S. Pearlman, “CONCORD, A Program for the Rapid Generation of High Quality Approximate 3-Dimensional Molecular Structures,” (1988) The University of Texas at Austin and Tripos Associates, available from Tripos, Inc., 1699 South Hanley Road, St. Louis, Mo.).

To perform the virtual screening of IDO inhibitory compounds, each 3D structure is docked to the IDO catalytic site using high-throughput screening software. Such a procedure can normally be subjected to a number of user-defined parameters and thresholds according to desired speed of throughput and accuracy of result. Such parameters include the number of different starting positions from which to start a docking simulation and the number of energy calculations to carry out before rejecting or accepting a docked structure. Such parameters and their choices are familiar to one of ordinary skill in the art. Structures from the database can be selected for synthesis to test their ability to modulate nuclear receptor activity if their docked energy is below a certain threshold. Methods of docking are further described elsewhere herein. For example the high throughput virtual screening can be performed by using the computer software GLIDE (Schrodinger, Inc., Portland, Oreg.). GLIDE searches the protein active site for the best possible location and orientation for the docked ligand. Its docking algorithm examines the conformational space, employing a heuristic screening process that eliminates unfavorable conformations. The software generates a score that rewards favorable lipophilic, hydrogen bonding, and metal ligation contacts and penalizes frozen rotatable bonds and steric clashes. In addition, the score takes into account an evaluation of the Coulomb-van der Walls interactions, as well as a small number of potential energy terms that reward hydrogen bond donors found in the active site's hydrophilic regions and penalizes hydrogen bond donors and acceptors found in the hydrophobic regions. The software yields a Docking Score value for each compound, expressed in energy units of kcal/mol.

Alternatively, it is possible to carry out a “molecular similarity” search for molecules that are potential IDO inhibitors. A similarity search attempts to find molecules in a database that have at least one favorable 3D conformation whose structure overlap favorably with a pharmacophore that has been previously defined as a favorable IDO inhibitor. For example, a pharmacophore may bind to a lipophilic pocket at a particular position, a hydrogen-bond acceptor site at another position and a hydrogen bond donor site at yet another specified position accompanied by distance ranges between them. A molecule that could potentially fit into the active site is one that can adopt a conformation in which a H-bond donor in the active site can reach the H-bond acceptor site on the pharmacophore, a H-bond acceptor in the active site can simultaneously reach the H-bond donor site of the pharmacophore and, for example, a group such as a phenyl ring can orient itself into the lipophilic pocket.

Even where a pharmacophore has not been developed, molecular similarity principles may be employed in a database searching regime (see, for example, Johnson, M. A.; Maggiora, G. M., Eds. Concepts and Applications of Molecular Similarity, New York: John Wiley & Sons (1990)) if at least one molecule that fits well in the IDO catalytic site is known.

In one embodiment, it is possible to search for molecules that have certain properties in common with those of the molecule(s) known to bind. For example, such properties include numbers of hydrogen bond donors or numbers of hydrogen bond acceptors, or overall hydrophobicity within a particular range of values. Alternatively, even where a pharmacophore is not known, similar molecules may be selected on the basis of optimizing an overlap criterion with the molecule of interest.

Considerations of the Rational Design of IDO Inhibitors

Molecules that bind to the IDO catalytic site can be designed by a number of methods, including: 1) structural analogy to known IDO inhibitor or 2) structural analogy to intermediates structures participating in the mechanism of tryptophan dioxygenation catalyzed by IDO.

In another embodiment, IDO inhibitors can be design by mimicking the structures of molecular species representing the transition state of tryptophan dioxygenation. The current understanding of the mechanism catalyzed by IDO involves the formation of an adduct between the indole core of tryptophan, oxygen and the iron atom present in the heme cofactor. Reviewed in Malachowski et al, Drugs of Future 2005, 30(9), 1-9 and Sugimoto H et al., 2006, Proc. Natl. Acad. Sci. USA 103(8), 2611-2616. There are three suggested mechanism proposed for the formation of this adduct that involve an ionic mechanism, a pericyclic mechanism or a radical mechanism. The adduct suffers a molecular reorganization that involves electron transfer with a base aminoacid present at the catalytic site. The molecular reorganization of the adduct proceeds either through a Criegee-type of rearrangement or through a dioxetane retro-cycloaddition mechanism to yield kynurenine and the free enzyme. Further provided are the structures of IDO inhibitory molecules designed by mimicking the structural features of these intermediate molecular species, or structurally modified substrate mimics that do not allow progression of one of the mechanistic steps of the reaction.

The design of molecules that inhibit IDO generally involves consideration of two factors. The molecule must be capable of first physically, and second structurally, associating with IDO. The physical interactions supporting this association can be covalent or non-covalent. For example, covalent interactions may be important for designing irreversible or “suicide” inhibitors of a protein. Non-covalent molecular interactions that are important in the association of IDO with molecules that bind to it include hydrogen bonding, ionic, van der Waals, and hydrophobic interactions. Structurally, the compound must be able to assume a conformation that allows it to associate with the heme cofactor at the IDO catalytic active site.

In general, the potential inhibitory or binding effect of a compound on IDO may be analyzed prior to its actual synthesis and testing by the use of computer modeling techniques. If the theoretical structure of the given compound suggests insufficient interaction and association between it and the IDO active site, synthesis and testing of the compound need not be carried out. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to bind to the IDO catalytic pocket and thereby inhibit its activity. In this manner, synthesis of ineffective compounds may be avoided.

Among the computational techniques that enable the rational design of molecules that bind to IDO, it is key to have access to visualization tools, programs for calculating properties of molecules, and programs for fitting ligand structures into three-dimensional representations of the receptor binding site. Computer program packages for facilitating each of these capabilities have been referred to herein, and are available to one of ordinary skill in the art. Visualization of molecular properties, such as field properties that vary through space, can also be particularly important and may be aided by computer programs such as MOLCAD (Brickmann, J., and coworkers, see, for example, J. Comp.-Aid. Molec. Des., 7:503, (1993); available from Tripos, Inc., 1699 South Hanley Road, St. Louis, Mo.).

A molecular property of particular interest when assessing suitability of drug compounds is its hydrophobicity. An accepted and widespread measure of hydrophobicity is Log P, the Log 10 of the octanol-water partition coefficient. It is customary to use the value of Log P for a designed molecule to assess whether the molecule could be suitable for transport across a cell membrane, if it were to be administered as a drug. Measured values of Log P are available for many compounds. Methods and programs for calculating Log P are also available, and are particularly useful for molecules that have not been synthesized or for which no experimental value of Log P is available. See for example: CLOGP (Hansch, C., and Leo, A.; available from Biobyte, Inc., Pomona, Calif.) and ACD/Log P DB (Advanced Chemistry Development Inc., 90 Adelaide Street West, Suite 702, Toronto, Ontario, Canada).

Labeled Compounds and Assay Methods

Another aspect relates to fluorescent dye, spin label, heavy metal or radio-labeled derivatives of the compounds described herein that would be useful not only in imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the IDO enzyme in tissue samples, including human, and for identifying IDO enzyme ligands by inhibition binding of a labeled compound. Accordingly, further provided are IDO enzyme assays that contain such labeled compounds.

Further provided are isotopically-labeled compounds of the compounds described herein. An “isotopically” or “radio-labeled” compound is a compound described herein where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be include but are not limited to 2H (also written as D for deuterium), 3H (also written as T for tritium), ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ¹⁸F, ³⁵S, ³⁶Cl, ⁸²Br, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I, ¹²⁵I and a ¹³¹I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro IDO enzyme labeling and competition assays, compounds that incorporate ³H, ¹⁴C, ⁸²Br, ¹²⁵I, ¹³¹I, ³⁵S or will generally be most useful. For radio-imaging applications ¹¹C, ¹⁸F, ¹²5I, ¹²³I, ¹²⁴I, ¹³¹I, ⁷⁵Br, ⁷⁶Br or ⁷⁷Br will generally be most useful.

It is understood that a “radio-labeled” or “labeled compound” is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of ³H, ¹⁴C, ¹²⁵I, ³⁵S and ⁸²Br.

Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds described herein and are well known in the art.

A radio-labeled compound described herein can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the radio-labeled compound described herein to the IDO enzyme. Accordingly, the ability of a test compound to compete with the radio-labeled compound for binding to the IDO enzyme directly correlates to its binding affinity.

Kits

Also included are pharmaceutical kits useful, for example, in the treatment or prevention of IDO-associated diseases or disorders, obesity, diabetes and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound described herein. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.

The following examples are offered for illustrative purposes, and are not intended to limit the disclosure in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results. The example compounds below were found to be inhibitors of IDO according to one or more of the assays described herein.

EXAMPLES
General Experimental Methods

All reagents and solvents were purchased from commercial sources and used as received without further purification. The reactions were monitored using analytical thin layer chromatography (TLC) with 0.25 mm EM Science silica gel plates (60E-254). The developed TLC plates were visualized by immersion in potassium permanganate solution followed by heating on a hot plate. Flash chromatography was performed with Selecto Scientific silica gel, 32-63 μm particle sizes. All reactions were performed in flame- or oven-dried glassware under a nitrogen atmosphere. All reactions were stirred magnetically at ambient temperature unless otherwise indicated. ¹H NMR and ¹³C NMR spectra were obtained with a Bruker DRX400, Varian VXR300 and VXR400. ¹H NMR spectra were reported in parts per million (δ) relative to CDCl₃(7.27 ppm), CD₃OD (4.80) or DMSO-d₆(2.50) as an internal reference.

The following compounds were synthesized by known literature procedures: (2-(benzylamino)phenyl)methanol (Organic Letters 2002, 581-584), (3-(benzylamino)phenyl)methanol (European Patent Application 1989, 91 pp), (2-(phenylamino)phenyl)methanol (Journal of Heterocyclic Chemistry 1986, 23, 223-224), tert-butyl 2-hydroxy-2-phenylethylcarbamate (Bioorganic and Medicinal Chemistry 2004, 12, 1483-1491), tert-butyl 3-hydroxy-3-phenylpropylcarbamate (US Patent 2000, 5 pp), methyl 4-hydroxy-4-phenylbutanoate (Journal of Medicinal Chemistry 1986, 230-238), 3-morpholino-1-phenylpropan-1-ol (Chemistry Letters 1978, 11, 1285-1288), 1,2-diphenylethanol (Organic Letters 2006, 8, 773-776), 2-morpholino-1-phenylethanol (Organic Letters 2005, 7, 3649-3651), cyclohexyl(phenyl)methanol (Tetrahedron Letters 1989, 30, 6709-6712), (R)-3-(tert-butyldimethylsilyloxy)-1-phenylpropan-1-ol (Bioorganic and Medicinal Chemistry Letters 2005, 15, 4130-4135), biphenyl-3-ylmethanol (European Journal of Medicinal Chemistry 2007, 42, 293-306), biphenyl-2-ylmethanol (Journal of the American Chemical Society 1999, 121, 9550-9561), (4′-methylbiphenyl-3-yl)methanol (Tetrahedron 1994, 50, 8301-16), (4′-methylbiphenyl-2-yl)methanol (Tetrahedron Letters 2000, 41, 6415-6418), (4′-methoxybiphenyl-2-yl)methanol (Journal of Organic Chemistry 1987, 52, 4953-61), (4′-methoxybiphenyl-3-yl)methanol (Synlett 1998, 6, 671-675), 2-hydroxy-N-methyl-2-phenylacetamide (Journal of Organic Chemistry 1992, 57, 5700-7), 2-cyclohexyl-1-phenylethanol (Journal of Organic Chemistry 1936, 1, 288-99), 2-phenoxy-1-phenylethanol (Tetrahedron 2008, 64, 3867-3876).

Example 1
Method A: Syntheses of Dithiocarbamates with Variations in S-Alkyl Groups (Scheme 1)

embedded image

A solution of tryptamine 1 (1.0 equiv) in anhydrous CH₂Cl₂(10 mL) at 0° C. was treated sequentially with triethylamine (1.1 equiv) then carbon disulfide (1.1 equiv) and stirred for 30 min. After this time, alkyl bromide 2 (1.2 equiv unless indicated otherwise) was added and the reaction was allowed to warm to room temperature and stirred overnight. The reaction mixture was then poured into 1 M H₂SO₄and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated. Purification by flash chromatography (silica, EtOAc/hexanes) afforded the desired product. The dithiocarbamate product typically exists as a ≈7:3 mixture of tautomers observed by ¹H NMR, and are listed with spectral data.

Example 2
Phenethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00001]

embedded image

The reaction of 1 with (2-bromoethyl)benzene (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00001 (0.148 g, 35%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.04 (br s, 1H), 7.62 (d, J=7.5 Hz, 1H), 7.38 (d, J=8.0 Hz, 1H), 7.32-7.25 (m, 2H), 7.25-7.20 (m, 4H), 7.16-7.13 (m, 1H), 7.07-7.05 (m, 1H), 6.92 (br s, 1H), 4.11-4.06 (m, 2H), 3.48-3.45 (m, 2H), 3.13 (t, J=6.5 Hz, 2H), 2.97-2.94 (m, 2H) and signals due to a minor tautomer (ca. 31%): 3.78-3.74 (m), 3.59-3.55 (m), 3.10-3.08 (m), 3.05-3.01 (m); ESI MS m/z 341 [M+H]⁺, HPLC (Method 1)>99% (AUC), t_R=13.9 min.

Example 3
4-Fluorophenethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00003]

embedded image

The reaction of 1 with 4-fluorophenethyl bromide (0.6 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00003 (0.084 g, 31%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.04 (br s, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H), 7.24-7.13 (m, 4H), 7.08-7.04 (m, 1H), 7.00-6.94 (m, 2H), 6.92 (br s, 1H), 4.11-4.07 (m, 2H), 3.46-3.43 (m, 2H), 3.14 (t, J=7.0 Hz, 2H), 2.94-2.91 (m, 2H) and signals due to a minor tautomer (ca. 31%): 3.79-3.75 (m), 3.55-3.52 (m), 3.11-3.09 (m), 3.01-2.98 (m); ESI MS m/z 359 [M+H]⁺, HPLC (Method 1) 95.3% (AUC), t_R=13.7 min.

Example 4
3-Methoxyphenethyl 2-1H-indol-3-yl)ethylcarbamodithioate [Compound 00010]

embedded image

The reaction of 1 with 3-methoxyphenethyl bromide (0.6 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00010 (0.094 g, 33%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.04 (br s, 1H), 7.62 (d, J=7.5 Hz, 1H), 7.38 (d, J=8.5 Hz, 1H), 7.24-7.19 (m, 2H), 7.16-7.13 (m, 1H), 7.07-7.06 (m, 1H), 6.92 (br s, 1H), 6.83-6.75 (m, 3H), 4.10-4.06 (m, 2H), 3.80 (s, 3H), 3.48-3.45 (m, 2H), 3.13 (t, J=6.5 Hz, 2H), 2.95-2.92 (m, 2H) and signals due to a minor tautomer (ca. 31%): 3.79-3.76 (m), 3.59-3.55 (m), 3.10-3.09 (m), 3.02-2.99 (m); ESI MS m/z 371 [M+H]⁺, HPLC (Method 1) 97.3% (AUC), t_R=13.1 min.

Example 5
4-Methoxyphenethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00002]

embedded image

The reaction of 1 with 4-methoxyphenethyl bromide (0.6 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00002 (0.078 g, 28%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.03 (br s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.38 (d, J=8.0 Hz, 1H), 7.24-7.18 (m, 2H), 7.16-7.13 (m, 3H), 7.08-7.05 (m, 1H), 6.92 (br s, 1H), 6.85-6.82 (m, 2H), 4.10-4.06 (m, 2H), 3.78 (s, 3H), 3.45-3.42 (m, 2H), 3.13 (t, J=6.5, 2H), 2.91-2.88 (m, 2H) and signals due to a minor tautomer (ca. 31%): 3.78-3.76 (m), 3.55-3.52 (m), 3.11-3.09 (m), 2.98-2.95 (m); ESI MS m/z 371 [M+H]⁺, HPLC (Method 1) 96.5% (AUC), t_R=13.3 min.

Example 6
4-Bromophenethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00004]

embedded image

The reaction of 1 with 4-bromophenethyl bromide (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00004 (0.245 g, 46%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.04 (br s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.43-7.38 (m, 3H), 7.25-7.22 (m, 1H), 7.16-7.05 (m, 4H), 6.92 (br s, 1H), 4.10-4.06 (m, 2H), 3.46-3.42 (m, 2H), 3.14 (t, J=6.5 Hz, 2H), 2.93-2.90 (m, 2H) and signals due to a minor tautomer (ca. 32%): 3.78-3.74 (m), 3.55-3.52 (m), 3.11-3.09 (m), 3.00-2.97 (m); ESI MS m/z 419 [M+H]⁺, HPLC (Method 1)>99% (AUC), t_R=15.6 min.

Example 7
3-Bromophenethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00007]

embedded image

The reaction of 1 with 3-bromophenethyl bromide (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00007 (0.329 g, 62%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.04 (br s, 1H), 7.62 (d, J=7.5 Hz, 1H), 7.42-7.34 (m, 3H), 7.24-7.20 (m, 1H), 7.18-7.13 (m, 3H), 7.07-7.06 (m, 1H), 6.93 (br s, 1H), 4.11-4.06 (m, 2H), 3.46-3.43 (m, 2H), 3.14 (t, J=7.0 Hz, 2H), 2.94-2.91 (m, 2H) and signals due to a minor tautomer (ca. 32%): 3.78-3.74 (m), 3.55-3.52 (m), 3.11-3.09 (m), 3.01-2.98 (m); ESI MS m/z 419 [M+H]⁺, HPLC (Method 1)>99% (AUC), t_R=15.5 min.

Example 8
3-Methylphenethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00020]

embedded image

The reaction of 1 with 1-(2-bromoethyl)-3-methyl-benzene (1.0 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00020 (0.039 g, 22%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.03 (br s, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H), 7.24-7.13 (m, 4H), 7.06-7.02 (m, 3H), 6.92 (br s, 1H), 4.10-4.06 (m, 2H), 3.47-3.44 (m, 2H), 3.13 (t, J=7.0 Hz, 2H) Hz, 2.93-2.90 (m, 2H) and signals due to a minor tautomer (ca. 32%): 3.79-3.75 (m), 3.57-3.54 (m), 3.11-3.09 (m), 3.01-2.98 (m); ESI MS m/z 355 [M+H]⁺, HPLC (Method 1) 96.3% (AUC), t_R=15.1 min.

Example 9
2-Phenylpropyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00006]

embedded image

The reaction of 1 with 1-bromo-2-phenylpropane (1.2 equiv) was performed as described in Method A. The reaction was at reflux (55° C.) overnight instead of room temperature. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00006 (0.022 g, 5%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.01 (br s, 1H), 7.61 (d, J=7.5 Hz, 1H), 7.38 (d, J=8.5 Hz, 1H), 7.33-7.20 (m, 6H), 7.15-7.12 (m, 1H), 7.05-7.04 (m, 1H), 6.88 (br s, 1H), 4.08-4.04 (m, 2H), 3.48-3.45 (m, 2H), 3.12-3.06 (m, 3H), 1.53 (s, 3H) and signals due to a minor tautomer (ca. 30%) 3.75-3.71 (m), 3.21-3.18 (m); ESI MS m/z 355 [M+H]⁺, HPLC (Method 1) 96.2% (AUC), t_R=14.3 min.

Example 10
(6,7-Dimethoxy-2-oxo-2H-chromen-4-yl)methyl 2-(1H-indol-3-yl)ethyl-carbamodithioate [Compound 00023]

embedded image

The reaction of 1 with 4-(bromomethyl)-6,7-dimethoxycoumarin (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00023 (0.063 g, 11%) as an off white solid: ¹H NMR (500 MHz, CDCl₃) δ 8.15 (br s, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.40-7.38 (m, 1H), 7.24-7.21 (m, 1H), 7.15-7.12 (m, 2H), 7.05-7.01 (m, 2H), 6.85-6.84 (m, 1H), 6.33 (s, 1H), 4.70 (s, 2H), 4.13-4.09 (m, 2H), 3.94 (s, 3H), 3.89 (s, 3H), 3.17 (t, J=6.5 Hz, 2H) and signals due to a minor tautomer (ca. 23%): 3.14-3.10 (m); ESI MS m/z 455 [M+H]⁺, HPLC (Method 1) 96.5% (AUC), t_R=11.5 min, MP=175-177° C.

Example 11
2-(1H-Indol-3-yl)ethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00030]

embedded image

The reaction of 1 with 3-(2-bromoethyl)indole (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00030 (0.086 g, 18%) as an off white solid: ¹H NMR (500 MHz, CDCl₃) δ 7.98-7.93 (m, 2H), 7.68 (d, J=8.0 Hz, 1H), 7.61 (d, J=8.0 Hz, 1H), 7.37-7.34 (m, 2H), 7.23-7.18 (m, 2H), 7.15-7.11 (m, 2H), 7.06-7.01 (m, 2H), 6.89 (s, 1H), 4.05-4.02 (m, 2H), 3.53 (t, J=7.5 Hz, 2H), 3.13-3.07 (m, 4H), and signals due to a minor tautomer (ca. 31%): 3.76-3.75 (m), 3.68 (t, J=7.5 Hz), 3.20 (t, J=7.5); ESI MS m/z 380 [M+H]⁺, HPLC (Method 1)>99% (AUC), t_R=12.4 min, MP=125-127° C.

Example 12
(2-Methylquinolin-6-yl)methyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00038]

embedded image

The reaction of 1 with 6-(bromomethyl)-2-methylquinoline (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00038 (0.079 g, 16%) as an off white solid: ¹H NMR (500 MHz, CDCl₃) δ 8.00-7.93 (m, 2H) 7.71 (s, 1H), 7.63-7.55 (m, 3H), 7.37 (d, J=8.0 Hz, 1H), 7.29-7.20 (m, 2H), 7.14-7.11 (m, 1H), 6.98-6.95 (m, 2H), 4.66 (s, 2H), 4.10-4.06 (m, 2H), 3.12 (t, J=7.0 Hz, 2H), 2.73 (s, 3H), and signals due to a minor tautomer (ca. 27%): 3.79-3.78 (m), 3.12-3.09 (m); ESI MS m/z 392 [M+H]⁺, HPLC (Method 1) 98.5% (AUC), t_R=8.2 min, MP=72-75° C.

Example 13
(3-Methylnaphthalen-2-yl)methyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00047]

embedded image

The reaction of 1 with 2-bromomethyl-3-methyl-naphthalene (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00047 (0.097 g, 71%) as an off white solid: ¹H NMR (500 MHz, CDCl₃) δ 7.93 (br s, 1H), 7.87 (br s, 1H), 7.76-7.71 (m, 1H), 7.64-7.60 (m, 1H), 7.43-7.35 (m, 4H), 7.21 (t, J=8.0 Hz, 1H), 7.13 (t, J=8.0 Hz, 1H), 6.99-6.94 (m, 2H), 4.64 (s, 2H), 4.10-4.06 (m, 2H), 3.13 (t, J=6.5 Hz, 2H), 2.50 (s, 3H), and signals due to a minor tautomer (ca. 33%): 4.7 (s), 3.77-3.76 (m), 3.12-3.08 (m); ESI MS m/z 391 [M+H]⁺, HPLC (Method 1)>99% (AUC), t_R=16.1 min, MP=129-131° C.

Example 14
(6-Bromobenzo[d][1,3]dioxol-5-yl)methyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00065]

embedded image

The reaction of 1 with 5-bromo-6-bromomethyl-1,3-benzodioxole (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00065 (0.368 g, 66%) as a clear oil: ¹H NMR (500 MHz, CDCl₃) δ 8.02 (br s, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.37 (d, J=8.5 Hz, 1H), 7.22 (t, J=8.0 Hz, 1H), 7.13 (t, J=7.5 Hz, 1H), 7.06 (s, 1H), 7.03 (s, 1H), 6.96 (s, 1H), 6.92 (br s, 1H), 5.94 (s, 2H), 4.58 (s, 2H), 4.09-4.05 (m, 2H), 3.12 (t, J=7.0 Hz, 2H), and signals due to a minor tautomer (ca. 29%): 4.68 (s), 3.77-3.76 (m), 3.11-3.08 (m); ESI MS m/z 450 [M+H]⁺, HPLC (Method 1) 98.7% (AUC), t_R=14.4 min.

Example 15
Benzo[d]isoxazol-3-ylmethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00052]

embedded image

The reaction of 1 with 3-(bromomethyl)-1,2-benzisoxazole (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00052 (0.304 g, 66%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.03 (br s, 1H), 7.82 (d, J=8.0 Hz, 1H), 7.61 (d, J=8.0 Hz, 1H), 7.56-7.55 (m, 1H), 7.37 (d, J=8.0 Hz, 1H), 7.32-7.29 (m, 1H), 7.22-7.20 (m, 2H), 7.15-7.10 (m, 1H), 7.07-7.05 (m, 1H), 4.90 (s, 2H), 4.14-4.09 (m, 2H), 3.16 (t, J=6.5 Hz, 2H), and signals due to a minor tautomer (ca. 20%): 5.10 (s), 3.83-3.78 (m), 3.12-3.10 (m); ESI MS m/z 368 [M+H]⁺, HPLC (Method 1) 98.8% (AUC), t_R=12.4 min.

Example 16
2-Chlorophenethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00021]

embedded image

The reaction of 1 with 2-chlorophenethyl bromide (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00021 (0.054 g, 11%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.02 (br s, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H), 7.39-7.29 (m, 2H), 7.24-7.13 (m, 4H), 7.08-7.04 (m, 1H), 6.95 (br s, 1H), 4.11-4.07 (m, 2H), 3.49-3.46 (m, 2H), 3.16-3.13 (m, 2H), 3.11-3.07 (m, 2H), and signals due to a minor tautomer (ca. 30%): 3.80-3.76 (m), 3.60-3.57 (m), 3.18-3.14 (m); ESI MS m/z 375 [M+H]⁺, HPLC (Method 1) 97.4% (AUC), t_R=16.0 min.

Example 17
4-Methylphenethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00009]

embedded image

The reaction of 1 with 4-methylphenethyl bromide (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00009 (0.225 g, 50%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.02 (br s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.37 (d, J=8.5 Hz, 1H), 7.24-7.20 (m, 1H), 7.17-7.08 (m, 5H), 7.03 (s, 1H), 6.91 (br s, 1H), 4.08 (m, 2H), 3.45-3.42 (m, 2H), 3.11 (t, J=7.0 Hz, 2H), 2.93-2.90 (m, 2H), and signals due to a minor tautomer (ca. 32%): 3.77-3.73 (m), 3.56-3.53 (m), 3.10-3.07 (m), 3.00-2.97 (m); ESI MS m/z 355 [M+H]⁺, HPLC (Method 1) 95.3% (AUC), t_R=16.1 min.

Example 18
4-((2-(1H-Indol-3-yl)ethylcarbamothioylthio)methyl)-2-oxo-2H-chromen-7-yl acetate [Compound 00049]

embedded image

The reaction of 1 with 7-acetoxy-4(bromomethyl) coumarine (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00049 (0.130 g, 28%) as an off white solid: ¹H NMR (500 MHz, CDCl₃) δ 8.18 (br s, 1H), 7.71 (d, J=9.0 Hz, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.39-7.37 (m, 1H), 7.23-7.20 (m, 1H), 7.15-7.11 (m, 2H), 7.09-7.06 (m, 2H), 7.01-7.00 (m, 1H), 6.49 (s, 1H), 4.66 (s, 2H), 4.11-4.08 (m, 2H), 3.16 (t, J=6.5 Hz, 2H), 2.34 (s, 3H), and signals due to a minor tautomer (ca. 21%): 4.71 (s), 3.83-3.80 (m), 3.12-3.10 (m); ESI MS m/z 453 [M+H]⁺, HPLC (Method 1) 95.6% (AUC), t_R=11.5 min, MP=132-134° C.

Example 19
3-Chlorophenethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00008]

embedded image

The reaction of 1 with 1-(2-bromoethyl)-3-chlorobenzene (1.2 equiv) was performed as described in Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00008 (0.290 g, 61%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.04 (br s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H), 7.27-7.18 (m, 4H), 7.16-7.11 (m, 2H), 7.08-7.06 (m, 1H), 6.93 (br s, 1H) 4.12-4.07 (m, 2H), 3.47-3.44 (m, 2H), 3.14 (t, J=6.5 Hz, 2H), 2.95-2.92 (m, 2H), and signals due to a minor tautomer (ca. 34%): 3.79-3.75 (m), 3.56-3.53 (m), 3.13-3.09 (m), 3.02-2.99 (m); ESI MS m/z 375 [M+H]⁺, HPLC (Method 1) 97.5% (AUC), t_R=15.4 min.

Example 20
2-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)ethyl 2-(1H-indol-3-yl)ethyl-carbamodithioate (6, Scheme 2) [Compound 00053]

embedded image

Sodium borohydride (18 mmol, 12 equiv) was added to stirred trifluoroacetic acid (0.19 mL, 1.38 mmol) over a period of 30 min. To the mixture was then added a solution of 2-bromo-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethan-1-one 4 in CH₂Cl₂over 30 min. After the addition of 4 was complete, the reaction was stirred at room temperature overnight. After this time, the reaction mixture was diluted with H₂O (75 mL), cooled with an ice/water bath, and pH was adjusted to 12 with the addition of NaOH beads. The aqueous layer was separated, and extracted with CH₂Cl₂(3×50 mL). The combined organic solutions were washed with brine, dried over anhydrous Na₂SO₄, and concentrated to afford crude product which was purified by chromatography (silica, hexanes-EtOAc), affording 5 (55 mg, 15%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 6.79 (d, J=8.0 Hz, 1H), 6.71 (d, J=2.0 Hz, 1H), 6.67-6.65 (m, 1H), 4.23 (s, 4H), 3.50 (t, J=8.0 Hz, 2H), 3.04 (t, J=7.5 Hz, 2H).

Coupling of tryptamine 1 with 5 following Method A afforded product 6 (00053, 40 mg, 54% yield) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) 08.04 (br s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H), 7.22 (t, J=8.0 Hz, 1H), 7.14 (t, J=8.0 Hz, 1H), 7.07-7.05 (m, 1H), 6.91 (br s, 1H), 6.78-6.68 (m, 3H), 4.25-4.22 (m, 4H), 4.09-4.05 (m, 2H), 3.43-3.40 (m, 2H), 3.13 (t, J=6.5 Hz, 2H), 2.86-2.83 (m. 2H), and signals due to a minor tautomer (ca. 31%): 3.77-3.76 (m), 3.52-3.50 (m), 3.12-3.09 (m), 2.93-2.91 (m); ESI MS m/z 399 [M+H]⁺, HPLC (Method 1) 97.9% (AUC), t_R=13.1 min.

Example 21
Benzo[d][1,3]dioxol-5-ylmethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00050] (Scheme 4)

embedded image

Piperonyl alcohol (1.25 mmol, 1 equiv) was dissolved in anhydrous CH₂Cl₂(10 mL) at 0° C., trifluoroacetic anhydride (1.38 mmol, 1.1 equiv) added, and the reaction mixture was stirred for 1 hour, concentrated to about 3 mL. This material was then treated with 1 following general Method A. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00050 (0.103 g, 88%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 8.03 (br s, 1H), 7.61 (d, J=8.0 Hz, 1H), 7.38 (d, J=8.0 Hz, 1H), 7.24-7.21 (m, 1H), 7.16-7.13 (m, 1H), 7.04-7.03 (m, 1H), 6.92-6.82 (m, 2H), 6.75-6.74 (m, 1H), 6.68-6.67 (m, 1H), 5.92 (s, 2H), 4.40 (s, 2H), 4.09-4.06 (m, 2H), 3.12 (t, J=6.5 Hz, 2H), and signals due to a minor tautomer (ca. 31%): 5.94 (s), 4.52 (m), 3.77-3.76 (m), 3.11-3.08 (m); ESI MS m/z 371 [M+H]⁺, HPLC (Method 1)>99% (AUC), t_R=12.6 min.

Example 22
Method B: Syntheses of Dithiocarbamates of the Brassinin Family where the Indole Group is Replaced by Other Cyclic Structures (Scheme 5)

embedded image

To a solution of amine 12 (Scheme 5, 1.0 equiv) in anhydrous CH₂Cl₂(10 mL) cooled in an ice/water bath were sequentially added triethylamine (1.1 equiv) and then carbon disulfide (1.1 equiv). The solution was stirred for 30 min at 0° C. After this time, methyl iodide (1.2 equiv) was then added and the reaction was allowed to warm to room temperature and stirred overnight. The reaction mixture was then poured into 1 M H₂SO₄and extracted with EtOAc (3×10 mL). The combined organic solutions were washed with brine, dried over anhydrous Na₂SO₄, and concentrated to afford crude material 13 which was purified by chromatography (silica, EtOAc/hexanes). The majority of the dithiocarbamates exist in tautomeric form (25% to 35%) as observed by ¹H NMR, and are listed with spectral data.

Example 23
Methyl 3-chlorophenethylcarbamodithioate [Compound 00014]

embedded image

Compound 00014 was synthesized as described in EP 656351 (1995). Briefly, 2-(3-Chlorophenyl)ethylamine (1 equiv) was used as amine 12 (Scheme 5) as described in Method B. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00014 (0.220 g, 69%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.27-7.21 (m, 3H), 7.10 (d, J=7.0 Hz, 1H), 6.93 (br s, 1H), 4.00-3.96 (m, 2H), 2.96 (t, J=7.0 Hz, 2H), 2.62 (s, 3H), and signals due to a minor tautomer (ca. 28%): 3.70-3.69 (m), 2.69 (s); ESI MS m/z 246 [M+H]⁺, HPLC (Method 1) 98.2% (AUC), t_R=12.0 min.

Example 24
Methyl 2-(pyridin-4-yl)ethylcarbamodithioate [Compound 00069]

embedded image

4-(2-Aminoethyl)pyridine (1 equiv) was used as amine 12 (Scheme 5) as described in Method B. In addition to the general method, the acidic aqueous layer was neutralized with 1 M NaOH and extracted with EtOAc (3×30 mL). Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00069 (0.093 g, 26%) as a white solid: ¹H NMR (500 MHz, CDCl₃) δ 8.54-8.53 (m, 2H), 7.15 (d, J=5.5 Hz, 2H), 7.02 (br s, 1H), 4.04-4.01 (m, 2H), 3.00 (t, J=7.0 Hz, 2H), 2.64 (s, 3H); ESI MS m/z 213 [M+H]⁺, HPLC (Method 1) 98.6% (AUC), t_R=9.6 min, MP=94-96° C.

Example 25
Methyl 2,4-dimethylphenethylcarbamodithioate [Compound 00066]

embedded image

2,4-Dimethylphenethylamine (1 equiv) was used as amine 12 (Scheme 5) as described in Method B. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00066 (0.161 g, 52%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.08 (d, J=7.5 Hz, 1H), 7.03-6.87 (m, 3H), 3.99-3.93 (m, 2H), 2.95-2.86 (m, 2H), 2.60 (s, 3H), 2.29 (s, 3H), 2.25 (s, 3H); ESI MS m/z 240 [M+H]⁺, HPLC (Method 1) 97.5% (AUC), t_R=12.9 min.

Example 26
Method C: Syntheses of Dithiocarbamate Isostere Equivalents (Scheme 9)

embedded image

To a solution of 23 (such as thiazole-2-thiol, 1.0 equiv, R═H, n=1) in anhydrous THF (10 mL) cooled in an ice/water bath was added NaH (1.1 eq unless indicated otherwise), and the solution was stirred for 2 h at 0° C. After this time, a bromide 25 (1.2 equiv) was added and the reaction was allowed to warm to room temperature and stirred overnight. Reaction mixture was then quenched by addition of a few drops of H₂O and concentrated. The residue was taken up into EtOAc, washed with brine, dried over anhydrous Na₂SO₄, and concentrated. Purification of the residue by chromatography (silica) afforded the desired product.

Example 27
3-Benzyloxazolidine-2-thione [Compound 00081]

embedded image

Compound 00081 was previously described by Baba, et al, Bull. Chem. Soc. Jpn., 1986, 59(1), 341-343; b) and Y. Nagao, et al, Chem. Pharma. Bull., Jpn., 1988, 36(11), 4293-4300). Its synthesis was achieved by treating 2-Thioxotetrahydro-1,3-oxazole with NaH (3.0 equiv instead of 1.1 equiv) as described in Method C. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00081 (0.198 g, 53%) as a clear oil: ¹H NMR (500 MHz, CDCl₃) δ 7.38-7.36 (m, 2H), 7.32-7.29 (m, 2H), 7.27-7.25 (m, 1H), 4.35 (t, J=9.0 Hz, 2H), 4.26 (s, 2H), 3.90 (t, J=9.0 Hz, 2H); ESI MS m/z 194 [M+H]⁺, HPLC (Method 1) 96.2% (AUC), t_R=7.8 min.

Example 28
3-Benzyl-1,3-thiazinane-2-thione [Compound 00077]

embedded image

Synthesis of compound 0077 was performed as described by W. Hanefeld, Archiv der Pharmazie, 1977, 310(5), 409-417; b) W. Hanefeld, et al, J. Heterocycl. Chem. 1997, 34(5), 1621-1624). Briefly, 1,3-Thiazinane-2-thine was treated with 1.5 equiv NaH (instead of 1.1 equiv) as described in Method C. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00077 (0.020 g, 6%) as a yellow oil: ¹H NMR (300 MHz, CDCl₃) δ 7.34-7.22 (m, 5H), 4.23 (s, 2H), 3.77 (t, J=5.7 Hz, 2H), 3.06 (t, J=6.0 Hz, 2H), 1.95-1.88 (m, 2H); ESI MS m/z 224 [M+H]⁺, HPLC (Method 1) 98.5% (AUC), t_R=7.9 min.

Example 29
3-Benzyl-2-thioxothiazolidin-4-one [Compound 00079]

embedded image

Synthesis of compound 00079 was performed as described in A. Martinez, et al, J. Med. Chem., 2005, 48(23), 7103-7112; and in M. Pulici, et al, Tetrahedron Lett., 2005, 46, 2387-2391). Briefly, rhodanine (1.0 equiv) was used as starting material 23 as described in Method C. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00079 (0.191 g, 57%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.34-7.30 (m, 5H), 4.59 (s, 2H), 3.99 (s, 2H); ESI MS m/z 224 [M+H]⁺, HPLC (Method 1)>99% (AUC), t_R=10.0 min.

Example 30
3-(Naphthalen-2-ylmethyl)-2-thioxothiazolidin-4-one [Compound 00830]

embedded image

Rhodanine (1.0 equiv) was reacted with 2-(bromomethyl)naphthalene (1.5 equiv) as described in Method C. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00830 (0.093 g, 30%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.86-7.81 (m, 4H), 7.50-7.46 (m, 3H), 4.76 (s, 2H), 4.00 (s, 2H); ESI MS m/z 274 [M+H]⁺, HPLC (Method 1) 95.8% (AUC), t_R=8.5 min, MP=120-123° C.

Example 31
3-(Naphthalen-2-ylmethyl)oxazolidine-2-thione [Compound 00786]

embedded image

2-Thioxotetrahydro-1,3-oxazole was reacted with 2-(bromomethyl)naphthalene (1.5 equiv) as described in Method C. Purification by flash chromatography (silica, gradient of 12% EtOAc/Hexanes to 100% EtOAc) afforded product 00786 (0.292 g, 61%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.82-7.79 (m, 4H), 7.50-7.45 (m, 3H), 4.42 (s, 2H), 4.37 (t, J=9.5 Hz, 2H), 3.92 (t, J=9.5 Hz, 2H); ESI MS m/z 244 [M+H]⁺, HPLC (Method 1) 95.9% (AUC), t_R=8.5 min, MP=120-123° C.

Example 32
2-Methyl-3-(naphthalen-2-ylmethylthio)-1,2-dihydro-1,2,4-triazine-5,6-dione [Compound 00682]

Entry
Scale
Yield
Conditions

1
1.00 g
1.10 g (58%)
K₂CO₃, DMF, 50° C., 3 h,

Example 33
Naphthalen-2-ylmethyl-2-(benzo[b]thiophen-3-yl)ethylcarbamodithioate [Compound 00060]

Scale
Yield
Conditions

0.41 g
0.35 g
44, Et₃N (1.1 equiv), CS₂(1.2 equiv), 45

(31%)
(1.2 equiv), pyridine, 0° C. tort, 15 h;

product consistent by ESI-MS and ¹H NMR analysis.

Example 34
Naphthalen-2-ylmethyl-2-(benzo[d]isoxazol-3-yl)ethylcarbamodithioate [Compound 00058]

Reaction
Scale
Yield
Conditions

52 to 53
0.10 g
0.090 g
EDCI (1.2 equiv), HOBt (0.5 equiv), NH₃(1.2 equiv),

(89%)
DMF, rt, 4 h; product consistent by ESI-

MS and ¹H NMR analysis.

53 to 54
0.090 g
0.10 g
LiAlH₄(4 equiv), THF, 40° C., overnight; crude

(crude)
used for next step.

54 to 55
0.14 g
0.04 g
Et₃N (1.1 equiv), CS₂(1.2 equiv), 50 (1.2 equiv),

(12%)
pyridine, 0° C. to r.t.: product consistent by ESI-

MS and ¹H NMR analysis.

Example 35
Methyl 2-(5,7-dichloro-1H-indol-3-yl)ethylcarbamodithioate [Compound 00042]

Reaction
Scale
Yield
Conditions

33 to 34
1.00 g
0.46 g
PCC (1.2 equiv), rt; 2.5 h, DCM; product consistent

(47%)
by ESI-MS and ¹H NMR analysis.

33 to 34
3.00 g
2.30 g
DMSO (2 equiv), Et₃N (5 equiv), (COCl)₂(1.5

(78%)
equiv), DCM, -78° C. to rt; product consistent by

ESI-MS and ¹H NMR analysis.

34 to 35
1.00 g
1.20 g
HC(OMe)₃(excess as neat), PTSA (0.1 equiv), rt;

(84%)
product consistent by ESI-MS and ^lH NMR analysis.

37 to 39
0.10 g
0.021 g
37 (1.05 equiv), 35 (1.0 equiv), EtOH/H₂O, 100° C.,

(16%)
4.5 h; product consistent by ESI-MS and ¹H NMR analysis.

37 to 39
0.10 g
0.035 g
37 (1.05 equiv), 35 (1.0 equiv), EtOH/H₂O, 100° C.,

(27%)
overnight; product consistent by ESI-MS and ¹H NMR analysis.

37 to 39
0.10 g
0.011 g
37 (1.05 equiv), 35 (1.0 equiv), 4% aq. H₂SO₄, 70°

(8.5%)
C., 4 h; product consistent by ESI-MS and ¹H NMR analysis.

37 to 39
0.50 g
0.138 g
37 (1.05 equiv), 35 (1.0 equiv), EtOH/H₂O, 100° C.,

(21%)
overnight; product consistent by ESI-MS and ^lH NMR analysis.

39 to 40
0.090 g
72 mg
39, Et₃N (1.1 equiv), CS₂(1.2 equiv), MeI (1.2

(68%)
equiv), pyridine, 0° C. to rt, 15 h; product consistent

by ESI-MS and ^lH NMR analysis, 97% pure by HPLC.

Example 36
Methyl 2-(4,6-dichloro-1H-indol-3-yl)ethylcarbamodithioate [Compound 00043]

Reaction
Scale
Yield
Conditions

8 to 9
1.00 g
0.346 g
8, (1.05 equiv), 2 (1.0 equiv), EtOH/H₂O,

(32%)
microwave, 150° C., 15 min; product

consistent by LCMS and ¹H NMR analysis.

9 to 10
0.320 g
0.240 g
9, Et₃N (1.1 equiv), CS₂(1.2 equiv), MeI (1.2

(55%)
equiv), pyridine, 0° C. to rt, 16 h; product

consistent by LCMS and ¹H NMR analysis.

Example 37
Methyl 2-(4,5,6-trifluoro-1H-indol-3-yl)ethylcarbamodithioate [Compound 00045]

Reaction
Scale
Yield
Conditions

5 to 6
0.250 g
0.050 g
Ref 1; 5, NaNO₂(1.05 equiv), conc. HCl, 0° C., 30

(18%)
min followed by SnCl₂•2H₂O (3.5 equiv), conc. HCl,

0° C. to rt, 1 h; product consistent by ¹H NMR and

LCMS analysis.

5 to 6
0.500 g
0.450 g
Ref 2; 5, NaNO₂(1.2 equiv), conc. HCl, 0° C., 1 h

(81%)
followed by SnC1₂•2H₂O (2.2 equiv), conc. HCl, rt,

1 h; product consistent by ¹H NMR and LCMS

analysis.

6 to 8
0.430 g
0.122 g
6 (1.05 equiv), 35 (1.0 equiv), EtOH/H₂O, conc. HCl

(19%)
(1.1 equiv), microwave, 130° C., 10 min; product

consistent by ¹H NMR and LCMS analysis.

8 to 9
0.120 g
0.105 g
8, Et₃N (1.1 equiv), CS₂(1.2 equiv), MeI (1.2

(61%)
equiv), pyridine, 0° C. to rt; product consistent by ¹H

NMR and LCMS analysis.

Example 38
Methyl 2-(5-amino-1H-indol-3-yl)ethylcarbamodithioate [Compound 00039] and Methyl 2-(5-nitro-1H-indol-3-yl)ethylcarbamodithioate [Compound 00040]

Reaction
Scale
Yield
Conditions

16 to 17a
1.00 g
0.225 g
16, BH₃•THF (3 equiv), 35° C., 4 h followed by CsF,

(crude)

Na₂CO₃, EtOH, reflux, 16 h; purified by silica gel

chromatography; product consistent by ¹H NMR gel

and LCMS analysis.

17a to 18a
0.100 g
0.048 g
17a, Et₃N (1.1 equiv), CS₂(1.2 equiv), MeI (1.2

(33%)
equiv), pyridine, 0° C. to rt, 15 h; product consistent

by ESI-MS and ¹H NMR analysis.

17a to 17b
0.125 g
0.115 g
17a, H₂, 10% Pd/C (20 mol%), 40 psi, 8 h; product

(crude)
confirmed by ¹H NMR analysis.

17b to 18b
0.115 g
0.035 g
17b, Et₃N (1.1 equiv), CS₂(1.2 equiv), MeI (1.2

(crude)

equiv) pyridine 0° C. to rt, 15 h; product consistent

by ESI-MS and ¹H NMR analysis.

Example 39
Methyl 2-(4,6-bis(trifluoromethyl)-1H-indol-3-yl)ethylcarbamodithioate [Compound 00044]

Reaction
Scale
Yield
Conditions

6 to 7
0.010 g
0.005 g
6 (1.05 equiv), 2 (1.0 equiv), EtOH/H₂O, conc. HCl (1.1

(crude)
equiv), microwave, 130° C., 15 min; 40% conversion by

LCMS analysis.

6 to 7
0.030 g
—
6 (1.05 equiv), 2 (1.0 equiv), EtOH/H₂O, conc. HCl (1.1

equiv), microwave, 130° C., 20 min; 30% conversion to

desired product By LCMS analysis.

6 to 7
0.040 g
—
6 (1.05 equiv), 2 (1.0 equiv), EtOH/H₂O, conc. HCl (1.1

equiv), microwave, 120° C., 10 min followed by 130° C., 10

min; 25% conversion by LCMS analysis.

6 to 7
0.005 g
—
6 (1.05 equiv), 2 (1.0 equiv), EtOH/H₂O, conc. HCl (1.1

equiv), microwave, 120° C., 15 min; 45% conversion by

LCMS analysis.

6 to 7
0.165 g
0.035 g
6 (1.05 equiv), 2 (1.0 equiv), EtOH/H₂O, conc. HCl (1.1

(crude)
equiv), microwave, 120° C., 15 min; 45% conversion by

LCMS analysis; 85% pure by HPLC analysis.

7 to 8
0.030 g
0.020 g
3, Et₃N (1.1 equiv), CS₂(1.2 equiv), MeI (1.2 equiv),

(51%)
pyridine, 0° C. to rt; product consistent by ESI-MS and ¹H

NMR analysis.

Example 40
benzo[b]thiophen-3-ylmethyl 2-(1H-indol-3-yl)ethylcarbamodithioate [Compound 00054]

SM
Scale
Yield
Conditions

55
8.00 g
1.956 g
55, formaldehyde, HCl (gas), 65° C.

(18%)
vacuum distillation. NMR.

56
0.274 g
0.068 g
tryptamine, CS₂, standard procedure.

(14%)
98% by HPLC (254 nm), but ca. 90% by NMR.

further purification needed.

55
8.00 g
3.06 g
55, formaldehyde, HCl (gas), 65° C.

(28%)
vacuum distillation. NMR, GCMS.

56
0.457 g
0.208 g
tryptamine, CS₂, standard procedure.

(26%)
Pure by HPLC and NMR.

Example 41
2-Hydroxy-N-phenethylbenzothioamide [Compound 00634]

SM
Scale
Yield
Conditions

78
1.380 g
2.388 g (99%)
78 CDI, DKE, 1 h, rt,

then 79, overnight rt.

Purity: 80% by NMR,

89% by HPLC-MS.

80
2.390 g
0.254 g (10%)
80, toulene, Lawesson's reagent,

reflux, 2 h.

Purity: 98% by NMR,

100% by HPLC-MS.

Example 42
3-((1H-indol-3-yl)methyl)-2-thioxothiazolidin-4-one [Compound 00078]

SM
Scale
Yield
Conditions

70
0.22 g
0.132 g
70, MeOH, TEA (1 equiv.), CS₂(1.5 equiv.),

(33%)
rt, 30 min. 71(1.05 equiv.), reflux,

1 h; HPLC, NMR.

Example 43
Naphthalen-2-ylmethyl 2-(thiochroman-3-yl)ethylcarbamodithioate [Compound 00064]

embedded image

Example 44
N-((1H-indol-3-yl)methyl)-2-(2-thioxo-2,3-dihydrothiazol-4-yl)acetamide [Compound 00561]

SM
Scale
Yield
Conditions

68
5.00 g
2.70 g (63%)
NaOH, EtOH, water, 50° C., 4 h.

69
0.114 g
0.018 g
PS-DCC, DCM.

HPLC: 87 %.

69
0.26 g
0.10 g
CDI, DCE, N₂, rt.

Example 45
N-Benzyl-2-hydroxybenzothioamide [Compound 00656]

SM
Scale
Yield
Conditions

78
6.90 g
10.100 g
78, CDI, CHCl₃, 1 h, rt, then 89, overnight, rt.

(89 %)
Purity: 60% by NMR, 88% by HPLC-MS.

90
10.10 g
0.647 g
90, toulene, Lawesson's reagent, reflux, 2 h.

(6 %)
Purity: 98% by NMR, 100% by HPLC-MS.

Example 46
N-(2-(1H-indol-3-yl)ethyl)-2-hydroxybenzothioamide [Compound 00644]

SM
Scale
Yield
Conditions

78
4.14 g
6.22 g
78 CDI, DCM, 1 h, rt,

(74%)
then DIPEA and 60, overnight,

rt. Purity: 98% by NMR,

96% by HPLC-MS.

85
6.22 g
1.24 g
85, toulene, Lawesson's reagent,

(19%)
reflux, 2 h.

Purity: 97% by NMR,

100% by HPLC-MS.

Example 47
N-(2-(benzo[b]thiophen-3-yl)ethyl)-2-hydroxybenzothioamide [Compound 00672]

SM
Scale
Yield
Conditions

74
0.45 g
0.14 g
LAH, ether, reflux.

(31%)

74
1.00 g
0.90 g
LAH, AlCl₃, ether, 30 min,

(88%)
reflux.

75
0.50 g

CDI, DCE rt.

Example 48
N-(Naphthalen-2-ylmethyl)-2-(2-thioxo-2,3-dihydrothiazol-4-yl)acetamide [Compound 00701]

embedded image

Example 49
Methyl 6-(1H-indol-3-yl)hexylcarbamodithioate [Compound 00027]

Reaction
Scale
Yield
Conditions

36 to 37
0.80 g
0.80 g
LiAlH₄(6 equiv), dioxane,

(Crude)
reflux, 36 h; product

consistent by ESI-MS analysis.

37 to 38
0.80 g
0.09 g
Et₃N (1.1 equiv), CS₂

(8%)
(1.2 equiv), MeI (1.2 equiv),

pyridine, 0° C. to r.t., 15 h;

product consistent by

ESI-MS and ¹H NMR analysis

Example 50
Methyl 1-(1H-indol-3-yl)-2-methylpropan-2-ylcarbamodithioate [Compound 00028]

Scale
Yield
Conditions

260 mg
0.30 g
21, CS₂(1.2 equiv), NEt₃(1.3 equiv), pyridine,

(71%)
MeI (1.2 equiv), 0° C. to r.t., overnight;

consistent by ESI-MS and ¹H NMR analysis

Example 51
Methyl 2-(5-chloro-1H-indol-3-yl)ethylcarbamodithioate [Compound 00032]

Reaction
Scale
Yield
Conditions

25 to 30
100 mg
126 mg
25, CS₂(1.2 equiv), NEt₃

(85%)
(1.3 equiv), pyridine, MeI

(1.2 equiv), 0° C. to r.t.,

overnight; product consistent

by ESI-MS and ¹H NMR analysis.

27 to 32
500 mg
499 mg
27, CS₂(1.2 equiv),

(74%)
NEt₃(1.5 equiv), pyridine, MeI

(1.2 equiv), 0° C. to r.t.,

overnight; consistent by ESI-

MS and ¹H NMR analysis.

Example 52
Naphthalen-2-ylmethyl 2-(benzofuran-3-yl)ethylcarbamodithioate [Compound 00057]

Reaction
Scale
Yield
Conditions

49 to 51
0.10 g
0.19 g
Et₃N (1.1 equiv), CS₂(1.2 equiv),

(82%)
50 (1.2 equiv), pyridine, 0° C. to

r.t., 15 h; product consistent by

ESI-MS and ¹H NMR analysis.

Example 53
N-(2-aminophenyl)-3-phenylpropanamide [Compound 00581]

SM
Scale
Yield
Conditions

41
1.00 g
0.345 g
38 (3 equiv), DCE, 41, rt, 10 min.

Chromatographic

(24%)
purification. 95% pure by HPLC, MS, NMR.

Example 54
N-(2-aminophenyl)-4-(1H-indol-3-yl)butanamide [Compound 00588]

SM
Scale
Yield
Conditions

45
1.00 g
0.751 g (52%)
purity: 98% by HPLC-MS.

Example 55
N-(2-aminophenyl)-3-(benzo[b]thiophen-3-yl)propanamide [Compound 00739]

SM
Scale
Yield
Conditions

59
1.00 g
1.00 g
59, Meldrum's acid, triethylamine formate,

(79 %)
100° C., 2 h. HPLC: 94%, NMR: 95%.

61
0.50 g
0.13 g
61, CDI, DCE, rt, 1 h. 62, rt,

(18%)
16 h. LCMS, NMR.

Example 56
N-hydroxy-2-(naphthalen-2-yl)acetamide [Compound 00827]

Reaction
Scale
Yield

15 to 16
0.100 g
0.035 g

(31%)

Example 57
5-((1H-indol-3-yl)methyl)quinolin-8-ol [Compound 00655]

SM
Scale
Yield
Conditions

121
2.00 g

Ethanol, cat. piperidine acetate, reflux, 16 h.

crude: 15% product by HPLC, after chrom. 29%.

Example 58
5-Benzylquionolin-8-ol [Compound 00664]

SM
Scale
Yield
Comments

107
5.00 g
5.00 g
65% HNO₃(aq.), acetic acid, 12-15° C.,

(80%)
0.5 h. HPLC 97%, NMR.

108
2.29 g
1.80 g
20% HCl-solution, Sn powder (3.1 equiv.),

(90%)
reflux, 2 h. LC-MS: 96%, NMR.

109
0.50 g
0.135 g
109 (0.57 equiv.), glycerol (5.5 equiv.),

(14%)
acetic acid (80% aq. solution), sulfuric acid;

150-160° C., 1.5 h; NMR, 100%

pure by HPLC.

Example 59
General Method for Synthesis of Hydroxylamine Compounds

Alcohol (1.0 equiv.), N-hydroxypthalimide (1.1 equiv.) and triphenylphosphine (1.1 equiv.) were dissolved in dichloromethane (6 mL). Diethyl azodicarboxylate (DEAD) (1.1 equiv.) was added dropwise while stirring to the solution and the reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with dichloromethane (20 mL). The combined dichloromethane was washed with 10% NaOH (2×15 mL), water (2×15 mL) and brine (15 mL). The solvent was removed under reduced pressure and the crude product was used for the next step. The crude product was dissolved in ethanol (8 mL) and hydrazine monohydrate (2.0 equiv.) was added. The reaction was refluxed for 2 h and filtered. Ethanol was removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel.

The following compounds (Table A) were prepared essentially according to the preceding example with the proper substitution of starting materials:

TABLE A

Yield

¹H NMR (CDCl₃unless otherwise noted): δ

Compound
(%)
(ppm)

O-(3-
53
4.75 (s, 2 H), 5.53 (br s, 2 H), 7.48-7.54 (m, 1 H),

Nitrobenzyl)hydroxylamine

7.66 (d, 1 H, J = 10 Hz), 8.13 (d, 1 H, J = 11 Hz),

8.20 (s, 1 H)

O-(Pyridin-2-
11
4.77 (s, 2 H), 5.58 (br s, 2 H), 7.16 (dd, 1 H, J = 4.8,

ylmethyl)hydroxylamine

6.8 Hz), 7.32 (d, 1 H, J = 7.6 Hz), 7.64 (dt, 1 H, J = 2,

8 Hz), 8.54 (d, 1 H, J = 4.8 Hz)

O-(Pyridin-3-
10
4.66 (s, 2 H), 5.44 (br s, 2 H), 7.23-7.27 (m, 1 H),

ylmethyl)hydroxylamine

7.65 (d, 1 H, J = 8 Hz), 8.53 (d, 1 H, J = 4.4 Hz),

8.58 (s, 1 H)

O-(Pyridin-4-
37
4.64 (s, 2 H), 5.53 (br s, 2 H), 7.20 (dd, 2 H, J = 1.6,

ylmethyl)hydroxylamine

4.4 Hz), 8.53 (dd, 2 H, J = 1.6, 4.4 Hz)

O-(Benzo[d][1,3]dioxol-5-
48
4.56 (s, 2 H), 5.35 (br s, 2 H), 5.94 (s, 2 H),

ylmethyl)hydroxylamine

6.76-6.85 (m, 3 H)

O-((5-
51
4.87 (s, 2 H), 5.44 (br s, 2 H), 7.30 (dd, 2 H, J = 2,

Chlorobenzo[b]thiophen-3-

8.8 Hz), 7.45 (s, 1 H), 7.74 (dd, 1 H, J = 0.4, 8.4 Hz),

yl)methyl)hydroxylamine

7.87 (d, 1 H, J = 1.6 Hz)

O-(Naphthalen-2-
61
4.84 (s, 2 H), 5.42 (br s, 2 H), 7.46-7.49 (m, 3 H),

ylmethyl)hydroxylamine

7.80-7.85 (m, 4 H)

O-(Quinolin-6-
55
4.79 (s, 2 H), 5.46 (br s, 2 H), 7.32 (dd, 1 H, J = 4.4,

ylmethyl)hydroxylamine

8.4 Hz), 7.36-7.40 (m, 1 H), 7.65 (dd, 1 H, J = 1.6,

8.4 Hz), 7.71 (d, 1 H, J = 0.8 Hz), 8.03-8.07 (m, 2

H)

O-((2,3-
61
4.20 (s, 4 H), 4.52 (s, 2 H), 5.32 (br s, 2 H),

Dihydrobenzo[b][1,4]dioxin-

6.80-6.81 (m, 2 H), 6.85 (d, 1 H, J = 1.2 Hz).

6-yl)methyl)hydroxylamine

O-(Chroman-2-
43
1.71-1.82 (m, 1 H), 1.95-1.99 (m, 1 H),

ylmethyl)hydroxylamine

2.71-2.77 (m, 1 H), 2.81-2.90 (m, 1 H), 3.80-3.91 (m, 2 H),

4.25-4.31 (m, 1 H), 5.52 (br s, 2 H), 6.80-6.85 (m, 2

H), 7.01-7.08 (m, 1 H).

O-(Benzo[d]thiazol-2-
39
5.05 (s, 2 H), 5.78 (br s, 2 H), 7.34-7.38 (m, 1 H),

ylmethyl)hydroxylamine

7.43-7.47 (m, 1 H), 7.87 (dd, 1 H, J = 0.4, 7.6 Hz),

7.99 (d, 1 H, J = 8 Hz).

O-((4-Methyl-2-
53
2.59 (s, 3 H), 4.69 (s, 2 H), 5.47 (br s, 2 H),

phenylpyrimidin-5-

7.44-7.45 (m, 3 H), 8.40-8.43 (m, 2 H), 8.59 (s, 1 H).

yl)methyl)hydroxylamine

O-(Benzofuran-2-
28
4.76 (s, 2 H), 5.55 (br s, 2 H), 6.72 (s, 1 H),

ylmethyl)hydroxylamine

7.18-7.29 (m, 2 H), 7.47 (d, 1 H, J = 8 Hz), 7.54 (d, 1 H, J = 7.6 Hz).

O-(3-
42
4.65 (s, 2 H), 5.42 (br s, 2 H), 6.95-7.11 (m, 3 H),

Fluorobenzyl)hydroxylamine

7.23-7.29 (m, 1 H).

O-(3,5-
47
4.63 (s, 2 H), 5.47 (br s, 2 H), 6.69-6.72 (m, 1 H),

Difluorobenzyl)hydroxylamine

6.84-6.86 (m, 2 H).

O-(3-
57
4.71 (s, 2 H), 5.45 (br s, 2 H), 7.46-7.56 (m, 3 H),

(Trifluoromethyl)benzyl)hydroxylamine

7.61 (s, 1 H).

O-(3,5-
44
4.63 (s, 2 H), 5.50 (br s, 2 H), 7.25-7.27 (m, 2 H),

Dichlorobenzyl)hydroxylamine

7.30 (d, 1 H, J = 1.8 Hz).

O-(3-
58
4.62 (s, 2 H), 5.42 (br s, 2 H), 7.18-7.26 (m, 2 H),

Bromobenzyl)hydroxylamine

7.40-7.43 (m, 1 H), 7.50 (s, 1 H).

O-(2,5-
49
3.78 (s, 3 H), 3.80 (s, 3 H), 4.74 (s, 2 H), 5.44 (br s,

Dimethoxybenzyl)hydroxylamine

2 H), 6.82 (d, 2 H, J = 2 Hz), 6.95 (s, 1 H).

O-(4-
54
4.72 (s, 2 H), 5.45 (br s, 2 H), 7.45 (d, 2 H, J = 8 Hz),

(Trifluoromethyl)benzyl)hydroxylamine

7.60 (d, 2 H, J = 8 Hz).

O-(4-
57
4.61 (s, 2 H), 5.38 (br s, 2 H), 6.99-7.03 (m, 2 H),

Fluorobenzyl)hydroxylamine

7.28-7.31 (m, 2 H).

O-(2-Chloro-4-
48
4.74 (s, 2 H), 5.46 (br s, 2 H), 6.97 (dt, 1 H, J = 2.4,

fluorobenzyl)hydroxylamine

8.4 Hz), 7.11 (dd, 1 H, J = 2.4, 8.4 Hz), 7.39 (dd, 1

H, J = 6.4, 8.4 Hz).

O-(2-Chloro-6-
39
4.86 (s, 2 H), 5.47 (br s, 2 H), 6.96-7.01 (m, 1 H),

fluorobenzyl)hydroxylamine

7.17-7.25 (m, 2 H).

O-(2-
56
4.78 (s, 2 H), 5.49 (br s, 2 H), 7.15 (dt, 1 H, J = 1.6,

Bromobenzyl)hydroxylamine

7.6 Hz), 7.29 (dt, 1 H, J = 1.2, 7.6 Hz), 7.41 (dd, 1

H, J = 1.2, 7.6 Hz), 7.54 (dd, 1 H, J = 1.2, 7.6 Hz).

O-(3-
58
2.34 (s, 3 H), 4.64 (s, 2 H), 5.36 (br s, 2 H),

Methylbenzyl)hydroxylamine

7.10-7.16 (m, 3 H), 7.21-7.25 (m, 1 H).

Methyl 4-
35
3.89 (s, 3 H), 4.72 (s, 2 H), 5.44 (br s, 2 H), 7.38 (d,

(aminooxymethyl)benzoate

2 H, J = 7.6 Hz), 7.99 (d, 2 H, J = 6.8 Hz).

O-(3-Chloro-4-
42
4.59 (s, 2 H), 5.41 (br s, 2 H), 7.07-7.12 (m, 1 H),

fluorobenzyl)hydroxylamine

7.18-7.19 (m, 1 H), 7.40 (dd, 1 H, J = 1.6, 6.8 Hz).

O-(2-
48
3.82 (s, 3 H), 4.74 (s, 2 H), 5.39 (br s, 2 H), 6.87 (d,

Methoxybenzyl)hydroxylamine

1 H, J = 8 Hz), 6.93 (t, 1 H, J = 7.6 Hz),

7.25-7.32 (m, 2 H).

O-(2-
52
4.91 (s, 2 H), 5.54 (br s, 2 H), 7.39-7.43 (m, 1 H),

(Trifluoromethyl)benzyl)hydroxylamine

7.55-7.62 (m, 3 H).

O-(2-
39
5.05 (s, 2 H), 5.54 (br s, 2 H), 7.41-7.44 (m, 1 H),

Nitrobenzyl)hydroxylamine

7.61-7.63 (m, 2 H), 7.99-8.01 (m, 1 H).

O-(3-Chloro-5-
35
4.61 (s, 2 H), 5.47 (br s, 2 H), 6.94-6.97 (m, 1 H),

fluorobenzyl)hydroxylamine

7.01 (td, 1 H, J = 2, 8.4 Hz), 7.12 (s, 1 H).

O-
30
4.77 (s, 2 H), 5.51 (br s, 2 H).

(Perfluorobenzyl)hydroxylamine

O-(3-
47
2.97 (t, 2 H, J = 6.8 Hz), 3.88 (t, 2 H, J = 6.8 Hz),

Nitrophenethyl)hydroxylamine

5.40 (br s, 2 H), 7.40-7.43 (m, 1 H), 7.51-7.53 (m, 1

H), 8.01-8.05 (m, 2 H).

O-(4-
49
3.80 (s, 3 H), 4.62 (s, 2 H), 5.33 (br s, 2 H), 6.89 (d,

Methoxybenzyl)hydroxylamine

2 H, J = 8.4 Hz), 7.29 (d, 2 H, J = 8.4 Hz).

O-(4-
52
4.59 (s, 2 H), 5.38 (br s, 2 H), 7.08 (d, 2 H, J = 7.6 Hz),

Iodobenzyl)hydroxylamine

7.66 (d, 2 H, J = 7.6 Hz).

O-(3-
61
4.59 (s, 2 H), 5.41 (br s, 2 H), 7.07 (t, 1 H, J = 7.6 Hz),

Iodobenzyl)hydroxylamine

7.29 (d, 1 H, J = 7.2 Hz), 7.62 (d, 1 H, J = 7.6 Hz),

7.70 (s, 1 H).

O-(2-
57
4.71 (s, 2 H), 5.49 (br s, 2 H), 6.95-7.00 (m, 1 H),

Iodobenzyl)hydroxylamine

7.30-7.38 (m, 2 H), 7.82 (d, 1 H, J = 8 Hz).

2-(aminooxymethyl)-N-
32
4.72 (s, 2 H), 5.35 (br s, 2 H), 6.88-6.92 (m, 2 H),

phenylaniline

7.04-7.06 (m, 2 H), 7.22-7.27 (m, 4 H), 7.37-7.39 (d,

1 H, J = 8 Hz)

2-(aminooxymethyl)-N-
28
4.37 (s, 2 H), 4.73 (s, 2 H), 5.30 (br s, 3 H),

benzylaniline

6.61-6.69 (m, 2 H), 7.11-7.13 (dd, 1 H, J = 1.6, 7.6 Hz),

7.16-7.20 (dt, 1 H, J = 1.6, 8.4 Hz), 7.23-7.27 (m, 1 H),

7.30-7.35 (m, 4 H)

3-(aminooxymethyl)-N-
39
(CD₃OD) 4.59 (s, 2 H), 5.06 (s, 2 H), 7.38-7.40 (m,

benzylaniline

6 H), 7.48-7.56 (m, 3 H)

O-benzhydrylhydroxylamine
65
5.30 (br s, 2 H), 5.64 (s, 1 H), 7.23-7.35 (m, 10 H)

O-
57
0.81-1.25 (m, 6 H), 1.55-1.60 (m, 2 H), 1.71 (d, 1 H,

(cyclohexyl(phenyl)methyl)hydroxylamine

J = 12.4 Hz), 2.00 (d, 1 H, J = 12.8 Hz), 4.17 (d, 1H,

J = 8 Hz), 5.10 (br s, 2 H), 7.23-7.32 (m, 5 H)

O-(3-morpholino-1-
52
1.64-1.65 (m, 1 H), 1.89-1.93 (m, 1 H),

phenylpropyl)hydroxylamine

2.21-2.28 (m, 6 H), 3.56-3.57 (m, 4 H), 4.45-4.46 (m, 1 H),

5.09 (br s, 2 H), 7.20-7.25 (m, 5 H)

O-(1,2-
58
2.86-2.91 (dd, 1 H, J = 5.6, 13.6 Hz), 3.10-3.15 (dd,

diphenylethyl)hydroxylamine

1 H, J = 7.6, 13.6 Hz). 4.71-4.74 (dd, 1 H, J = 6, 7.6 Hz),

5.18 (br s, 2 H), 7.12 (d, 1 H, J = 6.8 Hz),

7.16-7.30 (m, 8 H)

O-(2-morpholino-1-
64
2.35-2.39 (dd, 1 H, J = 3.2, 13.6 Hz), 2.48-2.58 (m,

phenylethyl)hydroxylamine

4 H), 2.73-2.78 (dd, 1 H, J = 9.6, 13.6 Hz),

3.67-3.76 (m, 4 H), 4.74-4.77 (dd, 1 H, J = 3.2, 9.2 Hz),

5.24 (br s, 2 H), 7.27-7.36 (m, 5 H)

4-(aminooxy)-N-methyl-4-
41
1.98-2.11 (m, 2 H), 2.17-2.21 (m, 2 H), 2.75 (d, 3 H,

phenylbutanamide

J = 4 Hz), 4.48-4.51 (dd, 1 H, J = 5.6, 7.6 Hz),

5.20 (br s, 2 H), 5.56 (br s, 1 H), 7.24-7.32 (m, 5 H)

4-(aminooxy)-N-cyclohexyl-
38
1.05-1.18 (m, 2 H), 1.26-1.41 (m, 2 H),

4-phenylbutanamide

1.62-1.74 (m, 4 H), 1.88-1.97 (m, 2 H), 1.99-2.21 (m, 4 H),

3.71-3.77 (m, 1 H), 4.50-4.55 (dd, 1 H, J = 7.6, 10 Hz),

5.22 (br s, 2 H), 5.35 (d, 1 H, J = 10 Hz),

7.27-7.39 (m, 5 H)

methyl 4-(aminooxy)-4-
49
1.95-1.99 (m, 1 H), 2.06-2.11 (m, 1 H),

phenylbutanoate

2.34-2.38 (dd, 2 H, J = 1.2, 8.4 Hz), 3.63 (s, 3 H),

4.49-4.52 (dd, 1 H, J = 5.6, 7.6 Hz), 5.22 (br s, 2 H),

7.26-7.36 (m, 5 H)

2-(aminooxy)-2-
52
(CD₃OD) 3.22-3.71 (m, 2 H), 5.31-5.34 (m, 1 H),

phenylethanamine

7.41-7.45 (m, 5 H)

3-(aminooxy)-3-
45
1.78-1.85 (m, 1 H), 1.87-1.94 (m, 1 H),

phenylpropan-1-amine

3.13-3.24 (m, 2 H), 4.52-4.55 (m, 1 H), 4.76 (br s, 2 H),

5.22 (br s, 2 H), 7.23-7.32 (m, 5 H)

O-((3′,4-dichlorobiphenyl-2-
33
4.56 (s, 2H), 5.45 (br s, 2H), 7.19-7.23 (m, 2H),

yl)methyl)hydroxylammonium

7.33-7.36 (m, 4H), 7.54 (d, 1H, J = 1.5 Hz)

chloride

O-((3′,4,4′-trichlorobiphenyl-
62
4.54 (s, 2H), 5.46 (br s, 2H), 7.18-7.21 (m, 2H),

2-

7.33-7.36 (dd, 1H, J = 1.5, 4.5 Hz), 7.47-7.49 (m,

yl)methyl)hydroxylammonium

2H), 7.54 (s, 1H)

chloride

O-((4-chloro-4′-
31
4.54 (s, 2H), 5.46 (br s, 2H), 7.21 (d, 1H, J = 6.30 Hz),

(trifluoromethyl)biphenyl-2-

7.36 (d, 1H, J = 4.8 Hz), 7.47 (d, 2H, J = 6.0 Hz),

yl)methyl)hydroxylamine

7.56 (d, 1H, J = 1.5 Hz), 7.68 (d, 2H, J = 6.0 Hz)

O-(5-chloro-2-(pyrimidin-5-
45
4.52 (s, 2H), 5.48 (br s, 2H), 7.18-7.24 (m, 1H),

yl)benzyl)hydroxylamine

7.39 (d, 1H, J = 4.8 Hz), 7.57 (s, 1H), 8.75-8.82 (m, 2H),

9.21 (s, 1H)

O-(5-chloro-2-(thiophen-3-
62
4.64 (s, 2H), 5.42 (br s, 2H), 7.17 (dd, 1H, J = 1.32,

yl)benzyl)hydroxylamine

3.54 Hz), 7.31-7.39 (m, 4H), 7.53 (s, 1H)

O-(5-chloro-2-(thiophen-2-
36
4.71 (s, 2H), 5.30 (br s, 2H), 7.08-7.13 (m, 2H),

yl)benzyl)hydroxylamine

7.25-7.41 (m, 3H), 7.53 (d, 1H, J = 1.83 Hz)

O-((4′-chlorobiphenyl-2-
67
4.58 (s, 2H), 4.36 (s, 2H), 7.23-7.27 (m, 1H),

yl)methyl)hydroxylamine

7.30-7.33 (dd, 2H, J = 2, 6.6 Hz), 7.35-7.40 (m, 4H),

7.51-7.53 (m, 1H)

O-((4′-chlorobiphenyl-3-
78
DMSO-d6 5.10 (s, 2H), 7.43-7.45 (d, 1H, J = 7.6 Hz),

yl)methyl)hydroxylamine

7.51-7.64 (m, 4H), 7.71-7.73 (m, 3H), 11.02 (br

hydrochloride

s, 3H)

O-((4′-methylbiphenyl-3-
65
2.68 (s, 3H), 4.73 (s, 2H), 5.41 (s, 2H), 7.22-7.24 (d,

yl)methyl)hydroxylamine

2H, 7.9 Hz), 7.30-7.32 (d, 1H, J = 7.5 Hz),

7.39-7.42 (t, 1H, J = 7.6 Hz), 7.48-7.53 (m, 3H), 7.57 (s, 1H)

O-((4′-methoxybiphenyl-3-
62
3.84 (s, 3H), 4.74 (s, 2H), 5.43 (br s, 2H),

yl)methyl)hydroxylamine

6.96-6.98 (dd, 2H, J = 1.8, 6.9 Hz), 7.29-7.31 (d, 1H, J = 7.5 Hz),

7.39-7.42 (t, 1H, J = 7.5 Hz), 7.49-7.55 (m, 4H)

O-(3-(pyridin-4-
49
4.77 (s, 2H), 5.51 (br s, 2H), 7.43-7.53 (m, 4H),

yl)benzyl)hydroxylamine

7.58-7.60 (d, 2H, J = 7.6 Hz), 7.64 (s, 1H),

8.65-8.67 (dd, 2H, J = 1.6, 4.5 Hz)

O-(2-(pyridin-4-
50
4.60 (s, 2H), 5.42 (br s, 2H), 7.28-7.31 (dd, 1H, J = 1.9,

yl)benzyl)hydroxylamine

7.8 Hz), 7.34-7.36 (dd, 2H, J = 1.4, 4.5 Hz),

7.40-7.47 (m, 2H), 7.55-7.58 (dd, 1H, J = 2.0, 7.8 Hz),

8.65-8.66 (d, 2H, J = 5.9 Hz)

2-(aminooxy)-N-methyl-2-
44
2.79-2.81 (d, 3H, J = 5.0 Hz), 5.00 (s, 1H), 5.66 (br

phenylacetamide

s, 2H), 6.68 (br s, 1H), 7.31-7.39 (m, 5H)

tert-butyl 2-(aminooxy)-2-
70
1.42 (s, 9H), 2.85 (s, 3H), 3.28-3.33 (dd, 1H, J = 7.7,

phenylethyl(methyl)carbamate

14.5 Hz), 3.44-3.49 (dd, 1H, J = 4.5, 14.8 Hz),

4.74-4.79 (m, 1H), 5.21 (br s, 2H), 7.28-7.36 (m, 5H)

O-(naphthalen-1-
90
5.13 (s, 2H), 5.40 (br s, 2H), 7.40-7.54 (m, 4H),

ylmethyl)hydroxylamine

7.80-7.86 (m, 2H), 8.14 (d, 1H, J = 6.18 Hz)

O-((4,4′-dichlorobiphenyl-2-
85
4.55 (s, 2H), 5.43 (br s, 2H), 7.19 (d, 1H, J = 6.18 Hz),

yl)methyl)hydroxylamine

7.25-7.40 (m, 5H), 7.54 (d, 1H, J = 1.47 Hz)

O-((4′,5-dichlorobiphenyl-3-
75
4.70 (s, 2H), 5.49 (br s, 2H), 7.34 (s, 1H),

yl)methyl)hydroxylamine

7.39-7.49 (m, 6 H)

2-(aminooxy)-N-methyl-2-
70
DMSO-d6 2.61 (s, 3H), 3.21 (dd, 1H, J = 2.5, 11.3 Hz),

phenylethanamine

3.43 (dd, 1H, J = 9.74, 3.78 Hz), 5.60 (d, 1H, J = 7.3 Hz),

dihydrochloride

7.46 (s, 5H), 10.06 (br s, 3H)

O-((4-chlorobiphenyl-2-
62
4.58 (s, 2H), 5.41 (br s, 2H), 7.22 (d, 1H, J = 6.2 Hz),

yl)methyl)hydroxylamine

7.31-7.43 (m, 6H), 7.54 (d, 1H, J = 1.5 Hz)

O-((4-chloro-4′-
57
3.85 (s, 3H), 4.58 (s, 2H), 5.42 (br s, 2H), 6.94 (d,

methoxybiphenyl-2-

2H, J = 6.5 Hz), 7.19-7.32 (m, 4H), 7.52 (d, 1H, 1.6 Hz),

yl)methyl)hydroxylamine

O-((2′,4-dichlorobiphenyl-2-
10
4.40 (d, 1H, J = 9.45 Hz), 4.53 (d, 1H, J = 9.5 Hz),

yl)methyl)hydroxylamine

5.35 (br s, 2H), 7.13 (d, 1H, J = 6.2 Hz),

7.22-7.35 (m, 4H), 7.45-7.47 (m, 1H), 7.54 (d, 1H, J = 1.4 Hz)

O-(5-chloro-2-(1H-indol-5-
82
4.64 (s, 2H), 5.38 (br s, 2H), 6.56 (s, 1H), 7.13 (dd,

yl)benzyl)hydroxylamine

1H, J = 1.1, 5.2 Hz), 7.21-7.39 (m, 4H),

7.54-7.56 (m, 2H), 8.30 (br s, 1H)

2′-(aminooxymethyl)-4′-
71
2.99 (s, 6H), 4.63 (s, 2H), 5.40 (br s, 2H), 6.76 (d,

chloro-N,N-dimethylbiphenyl-

2H, J = 6.72 Hz), 7.20-7.30 (m, 4H), 7.51 (s, 1H)

4-amine

methyl 2′-(aminooxymethyl)-
83
3.95 (s, 3H), 4.56 (s, 2H), 5.44 (br s, 2H),

4′-chlorobiphenyl-4-

7.22-7.24 (d, 1H, J = 8.2 Hz), 7.34-7.37 (dd, 1H, J = 2.2, 8.2 Hz),

carboxylate

7.41-7.43 (d, 2H, J = 8.4 Hz), 7.55-7.56 (d, 1H,

J = 2.1 Hz), 8.08-8.10 (d, 2H, J = 8.3 Hz)

O-(biphenyl-3-
47
4.75 (s, 2 H), 5.43 (br s, 2 H), 7.33-7.36 (m, 2 H),

ylmethyl)hydroxylamine

7.41-7.45 (m, 3 H), 7.54 (d, 1 H, J = 8 Hz),

7.59-7.61 (m, 3 H).

O-(biphenyl-2-
28
4.64 (s, 2 H), 5.36 (br s, 2 H), 7.30-7.45 (m, 8 H),

ylmethyl)hydroxylamine

7.53-7.56 (m, 1 H).

(S)—O-(3-(tert-
28
0.01 (s, 3 H), 0.02 (s, 3 H), 0.08 (s, 9 H),

butyldimethylsilyloxy)-1-

1.75-1.82 (m, 1 H), 1.93-2.06 (m, 1 H), 3.52-3.54 (m, 1 H),

phenylpropyl)hydroxylamine

3.68-3.75 (m, 1 H), 4.63-4.65 (m, 1 H), 5.14 (br s, 2

H), 7.23-7.33 (m, 5 H).

O-(4-
61
4.67 (s, 2 H), 5.48 (br s, 2 H), 7.39 (d, 2 H, J = 8.0 Hz),

cyanobenzyl)hydroxylamine

7.57 (d, 2 H, J = 8.0 Hz)

O-(1,2,3,4-
23
1.66-1.84 (m, 3 H), 2.29-2.32 (m, 1 H),

tetrahydronaphthalen-1-

2.58-2.77 (m, 2 H), 5.33-5.35 (m, 1 H), 7.11 (d, 1 H, J = 7.6 Hz),

yl)hydroxylammonium

7.16-7.26 (m, 2 H), 7.41 (d, 1 H, J = 7.6 Hz),

chloride

11.10 (s, 3 H)

O-(2-cyclohexyl-1-
37
0.79-1.25 (m, 5 H), 1.35-1.82 (m, 6 H),

phenylethyl)hydroxylammonium

2.38-2.46 (m, 2 H), 7.34-7.39 (m, 5 H), 10.75 (s, 3 H)

chloride

O-(2-phenoxy-1-
47
4.18-4.22 (m, 1 H), 4.29-4.40 (m, 1 H),

phenylethyl)hydroxylammonium

5.41-5.51 (m, 1 H), 6.89-6.94 (m, 3 H), 7.23-7.27 (m, 2 H),

chloride

7.38-7.44 (m, 3 H), 7.46-7.52 (m, 2 H), 11.02 (br.

s, 3 H)

O-(2-(benzyloxy)-1-
52
3.58-3.62 (m, 1 H), 3.75-3.82 (m, 1 H),

phenylethyl)hydroxylammonium

4.48-4.57 (m, 2 H), 5.33-5.38 (m, 1 H), 7.16-7.35 (m, 5 H),

chloride

7.36-7.41 (m, 5 H), 10.98 (br. s, 3 H)

O-(1,3-
73
1.96-2.01 (m, 1 H), 2.15-2.28 (m, 1 H),

diphenylpropyl)hydroxylammonium

2.33-2.65 (m, 2 H), 5.00-5.15 (m, 1 H), 7.10-7.18 (m, 3 H),

chloride

7.19-7.27 (m, 2 H), 7.32-7.45 (m, 5 H), 11.00 (br. s,

3 H)

O-(3-cyclohexyl-1-
42
0.93-1.25 (m, 7 H), 1.56-1.86 (m, 8 H),

phenylpropyl)hydroxylammonium

4.98-5.10 (m, 1 H), 7.15-7.39 (m, 5 H), 10.81 (br. s, 3 H)

chloride

Example 60
General Method for Synthesis of bis(hydroxylamine) Compounds

Alcohol (1.0 equiv.), N-hydroxypthalimide (2.2 equiv.) and triphenylphosphine (2.2 equiv.) were dissolved in dichloromethane (6 mL). Diethyl azodicarboxylate (DEAD) (2.2 equiv.) was added dropwise while stirring to the solution and the reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with dichloromethane (20 mL). The combined dichloromethane was washed with 10% NaOH (2×15 mL), water (2×15 mL) and brine (15 mL). The solvent was removed under reduced pressure and the crude product was used for the next step. The crude product was dissolved in ethanol (8 mL) and hydrazine monohydrate (4.0 equiv.) was added. The reaction was refluxed for 2 h and filtered. Ethanol was removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel.

The following compounds (Table B) were prepared essentially according to the preceding example with the proper substitution of starting materials:

TABLE B

Yield

¹H NMR (CDCl₃unless otherwise

Compound
(%)
noted): δ (ppm)

O,O′-(1,3-
28
4.67 (s, 4 H), 5.42 (br s, 4 H),

phenylenebis(methylene))-

7.28-7.33 (m, 4 H).

bis(hydroxylamine)

O,O′-(1,2-
36
4.80 (s, 4 H), 5.42 (br s, 4 H),

phenylenebis(methylene))-

7.30-7.40 (m, 4 H).

bis(hydroxylamine)

O,O′-(1,4-
32
4.67 (s, 4 H), 5.40 (br s, 4 H),

phenylenebis(methylene))-

7.34-7.36 (m, 4 H).

bis(hydroxylamine)

Example 61
Synthesis of O-(1-(3-Nitrophenyl)but-3-enyl)hydroxylamine

3-Nitrobenzaldehyde (296 mg, 1.96 mmol) was dissolved in THF (4 mL) and cooled to −78° C. Allyl magnesium bromide (1 M in butyl ether, 2.4 mL, 2.35 mmol) was added dropwise and the reaction mixture was stirred at −78° C. for 1 h. It was then quenched with saturated ammonium chloride (5 mL) and extracted with ethyl acetate (2×30 mL). The combined organic layers were dried over Na₂SO₄and concentrated. The crude product was purified by flash column chromatography on silica gel using 25% EtOAc/hexanes as eluent to yield the desired product as yellow oil which was used in the next step. 1-(3-Nitrophenyl)but-3-en-1-ol (139 mg, 0.720), N-hydroxyphthalimide (129 mg, 0.792 mmol) and triphenylphosphine (208 mg, 0.792 mmol) were dissolved in dichloromethane (6 mL). Diethyl azodicarboxylate (DEAD) (0.13 mL, 0.792 mmol) was added dropwise while stirring to the solution and the reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with dichloromethane (20 mL). The combined dichloromethane was washed with 10% NaOH (2×15 mL), water (2×15 mL) and brine (15 mL). The solvent was removed under reduced pressure and the crude product was used for the next step. The crude product was dissolved in ethanol (6 mL) and hydrazine monohydrate (0.16 mL, 3.22 mmol) was added. The reaction was refluxed for 2 h and filtered. Ethanol was removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel using 20%-35% EtOAc/hexanes as eluent to yield the desired product as colorless oil. ¹H NMR (CDCl₃, 400 MHz): δ (ppm) 2.38-2.43 (m, 1H), 2.53-2.59 (m, 1H), 4.67 (t, 1H, J=6.8 Hz), 5.00-5.04 (m, 2H), 5.35 (br s, 2H), 5.67-5.74 (m, 2H), 7.49-7.53 (m, 1H), 7.62 (d, 1H, J=7.6 Hz), 8.11-8.16 (m, 2H).

Example 62
Synthesis of N-Boc-Indole-3-carbinol

To a solution of indole-3-carbinol (250 mg, 1.70 mmol) and (Boc)₂O (371 mg, 1.70 mmol) in dichloromethane (6 mL) was added triethylamine (0.47 mL, 3.40 mmol) followed by DMAP (21 mg, 0.170 mmol). The reaction mixture was stirred at room temperature for 1 h and poured into water. The dichloromethane layer was separated, dried over Na₂SO₄and concentrated. The crude product was purified by flash column chromatography on silica gel using 20%-30% EtOAc/hexanes as eluent to afford Boc protected indole as solid (60 mg, 0.243 mmol, 15%). ¹H NMR (CDCl₃, 300 MHz): δ (ppm) 1.66 (s, 9H), 1.84 (br s, 1H), 4.82 (s, 2H), 7.22-7.36 (m, 2H), 7.57 (s, 1H), 7.64 (dd, 1H, J=0.6, 7.5 Hz), 8.14 (d, 1H, J=8.1 Hz).

Example 63
Synthesis of O-((1H-Indol-3-yl)methyl)hydroxylamine hydrochloride

N-Boc-Indole-3-carbinol (120 mg, 0.486 mmol), N-hydroxyphthalimide (87 mg, 0.534 mmol) and triphenylphosphine (140 mg, 0.534 mmol) were dissolved in dichloromethane (6 mL). Diethyl azodicarboxylate (DEAD) (0.08 mL, 0.534 mmol) was added dropwise while stirring to the solution and the reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with dichloromethane (20 mL). The combined dichloromethane was washed with 10% NaOH (2×15 mL), water (2×15 mL) and brine (15 mL). The solvent was removed under reduced pressure and the crude product was used for the next step. The crude product was dissolved in ethanol (5 mL) and hydrazine monohydrate (0.07 mL, 1.42 mmol) was added. The reaction was refluxed for 2 h and filtered. Ethanol was removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel using 20%-35% EtOAc/hexanes as eluent to yield the desired product as colorless oil. The product was dissolved in dioxane (1 mL) and HCl (4M in dioxane, 2 mL) was added. The reaction was stirred at room temperature for 20 h and concentrated. The crude product was triturated with 20% EtOAc/hexanes and dried to afford the final product as hydrochloride salt (34 mg, 0.171, 35% over two steps). ¹H NMR (CD₃OD, 400 MHz): δ (ppm) 3.62 (s, 2H), 7.27-7.36 (m, 2H), 7.67-7.69 (m, 1H), 7.87 (s, 1H), 8.17 (d, 1H, J=8.4 Hz).

Example 64
General Method for the Synthesis of Sulfonamides

To a solution of O-(3-nitrobenzyl)hydroxylamine (1.0 equiv.) in dichloromethane (2 mL) was sequentially added pyridine (2.0 equiv.) and sulfonylchloride (1.2 equiv.). The reaction mixture was stirred at room temperature for 18 h and then poured into water (5 mL). The aqueous layer was extracted with dichloromethane (2×15 mL). The combined organic layers were concentrated and the crude product was purified by flash column chromatography on silica gel using 10%-27% EtOAc/hexanes as eluent.

The following compounds (Table C) were prepared essentially according to the preceding example with the proper substitution of starting materials:

TABLE C

Yield

¹H NMR (CDCl₃unless otherwise

Compound
(%)
noted): δ (ppm)

4-Methyl-N-(3-
62
2.41 (s, 3 H), 5.03 (d, 2 H), 7.17 (s, 1

nitrobenzyloxy)-

H), 7.31 (d, 2 H, J = 8 Hz),

benzenesulfonamide

7.47-7.51 (m, 1 H), 7.63 (d, 1 H,

J = 7.6 Hz), 7.78 (d, 2 H, J = 8 Hz),

8.13-8.15 (m, 2 H).

N-(3-Nitrobenzyloxy)-
71
3.08 (s, 3 H), 5.09 (s, 2 H), 6.93 (s, 1

methanesulfonamide

H), 7.55 (t, 1 H, J = 7.6 Hz), 7.70 (d,

1 H, J = 7.6 Hz), 8.20-8.24 (m, 2 H).

2-Methyl-5-nitro-N-(3-
65
2.73 (s, 3 H), 5.02 (s, 2 H), 7.40 (s, 1

nitrobenzyloxy)-

H), 7.50-7.53 (m, 1 H), 7.64 (d, 1 H,

benzenesulfonamide

J = 7.6 Hz), 8.09 (s, 1 H),

8.14-8.16 (m, 1 H), 8.31 (dd, 1 H, J = 2.4,

8.4 Hz), 8.82 (d, 1 H, J = 2.4 Hz).

Example 65
Synthesis of (3-(aminooxymethyl)phenyl)methanamine

3-Cyanobenzyl alcohol (308 mg, 2.32 mmol), N-hydroxyphthalimide (416 mg, 2.55 mmol) and triphenylphosphine (668 mg, 2.55 mmol) were dissolved in THF (8 mL). Diethyl azodicarboxylate (DEAD) (0.40 mL, 2.55 mmol) was added dropwise while stirring to the solution and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was filtered and the residue washed with THF (4 mL) and dried under high vacuum. The crude product (1.24 g, 4.46 mmol) was dissolved in ethanol (8 mL) and hydrazine monohydrate (0.43 mL, 8.92 mmol) was added. The reaction was refluxed for 2 h and filtered. Ethanol was removed under reduced pressure and the residue suspended in ethyl ether. The ethyl ether layer was washed with 3% Na₂CO₃(2×10 mL), brine (10 mL) and concentrated. The crude product (830 mg, 5.61 mmol) was dissolved in THF (15 mL) and cooled to 0° C. Lithium aluminum hydride (1 M in THF, 11.2 mL, 11.2 mmol) was added dropwise and the reaction was stirred overnight at room temperature. It was then quenched with methanol (10 mL) and water (2 mL). The mixture for stirred for a further 30 min. The salts were filtered off and the solvent removed by evaporation in vacuo. The crude product was purified by silica gel flash column chromatography using 20% MeOH/dichloromethane as eluent to afford the desired product as white solid (59 mg, 0.388 mmol, 17% over 3 steps). ¹H NMR (CDCl₃, 300 MHz): δ (ppm) 4.07 (s, 2H), 4.63 (s, 2H), 5.18 (s, 4H), 7.36-7.44 (m, 4H).

Example 66
General Procedure for Suzuki Reaction

To a degassed solution of appropriate halo-substituted benzyl alcohol (1.5 mmol), aryl boronic acid (1.5 equiv), and sodium carbonate (2.0 equiv) in DME/water (6 mL/3 mL) was added Pd(PPh₃)₄(2 mol %). The mixture was heated to 85° C. until the reaction was complete as indicated by TLC. The mixture was allowed to cool to room temperature, and then partition between EtOAc and water. The layers were separated and the aqueous layer was extracted with EtOAc (2×20 mL) and the combined organic layers were washed with water (10 mL), brine (10 mL), and dried over sodium sulfate. The solvent was removed under reduced pressure and the crude product was purified by silica gel flash column chromatography.

The following compounds (Table D) were prepared essentially according to the preceding example with the proper substitution of starting materials:

TABLE D

Yield

Compound
(%)

¹H NMR (CDCl₃unless otherwise noted): δ (ppm)

(3-(pyridin-4-
91
4.22 (br s, 1H), 4.78 (s, 2H), 7.44-7.52 (m, 5H),

yl)phenyl)methanol

7.63 (s, 1H), 8.53-8.54 (dd, 2H, J = 4.8 Hz)

(2-(pyridin-4-
40
4.56 (s, 2H), 4.68 (br s, 1H), 7.20-7.23 (dd, 1H, J = 1.6,

yl)phenyl)methanol

7.4 Hz), 7.30-7.32 (dd, 2H, J = 1.6, 4.5 Hz),

7.34-7.43 (m, 2H), 7.58-7.61 (dd, 1H, J = 1.1, 7.9 Hz),

8.45-8.47 (dd, 2H, J = 1.6, 4.5 Hz)

(4′-chlorobiphenyl-3-
67
2.51 (br s, 1H), 4.66 (s, 2H), 7.27-7.28 (d, 1H, J = 7.1 Hz),

yl)methanol

7.33-7.38 (dt, 3H, J = 1.9, 6.6 Hz),

7.41-7.45 (m, 3H), 7.48 (s, 1H)

(4′-chlorobiphenyl-2-
75
2.08 (br s, 1H), 4.51 (s, 2H), 7.21-7.23 (m, 1H),

yl)methanol

7.26-7.27 (t, 1H, J = 2.2 Hz), 7.28-7.29 (t, 1H, J = 2.2 Hz),

7.31-7.39 (m, 4H), 7.49-7.51 (dd, 1H, J = 1.6,

7.4 Hz)

(4,4′-dichlorobiphenyl-2-
89
1.73-1.75 (t, 1H, J = 5.7 Hz), 4.55-4.56 (d, 2H, J = 5.7 Hz),

yl)methanol

7.16-7.18 (d, 1H, J = 8.1 Hz) 7.25-7.27 (d,

2H, J = 8.3 Hz), 7.31-7.33 (dd, 1H, J = 2.1, 8.2 Hz),

7.39-7.40 (d, 2H, J = 8.3 Hz), 7.56-7.57 (d, 1H, J = 2.0 Hz)

(4-chlorobiphenyl-2-
91
2.02 (br s, 1H), 4.53 (s, 2H), 7.16-7.19 (d, 1H, J = 8.2 Hz),

yl)methanol

7.26-7.43 (m, 6H), 7.54-7.55 (d, 1H, J = 2.9 Hz)

(4-chloro-4′-
98
2.31 (br s, 1H), 3.82 (s, 3H), 4.52 (s, 2H),

methoxybiphenyl-2-

6.89-6.94 (td, 2H, J = 2.2, 8.7 Hz), 7.13-7.28 (m 4H),

yl)methanol

7.50-7.51 (d, 1H, J = 2.1 Hz)

(2′,4-dichlorobiphenyl-2-
96
1.77-1.80 (t, 1H, J = 5.8 Hz), 4.35-4.40 (dd, 1H, J = 5.9,

yl)methanol

13.5 Hz), 4.45-4.50 (dd, 1H, J = 5.1, 13.4 Hz),

7.09-7.11 (d, 1H, J = 8.0 Hz), 7.20-7.22 (m, 1H),

7.31-7.36 (m, 3H), 7.45-7.48 (m, 1H), 7.60-7.61 (d,

1H, J = 1.8 Hz)

methyl 4′-chloro-2′-
92
1.73 (br s, 1H), 3.95 (s, 3H), 4.57 (s, 2H),

(hydroxymethyl)biphenyl-

7.20-7.22 (d, 1H, 8.2 Hz), 7.33-7.36 (dd, 1H, J = 2.1, 8.2 Hz),

4-carboxylate

7.39-7.42 (d, 2H, J = 8.4 Hz), 7.61-7.62 (d, 1H, J = 1.8 Hz),

7.08-8.11 (d, 2H, J = 8.4 Hz)

(4′,5-dichlorobiphenyl-3-
95
2.01 (br s, 1H), 4.72 (s, 2H), 7.34 (s, 1H),

yl)methanol

7.39-7.48 (m, 6H)

(5-chloro-2-(1H-indol-5-
97
1.72 (br s, 1H), 7.62 (s, 2H), 6.56-6.58 (m, 1H),

yl)phenyl)methanol

7.10-7.13 (dd, 1H, J = 1.5, 8.4 Hz), 7.21-7.26 (m,

2H merged with CDCl₃), 7.29-7.32 (dd, 1H, J = 2.2,

8.2 Hz), 7.39-7.42 (d, 1H, J = 8.3 Hz), 7.55 (s, 2H),

8.29 (br s, 1H)

(4-chloro-4′-
37
1.25 (br s, 1H), 2.96 (s, 6H), 4.60 (s, 2H),

(dimethylamino)biphenyl-

6.75-6.77 (d, 2H, J = 8.4 Hz), 7.17-7.28 (m, 4H), 7.51-7.52 (d,

2-yl)methanol

1H, J = 2.0 Hz)

(3′,4-dichlorobiphenyl-2-
88
1.77 (br s, 1H), 4.56 (d, 2H, J = 3.3 Hz),

yl)methanol

7.16-7.57 (m, 6H), 7.58 (s, 1H)

(4-chloro-4′-
78
1.68 (t, 1H, J = 3.9 HZ), 4.56 (d, 2H, J = 3.9 HZ),

(trifluoromethyl)biphenyl-

7.19 (d, 1H, J = 6.3 Hz), 7.34-7.36 (m, 1H), 7.46 (d,

2-yl)methanol

2H, J = 6.3 Hz), 7.60 (d, 1H, J = 1.5 Hz), 7.68 (d,

2H, J = 6.3 Hz)

(3′,4,4′-trichlorobiphenyl-
83
1.73 (t, 1H, J = 4.2 Hz), 4.56 (d, 2H, J = 4.2 Hz),

2-yl)methanol

7.16-7.19 (m, 2H), 7.32-7.57 (m, 3H), 7.58 (s, 1H)

(5-chloro-2-(thiophen-3-
87
1.67 (s, 1H), 4.64 (s, 2H), 7.13 (d, 1H, J = 0.9 Hz),

yl)phenyl)methanol

7.15-7.39 (m, 4H), 7.52 (s, 1H)

(5-chloro-2-(thiophen-2-
62
1.96 (s, 1H), 4.69 (s, 2H), 7.06-7.09 (m, 2H),

yl)phenyl)methanol

7.23-7.35 (m, 3H), 7.55 (d, 1H, J = 1.5 Hz)

(5-chloro-2-(pyrimidin-5-
88
2.46 (br s, 1H), 4.56 (s, 2H), 7.21 (d, 1H, J = 8.19 Hz),

yl)phenyl)methanol

7.39-7.65 (m, 2H), 8.78 (s, 2H), 9.21 (s, 1H)

Example 67
Synthesis of (3-(phenylamino)phenyl)methanol

To a degassed solution of racemic-BINAP (67 mg, 0.107 mmol) in toluene (6 mL) was added palladium (II) acetate (36 mg, 0.054 mmol) and stirred at room temperature for 10 min. 3-Bromobenzyl alcohol (200 mg, 1.07 mmol) and aniline (149 mg, 1.60 mmol) were added and stirred for 5 min, cesium carbonate (522 mg, 1.60 mmol) was then added and stirred for 5 min. The mixture was then heated at 90° C. for 16 h diluted with ether (containing 1% triethylamine) and filtered. The solvent was removed under reduced pressure and the crude product was purified by silica gel flash column chromatography using 15-30% EtOAc/hexanes as eluent to afford the desired product as yellow oil (67 mg, 0.337 mmol, 32%). ¹H NMR (CDCl₃, 400 MHz): δ (ppm) 1.74 (br s, 1H), 4.61 (s, 2H), 5.72 (br s, 1H), 6.87-7.07 (m, 6H), 7.21-7.28 (m, 3H).

Example 68
Synthesis of 3-(aminooxymethyl)-N-phenylaniline

(3-(Phenylamino)phenyl)methanol (67 mg, 0.337 mmol), N-hydroxyphthalimide (66 mg, 0.404 mmol) and triphenylphosphine (106 mg, 0.404 mmol) were dissolved in THF (4 mL). Diethyl azodicarboxylate (DEAD) (0.07 mL, 0.404 mmol) was added dropwise while stirring to the solution and the reaction mixture was stirred at room temperature for 2 h. THF was evaporated under reduced pressure and the residue dissolved in dichloromethane (20 mL). The dichloromethane solution was washed with 10% NaOH (2×15 mL), water (2×15 mL) and brine (15 mL). The solvent was removed under reduced pressure and the crude product was used for the next step. The crude product (267 mg, 0.778 mmol) was dissolved in ethanol (4 mL) and hydrazine monohydrate (0.08 mL, 1.56 mmol) was added. The reaction was refluxed for 2 h and filtered. Ethanol was removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel using 20%-40% EtOAc/hexanes as eluent to yield the desired product as white solid (50 mg, 0.234 mmol, 69% over 2 steps). ¹H NMR (CDCl₃, 300 MHz): δ (ppm) 4.65 (s, 2H), 5.41 (br s, 2H), 5.74 (br s, 1H), 6.90-7.09 (m, 5H), 7.22-7.30 (m, 4H).

Example 69
Synthesis of 2-(aminooxy)-2-phenylethanol

Methyl 2-aminooxy-2-phenylacetate (35 mg, 0.193 mmol) was dissolved in ether (3 mL) and LAH (1 M in THF, 0.39 mL, 0.387 mmol) was added at 0° C. The mixture was allowed to warm to room temperature over 2 h, and then quenched with water (0.3 mL) and 10% NaOH (0.3 mL) and additional water (1 mL). The product was extracted with ethyl acetate and the organic phase was washed with brine, dried and evaporated. The crude product was purified by silica gel flash column chromatography using 48% EtOAc/hexanes as eluent to yield the desired alcohol as clear oil (15 mg, 0.098 mmol, 51%). ¹H NMR (CDCl₃, 400 MHz): δ (ppm) 2.38 (br s, 1H), 2.82 (br s, 2H), 3.62-3.67 (dd, 1H, J=8, 11.2 Hz), 3.73-3.76 (dd, 1H, J=3.6, 11.6 Hz), 4.79-4.82 (dd, 1H, J=3.2, 8 Hz), 7.25-7.36 (m, 5H).

Example 70
Synthesis of 4-(aminooxy)-4-phenylbutan-1-ol

Methyl 4-(aminooxy)-4-phenylbutanoate (45 mg, 0.215 mmol) was dissolved in ether (3 mL) and LAH (1 M in THF, 0.4 mL, 0.431 mmol) was added at 0° C. The mixture was allowed to warm to room temperature over 2 h, and then quenched with water (0.3 mL) and 10% NaOH (0.3 mL) and additional water (1 mL). The product was extracted with ethyl acetate and the organic phase was washed with brine, dried and evaporated. The crude product was purified by silica gel flash column chromatography using 48% EtOAc/hexanes as eluent to yield the desired alcohol as clear oil (18 mg, 0.099 mmol, 46%). ¹H NMR (CDCl₃, 400 MHz): δ (ppm) 1.62-1.68 (m, 2H), 1.80-1.87 (m, 2H), 2.68 (br s, 2H), 3.62-3.67 (m, 2H), 4.68-4.72 (m, 1H), 7.24-7.33 (m, 5H).

Example 71
Synthesis of (S)-3-(aminooxy)-3-phenylpropan-1-ol

A solution of TBS protected (R)-1-phenyl-1-aminooxy-3-propanol (199 mg, 0.708 mmol) in THF (3 mL) at was cooled to 0° C. TBAF (1 M in THF, 1.4 mL, 1.42 mmol) was added dropwise. The reaction mixture was stirred at RT for 1 h and concentrated. The residue was dissolved in EtOAc (40 mL), washed with 3% sodium carbonate (10 mL) and dried over sodium sulfate. The solvent was removed under reduced pressure and the crude product was purified by silica gel flash column chromatography using 25%-40% EtOAc/hexanes as eluent to afford the desired alcohol as colorless oil (75 mg, 0.449 mmol, 63%). ¹H NMR (CDCl₃, 400 MHz): δ (ppm) 1.82-1.88 (m, 2H), 2.02-2.09 (m, 2H), 2.28 (br s, 1H), 3.69-3.77 (m, 2H), 4.70-4.73 (dd, 1H, J=4.4, 8.8 Hz), 5.27 (br s, 2H), 7.27-7.38 (m, 5H).

Example 72
General Method for the Synthesis of Aryl Hydroxylamine Compounds

In a 20 mL vial containing N-hydroxypthalamide (1 equiv), CuCl (1 equiv), freshly activated 4 Å molecular sieves (500 mg), and 1-naphthaleneboronic acid (2 equiv). The 1,2-dichloroethane solvent (5 mL) was added followed by pyridine (1.1 equiv), resulting in a light brown suspension. The cap was loosely applied such that the reaction was open to the atmosphere. Reaction progress was followed by TLC and was complete in 48 h. The reaction mixture became green as the reaction proceeded. The reaction products were adsorbed to SiO2 and the solvent was removed under reduced pressure. Chromatography of the reaction mixture (hexanes followed by DCM) afforded product as a light brown liquid. To the solution of phthalimide protected hydroxylamine and ethanol at room temperature, hydrazine hydrate (2 equiv) was added drop wise. The reaction was allowed to run for 1 hour at 50° C. The solution was filtered to remove the white precipitate and was concentrated under reduced pressure. To the concentrated mixture ethyl ether was added and the resulting solution was filtered and dried in to give pure product.

The following compounds (Table E) were prepared essentially according to the preceding example with the proper substitution of starting materials:

TABLE E

Yield

¹H NMR (CDCl₃unless otherwise

Compound
(%)
noted): δ (ppm)

O-phenylhydroxylamine
43
6.84-6.89 (m, 1 H), 7.03-7.09 (m, 2 H),

7.19-7.25 (m, 2 H)

O-(naphthalen-1-
35
7.16 (dd, 1 H, J = 9 Hz), 7.24-7.32

yl)hydroxylamine

(m, 1 H), 7.35-7.42 (m, 1 H), 7.55

(d, 1 H, J = 2 Hz), 7.67-7.76

(m, 3 H)

Example 73
Synthesis of 2-(benzyloxy)-1-phenylethanol

A solution of benzoyloxyacetaldehyde (350 mg, 2.33 mmol) and THF (10 mL) was flushed with nitrogen and cooled to 0° C. and phenylmagnesium bromide (2.6 mL, 2.6 mmol, 1M in THF) was added drop wise. The resulting solution was allowed to stir for additional 12 hours at room temperature. After reaction was finished the reaction mixture was cooled to 0° C. and 1 mL of water was added drop wise. The mixture was concentrated in vacuum and diluted with DCM washed with NaHCO₃solution, water, and brine respectively. The organic layer was dried with Na₂SO₄and concentrated. The crude product was purified by column chromatography using hexanes and EtOAc (10:1) as eluent. The pure product was obtained as colorless oil in 83% yield. ¹H NMR (DMSO-d6, 400 MHz): 3.36-3.50 (m, 2H), 4.65 (s, 2H), 4.69-4.73 (m, 1H), 5.37 (d, 1H, J=4.4 Hz), 5.20-5.33 (m, 1H), 7.18-7.32 (m, 10H).

Example 74
Synthesis of 1,3-diphenylpropan-1-ol

Solution of hydrocinnamaldehyde (540 mg, 4.0 mmol) and THF was flushed with nitrogen and cooled to 0° C. and Phenylmagnesium bromide (4.4 mL, 1M in THF) was added dropwise. The resulting solution was allowed to stir for additional 12 hours at room temperature. After reaction was finished the reaction mixture was cooled to 0° C. and 1 mL of water was added dropwise. The mixture was concentrated in vacuum and diluted with DCM washed with NaHCO₃solution, water, and brine respectively. The organic layer was dried with Na₂SO₄and concentrated. The crude product was purified by column chromatography using hexanes and EtOAc (10:1) as eluent. The product was obtained as pale yellow oil in 58% yield. ¹H NMR (DMSO-d6, 400 MHz): 1.80-1.87 (m, 2H), 2.52-2.62 (m, 2H), 4.46-4-51 (m, 1H), 5.24 (d, 1H, J=4.8 Hz), 7.09-7.14 (m, 3H), 7.16-7.25 (m, 3H) 7.27-7.31 (m, 4H).

Example 75
Synthesis of 3-cyclohexyl-1-phenylpropan-1-ol

To the stirred solution of CuI and THF (5 mL) at −78° C. and under nitrogen cyclohexylmethyl magnesium bromide (7.2 mL, 3.6 mmol, 0.5 M in THF) was added. This mixture was allowed to stir for additional 10 minutes and styrene oxide (360.5 mg, 3 mmol) dissolved in 1 mL of THF was added. The resulting mixture was stir overnight at room temperature. After the reaction was over water 5 mL was added. The mixture was concentrated in vacuum and diluted with DCM washed with NaHCO₃solution, water, and brine respectively. The organic layer was dried with Na₂SO₄and concentrated. The crude mixture was purified by column chromatography using EtOAc/Hexanes (1:10) to give the desired product as colorless liquid in 17% yield. ¹H NMR (CDCl₃, 400 MHz): 0.71-0.90 (m, 2H), 1.08-1.34 (m, 6H), 1.60-1.82 (m, 7H), 1.90 (br. s, 1H), 4.58-5.59 (m, 1H), 7.31-7.34 (m, 1H) 7.23-7.28 (m, 4H).

Example 76
Synthesis of tert-Butyl 2-hydroxy-2-phenylethylcarbamate

To a solution of 2-amino-1-phenylethanol (685 mg, 5.0 mmol) in dichloromethane (20 mL), triethylamine (1.04 mL, 7.5 mmol) followed by di-tert-butyl dicarbonate (1.14 mL, 5.0 mmol) were added. The reaction mixture was stirred overnight at room temperature then saturated ammonium chloride solution added. The phases were separated and the aqueous layer extracted with dichloromethane (2×30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The product was purified by column chromatography using EtOAc/hexanes (1:2) as eluent to give desired product as white solid in 83% yield. ¹H NMR (CDCl₃, 400 MHz): 1.45 (s, 9H); 3.0 (s, 1H), 3.27-3.47 (m, 2H), 4.84 (m, 1H), 4.91 (br. s, 1H), 7.28-7.37 (m, 5H).

Example 77
Synthesis of tert-Butyl 2-(1,3-dioxoisoindolin-2-yloxy)-2-phenylethylcarbamate

To the solution of tert-Butyl 2-hydroxy-2-phenylethylcarbamate (878.0 mg, 3.6 mmol), N-hydroxyphthalimide (664.2 mg, 4.06 mmol), and triphenylphosphine (1067.6 mg, 4.06 mmol) in THF (16 mL), Diethyl azodicarboxylate (DEAD) (1.66 mL, 4.06 mmol, 40 wt % in toluene) was added dropwise. The solution was allowed to stir at 50° C. for 12 h. Water (5 mL) was added after the reaction was over. The organic layer was extracted in DCM and was dried over sodium sulfate. After concentrating in vacuum the crude product was purified by silica gel flash column chromatography using EtOAc/hexanes (1:2) as eluent to give desired product as off white solid in 69% yield. ¹H NMR (CDCl₃, 400 MHz): 1.42 (s, 9H); 3.52-3.68 (m, 2H), 5.25-5.50 (m, 1H), 5.56 (br. s, 1H), 7.25-7.40 (m, 3H), 7.41-7.59 (m, 2H), 7.72-7.82 (m, 4H).

Example 78
Synthesis of 2-(2-amino-1-phenylethoxy)isoindoline-1,3-dione

To a solution of tert-Butyl 2-aminooxy-2-phenylethylcarbamate (554.4 mg, 2.2 mmol) in dichloromethane (5 ml) was added trifluoroacetic acid (2 ml). The mixture was stirred at room temperature for 1 h and concentrated under reduced pressure to yield the desired crude product as clear oil. The crude product was then purified by column chromatography using MeOH/DCM (10:90) as an eluent to give the product as colorless oil in 72% yield. ¹H NMR (CDCl₃, 400 MHz): 3.40-3.51 (m, 1H); 3.57-3.66 (m, 1H); 5.50-5.52 (m, 1H), 7.32-7.45 (m, 3H), 7.46-7.51 (m, 2H), 7.57-7.62 (m, 4H). 8.61 (br, s, 2H).

Example 79
Synthesis of N-(2-(1,3-dioxoisoindolin-2-yloxy)-2-phenylethyl)acetamide

To a solution of 2-amino-1-phenylethanol (400.0 mg, 1.41 mmol) in THF (5 mL) was added NaHCO₃(238 mg, 2.83 mmol) and cooled to 0° C. Acetyl chloride (0.11 mL, 1.56 mmol) was added and the reaction mixture stirred at room temperature for 4 h. The THF was removed under reduced pressure and 5 mL of water was added to the remaining solution. The aqueous layer was extracted with dichloromethane (3×10 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was then purified by column chromatography using ethyl acetate as an eluent to give the product as colorless oil in 71% yield. ¹H NMR (CDCl₃, 400 MHz): 2.06 (s, 3H); 3.63-3.68 (m, 1H); 3.82-3.88 (m, 1H), 5.17-5.20 (m, 1H), 6.82 (br, s, 1H), 7.15-7.42 (m, 3H), 7.45-7.50 (m, 2H), 7.67-7.91 (m, 4H).

Example 80
Synthesis of N-(2-(aminooxy)-2-phenylethyl)acetamide

To the solution of N-(2-(1,3-dioxoisoindolin-2-yloxy)-2-phenylethyl)acetamide (83 mg, 0.25 mmol) and ethanol (3 mL), methyl hydrazine (0.25 mL, 1M solution in Ethanol) was added drop wise. The reaction was allowed to run for 1 hour at room temperature. The solution was filtered to remove the white precipitate and was concentrated. Ethyl ether was added and the resulting solution was filtered and dried in vacuum to give the desired product as white solid in 51% yield. ¹H NMR (DMSO, 400 MHz): 1.75 (s, 3H); 3.22-3.32 (m, 1H), 4.43-4.62 (m, 1H), 5.89 (br, s, 2H), 7.03-7.25 (m, 3H), 7.26-7.34 (m, 2H), 7.89 (br, s, 1H).

Example 81
Synthesis of tert-Butyl 3-hydroxy-3-phenylpropyl(methyl)carbamate

To a solution of 3-(methylamino)-1-phenylpropan-1-ol (495 mg, 3 mmol) in dichloromethane (8 mL), triethylamine (0.62 mL, 4.5 mmol), followed by di-tert-butyl dicarbonate (0.68 mL, 3 mmol) were added. The reaction mixture was stirred overnight at room temperature then saturated ammonium chloride solution added. The phases were separated and the aqueous layer extracted with dichloromethane (2×30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated and purified by column chromatography using EtOAc/hexanes (1:5) as an eluent to give the product as colorless oil in 67% yield. ¹H NMR (300 MHz, CDCl₃): 1.46 (s, 9H), 1.86-2.02 (m, 2H), 2.86 (s, 3H), 3.08 (br, s, 1H), 3.86 (br, s, 1H), 4.59 (d, 1H, J=7.7 Hz), 7.35-7.23 (m, 5H).

Example 82
Synthesis of tert-Butyl 3-(1,3-dioxoisoindolin-2-yloxy)-3-phenylpropyl(methyl)carbamate

To the solution of tert-Butyl 2-hydroxy-2-phenylethylcarbamate (785.0 mg, 3.0 mmol), N-hydroxyphthalimide (579.0 mg, 3.55 mmol), and triphenylphosphine (930.1 mg, 3.55 mmol) in THF (12 mL), Diethyl azodicarboxylate (DEAD) (1.50 mL, 3.55 mmol, 40 wt % in toluene) was added dropwise. The solution was allowed to stir at 50° C. for 12 h. Water (5 mL) was added after the reaction was over. The organic layer was extracted in DCM and was dried over sodium sulfate. After concentrating in vacuum the crude product was purified by silica gel flash column chromatography using EtOAc/hexanes (1:2) as eluent to give desired product as off white solid in 69% yield. ¹H NMR (CDCl₃, 400 MHz): 1.38 (s, 9H); 1.98-2.2 (m, 1H), 2.30-2.42 (m, 1H), 2.85 (s, 3H), 3.25-3.44 (m, 2H), 5.25-5.32 (m, 1H), 7.22-7.35 (m, 3H), 7.38-7.47 (m, 2H), 7.55-7.72 (m, 4H).

Example 83
Synthesis of 3-(Ammoniooxy)-N-methyl-3-phenylpropan-1-aminium chloride

To the solution of tert-butyl 3-(1,3-dioxoisoindolin-2-yloxy)-3-phenylpropyl(methyl)carbamate (410 mg, 1 mmol) and ethanol (3 mL) at room temperature Hydrazine Hydrate (3 mL, 1M solution in Ethanol) was added drop wise. The reaction was allowed to run for 1 hour. The solution was filtered to remove the white precipitate and was concentrated. Ethyl ether was added and the resulting solution was filtered and dried in vacuum. Resulting solid was dissolved in 2 mL of dioxane and solution of HCl (2 mL, 4M in Dioxane) was added drop wise. The resulting solution was allowed to stir for 24 h at room temperature. The white precipitate was collected by filtration and dried in vacuum to give the desired product in 83% overall yield. ¹H NMR (CDCl₃, 400 MHz): 2.0-2.10 (m, 1H), 2.14-2.32 (m, 1H), 2.46 (s, 3H), 2.64-3.00 (m, 2H), 5.20-5.33 (m, 1H), 7.31-7.48 (m, 5H), 9.21 (br, s, 2H), 11.05 (br, s, 3H).

Example 84
Virtual Screening of IDO Inhibitors and Molecular Docking

The published crystal structure of human IDO complexed with cyanide (pdb code:2D01) or with the IDO inhibitor 4-phenylimidazole (pdb code:2D0T) has been published by Sugimoto et al. (Sugimoto et at 2006, Proc. Natl. Acad. Sci. USA, 103(8) 2611-2616). Additionally, site directed mutagenesis and comparison with the mouse IDO aminoacid sequence identified aminoacids important for catalysis and substrate binding.

All molecular modeling studies including docking were carried out using GLIDE v4.0 (SCHRODINGER L.L.C, New York). The published X-ray crystal structure of the human IDO complexed with 4-phenylimidazole provided the structural framework for molecular docking studies.

A database with a library of 400,000 compounds was obtained from Albany Molecular Research Inc (Albany, N.Y.). Glide scores were obtained for known IDO inhibitors and used as reference to evaluate the results for other series of compounds. The known IDO inhibitors docked were: a) 1-methyl-tryptophan (Docking Score: −9.31), b) 4-phenylimidazole (Docking Score: −7.96), c) brassinin (Docking Score: −5.07) and d) 3-butyl-b-carboline (a non-competitive inhibitor, docking score: N/A). The more negative the value of the docking score, the better the result for the respective compounds. The calculations for known reference competitive inhibitors of IDO suggested that values between −7 kcal/mol and −10 kcal/mol would indicate compounds that are likely inhibitors of IDO. The library of 400,000 compounds was docked at the active site of IDO, yielding 852 structures with acceptable binding. The top 10% of these structures (88 compounds) were selected and used as a query in a 2D similarity search on a more extensive library of compounds (ACD). This broadened the diversity set of compounds to ˜30000 structures, which were subsequently docked using more stringent docking parameters (fine tuning of structures), yielding ˜800 structures with good docking scores (shown in Tables 1-11).

In addition to compounds identified via virtual screening, several rationally designed IDO inhibitors were docked to IDO to evaluate their potential as good IDO inhibitors. Such compounds belong to families of known IDO inhibitors such as derivatives of brassinin, analogs of tryptophan, indole derivatives, known metal chelators, naphtoquinones, and compounds that mimic the transition state of tryptophan dioxygenation. The whole focused set of compounds was re-docked, yielding ˜1200 compounds with favorable docking scores (shown in Tables 1-11 of the present application). Docking scores for the compounds in Tables 1-12 are report in Table 13.

TABLE 13

Docking

Score

Cmpd #
(kcal/mol)

00001
−8.56

00002
−7.98

00003
−8.71

00004
−8.25

00006
−8.24

00007
−8.8

00008
−8.91

00009
−7.24

00010
−7.83

00012
−8.6

00020
−6.56

00021
−8.07

00027
−8.5

00028
−7.61

00030
−8.61

00047
−6.1

00053
−8.58

00062
−8.18

00063
−7.62

00064
−7.28

00077
−6.04

00078
−8.13

00079
−7.23

00080
−8.24

00081
−7.6

00138
−9.56

00140
−9.05

00141
−7.36

00142
−7

00144
−6.73

00145
−6.84

00146
−6.62

00147
−6.95

00148
−6.03

00149
−5.25

00150
−6.63

00151
−7.35

00152
−5.6

00154
−6.64

00155
−6.73

00157
−5.93

00167
−6.48

00168
−7.75

00209
−6.69

00210
−9.02

00214
−7.58

00215
−8.4

00216
−6.17

00217
−7.27

00218
−6.57

00219
−7.73

00220
−7

00221
−6.4

00222
−7.49

00224
−6.14

00225
−7.6

00226
−7.64

00228
−7.09

00230
−8.61

00233
−7.24

00239
−7.9

00240
−8.6

00252
−7.06

00254
−8.31

00256
−8.65

00261
−8

00262
−7.39

00267
−8.27

00268
−6.56

00271
−7.65

00272
−6.37

00281
−6.3

00282
−8.22

00288
−8.8

00289
−5.52

00291
−5.65

00292
−8.32

00293
−8.08

00300
−8.62

00305
−6.9

00307
−7.65

00309
−6.08

00310
−8.44

00311
−6.97

00312
−7.84

00313
−8.24

00317
−8.06

00319
−8.03

00320
−6.2

00324
−6.77

00325
−8.82

00327
−8.78

00332
−7.66

00334
−6.05

00335
−9.29

00337
−6.49

00342
−6.78

00343
−8.63

00345
−6.81

00346
−7.18

00347
−8.11

00348
−6.75

00352
−9.49

00356
−6.91

00360
−7.44

00363
−6.97

00364
−6.31

00366
−7.53

00367
−7.43

00368
−8.02

00378
−7.53

00379
−8.44

00380
−6.79

00382
−5.85

00385
−7.62

00386
−9.31

00388
−9.05

00389
−8.63

00390
−8.94

00391
−5.82

00392
−5.93

00394
−7.85

00396
−7.84

00398
−6.07

00464
−6.29

00477
−6.12

00507
−6.55

00515
−5.22

00516
−4.69

00523
−3.79

00525
−4.28

00526
−7.67

00527
−6.32

00528
−6.41

00530
−5.91

00531
−4.57

00532
−5.24

00533
−6.16

00535
−6.64

00539
−6.2

00541
−5.54

00545
−6.99

00546
−6.97

00549
−6.44

00550
−6.87

00552
−9.11

00553
−9.64

00554
−8.12

00555
−8.23

00561
−10.64

00562
−10.44

00563
−10.3

00564
−10.27

00565
−10.22

00566
−10.17

00567
−10.11

00568
−9.96

00571
−9.87

00572
−9.83

00577
−9.72

00578
−9.65

00586
−9.49

00587
−9.46

00588
−9.45

00589
−9.45

00590
−9.42

00591
−9.38

00592
−9.35

00593
−9.32

00596
−9.29

00599
−9.21

00601
−9.19

00602
−9.18

00603
−9.14

00604
−9.14

00605
−9.13

00606
−9.11

00607
−9.11

00608
−9.1

00610
−9.09

00611
−9.08

00613
−9.04

00616
−9

00620
−8.97

00621
−8.97

00622
−8.97

00623
−8.95

00627
−8.92

00628
−8.92

00630
−8.89

00632
−8.88

00634
−8.86

00636
−8.85

00637
−8.84

00644
−8.8

00645
−8.79

00646
−8.78

00649
−8.76

00650
−8.75

00655
−8.71

00656
−8.71

00657
−8.7

00658
−8.69

00660
−8.68

00662
−8.67

00663
−8.66

00664
−8.65

00665
−8.64

00667
−8.64

00668
−8.63

00669
−8.61

00670
−8.61

00671
−8.61

00672
−8.58

00673
−8.58

00674
−8.57

00675
−8.57

00678
−8.56

00681
−8.53

00682
−8.53

00683
−8.53

00685
−8.52

00686
−8.5

00687
−8.49

00688
−8.49

00689
−8.49

00690
−8.48

00691
−8.48

00692
−8.47

00695
−8.46

00697
−8.46

00698
−8.45

00699
−8.44

00700
−8.44

00701
−8.44

00705
−8.43

00707
−8.42

00711
−8.4

00714
−8.4

00716
−8.39

00717
−8.39

00718
−8.38

00720
−8.37

00721
−8.36

00722
−8.36

00724
−8.36

00725
−8.36

00727
−8.35

00729
−8.34

00732
−8.34

00737
−8.31

00738
−8.3

00739
−8.3

00740
−8.29

00741
−8.29

00744
−8.28

00745
−8.26

00746
−8.26

00748
−8.26

00749
−8.25

00750
−8.25

00751
−8.62

00752
−8.25

00753
−8.25

00755
−8.23

00757
−8.21

00758
−8.21

00759
−8.21

00760
−8.2

00761
−8.2

00762
−8.2

00764
−8.18

00766
−8.17

00767
−8.16

00768
−8.15

00770
−8.15

00772
−8.15

00773
−8.14

00774
−8.14

00775
−8.14

00777
−8.14

00778
−8.13

00781
−8.12

00782
−8.11

00783
−8.11

00784
−8.09

00786
−8.08

00787
−8.07

00788
−8.07

00789
−8.06

00791
−8.04

00793
−8.03

00796
−8

00797
−8

00799
−8

00801
−8

00803
−7.99

00805
−7.99

00806
−7.99

00807
−7.98

00808
−7.98

00809
−7.97

00810
−7.97

00811
−7.97

00812
−7.96

00813
−7.96

00814
−7.96

00815
−7.96

00819
−7.95

00820
−7.95

00821
−7.94

00822
−7.94

00824
−7.94

00827
−7.94

00828
−7.92

00830
−7.92

00834
−7.91

00835
−7.9

00836
−7.9

00837
−7.89

00840
−7.89

00843
−7.88

00848
−7.87

00849
−7.86

00850
−7.86

00852
−7.85

00855
−7.84

00856
−7.84

00857
−7.83

00858
−7.83

00861
−7.81

00862
−7.81

00864
−7.81

00867
−7.79

00868
−7.79

00869
−7.78

00870
−7.77

00871
−7.77

00872
−7.77

00874
−7.76

00875
−7.76

00877
−7.76

00880
−7.74

00881
−7.74

00882
−7.74

00883
−7.73

00886
−7.72

00887
−7.72

00888
−7.71

00889
−7.71

00890
−7.71

00891
−7.68

00892
−7.68

00894
−7.67

00895
−7.67

00896
−7.67

00897
−7.66

00898
−7.66

00899
−7.66

00900
−7.65

00901
−7.65

00902
−7.65

00903
−7.64

00905
−7.62

00906
−7.62

00909
−8

00910
−7.61

00912
−7.61

00913
−7.6

00914
−7.59

00915
−7.59

00916
−7.59

00917
−7.59

00918
−7.59

00919
−7.59

00920
−7.58

00921
−7.57

00922
−7.57

00924
−7.57

00927
−7.56

00929
−7.52

00930
−7.52

00931
−7.52

00932
−7.51

00934
−7.5

00935
−7.5

00938
−7.48

00939
−7.47

00940
−7.47

00943
−7.46

00944
−7.45

00945
−7.45

00946
−7.45

00947
−7.45

00949
−7.45

00950
−7.45

00951
−7.45

00952
−7.44

00953
−7.44

00954
−7.44

00955
−7.44

00957
−7.43

00958
−7.43

00959
−7.43

00960
−7.42

00961
−7.42

00963
−7.42

00964
−7.41

00965
−7.41

00966
−7.4

00967
−7.4

00969
−7.39

00970
−7.39

00973
−7.37

00974
−7.35

00975
−7.35

00976
−7.35

00977
−7.35

00978
−7.35

00979
−7.35

00980
−7.34

00981
−7.34

00982
−7.34

00983
−7.33

00984
−7.33

00985
−7.33

00988
−7.31

00989
−7.31

00990
−7.31

00991
−7.3

00993
−7.29

00994
−7.29

00995
−7.29

00996
−7.28

00997
−7.28

00998
−7.27

00999
−7.27

01000
−7.27

01001
−7.26

01003
−7.26

01004
−7.26

01007
−7.24

01008
−7.24

01009
−7.24

01010
−7.24

01011
−7.24

01012
−7.24

01013
−7.23

01014
−7.23

01015
−7.22

01016
−7.22

01017
−7.21

01018
−7.21

01019
−7.2

01020
−7.2

01021
−7.2

01022
−7.19

01024
−7.18

01026
−7.17

01027
−7.16

01028
−7.16

01029
−7.16

01030
−7.16

01031
−7.15

01033
−7.15

01034
−7.15

01036
−7.14

01037
−7.14

01038
−7.13

01039
−7.11

01040
−7.11

01041
−7.11

01042
−7.1

01043
−7.1

01044
−7.09

01045
−7.07

01046
−7.07

01048
−7.04

01051
−7.04

01052
−7.03

01056
−7.01

01057
−7

01058
−7

01059
−6.99

01060
−6.97

01061
−6.97

01062
−6.97

01063
−6.97

01064
−6.96

01065
−6.96

01066
−6.94

01067
−6.94

01068
−6.94

01069
−6.92

01070
−6.92

01071
−6.92

01072
−6.92

01073
−6.91

01074
−6.91

01075
−6.91

01076
−6.91

01077
−6.91

01078
−6.9

01079
−6.9

01080
−6.89

01081
−6.89

01082
−6.89

01083
−6.88

01087
−6.86

01088
−6.86

01089
−6.85

01090
−6.85

01091
−6.85

01092
−6.84

01093
−6.84

01094
−6.83

01096
−6.82

01098
−6.81

01099
−6.81

01100
−6.81

01101
−6.81

01104
−6.79

01105
−6.79

01106
−6.78

01107
−6.78

01108
−6.78

01109
−6.78

01110
−6.77

01111
−6.76

01113
−6.74

01114
−6.74

01115
−6.73

01116
−6.72

01118
−6.72

01119
−6.7

01120
−6.7

01121
−6.7

01123
−6.69

01124
−6.68

01125
−6.68

01126
−6.66

01127
−6.64

01128
−6.64

01129
−6.63

01130
−6.63

01131
−6.63

01133
−6.61

01134
−6.6

01135
−6.59

01137
−6.58

01138
−6.57

01139
−6.57

01140
−6.56

01141
−6.56

01142
−6.56

01143
−6.55

01144
−6.54

01145
−6.52

01146
−6.52

01147
−6.51

01148
−6.51

01149
−6.51

01150
−6.49

01151
−6.48

01152
−6.46

01153
−6.46

01154
−6.46

01156
−6.44

01158
−6.43

01159
−6.43

01160
−6.42

01161
−6.42

01163
−6.4

01164
−6.4

01165
−6.39

01167
−6.39

01168
−6.38

01169
−6.38

01170
−6.38

01171
−6.35

01173
−6.33

01174
−6.32

01175
−6.32

01177
−6.29

01178
−6.29

01179
−6.26

01180
−6.26

01181
−6.26

01182
−6.25

01183
−6.24

01184
−6.23

01185
−6.21

01187
−6.21

01188
−6.19

01189
−6.19

01190
−6.19

01191
−6.16

01192
−6.16

01194
−6.13

01195
−6.11

01196
−6.1

01197
−6.1

01198
−6.07

01199
−6.05

01200
−6.03

01202
−6.01

01204
−6

01205
−6

01206
−5.98

01207
−5.97

01209
−5.95

01210
−5.95

01212
−5.92

01213
−5.92

01214
−5.91

01215
−5.9

01217
−5.88

01218
−5.88

01219
−5.86

01220
−5.84

01222
−5.8

01224
−5.75

01225
−5.74

01226
−5.66

01228
−5.6

01229
−5.6

01230
−5.56

01231
−5.54

01232
−5.51

01233
−5.49

01234
−5.48

01235
−5.47

01236
−5.42

01237
−5.42

01238
−5.34

01239
−5.33

01240
−5.26

01241
−5.19

01242
−5.14

01243
−5.14

01244
−5.1

01245
−5.09

01246
−5.03

01247
−5.01

01248
−4.91

01249
−4.87

01250
−4.86

01251
−4.82

01252
−4.82

01253
−4.8

01254
−4.67

01255
−4.66

01256
−4.52

01257
−3.63

01258
−3.5

01259
−3.43

01260
−8.06

01261
−8.68

01262
−9.34

01263
−7.45

01264
−7.51

01265
−6.92

01266
−7.48

01267
−7.87

01268
−8.81

01269
−8.32

01270
−8.9

01271
−9.3

01272
−8.3

01273
−8.75

01274
−8.41

01275
−8.54

01276
−9

01277
−8.11

01278
−8.88

01279
−8.71

01280
−8.61

01281
−8.29

01282
−7.3

01283
−9.08

01284
−6.02

01285
−8.67

01286
−8.42

01287
−8.11

01288
−7.4

01289
−7.76

01290
−7.47

01291
−8.03

01292
−6.99

01293
−8.52

01294
−7.91

01295
−7.17

01296
−6.95

01298
−7.27

01299
−8.39

01300
−8.57

01301
−8.72

01302
−8.12

01305
−9.18

01306
−8.99

01307
−8.93

01308
−9.24

01309
−8.99

01310
−9.21

01311
−5.72

01360
−8.27

01361
−8.01

01362
−6.42

01363
−6.38

01364
−6.77

01365
−8.65

01366
−5.7

01367
−8.92

01368
−8.89

01369
−8.57

01370
−7.91

01371
−7.65

01372
−7.96

01373
−6.63

01374
−8.06

01375
−7.4

01376
−5.83

01377
−6.24

01378
−7.85

01379
−7.04

01380
−7.8

01381
−7.7

01382
−7.91

01383
−6.63

01384
−6.69

01385
−6.81

01386
−3.58

01387
−10.21

01388
−5.56

01389
−6.8

01390
−5.2

01391
−9.34

01392
−8.41

01393
−6.19

01394
−3.58

01395
−4.35

01396
−4.24

01397
−6.7

01398
−7.22

01399
−7.35

01400
−4.29

01401
−5.75

01402
−6.96

01403
−8.93

01404
−7.78

01406
−8.09

01407
−5.12

01408
−5.23

01409
−4.43

01410
−5.44

01410
−5.44

01411
−4.19

01412
−7.09

01413
−6.52

01414
−7.71

01415
−6.1

01416
−5.18

01417
−6.51

01418
−5.29

01419
−5.33

01420
−8.16

01421
−7.05

01422
−7.38

01423
−6.99

01424
−7.05

01425
−6.76

01427
−4.02

01429
−7.11

01430
−5.3

01431
−7.11

01432
−5.86

01433
−6.42

01434
−6.1

01435
−7.28

01436
−8.59

01438
−6.91

01439
−5.89

01440
−9.26

01442
−9.3

01443
−8.26

01444
−9.85

01445
−9.38

01446
−8.11

01447
−8.13

01448
−8.52

01449
−6.89

01450
−4.88

01451
−6.51

01452
−4.98

01453
−6.97

01454
−4.33

01455
−5.72

01456
−5.63

01457
−5.72

01458
−8.89

01459
−5.73

01460
−5.42

01461
−6.68

01462
−6.51

01463
−6.02

01464
−6.15

01465
−6.55

01467
−5.56

01469
−5.9

01470
−6.25

01471
−4.97

01472
−5.25

01473
−6.81

01474
−6.22

01475
−6.86

01476
−6.96

01478
−8.09

01479
−8.31

01480
−5.93

01481
−6.41

01482
−6.83

01483
−5.77

01484
−5.96

01485
−5.34

01486
−5.61

01487
−5.34

01488
−7.08

01489
−6.71

01490
−6.47

01491
−6.95

Example 85
Human IDO Protein Cloning, Expression and Purification

Expression vectors for human indoleamine-2,3-dioxygenase (IDO) protein were prepared by amplification of a 1219 bp fragment of the sequence present in vector phIDO6His cDNA with primers 5′-ggagcatgctaATGGCACACGCTATGGAAAAC-3′ and 5′-gagagatctACCTTCCTTCAAAAGGGATTTC-3′ and cloning the SphI-BglII 1213 bp fragment into pQE70 (Qiagen), to yield vector pQE70-hIDO. This construct adds 2 extra amino acids and a 6-Histidine tag to the C-terminus of the natural human IDO protein while preserving intact the natural start codon and N-terminus amino acid sequence. The amplified allele of human IDO shows two polymorphisms with respect to the sequence deposited in accession file P14902 of SwissProt database. These polymorphisms result in a P110S and E119G amino acid changes.

Plasmid pQE70-hIDO was transformed into M15(pREP4) cells (Qiagen) and clones were selected in LB-agar plates supplemented with carbenicillin 50 μg/mL and kanamycin 30 μg/mL. Protein expression was carried out by growing an overnight culture of the M15pREP4/pQE70-hIDO clone in 100 mL LB supplemented with 100 μg/mL carbenicillin, 50 μg/mL kanamycin and 50 μg/mL of L-tryptophan (LBCKT medium). 40 mL of this culture were inoculated into 750 mL of LBCKT for 4 hours at 37° C. This culture was diluted 1:10 into LBCKT medium and cultured for another 2 hours at 37° C. until OD600 was higher than 0.8. At this point the cultures were inoculated with Hemin to 7 μM and L-Tryptophan to 75 μg/mL and incubated at 37° C. for 2 h. Induction of protein expression was carried out by supplementing the cultures with IPTG to 1 mM, PMSF to 200 μM, EDTA to 1 mM and L-tryptophan to 50 μg/mL. Incubation was continued for additional 16 h at 25° C. Cells were collected by centrifugation, and the cell pellets were washed with PBS buffer supplemented with 200 μM PMSF and 1 mM EDTA and stored at −80° C. until protein purification.

The equivalent of 16 L of culture were processed in one batch of purification. Cell pellets were thawed, resuspended in 50 mM potassium phosphate buffer pH 7.0, 200 μM PMSF, 1 mM EDTA, 1 mg/mL lysozyme to 10 mL per liter of bacterial culture and incubated 30 minutes on ice. Cells were then lysed by sonication. Cell lysates were centrifuged 20 min at 20000 g and the supernatant was filtered through 0.45 μm filters. The filtered supernatant was loaded onto a 60 mL phosphocellulose column equilibrated with 50 mM potassium phosphate buffer pH 6.5 (KPB) at 1-3 mL/min. The column was washed with 3 volumes of 50 mM KPB, 3 volumes of 100 mM KPB and the protein was eluted with 15 volumes of a linear gradient of 100-500 mM KPB. Fractions were collected and IDO activity assay was performed by measuring kynurenine production. This was carried out by mixing 50 μL of each fraction with 100 μL of reaction mix to yield a final concentration of 50 mM KPB buffer, 20 mM ascorbic acid, 200 μg/mL catalase, 20 μM methylene blue and 400 μM L-tryptophan. Fractions demonstrating IDO activity were loaded onto a Ni-NTA purification column (15 mL). This affinity purification column was washed with 10 volumes of 250 mM KPB, 150 mM NaCl, 50 mM imidazole pH 8, and eluted with 10 volumes of buffer containing 250 mM KPB, 150 mM NaCl and a 50 to 250 mM imidazole linear gradient. Collected fractions were assayed by IDO enzymatic assay described above and the positive fractions were pooled and concentrated by ultrafiltration and dialyzed against a buffer containing 250 mM KPB, 50% glycerol. This process yields ˜8-10 mg of pure protein (>98%) with a specific activity of 170 μmol/h/mg.

Example 86
Testing of IDO Inhibitory Compounds by Enzymatic IDO Assay

The IC₅₀values for each compound were determined by testing the activity of IDO in a mixture containing 50 mM potassium phosphate buffer at pH 6.5; 70 nM purified human IDO protein, 200 μM L-tryptophan, 20 mM ascorbate, 20 μM methylene blue, 0.1% DMSO. The inhibitors were initially diluted in DMSO at 100 mM and were diluted in potassium phosphate 50 mM, added to the reaction mixture at final concentrations raging from 1 mM to 5 nM and preincubated with the enzyme for 5 min at 25° C. The reaction was started by addition of L-tryptophan to 200 μM and incubated 15 min at 37° C. The reaction was stopped by addition of 0.5 vol of 30% trichloroacetic acid and incubated 30 min at 60° C. to hydrolyze N-formylkynurenine to kynurenine. The reaction was centrifuged at 3400 g for 5 min to remove precipitated protein and the supernatant was reacted with 2% (w/v) of p-dimethylaminobenzaldehyde in acetic acid. The reaction was incubated 10 min at 25° C. and read at 480 nm in a spectrophotometer. Control samples with no IDO inhibitor, or with no IDO enzyme or with the reference inhibitors 1-methyl-tryptophan (200 μM) and menadione (1.2 μM) were used as controls to set the parameters for the non-linear regressions necessary for determination of the IC₅₀for each compound. Nonlinear regressions and determination of the IC₅₀values were performed using the GraphPad Prism 4 software. Compounds with an IC₅₀of less than 500 μM were considered as active inhibitors in this assay.

Example 87
Determination of IDO Inhibitory Activity and Toxicity in Cell Based IDO/Kynurenine Assay

293-T-REx™ cells (Invitrogen) constitutively express a tet operator binding repressor protein and are maintained in DMEM, 10% FBS, 1× Penicillin+Streptomycin, 2 mM L-glutamine, 5 μg/mL blasticidin at 37° C. with a 5% CO₂in air atmosphere and typically split prior to confluency. Cells were passed by splitting the culture 1/10—by removing media by aspiration, washing 1× with PBS, incubating with 0.25% trypsin/EDTA until the cells detach, disbursing the cells in fresh growth media, and plating at 1/10 dilutions in fresh growth media. For long term cryopreservation, cells are detached from the plate as described above, collected by centrifugation, resuspended in freeze medium (growth medium, 10% DMSO), stored in 1.8 mL cryopreservation vials (˜2−5×10⁶cells per vial), in liquid nitrogen vapor storage tanks.

IDOL—expressing 293-T-Rex™ cell lines were generated by stable transfection of plasmid pcDNA-tetO-IDO expressing human IDO or murine IDO under the control of the doxycycline-inducible CMV-tet promoter. Transfected cells were selected in DBZ medium (DMEM, 10% FBS, 1× Penicillin+Streptomycin, 2 mM L-glutamine, 5 μg/mL blasticidin and 25 μg/ml Zeocin) at 37° C. with a 5% CO₂in air atmosphere. Individual clones were isolated by limiting dilution cloning from these populations. These clones were assayed for IDO activity and the clones that showed the highest levels of IDO activity inducible by doxycycline were used for subsequent cell based IDO assays.

To setup an IDO cell based activity assay, IDO-293-T-Rex cells were harvested and resuspended in DBZ media at 10⁶cells/mL, and split into poly-D-lysine coated 96-well plates at 100,000 cells per well. 100 μL of Neutral medium (DBZ medium, 200 μM L-tryptophan) or Induction media (Neutral medium supplemented with 5 μM doxycycline) are added to the cells and incubated 28 h at 37° C. After the IDO induction period, medium is removed and replaced with Induction or Neutral medium containing different concentrations of each inhibitor (1 mM to 0.5 nM). The cells incubated in Neutral medium serve as negative control of the assay. The cells incubated in Induction medium and without inhibitor serve as the positive control of the assay. The incubation is carried out for 16 h at 37° C. in a cell culture incubator. 200 μL of medium are transferred to U-bottom polypropylene 96-well plates containing 25 μL of 30% TCA, incubated 30 minutes at 60° C. and centrifuged at 3400 g for 5 minutes. 150 μL of the clear supernatant is transferred to a polystyrene 96-well plate containing 50 μL of 4% (w/v) of p-dimethylaminobenzaldehyde in acetic acid, incubated for 10 min. Kynurenine concentration is determined by measuring the absorbance at 480 nm.

To measure the toxicity of each compound after 16 h incubation with cells, cell viability is measured via a WST-1 assay (Roche) according to instructions from the manufacturer. Briefly, after the incubation with each compound, medium is aspirated and replaced with 100 mL of WST-1 reagent, and incubated 30 min at 37° C. Absorbance at 540 nm is correlated with the number of viable cells. Determination of IC₅₀(Kynurenine assay) or LD₅₀(WST-1 assay) is performed via non-linear regression analysis using GraphPad Prism software.

Example 88
Reversal of IDO-Mediated Suppression of T-Cell Proliferation by IDO Inhibitors

Human monocytes were collected from peripheral mononuclear cells by leukoapheresis and cultured overnight at 10⁶cells/well in a 96-well plate in RPMI 1640 medium supplemented with 10% fetal calf serum and 2 mM L-glutamine. Adherent cells were retained and cultured for 7 days with 200 ng/ml IL-4, 100 ng/ml GM-CSF. Cells were matured for 2 days with a cytokine cocktail containing TNF-α, IL-β, IL-6 and PGE2 for additional 2 days to induce dendritic cell maturation. At the end of maturation, loosely adherent cells were detached by gentle aspiration and plated in V-bottom 96 well plates, at 5000 cells/well. These cells are >80% IDO+ dendritic cells. Human allogeneic T cells (3×10⁵) from normal donors were resuspended in RPMI 1640 supplemented with 100-200 U/mL IL-2 and 100 ng/mL anti-CD3 antibody and added to the wells. Serial dilutions of IDO compounds dissolved in phenol red-free RPMI was added to yield a final concentration of IDOi between 500 and 1 μM. After incubation for 2-4 days, T cell proliferation was measured by BrdU incorporation assay after an overnight pulse with BrdU labeling mix (Roche Molecular Biochemicals). At the en of the pulse, the cells were fixed and incubated with 100 μL/well anti-BrdU-POD antibody following the instructions from the manufacturer. Plates were read in a microplate reader.

Alternatively, testing of IDO inhibitors in an in vitro mouse model of IDO-mediated suppression of T cell proliferation is performed by the following procedure. C57b16 mice are inoculated with 1×10⁶B78H1-GMCSF tumor cells in the right flank. After 10-12 days, tumor draining lymph nodes are collected and cells are stained with anti-CD11c and anti-B220 monoclonal antibodies. Cells are sorted by high-speed fluorescence activated cell sorting and the CD11c+/B220+ plasmacytoid dendritic cells are collected and seeded at 2000 cells/well in 96 well V-bottom plates. Splenocytes are collected from BM3 transgenic mice (in CBA background) and collected by nylon wool enrichment. BM3 T cells (10⁵cells/well) are added to each well in 200 μL of RPMI, 10% FCS, 50 μM β-mercaptoetanol. Alternatively, T cells are obtained from spleens of OT-I transgenic mice and added to the culture in combination with OVA peptide. IDO inhibitors are added dissolved in RPMI at final concentrations ranging from 1 mM to 10 nM. After 3 days of stimulation, cells are pulsed by 16 h with BrdU or ³H-thymidine. Cells are collected, fixed and tested for BrdU incorporation following the instructions from the BrdU labeling kit manufacturer (Roche Diagnostics). If ³H-tymidine is used to measure T cell proliferation, cells are harvested and dpm counts are measured in a scintillation counter following procedures widely known in the art. Control CD11c⁺ cells taken from the contralateral lymph node or CD11c⁺/B220⁻ cells (IDO⁻ population) from the TDLN are used as positive control for proliferation.

Example 89
In Vivo Testing of IDO Inhibitors for Antitumor Activity in Combination with Chemotherapeutic Agents

In vivo anti-tumor efficacy can be tested using modified tumor allograft protocols. For instance, it has been described in the literature that IDO inhibition can syngerize with cytotoxic chemotherapy in immune-competent mice. Due to different susceptibilities of different tumor cell lines to chemotherapeutic drugs and to immune mediated rejection, each IDO inhibitor is tested alone and in combination with 2 different chemotherapeutic drugs in 4 different animal tumor models, represented by 4 different mouse tumor cell lines, of different tissue origin (colorectal, bladder, mammary and lung carcinoma), implanted subcutaneously in syngeneic strains of mice. These cell lines have been selected based on their known susceptibility to chemotherapeutic drugs, their partial response to IDO inhibitors as single agents, their presumed pattern of IDO expression according to their tissue of origin, and their ability to elicit an immune reaction.

For every animal tumor model, 2 different chemotherapeutic drugs are tested in separate groups of mice according to the following list: 1] LLC tumor: cyclophosphamide and paclitaxel; 2] EMT6 tumor: cyclophosphamide and paclitaxel; 3] CT26 tumor: cyclophosphamide and doxorubicin; and 4] MB49 tumor: cyclophosphamide and gemcitabine.

The following chemotherapeutic drugs are used, at the indicated doses. The maximum tolerated dose for the following chemotherapeutic agents in mice depends on the formulation, concentration, frequency of administration, route of administration and number of doses. The chemotherapeutic drugs administered in conjunction with each IDO inhibitor drug are: 1] Paclitaxel: 20 mg/kg/day i.p, every 4 days, 4 times (q4d×4) (in Cremophor); 2] Doxorubicin: mg/kg, once a week for 3 weeks (q7d×3); 3] Cyclophosphamide: 100 mg/kg, I.P., every 4 days, 4 times (q4d×4); 4] Gemcitabine: 80 mg/kg every 4 days, 4 times, i.p. (q4d×4).

All animals receive a subcutaneous injection of a tumor forming dose of live tumor cells (˜50000-1000000 cells) suspended in 0.1 mL of PBS or saline on day 1. Subcutaneous injection forms a localized tumor that allows monitoring tumor growth over time.

To mimic the effect of IDO inhibitor drugs as therapeutic compositions, administration of IDO inhibitor drugs begins at day 5-8 after tumor inoculation. Dosing, route of administration, dosing frequency varies depending on the toxicity and pharmacokinetics profile of each drug. Duration of the treatment is 2 weeks. Most preferably, drug is administered continuously via oral gavage or dissolution in the drinking water. Alternatively, subcutaneous slow release pellets containing 100 mg of each drug are implanted under the skin by surgical procedure. IDO inhibitor drug are administered at the maximum tolerated dose or at a concentration corresponding to the LD₁₀.

Example 90
Pharmacological Values

Tables 14-16 report pharmacological values for compounds tested according to one or more of the preceding examples, including,

Human IDO IC₅₀: this is the concentration of the compound at which we observe 50% of enzymatic activity using recombinant human IDO under the assay conditions described in one of the examples;

Human IDO EC₅₀: This is the concentration of the compound at which we observe 50% of kynurenine production in a cell based assay using a 293T cell lines stably transfected with an expression cassette expressing human IDO. The conditions of the assay were as described in the examples.

Human IDO LD₅₀: This is the concentration of the compound at which we observe 50% of cell viability loss in the IDO cell based assay. Viability was measure by the WST assay as described in one of the examples.

In Table 14, values are reported in ranges: A: 1-10 mM; B: 0.1-1 mM; C: 20-100 μM; D: <20 μM.

TABLE 14

hIDO
hIDO
hIDO

Cmpd #
IC₅₀
EC₅₀
LD₅₀
Docking_Score

1
B
B
B
−8.56

2
B
B
B
−7.98

3
B
B
B
−8.71

4
B
C
B
−8.25

6
B
B
B
−8.24

7
B
B
B
−8.8

8
B
B
B
−8.91

9
B
C
B
−7.24

10
B
B
B
−7.83

12
B
B
B
−8.6

13
B

−7.88

14
B
B
B
−7.19

20
B

−6.56

21
B
B
B
−8.07

23
B
C
C
−4.45

27
B
B
B
−8.5

28
B
C
A
−7.61

30
B
C
B
−8.61

32
B
C
B
−7.57

38
B
C
C
−6.22

40
B
B
B
−8.29

42
B
B
B
−6.13

43
B
B
B
−6.31

44
B
A
A
−5.34

45
B
B
B
−7.39

47
B
C
C
−6.1

50
C
C
C
−8.92

52
C
C
B
−9.51

53
B
C
C
−8.58

57
D
C
B
−8.73

58
B
C
C
−7.84

60
C
C
B
−8.04

63
C
C
B
−7.62

64
B
C
B
−7.28

65
C
C
B
−8.57

66
B
B
B
−6.05

69
B

−7.19

77
B

−6.04

78
B
B
A
−8.13

79
C
D
A
−7.23

81
B

−7.6

138
B
C
C
−9.56

140
B
C
C
−9.05

142
D
B
A
−7

148
B
B
B
−6.03

149
B
C
B
−5.25

150
B
B
C
−6.63

151
B
B
B
−7.35

152
C
C
A
−5.6

162
D
B
B
−6.26

163
D
D
D
−5.85

167
D
C
B
−6.48

168
B
B
A
−7.75

209
B
A
B
−6.69

222
B
C
B
−7.49

252
B
C
A
−7.06

261
B
C
B
−8

267
B

−8.27

280
B
A
A
−8.02

282
B
A
A
−8.22

289
B
A
A
−5.52

307
D
A
B
−7.65

309
C
B
B
−6.08

312
D
D
A
−7.84

313
B
B
A
−8.24

317
D
D
A
−8.06

320
D
A
A
−6.2

321
B
B
B
−8.37

325
B
A
A
−8.82

352
B
A
A
−9.49

463
C

−5.49

464
C
A
A
−6.29

477
D
C
A
−6.12

525
B

−4.28

552
B
C
A
−9.11

561
B
C
A
−10.64

565
B

−10.22

568
B

−9.96

581
B
B
A
−9.6

588
B
B
B
−9.45

591
B

−9.38

592
B

−9.35

606
B

−9.11

607
C
C
B
−9.11

634
B
B
A
−8.86

644
B
C
B
−8.8

656
B
C
C
−8.71

664
B

−8.65

672
B
C
B
−8.58

673
B

−8.58

682
B
B
A
−8.53

701
B
B
A
−8.44

707
B

−8.42

739
B
B
A
−8.3

786
B

−8.08

827
B
C
B
−7.94

830
C
C
A
−7.92

889
B

−7.71

1359
B
C
B
−9.52

In Tables 15 and 16, values are reported in ranges: A: <10 μM; B: 10-100 μM; C: 100-1000 μM; D>1000 μM.

TABLE 15

Cpd

hIDO
mIDO

#
Structure
Name
IC₅₀
EC₅₀
LD₅₀
EC₅₀
LD₅₀

1769

embedded image

O-(3,5-dichlorobenzyl) hydroxylamine
A
A
D
A
D

1914

embedded image

O-((4-chloro-4′- methoxybiphenyl-2- yl)methyl)hydroxylamine
A
A
C
B
D

1935

embedded image

methyl 2′-(aminooxymethyl)-4′- chlorobiphenyl-4-carboxylate
A
A
C

1892

embedded image

O-((4,4′-dichlorobiphenyl-2- yl)methyl)hydroxylamine
A
A
B
A
D

1932

embedded image

O-(5-chloro-2-(thiophen-3- yl)benzyl)hydroxylamine
A
A
D

1918

embedded image

O-((3′,4-dichlorobiphenyl-2- yl)methyl)hydroxylamine
A
A
D
B
C

1916

embedded image

O-((4-chlorobiphenyl-2- yl)methyl)hydroxylamine
A
A
C
B
C

1937

embedded image

O-(2-phenoxy-1- phenylethyl)hydroxylamine
A
A
C

1825

embedded image

O-(biphenyl-3- ylmethyl)hydroxylamine
A
A
D
B
D

1879

embedded image

O-((4′-chlorobiphenyl-2- yl)methyl)hydroxylamine
A
A
D
B
D

1931

embedded image

O-(5-chloro-2-(thiophen-2- yl)benzyl)hydroxylamine
A
A
D

1743

embedded image

O-((5-chlorobenzo[b] thiophen-3- yl)methyl)hydroxylamine
A
A
D
B
D

1880

embedded image

methyl 4-(aminooxy)-4- phenylbutanoate
A
A
D
C
D

1915

embedded image

O-((2′,4-dichlorobiphenyl-2- yl)methyl)hydroxylamine
A
B
C
C
C

1749

embedded image

O-(benzo[d]thiazol-2- ylmethyl)hydroxylamine
A
A
D
A
D

1878

embedded image

O-((4′-chlorobiphenyl-3- yl)methyl)hydroxylamine
A
A
D
B
D

1919

embedded image

O-((3′,4,4′- trichlorobiphenyl-2- yl)methyl)hydroxylamine
A
A
C
B
C

1923

embedded image

O-(5-chloro-2-(pyrimidin-5- yl)benzyl)hydroxylamine
A
A
C
A
D

1774

embedded image

O-(benzofuran-2- ylmethyl)hydroxylamine
A
A
D
A
D

1882

embedded image

O-((4′-methoxybiphenyl-3- yl)methyl)hydroxylamine
A
A
D
B
D

1930

embedded image

O-(5-chloro-2-(1H-indo1-5- yl)benzyl)hydroxylamine
A
A
C

1873

embedded image

3-(aminooxymethyl) benzonitrile
A
A
D
A
D

2033

embedded image

(S)-2-(aminooxy)-N-methyl-2- phenylacetamide
A

1770

embedded image

O-(3,5-difluorobenzyl) hydroxylamine
A
A
D
2.3
D

1886

embedded image

methyl 2-(aminooxy)- 2-phenylacetate
A
A
D
A
D

1924

embedded image

O-(1,3- diphenylpropyl)hydroxylamine
A
A
C
B
C

1829

embedded image

3-(aminooxymethyl)-N- phenylaniline
A
A
D
A
C

1933

embedded image

O-(2-(benzyloxy)-1- phenylethyl)hydroxylamine
A
A
D

1827

embedded image

O-(biphenyl-2- ylmethyl)hydroxylamine
A
A
D
B
D

1660

embedded image

O-(3-chloro-5- fluorobenzyl)hydroxylamine
A
A
D
A
D

1903

embedded image

O-(naphthalen-1-yl) hydroxylamine
A
B
B
B
B

1893

embedded image

O-((4′,5-dichlorobiphenyl-3- yl)methyl)hydroxylamine
A
A
D
B
D

1662

embedded image

2-(aminooxymethyl)-N- benzylaniline
A
A
D
C
D

1771

embedded image

O-(2,5- dimethoxybenzyl) hydroxylamine
A
A
D
A
D

1938

embedded image

O-(3-cyclohexyl-1- phenylpropyl)hydroxylamine
A
A
C

1871

embedded image

2-(aminooxymethyl)-N- phenylaniline
A
A
D
B
D

1736

embedded image

O-(naphthalen-2- ylmethyl)hydroxylamine
A
A
D
A
D

1920

embedded image

O- (cyclohexyl(phenyl)methyl) hydroxylamine
A
A
D
B
B

1917

embedded image

O-((4-chloro-4′- (trifluoromethyl)biphenyl-2- yl)methyl)hydroxylamine
A
A
C
B
C

1744

embedded image

O-(benzo[d][1,3]dioxol-5- ylmethyl)hydroxylamine
A
A
D
B
D

1897

embedded image

2-(aminooxy)-N-methyl-2- phenylacetamide
A
A
D
A
D

1921

embedded image

O-(1,2-diphenylethyl) hydroxylamine
A
A
C
B
D

1895

embedded image

O-(1,2,3,4- tetrahydronaphthalen-1- yl)hydroxylamine
A
A
D
B
D

1676

embedded image

O-(2-chloro-4- fluorobenzyl)hydroxylamine
A
A
D
B
D

1896

embedded image

4-(aminooxymethyl) benzonitrile
A
A
D
B
D

1768

embedded image

O-(chroman-2- ylmethyl)hydroxylamine
A
A
D
A
D

1872

embedded image

3-(aminooxymethyl)-N- benzylaniline
A
A
D
A
D

1934

embedded image

2′-(aminooxymethyl)-4′- chloro-N,N- dimethylbiphenyl-4-amine
A
A
D

1739

embedded image

O-(pyridin-2-ylmethyl) hydroxylamine
B
A
D
A
D

1674

embedded image

O-(2-chloro-6- fluorobenzyl)hydroxylamine
B
A
D
B
D

1889

embedded image

O-(2-(pyridin-4- yl)benzyl)hydroxylamine
B
A
D
C
D

1742

embedded image

O-((1H-indol-3- yl)methyl)hydroxylamine
B
A
D
A
D

1737

embedded image

O-(pyridin-4-ylmethyl) hydroxylamine
B
A
D
A
D

1738

embedded image

O-(pyridin-3-ylmethyl) hydroxylamine
B
A
D
B
D

1888

embedded image

O-(3-(pyridin-4- yl)benzyl)hydroxylamine
B
A
D
C
D

1750

embedded image

O-((2,3-dihydrobenzo[b] [1,4]dioxin- 6-yl)methyl)hydroxylamine
B
A
D
B
B

1824

embedded image

3-(aminooxymethyl)aniline
B
A
D
B
D

1741

embedded image

O-(quinolin-6- ylmethyl)hydroxylamine
B
A
D
A
D

1925

embedded image

O-(2-cyclohexyl-1- phenylethyl)hydroxylamine
B
A
C
B
C

1881

embedded image

O-((4′-methylbiphenyl-3- yl)methyl)hydroxylamine
B
A
D
B
D

1898

embedded image

4-(aminooxy)-N-methyl-4- phenylbutanamide
B
A
D
B
B

1875

embedded image

2-(aminooxy)-2- phenylethanamine
B
D
D

1877

embedded image

3-(aminooxy)-3- phenylpropan-1- amine
B

1936

embedded image

O-(2-morpholino-1- phenylethyl)hydroxylamine
B

1740

embedded image

O-((4-methyl-2- phenylpyrimidin-5- yl)methyl)hydroxylamine
B
A
D
A
D

1828

embedded image

3-(aminooxymethyl)-N- benzylaniline
C
B
D
C
C

1902

embedded image

2-(aminooxy)-N-methyl-2- phenylethanamine
C

1901

embedded image

4-(aminooxy)-N-cyclohexyl-4- phenylbutanamide
C

1876

embedded image

tert-butyl 2-(aminooxy)-2- phenylethylcarbamate
C

2034

embedded image

(R)-2-(aminooxy)-N-methyl-2- phenylacetamide
C

1904

embedded image

3-(aminooxy)-N-methyl-3- phenylpropan-1-amine
C

1899

embedded image

N-(2-(aminooxy)-2- phenylethyl)acetamide
C

1929

embedded image

O-(3-morpholino-1- phenylpropyl)hydroxylamine
C

1883

embedded image

(S)-3-(aminooxy)- 3-phenylpropan-1-ol
C

TABLE 16

Cpd

hIDO
mIDO

#
Structure
Name
IC50
EC50
LD50
EC50
LD50

1656

embedded image

O-(3-bromobenzyl) hydroxylamine
A
A
D
A
D

1672

embedded image

O-(3-chlorobenzyl) hydroxylamine
A
A
D
A
D

1775

embedded image

O-(3-(trifluoromethyl) benzyl)hydroxylamine
A
A
D
A
D

1816

embedded image

O-(3-iodobenzyl) hydroxylamine
A
A
D
B
D

317

embedded image

O-(3-nitrobenzyl) hydroxylamine
A
A
D
A
D

762

embedded image

O-(3-fluorobenzyl) hydroxylamine
A
A
D
A
D

1817

embedded image

O-(2-iodobenzyl) hydroxylamine
A
A
D
B
D

1657

embedded image

O-(3,5-dinitrobenzyl) hydroxylamine
A
A
D
A
D

1767

embedded image

O-(naphthalen-1-ylmethyl) hydroxylamine
A
A
D
B
D

1922

embedded image

O-benzhydrylhydroxylamine
A
A
C
A
C

1666

embedded image

O-benzylhydroxylamine
A
A
D
A
D

774

embedded image

O-(4-fluorobenzyl) hydroxylamine
A
A
D
A
D

1677

embedded image

O-(2-(trifluoromethyl)benzyl) hydroxylamine
A
A
D
B
D

1818

embedded image

O-(4-iodobenzyl)hydroxylamine
A
A
D
B
D

934

embedded image

O-(4-(trifluoromethyl)benzyl) hydroxylamine
A
A
D
A
D

1679

embedded image

O-(2-phenoxyethyl) hydroxylamine
A
A
D
A
D

1682

embedded image

O-(3-methoxybenzyl) hydroxylamine
A
A
D
A
D

1752

embedded image

O-(3-nitrophenethyl) hydroxylamine
A
A
D
A
D

1675

embedded image

O-(2-bromobenzyl) hydroxylamine
A
A
D
A
D

1755

embedded image

O-(1-(3-nitrophenyl)but-3-enyl) hydroxylamine
A
A
D
A
D

1684

embedded image

methyl 4-(aminooxymethyl) benzoate
A
A
D
B
D

811

embedded image

O-(2-nitrobenzyl) hydroxylamine
A
A
D
B
D

1669

embedded image

O-(tetrahydro-2H-pyran-2-yl) hydroxylamine
B
A
D
A
D

1692

embedded image

O-(3-methylbenzyl) hydroxylamine
B
A
D
B
D

1822

embedded image

O,O′-(1,2- phenylenebis(methylene)) bis(hydroxylamine)
B
B
D
B
D

1667

embedded image

O-(perfluorobenzyl) hydroxylamine
B
A
D
B
D

1823

embedded image

O,O′-(1,3- phenylenebis(methylene)) bis(hydroxylamine)
B
B
D
A
D

1678

embedded image

O-(2-methoxybenzyl) hydroxylamine
B
A
D
B
D

1492

embedded image

O,O′-(1,4- phenylenebis(methylene)) bis(hydroxylamine)
B
A
D
B
C

1815

embedded image

O-(4-methoxybenzyl) hydroxylamine
B
A
D
B
C

1014

embedded image

O-(4-nitrobenzyl) hydroxylamine
B
A
D
B
D

1900

embedded image

O-phenylhydroxylamine
B

1693

embedded image

O-(3-phenylpropyl) hydroxylamine
B
A
D
B
D

1673

embedded image

O-(3-chloro-4-fluorobenzyl) hydroxylamine
C
A
C
D
DS

1690

embedded image

(R)-2-(aminooxy)-3- phenylpropanoic acid
C

Number	Name	Date	Kind
3192110	Biel et al.	Jun 1965	A
3215706	Lutz	Nov 1965	A
3226446	Drain et al.	Dec 1965	A
3240802	Robertson	Mar 1966	A
3245878	Berger et al.	Apr 1966	A
3245879	Purdy et al.	Apr 1966	A
3262978	Robertson	Jul 1966	A
3284299	McGrath et al.	Nov 1966	A
3313824	Paquette	Apr 1967	A
3329677	Schumann	Jul 1967	A
3342678	Berger et al.	Sep 1967	A
3349135	Drain et al.	Oct 1967	A
3375273	Drain et al.	Mar 1968	A
3378592	Lutz	Apr 1968	A
3758546	Kasztreiner et al.	Sep 1973	A
3766235	Kisfaludy et al.	Oct 1973	A
4009175	Hester, Jr.	Feb 1977	A
4144393	Bradshaw et al.	Mar 1979	A
4287194	Kosa et al.	Sep 1981	A
4331665	Teraji et al.	May 1982	A
4332798	Teraji et al.	Jun 1982	A
4390534	Teraji et al.	Jun 1983	A
4472194	Van Assche et al.	Sep 1984	A
4840945	Ohnishi et al.	Jun 1989	A
4923896	Trivedi	May 1990	A
5081248	Zama et al.	Jan 1992	A
5120849	Wild et al.	Jun 1992	A
5155127	Trivedi	Oct 1992	A
5233035	Hara et al.	Aug 1993	A
5322852	Frei et al.	Jun 1994	A
5358955	Brooks et al.	Oct 1994	A
5378716	Hamanaka et al.	Jan 1995	A
5403835	Nakagawa et al.	Apr 1995	A
5407902	Oda et al.	Apr 1995	A
5438052	Angehrn et al.	Aug 1995	A
5455238	Aszodi et al.	Oct 1995	A
5512581	Brooks et al.	Apr 1996	A
5516806	Frei et al.	May 1996	A
5587372	Aszodi et al.	Dec 1996	A
5594009	Hudkins et al.	Jan 1997	A
5606095	Pfiffner et al.	Feb 1997	A
5616806	Nagata et al.	Apr 1997	A
5705511	Hudkins et al.	Jan 1998	A
6057269	Klintz et al.	May 2000	A
6107291	Russo-Rodriguez et al.	Aug 2000	A
6121459	Schwindt et al.	Sep 2000	A
6221865	Sebti et al.	Apr 2001	B1
6451840	Munn et al.	Sep 2002	B1
6482416	Munn et al.	Nov 2002	B2
6552006	Raz et al.	Apr 2003	B2
6635677	Gerson et al.	Oct 2003	B2
6936416	Zhu et al.	Aug 2005	B2
7160539	Munn et al.	Jan 2007	B2
7312200	Malsam et al.	Dec 2007	B2
7384558	Hai et al.	Jun 2008	B2
7465448	Munn et al.	Dec 2008	B2
7598287	Munn et al.	Oct 2009	B2
7705022	Prendergast et al.	Apr 2010	B2
7714139	Prendergast et al.	May 2010	B2
7799776	Andersen et al.	Sep 2010	B2
8034953	Combs et al.	Oct 2011	B2
8324282	Gerson et al.	Dec 2012	B2
20020002152	Craig et al.	Jan 2002	A1
20020035136	Liu et al.	Mar 2002	A1
20030139361	Yuda et al.	Jul 2003	A1
20030194803	Mellow et al.	Oct 2003	A1
20030212028	Raz et al.	Nov 2003	A1
20030225133	Dutta	Dec 2003	A1
20050186289	Munn et al.	Aug 2005	A1
20050191276	Gurtner et al.	Sep 2005	A1
20050238651	Gurtner et al.	Oct 2005	A1
20050249666	Nakamura et al.	Nov 2005	A1
20060142214	Or et al.	Jun 2006	A1
20060160883	Stoops	Jul 2006	A1
20060165665	Min et al.	Jul 2006	A1
20060241186	Gerson et al.	Oct 2006	A1
20060258719	Combs et al.	Nov 2006	A1
20060270618	Bevec	Nov 2006	A1
20060292618	Mellor et al.	Dec 2006	A1
20070048769	Mellor et al.	Mar 2007	A1
20070077224	Munn et al.	Apr 2007	A1
20070077234	Munn et al.	Apr 2007	A1
20070082853	Or et al.	Apr 2007	A1
20070092881	Ohnishi et al.	Apr 2007	A1
20070099844	Prendergast et al.	May 2007	A1
20070203140	Combs et al.	Aug 2007	A1

Number	Date	Country
952113	Jul 1974	CA
0 578 847	Jul 1992	EP
0 544 958	Jun 1993	EP
0 658 547	Jun 1995	EP
0 838 452	Apr 1998	EP
0 949 243	Oct 1999	EP
1 281 707	Feb 2003	EP
1 595 865	Nov 2005	EP
1034198	Oct 1963	GB
964 721	Jul 1964	GB
1 042 191	Sep 1966	GB
1 264 261	Feb 1972	GB
1 331 203	Sep 1973	GB
1331203	Sep 1973	GB
1 496 757	Jan 1978	GB
35932	Nov 1974	IL
2005232009	Sep 2005	JP
WO 2002034745	May 2002	WO
04018479	Mar 2004	WO
2004093871	Nov 2004	WO
2004094409	Nov 2004	WO
2006005185	Jan 2006	WO
2007050963	May 2007	WO
08008398	Jan 2008	WO
08024725	Feb 2008	WO
08150447	Dec 2008	WO

	Number	Date	Country
	61050646	May 2008	US
	60991518	Nov 2007	US

IDO inhibitors

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

CPC

International Classifications

Term Extension

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATIONS

PCT Information

US Referenced Citations (86)

Foreign Referenced Citations (26)

Non-Patent Literature Citations (72)

Related Publications (1)

Provisional Applications (2)